0001493152-23-012482.txt : 20230417 0001493152-23-012482.hdr.sgml : 20230417 20230417134521 ACCESSION NUMBER: 0001493152-23-012482 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 69 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230417 DATE AS OF CHANGE: 20230417 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CalEthos, Inc. CENTRAL INDEX KEY: 0001174891 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 000000000 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-50331 FILM NUMBER: 23823496 BUSINESS ADDRESS: STREET 1: THREE SUGAR CREEK CENTER STREET 2: SUITE 100 CITY: SUGAR LAND STATE: TX ZIP: 77478 BUSINESS PHONE: 713-929-3863 MAIL ADDRESS: STREET 1: THREE SUGAR CREEK CENTER STREET 2: SUITE 100 CITY: SUGAR LAND STATE: TX ZIP: 77478 FORMER COMPANY: FORMER CONFORMED NAME: RealSource Residential, Inc DATE OF NAME CHANGE: 20130814 FORMER COMPANY: FORMER CONFORMED NAME: UPSTREAM BIOSCIENCES INC. DATE OF NAME CHANGE: 20090422 FORMER COMPANY: FORMER CONFORMED NAME: FORCE ENERGY CORP. DATE OF NAME CHANGE: 20090415 10-K 1 form10-k.htm
0001174891 false FY 0001174891 2022-01-01 2022-12-31 0001174891 2022-06-30 0001174891 2023-04-13 0001174891 2022-12-31 0001174891 2021-12-31 0001174891 BUUZ:SeriesAConvertiblePreferredStockMember 2022-12-31 0001174891 BUUZ:SeriesAConvertiblePreferredStockMember 2021-12-31 0001174891 2021-01-01 2021-12-31 0001174891 us-gaap:PreferredStockMember BUUZ:SeriesAConvertiblePreferredStockMember 2020-12-31 0001174891 us-gaap:CommonStockMember 2020-12-31 0001174891 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001174891 BUUZ:StockSubscriptionReceivableMember 2020-12-31 0001174891 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001174891 us-gaap:RetainedEarningsMember 2020-12-31 0001174891 2020-12-31 0001174891 us-gaap:PreferredStockMember BUUZ:SeriesAConvertiblePreferredStockMember 2021-12-31 0001174891 us-gaap:CommonStockMember 2021-12-31 0001174891 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001174891 BUUZ:StockSubscriptionReceivableMember 2021-12-31 0001174891 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001174891 us-gaap:RetainedEarningsMember 2021-12-31 0001174891 us-gaap:PreferredStockMember BUUZ:SeriesAConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001174891 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001174891 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001174891 BUUZ:StockSubscriptionReceivableMember 2021-01-01 2021-12-31 0001174891 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001174891 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001174891 us-gaap:PreferredStockMember BUUZ:SeriesAConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001174891 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001174891 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001174891 BUUZ:StockSubscriptionReceivableMember 2022-01-01 2022-12-31 0001174891 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001174891 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001174891 us-gaap:PreferredStockMember BUUZ:SeriesAConvertiblePreferredStockMember 2022-12-31 0001174891 us-gaap:CommonStockMember 2022-12-31 0001174891 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001174891 BUUZ:StockSubscriptionReceivableMember 2022-12-31 0001174891 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001174891 us-gaap:RetainedEarningsMember 2022-12-31 0001174891 BUUZ:AIQSystemIncMember 2021-11-05 0001174891 BUUZ:AIQSystemIncMember 2021-11-04 2021-11-05 0001174891 BUUZ:AIQSystemIncMember 2021-11-05 0001174891 BUUZ:RestrictedStockAwardMember 2022-01-01 2022-12-31 0001174891 BUUZ:RestrictedStockAwardMember 2021-01-01 2021-12-31 0001174891 BUUZ:ConvertiblePromissoryNotesAndAccruedInterestMember 2022-01-01 2022-12-31 0001174891 BUUZ:ConvertiblePromissoryNotesAndAccruedInterestMember 2021-01-01 2021-12-31 0001174891 BUUZ:SeriesAWarrantsIssuedWithConvertiblePromissoryNotesMember 2022-01-01 2022-12-31 0001174891 BUUZ:SeriesAWarrantsIssuedWithConvertiblePromissoryNotesMember 2021-01-01 2021-12-31 0001174891 BUUZ:SeriesBWarrantsToBeIssuedUponExerciseOfSeriesAWarrantMember 2022-01-01 2022-12-31 0001174891 BUUZ:SeriesBWarrantsToBeIssuedUponExerciseOfSeriesAWarrantMember 2021-01-01 2021-12-31 0001174891 BUUZ:WarrantsIssuedForServicesMember 2022-01-01 2022-12-31 0001174891 BUUZ:WarrantsIssuedForServicesMember 2021-01-01 2021-12-31 0001174891 BUUZ:MOneAdvisorsMember 2022-01-01 2022-12-31 0001174891 BUUZ:MOneAdvisorsMember 2021-01-01 2021-12-31 0001174891 BUUZ:TechnologyDevelopmentAgreementMember BUUZ:PICOCELCoLtdMember 2021-12-23 0001174891 BUUZ:TechnologyDevelopmentAgreementMember BUUZ:PICOCELCoLtdMember 2022-01-01 2022-12-31 0001174891 BUUZ:AIQMember 2022-04-05 0001174891 BUUZ:TechnologyDevelopmentAgreementMember BUUZ:NNSCoLtdMember 2022-01-01 2022-12-31 0001174891 BUUZ:ValueAddedTaxMember 2022-01-01 2022-12-31 0001174891 BUUZ:WithinFiveDaysAfterSigningTheContractMember 2022-04-05 0001174891 BUUZ:WithinFiveDaysAfterallConditionsAreMetMember 2022-04-05 0001174891 2022-04-05 0001174891 BUUZ:PICOCELMember BUUZ:AmountMember 2022-12-31 0001174891 BUUZ:PICOCELMember BUUZ:ValueAddedTaxMember 2022-12-31 0001174891 BUUZ:PICOCELMember 2022-12-31 0001174891 BUUZ:NNSMember BUUZ:AmountMember 2022-12-31 0001174891 BUUZ:NNSMember BUUZ:ValueAddedTaxMember 2022-12-31 0001174891 BUUZ:NNSMember 2022-12-31 0001174891 BUUZ:AmountMember 2022-12-31 0001174891 BUUZ:ValueAddedTaxMember 2022-12-31 0001174891 BUUZ:AmountMember 2022-01-01 2022-12-31 0001174891 BUUZ:PromissoryNoteMember 2020-07-07 0001174891 BUUZ:PromissoryNoteMember 2020-07-06 2020-07-07 0001174891 BUUZ:PromissoryNoteMember BUUZ:BorrowerMember 2020-07-06 2020-07-07 0001174891 BUUZ:PromissoryNoteMember 2022-12-31 0001174891 BUUZ:PromissoryNoteMember 2021-02-19 0001174891 BUUZ:PromissoryNoteMember 2021-02-18 2021-02-19 0001174891 BUUZ:PromissoryNoteOneMember 2021-04-22 0001174891 BUUZ:PromissoryNoteOneMember 2021-04-20 2021-04-22 0001174891 BUUZ:PromissoryNoteOneMember 2022-12-31 0001174891 BUUZ:PromissoryNoteTwoMember 2021-07-01 0001174891 BUUZ:PromissoryNoteTwoMember 2021-06-29 2021-07-01 0001174891 BUUZ:PromissoryNoteMember 2022-01-01 2022-12-31 0001174891 BUUZ:PromissoryNoteMember 2021-01-01 2021-12-31 0001174891 BUUZ:ConvertiblePromissoryNoteOneMember 2021-12-31 0001174891 BUUZ:ConvertiblePromissoryNoteTwoMember 2021-12-31 0001174891 BUUZ:ConvertiblePromissoryNoteTwoMember 2021-01-01 2022-12-31 0001174891 BUUZ:ConvertiblePromissoryNoteOneMember 2021-01-01 2021-12-31 0001174891 BUUZ:ConvertiblePromissoryNoteTwoMember 2021-01-01 2021-12-31 0001174891 us-gaap:WarrantMember 2022-12-31 0001174891 us-gaap:WarrantMember srt:MinimumMember 2022-12-31 0001174891 us-gaap:WarrantMember srt:MaximumMember 2022-12-31 0001174891 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001174891 us-gaap:WarrantMember srt:MinimumMember 2022-01-01 2022-12-31 0001174891 us-gaap:WarrantMember srt:MaximumMember 2022-01-01 2022-12-31 0001174891 us-gaap:ConvertibleNotesPayableMember srt:MinimumMember 2022-12-31 0001174891 us-gaap:ConvertibleNotesPayableMember srt:MinimumMember 2021-12-31 0001174891 us-gaap:ConvertibleNotesPayableMember srt:MaximumMember 2022-12-31 0001174891 us-gaap:ConvertibleNotesPayableMember srt:MaximumMember 2021-12-31 0001174891 us-gaap:ConvertibleNotesPayableMember 2021-12-31 0001174891 us-gaap:ConvertibleNotesPayableMember 2020-12-31 0001174891 us-gaap:ConvertibleNotesPayableMember 2022-01-01 2022-12-31 0001174891 us-gaap:ConvertibleNotesPayableMember 2021-01-01 2021-12-31 0001174891 us-gaap:ConvertibleNotesPayableMember 2022-12-31 0001174891 srt:MinimumMember 2022-12-31 0001174891 srt:MaximumMember 2022-12-31 0001174891 srt:MinimumMember 2021-12-31 0001174891 srt:MaximumMember 2021-12-31 0001174891 2022-01-02 2022-01-03 0001174891 2022-06-09 0001174891 BUUZ:SeriesAConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001174891 BUUZ:SeriesAConvertiblePreferredStockMember 2020-02-10 2020-02-11 0001174891 BUUZ:TerminationAgreementMember 2021-01-01 2021-01-31 0001174891 srt:ChiefExecutiveOfficerMember 2021-01-01 2021-03-31 0001174891 srt:ChiefFinancialOfficerMember srt:MinimumMember 2021-03-01 2021-03-31 0001174891 srt:ChiefFinancialOfficerMember srt:MaximumMember 2021-03-01 2021-03-31 0001174891 srt:ChiefFinancialOfficerMember 2021-01-01 2021-03-31 0001174891 2021-03-31 0001174891 BUUZ:ConsultantsMember 2021-10-01 2021-10-31 0001174891 BUUZ:ConsultantsMember 2021-08-16 2021-08-17 0001174891 srt:ChiefExecutiveOfficerMember 2021-08-16 2021-08-17 0001174891 BUUZ:ConsultantsMember 2022-01-01 2022-12-31 0001174891 BUUZ:ChiefTechnologyOfficerMember 2022-01-01 2022-12-31 0001174891 BUUZ:ConsultantsMember 2022-12-31 0001174891 BUUZ:NewConsultingAgreementMember BUUZ:ShareholderMember 2021-02-01 2021-02-28 0001174891 BUUZ:NewConsultingAgreementMember BUUZ:ShareholderMember 2021-02-28 0001174891 BUUZ:NewConsultingAgreementMember BUUZ:ShareholderMember 2020-01-01 2020-12-31 0001174891 BUUZ:NewConsultingAgreementMember BUUZ:ShareholderMember 2021-01-01 2021-12-31 0001174891 BUUZ:LetterofUnderstandingMember 2021-05-31 0001174891 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-05-01 2021-05-31 0001174891 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-05-01 2021-05-31 0001174891 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2021-05-01 2021-05-31 0001174891 2021-05-31 0001174891 2021-05-01 2021-05-31 0001174891 2021-09-15 0001174891 us-gaap:RestrictedStockMember 2022-12-31 0001174891 BUUZ:TwoThousandTwentyTwoAccretionExpenseMember 2022-01-01 2022-12-31 0001174891 BUUZ:ReversalTwoThousandTwentyOneAccretionExpenseMember 2022-01-01 2022-12-31 0001174891 BUUZ:ReversalTwoThousandTwentyTwoAccretionExpenseMember 2022-01-01 2022-12-31 0001174891 us-gaap:MeasurementInputExpectedTermMember 2022-12-31 0001174891 us-gaap:MeasurementInputExpectedTermMember 2021-12-31 0001174891 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2021-12-31 0001174891 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2021-12-31 0001174891 us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2021-12-31 0001174891 us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2021-12-31 0001174891 us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001174891 us-gaap:MeasurementInputSharePriceMember 2022-12-31 0001174891 us-gaap:MeasurementInputSharePriceMember srt:MinimumMember 2021-12-31 0001174891 us-gaap:MeasurementInputSharePriceMember srt:MaximumMember 2021-12-31 0001174891 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001174891 BUUZ:ConvertibleNotesMember 2021-01-01 2021-12-31 0001174891 BUUZ:RestrictedStockUnitsMember 2021-01-01 2021-12-31 0001174891 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001174891 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001174891 us-gaap:SubsequentEventMember 2023-03-30 0001174891 us-gaap:SubsequentEventMember 2023-03-29 2023-03-30 0001174891 us-gaap:SubsequentEventMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-03-30 0001174891 us-gaap:SubsequentEventMember BUUZ:EmploymentAgreementMember 2023-03-26 2023-03-27 0001174891 us-gaap:SubsequentEventMember srt:MaximumMember BUUZ:EmploymentAgreementMember 2023-03-26 2023-03-27 0001174891 us-gaap:RestrictedStockMember BUUZ:HyuncheolPeterKimMember us-gaap:SubsequentEventMember 2023-04-07 2023-04-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares iso4217:KRW xbrli:pure utr:acre

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

(Mark One)

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2022

 

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission file number 000-50331

 

CALETHOS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   98-0371433
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)

 

11753 Willard Avenue Tustin, California   92782
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (714) 352-5315

 

Securities registered under Section 12(b) of the Act:

 

None   N/A
Title of each class   Name of each exchange on which registered

 

Securities registered under Section 12(g) of the Act:

 

Common Stock, $0.001 par value

(Title of class)

 

Indicate by checkmark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No

 

Indicate by checkmark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No

 

Indicate by checkmark whether the registrant has (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

 

Indicate by checkmark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No

 

The aggregate market value of the voting and non-voting common stock, other than shares held by persons who may be deemed affiliates of the registrant, as of June 30, 2022, the last day of the registrant’s most recently completed second fiscal quarter, was $13,041,055, computed by reference to the closing sales price for the registrant’s common stock on June 30, 2022, as reported on The OTC Pink Market.

 

As of April 13, 2023 there were 14,495,621 outstanding shares of the registrant’s common stock, par value $0.001 per share.

 

 

 

 
 

 

CalEthos, Inc.

 

Annual Report on Form 10-K

For the Fiscal-Year Ended December 31, 2022

 

TABLE OF CONTENTS

  

    Page
     
Cautionary Note Regarding Forward Looking Statements ii
     
PART I    
     
Item 1. Business. 1
Item 1A. Risk Factors. 4
Item 1B. Unresolved Staff Comments 4
Item 2. Properties. 4
Item 3. Legal Proceedings. 4

Item 4.

Mine Safety Disclosures 4
     
PART II    
     
Item 5. Market for Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities Market Information. 5
Item 6. Selected Financial Data. 5
Item 7. Management’s Discussion and Analysis of Financial Condition and Result of Operations. 5
Item 7A. Quantitative and Qualitative Disclosures about Market Risk. 9
Item 8. Financial Statements and Supplementary Data. 9
Item 9. Changes In and Disagreements with Accountants On Accounting and Financial Disclosure. 10
Item 9A. Controls and Procedures. 10
Item 9B. Other Information. 11
     
PART III    
     
Item 10. Directors, Executive Officers, Promoters and Control Persons; Compliance With Section 16(A) of the Exchange Act. 12
Item 11. Executive Compensation 15
Item 12. Security Ownership of Certain Beneficial Owners and Management 20
Item 13. Certain Relationships and Related Transactions and Director Independence. 21
Item 14. Principal Accountant Fees and Services. 21
     
Part IV    
     
Item 15. Exhibits 22

 

i

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

The statements contained in this report with respect to our financial condition, results of operations and business that are not historical facts are “forward-looking statements”. Forward-looking statements can be identified by the use of forward-looking terminology, such as “anticipate”, “believe”, “expect”, “plan”, “intend”, “seek”, “estimate”, “project”, “could”, “may” or the negative thereof or other variations thereon, or by discussions of strategy that involve risks and uncertainties. Management wishes to caution the reader of the forward-looking statements that any such statements that are contained in this report reflect our current beliefs with respect to future events and involve known and unknown risks, uncertainties and other factors, including, but not limited to, economic, competitive, regulatory, technological, key employees, and general business factors affecting our operations, markets, growth, services, products and other factors, some of which are described in this report and some of which are discussed in our other filings with the Securities and Exchange Commission. These forward-looking statements are only estimates or predictions. No assurances can be given regarding the achievement of future results, as actual results may differ materially as a result of risks facing our company, and actual events may differ from the assumptions underlying the statements that have been made regarding anticipated events.

 

Important factors to consider in evaluating any forward-looking statements include:

 

our ability to finance and complete the design and construction of our proposed data center operation;

 

our ability to implement our business plan;

 

our ability to attract key personnel;

 

our ability to operate profitably;

 

our ability to efficiently and effectively finance our operations;

 

inability to achieve future sales levels or other operating results;

 

inability to raise additional financing for working capital;

 

inability to efficiently manage our operations;

 

the inability of management to effectively implement our strategies and business plans;

 

the unavailability of funds for capital expenditures and/or general working capital;

 

the fact that our accounting policies and methods are fundamental to how we report our financial condition and results of operations, and they may require management to make estimates about matters that are inherently uncertain;

 

deterioration in general or regional economic conditions;

 

changes in U.S. GAAP or in the legal, regulatory and legislative environments in the markets in which we operate;

 

adverse state or federal legislation or regulation that increases the costs of compliance, or adverse findings by a regulator with respect to existing operations;

 

These risk factors should be considered in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may issue. All written and oral forward looking statements made in connection with this report that are attributable to our company or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. Given these uncertainties, we caution investors not to unduly rely on our forward-looking statements. We do not undertake any obligation to review or confirm analysts’ expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this report or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

 

Notwithstanding the above, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), expressly state that the safe harbor for forward-looking statements does not apply to companies that issue penny stock. If, as now, we are considered to be an issuer of penny stock, the safe harbor for forward-looking statements may not apply to us at certain times.

 

Throughout this report, unless otherwise designated, the terms “we,” “us,” “our,” “the Company” and “our company” refer to CalEthos, Inc., a Nevada corporation. All amounts are in U.S. Dollars, unless otherwise indicated.

 

ii

 

 

Item 1. Business.

 

Corporate History and Recent Developments

 

We were incorporated pursuant to the laws of the State of Nevada on March 20, 2002 under the name Integrated Brand Solutions Inc., and on February 6, 2006, we changed our name to Upstream Biosciences Inc. From 2006 to December 2009, our company operated as a biotechnology company, and from 2010 until May 2013, our company had no operating business.

 

On May 24, 2013, our then majority stockholders sold their interests in our company to RealSource Acquisition Group, LLC, a Utah limited liability company, and Chesterfield Faring Ltd., a New York corporation, and on July 11, 2013, we changed our corporate name to RealSource Residential, Inc. Our initial business strategy in 2013 was to engage in various real estate related businesses. However, in 2016 we disposed of all of our real estate and other assets and continued operations as a public “shell” company.

 

On September 12, 2018, M1 Advisors, LLC, a Delaware limited liability company controlled by Michael Campbell, our current Chief Executive Officer and a director of our company (“M1 Advisors”), acquired a controlling interest in our company, and on December 20, 2018, we filed a Certificate of Amendment to our Articles of Incorporation with the Secretary of State of the State of Nevada to (i) change our corporate name from “RealSource Residential, Inc.” to “CalEthos, Inc.” and (ii) to increased our authorized shares of common stock from 4,000,000 shares to 100,000,000 shares. This amendment became effective immediately upon filing on December 20, 2018.

 

Our intention in acquiring the public company was to use it as a financing and acquisition vehicle for building a chain of large-format cannabis retail superstores to serve the needs of the rapidly-growing Southern California market. Over the subsequent two-year period, management assembled a number of acquisitions for retail licenses, store leases and display agreements with numerous cannabis brands as part of executing its business plan. However, once the COVID 19 pandemic lockdowns hit in early 2020 and Federal legalization of cannabis did not materialize after the 2020 elections, funding for cannabis-related businesses became less available and by the end of 2020, we concluded it would be better to pursue other business opportunities for our public company. After months of research, we determined there was a sizable opportunity to develop and manufacture high-performance computer systems for the cryptocurrency mining industry. In March 2021, we created a new business plan to develop a five nanometer ASIC chip and bitcoin mining computer system in South Korea utilizing Samsung technology and foundry capacity.

 

In August 2021, we hired an experienced chief technology officer from the chip industry to lead our product development and in September 2021, we closed a convertible debt financing of $3.5 million to fund the initial phase of product development. In connection with such capital raise, our board of directors determined that we are no longer a shell company, as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

 

On November 5, 2021, we incorporated AIQ System Inc. (“AIQ”), as a wholly-owned subsidiary in Seoul, Republic of Korea to support our product development efforts and to manage all of our computer chip and system development teams and activities. During the subsequent eight months ended June 30, 2022, the bitcoin market went into decline, and we decided to abandon our chip and system development efforts and to discontinue the operations of AIQ as of July 1, 2022.

 

During the development of our computer chip and system in Korea, we had also developed a plan to build a large-scale, clean-energy powered, containerized, immersion-cooled data center operation in Southern California to support the use of the systems we were developing for our company and for others. After the bitcoin market bottomed out in June 2022, we determined that we could develop a profitable business by offering data center colocation services to a larger customer base of enterprise companies.

 

As of July 1, 2022, we commenced our current operating plan to focus solely on the development and construction of clean-energy powered data centers that will utilize immersion and liquid-cooled and conventional energy efficient systems and will provide clean-energy-powered colocation services to large enterprise information technology (IT) customers.

 

To this end and to implement our going-forward plan, on March 28, 2023 we hired Joel Stone. a senior data center executive with 24 years of data center experience, as our President and Chief Operating Officer, and on March 30, 2023, we completed negotiations and signed an option agreement to acquire 80 acres of commercially-zoned land in Imperial County, California that is surrounded by nearby geothermal power plants and solar farms. We are currently in the process of negotiating with various power producers in the area to provide us with clean energy and with communication companies for access to their close-by long-haul and dark fiber networks.

 

With an experienced data center executive on board and the property under contract, we intend to complete a land use plan that will be submitted for approval to local authorities and to apply for permits to start construction. We expect, based on all related factors, that a submittable plan, which will include data center and infrastructure design, will take between four to six months to complete. Once submitted for approvals and permits, it is expected that it could take another three to six months or more before we receive the required permits for construction, and that the construction could take another six to eight months or more to complete depending on supply chain issues at the time for data center, electrical and communication connectivity components of the data center build. The foregoing time estimates are preliminary and are subject to change. In addition, there can be no assurance that our use plan will receive all required regulatory approvals or that we will be issued the required approvals or permits necessary to complete construction of the data center we intend to build.

 

As we move through the development process to build a clean-energy powered data center for enterprise IT customers, we will continue to refine and finalize the courses of action needed to implement our business plan and operations. As a result, management has not fully determined our actual short-term or long-term capital requirements, which management expects to be substantial.

 

1

 

 

Plan of Operations

 

As of the filing of this Report, we have hired Joel Stone as our President and Chief Operating Officer and signed an option agreement to acquire land for our planned large-scale, 100% geothermal/solar-powered, clean energy, data center operation.

 

To complete the initial phase of our planned data center, we are now negotiating agreements for clean energy and fiber connectivity. Over the next couple of months, we plan to finish negotiations with the local geothermal and solar power producers to deliver the clean energy we require to power our data center and to complete agreements with multiple communication providers for access to their close-by long-haul and dark fiber communication networks for data center connectivity.

 

We believe that the significant experience of our new President and Chief Operating Officer in both building and operating data centers and his industry relationships will be instrumental in helping us acquire the required third-party resources and assets and the management team and staff necessary to execute our business plan. In addition to acquiring the principal components (experienced personnel, land, clean energy, and fiber connectivity) for our data center plan, we are also in the process of developing partnerships with leading-edge containerized and modular designed immersion and liquid cooled data center system providers, whose systems we will offer for rent to our customers. We believe that, when construction of our data center is complete, the principal differentiators of our data center operation in the marketplace are expected to be – we are powered by 100% certified clean energy, and we provide leading-edge immersion and liquid cooled data center systems that will support the ever-increasing power and cooling needs of high-performance enterprise IT computer systems.

 

In the colocation segment of the data center industry, the customer typically leases the building/shell or data hall/suite level rather than the smaller scale of retail colocation (racks/cages/cabinets). Projects generally involve heavily-customized builds, although many operators in this segment are moving toward a mix of build-to-suit and turnkey offerings. Customers of colocation are typically hyperscale content and media/entertainment providers, scale-oriented cloud service providers, hosting and IT managed services providers, and telecommunications companies.

 

Currently, due to the ever-growing amounts of digital data being created on social media, and from internet streaming, gaming and overall internet use, and the need for digital data to be readily available for consumption on the internet, and because of the migration of software and computer applications to the cloud and their use, we believe there is a severe shortage of data center space in the global market. In some of the principal U.S. markets, there are wait times of up to a five-years for additional capacity. The need for new data center space is expected to continue growing at a high rate for the foreseeable future based on following recent industry reports:

 

Data Center Market - The market size is estimated to grow by $615.96 billion from 2021 to 2026, growing at a compound annual growth rate (CAGR) of 21.98% according to Technavio’s February 2022 market report.

 

Green Data Centers - The U.S. Green Data Center Market Size was valued at $13.79 billion in 2022 and is expected to reach $24.20 billion by 2028, growing at a CAGR of 9.82% during 2022 to 2028 according to Arizton’s March 2023 industry report.

 

Data Center as a Services (DCaaS) - The global data center as a service market size was valued at $52.7 billion in 2021 and is expected to expand at a CAGR of 26.2% from 2022 to 2030 according to Grand View Research’s January 2022 - Data Center As A Service Market Size & Growth Report.

 

We believe the Imperial County, California site we have optioned is a unique location in that it will provide us with a rare opportunity to acquire commercially-zoned land on which we can combine nearby direct clean geothermal/solar energy with a 24/7 data center operation.

 

We also believe 100% clean-energy-powered data centers are an important element in the ability of the U.S. to meet its carbon neutral climate goals and for enterprise IT companies to meet their shareholder and customer commitments to have an ESG-compliant, clean digital footprint before 2030.

 

We are developing our business model to compete in the colocation segment of the data center services industry, which is focused on providing the processing, networking, and storage of data. With the move to treat data as an asset, the data services market is expected to experience significant growth over the next decade. Industry automation and digital businesses are expanding, and these businesses are expected to require huge amounts of data for their businesses. North America is the most advanced region globally and data center services are in high demand.

 

2

 

 

Competition

 

The competition in the data center industry is primarily driven by the increasing presence of small and large-scale service providers globally. The key participants in the data center colocation market are Digital Realty Trust, Equinix, CenturyLink, CyrusOne and China Telecom Corporation Limited, among many others. Business ventures throughout the world are progressively competing for market share by providing services to arrange information, store data, and benefit from cloud services. This move, together with the increasing demand of businesses to store increasing amounts of media and other information, represents gigantic development in the market for cloud services.

 

The data center services market is segmented by service (infrastructure, cloud and hosting, networks, consulting, and virtualization), data-center (Tier 1, Tier 2, Tier 3, and Tier 4), end-user industry (BFSI, Healthcare, Retail, Manufacturing, and IT and Telecom), deployment mode (On-premise and Cloud), and geography.

 

As a new entrant into the data center marketplace, we will compete against larger, more established and better capitalized companies that today control the majority of market share. We believe our principal advantages will be our location, which provides us with access to an abundance of reasonably-priced local geothermal and solar energy to power a 24/7 data center operation, the various immersion and liquid cooled data center racking systems we will offer as a colocation service and our proximity to the Southern California market and the multitudes of companies utilizing high-performance computing that want close-by data center space.

 

Intellectual Property

 

Our intellectual property will consist of data center designs and systems for supporting containerized, immersion and liquid cooled data center systems that we will deploy for colocation services to enterprise IT customers. We intend to rely on a combination of patent, copyright, trademark and trade secret laws in the United States and other jurisdictions, as well as contractual protections, to protect our proprietary service offerings and data center management systems. However, as of the date of this Report, we do not have any patents or registered trademarks.

 

We cannot provide any assurance that our proprietary rights with respect to our data center designs, systems or services will be viable or have value in the future since the validity, enforceability and type of protection of proprietary rights in these industries are uncertain and continuingly evolving.

 

Despite our efforts to protect our proprietary rights, unauthorized parties may attempt to copy aspects of our design, systems and services or to obtain and use information that we regard as proprietary. Policing unauthorized use of our designs and services is difficult, and while we are unable to determine the extent to which piracy of our designs, systems and services will exist, intellectual piracy can be expected to be a persistent problem. In addition, the laws of some foreign countries do not protect proprietary rights to as great an extent as do the laws of the United States, and effective copyright, trademark, trade secret and patent protection may not be available in those jurisdictions. Our means of protecting our proprietary rights may not be adequate to protect us from the infringement or misappropriation of such rights by others.

 

Further, in recent years, there has been significant litigation in the United States involving patents and other intellectual property rights in the data center design, systems and service offerings and Internet-related data management industries. We can become subject to intellectual property infringement claims as the number of our competitors grows and our services overlap with competitive offerings. These claims, even if not meritorious, could be expensive to defend and could divert management’s attention from operating our business. If we become liable to third parties for infringing their intellectual property rights, we could be required to pay a substantial award of damages and to develop non-infringing design, systems and service offerings, obtain a license or cease providing the services that contain the infringing intellectual property. We may be unable to develop non-infringing data center design, systems and service offerings or obtain a license on commercially reasonable terms, if at all.

 

Employees

 

We currently have one employee, Joel Stone our President and Chief Operating Officer and our other officers and directors are serving our company as consultants and independent contractors.

 

3

 

 

Item 1A. Risk Factors.

 

We are a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

 

Item 1B. Unresolved Staff Comments.

 

None.

 

Item 2. Properties.

 

We do not own any real property. Our executive office is located at 11753 Willard Avenue, Tustin, California 92782, in the office of Michael Campbell, our Chief Executive Officer. We are not charged rent for the use of this space. We believe our existing facilities are sufficient for our current operations.

 

Item 3. Legal Proceedings.

 

We know of no material active or pending legal proceeding against our company, nor are we involved as a plaintiff in any material proceeding or pending litigation.

 

Item 4. Mine Safety Disclosures.

 

Not Applicable.

 

4

 

 

PART II

 

Item 5. Market For Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases Of Equity Securities.

 

Our common stock is listed for quotation on the OTC Pink Market under the trading symbol “BUUZ.”. Trading in our common stock in the over-the-counter market has been limited and the quotations set forth below are not necessarily indicative of actual market values. The following table sets forth, for the periods indicated, the high and low closing prices for each quarter within the last two fiscal years ended December 31, 2022 as reported by the quotation service operated by the OTC Markets Group. All quotations for the OTC Pink Market reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions.

 

Quarter Ended  High   Low 
December 31, 2022  $2.46   $1.06 
September 30, 2022   2.50    1.80 
June 30, 2022   2.80    1.70 
March 31, 2022   2.95    1.96 
December 31, 2021   4.25    1.97 
September 30, 2021   2.70    1.92 
June 30, 2021   3.30    0.40 
March 31, 2021   1.00    0.03 

 

On April 13, 2023, the closing price for our common stock on the OTC Pink Market as reported by the quotation service operated by the OTC Markets Group was $0.74.

 

Transfer Agent

 

Nevada Agency and Transfer Company is the registrar and transfer agent for our common shares. Their address is 50 West Liberty, Suite 880 Reno, Nevada, 89501 Telephone: 775-322-0626, Facsimile: 775-322-5623.

 

Holders of Our Common Stock

 

As of April 13, 2023, there were 56 registered holders of record of our common stock. As of such date, 14,495,621 shares of common stock were issued and outstanding. The number of our shareholders of record excludes any estimate by us of the number of beneficial owners of shares held in street name, the accuracy of which cannot be guaranteed.

 

Dividend Policy

 

We have not declared or paid any cash dividends since inception. Although there are no restrictions that limit our ability to pay dividends on our common shares, we do not intend to pay dividends for the foreseeable future.

 

Item 6. Selected Financial Data.

 

We are a “smaller reporting company” as defined by Regulation S-K and as such, are not required to provide the information contained in this item pursuant to Regulation S-K.

 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operation.

 

The following discussion should be read in conjunction with our audited financial statements and the related notes that appear elsewhere in this Annual report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward looking statements. Factors that could cause or contribute to such differences include those discussed below and elsewhere in this Annual Report.

 

Our audited financial statements are stated in United States dollars and are prepared in accordance with United States generally accepted accounting principles.

 

5

 

 

Plan of Operations

 

It is the intention of our board of directors for our company to pursue the development of the 80 acres of land in Imperial County, California that we recently put under an exclusive option agreement and develop it for a large-scale, 100% geothermal/solar-powered, certifiable clean energy, data center operation that will utilize immersion and liquid cooled and conventional energy efficient data center systems and provide colocation services to enterprise IT customers.

 

To implement our plan, we have optioned the land and hired an experienced data center builder and operator and we are now in the process of acquiring the other principal ingredients needed for our data center operation – clean energy and fiber connectivity. To this end, over the next couple of months, we plan to finish negotiations with local geothermal and solar power producers to deliver clean energy for our operation, and to complete agreements with multiple communication providers for access to their close-by long-haul and dark fiber communication networks for connectivity.

 

We are also in the process of developing partnerships with leading-edge containerized and modular immersion and liquid cooled data center system providers whose systems we will offer for rent to our customers. We believe that, when construction of our data center is complete, the principal differentiators of our data center operations in the marketplace are expected to be that we are powered by 100% certified clean energy and that we provide leading-edge immersion and liquid cooled energy-efficient data center systems that will support the ever-increasing power and cooling needs of high-performance enterprise IT computer systems.

 

It is anticipated that we will incur expenses in the implementation of the business plan described herein, and such expenses will require substantial financing to complete the development of the property for a data center operation and to achieve our goals. The failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development plans, any commercialization efforts or other operations. We may not be able to secure financing on favorable terms, or at all, to meet our future capital needs. In addition, even if we are able to obtain sufficient funding to commence our business operations, we may need to pursue additional financing in the future to make expenditures and/or investments to support the growth of our business and may require additional capital to pursue our business objectives and respond to new competitive pressures, pay extraordinary expenses or fund our growth, including through acquisitions. Additional funds, however, may not be available when we need them on terms that are acceptable to us, or at all. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, our ability to commence our proposed business operations, to continue to grow and support our business and to respond to business challenges could be significantly limited.

 

We currently have only limited capital with which to pay these anticipated expenses. To fund our business plan going forward, we intend to raise funds from investors by issuing common stock, preferred stock and/or debt securities.

 

Results of Operations for the years ended December 31, 2022 and 2021

 

The following summary should be read in conjunction with our audited financial statements for the years ended December 31, 2022 and 2021.

 

   For the years ended December 31, 
   2022   2021 
Revenues  $-   $- 
Operating Expenses          
Professional fees   667,000    1,033,000 
Restricted stock grants   (4,791,000)   5,062,000 
Impairment loss   154,000    - 
General and administrative   52,000    57,000 
Total operating (income) expenses   (3,918,000)   6,152,000 
Income (loss) from operations   3,918,000    (6,152,000)
Financing costs   (1,744,000)   (597,000)
Interest income   7,000    - 
Net income (loss)  $(2,181,000)  $(6,749,000)

 

6

 

 

Revenue

 

For the years ended December 31, 2022 and 2021, we had no revenues.

 

Operating Expenses

 

Professional fees

 

Our professional fees decreased from $1,033,000 in the year ended December 31, 2021 to $667,000 in the year ended December 31, 2022, which represented a decrease of approximately $366,000. The decrease was attributable to a reduction in the use of outside professional services.

 

Restricted stock grant expense (gain)

 

Our restricted stock grant expense (gain) decreased from an expense of $5,062,000 in the year ended December 31, 2021 to a gain of $(4,791,000) in the year ended December 31, 2022, which represented a decrease of $9,853,000 brought about by the cancellation of the stock grants made in 2021.

 

Impairment loss

 

Our impairment loss increased from nil in the year ended December 31, 2021 to $154,000 in the year ended December 31, 2022, which represented an increase of approximately $154,000 due to the impairment of intangibles and other assets as a result of the suspension of our South Korean subsidiary’s operations.

 

General and administrative expenses

 

Our general and administrative expenses decreased from $57,000 in the year ended December 31, 2021 to $51,000 in the year ended December 31, 2022, which represented a decrease of approximately $6,000.

 

Financing Costs

 

Our financing cost increased from $597,000 in the year ended December 31, 2021 to $1,744,000 in the year ended December 31, 2022, which represented an increase of $1,147,000. Financing costs increased due to the amortization of debt issuance costs.

 

Liquidity and Capital Resources

 

Our financial position as of December 31 in each of the years indicated was as follows:

 

Working Capital

 

   As of December 31, 
   2022   2021 
Current assets  $

2,071,000

   $

3,054,000

 
Current liabilities   (5,214,000)   (3,632,000)
Working deficit  $(3,143,000)  $(578,000)

 

Our working capital decreased from a $578,000 deficit as of December 31, 2021 to a deficit of $3,143,000 as of December 31, 2022 for a total change of $2,565,000. The decline in our working capital was due to (i) an increase in a book basis of our convertible promissory notes book basis increasing due to the amortization of debt issuance discounts and (ii) the decrease in our cash and cash equivalents.

 

Cash Flows

 

   For the years ended December 31, 
   2022   2021 
Net cash used in operating activities  $(820,000)  $(565,000)
Net cash used in investing activities   (105,000)   (38,000)
Net cash provided by financing activities   (50,000)   3,652,000 
Effect of exchange rate changes   (5,000)   (2,000)
Change in cash during the period   (980,000)   3,047,000 
Cash, beginning of period   3,047,000    - 
Cash, end of period  $2,067,000   $3,047,000 

 

7

 

 

Cash flows from operations

 

Cash used in operating activities decreased to approximately $255,000 in 2022 from approximately $382,000 in 2021, which was predominantly related to the reduction in our expenditures for filing fees, legal fees, transfer agent fees and consulting fees paid during the year.

 

Cash flow from investing

 

We made payments of $105,000 in 2022 and $38,000 in 2021 to an engineering and design firm for the design and development work for our planned ASIC chip development.

 

Cash flows from financing

 

We made payments of $50,000 to reduce notes payable in 2022 and 2021. Additionally, in 2021, we received $3,592,000 and $150,000 in proceeds from the issuance of convertible debentures and notes payable, respectively.

 

Going Concern

 

The audited financial statements included in this Report have been prepared on a going concern basis, which implies that our company will continue to realize its assets and discharge its liabilities and commitments in the normal course of business. We are presently in the development stage and, apart from our cash balances, have only limited assets. Our company has not generated revenues in the last two fiscal years, has never paid any dividends and is unlikely to pay dividends or generate earnings in the immediate or foreseeable future. The continuation of our company as a going concern is dependent upon: (i) continued financial support from our shareholders; (ii) the ability of our company to continue raising necessary debt or equity financing to achieve its operating objectives; and (iii) our ability to acquire assets and establish a business or merge or otherwise acquire business opportunities.

 

Our independent auditors included an explanatory paragraph in their report on our financial statements for the year ended December 31, 2022 regarding concerns about our ability to continue as a going concern. In addition, our financial statements contain further note disclosures in this regard. The implementation of our business plan is dependent upon our ability to continue raising sufficient new capital from equity or debt markets in order to fund our on-going operating losses and real estate acquisition activities. The issuance of additional equity securities could result in a significant dilution in the equity interests of our current stockholders.

 

Application of Critical Accounting Policies

 

The preparation of financial statements in conformity with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures of our company. Although these estimates are based on management’s knowledge of current events and actions that our company may undertake in the future, actual results may differ from such estimates.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary from the formation date. All material intercompany transactions and balances have been eliminated in consolidation.

 

8

 

 

Foreign Currency Translation

 

The financial statements of our foreign subsidiary, for which the functional currency is the local currency, are translated into U.S. dollars using the exchange rate at the consolidated balance sheet date for assets and liabilities and a weighted-average exchange rate during the year for revenue, expenses, gains and losses. Translation adjustments are recorded as other comprehensive income (loss) within shareholders’ equity (deficit). Gains or losses from foreign currency transactions are recognized in the consolidated statements of operations.

 

Debt and Debt Discounts

 

In accordance with ASC 470-20, Debt with Conversion and Other Options, we first allocate the cash proceeds of the notes between the notes and any warrants on a relative fair value basis. Proceeds are then allocated to the conversion feature.

 

We account for debt discounts originating in connection with conversion features that remain embedded in the related notes in accordance with ASC 470-20. These costs are classified on the balance sheet as a direct deduction from the debt liability. We amortize these costs over the term of our debt agreements as financing cost in the consolidated statement of operations and comprehensive loss.

 

Stock-Based Compensation

 

We account for our stock-based compensation under ASC 718, “Compensation – Stock Compensation” using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges it equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments.

 

We use the fair value method for equity instruments granted to non-employees and use the BSM model for measuring the fair value of options. The stock based fair value compensation is determined as of the date of the grant (measurement date) and is recognized over the vesting periods.

 

Recent Accounting Pronouncements

 

Our management reviewed all recently-issued accounting standard updates (“ASU’s”) not yet adopted by our company and does not believe the future adoptions of any such ASU’s may be expected to cause a material impact on the Company’s consolidated financial condition or the results of -our operations.

 

Off-Balance Sheet Arrangements

 

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial position, revenues and expenses, results of operations, liquidity, capital expenditures or capital resources that are material to stockholders.

 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk.

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide this information.

 

Item 8. Financial Statements and Supplementary Data.

 

Our financial statements and notes thereto and the reports of RBSM LLP, our independent registered public accounting firm, are set forth on pages F-1 through F-18 of this Report.

 

9

 

 

Item 9. Changes In and Disagreements With Accountants On Accounting and Financial Disclosure.

 

Not Applicable

 

Item 9A. Controls and Procedures.

 

Disclosure Controls and Procedures

 

As required by paragraph (b) of Rules 13a-15 or 15d-15 under the Exchange Act, our principal executive officer and principal financial officer evaluated our company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of the end of the period covered by this Annual Report on Form 10-K. Based on this evaluation, these officers concluded that as of the end of the period covered by this Annual Report on Form 10-K, these disclosure controls and procedures were not effective.

 

The conclusion that our disclosure controls and procedures were not effective was due to the presence of material weaknesses in internal control over financial reporting as identified below under the heading “Management’s Report on Internal Control Over Financial Reporting.” Management anticipates that such disclosure controls and procedures will not be effective until the material weaknesses are remediated.

 

Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdown can occur because of simple error or mistake.

 

Management’s Report on Internal Control Over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) for our company. Our internal control over financial reporting is designed to provide reasonable assurance, not absolute assurance, regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America. Internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles in the United States of America, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. In addition, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions and that the degree of compliance with the policies or procedures may deteriorate.

 

Our management, including our principal executive officer and principal financial officer, conducted an evaluation of the design and operation of our internal control over financial reporting as of December 31, 2022 based on the criteria set forth in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. This evaluation included review of the documentation of controls, evaluation of the design effectiveness of controls, testing of the operating effectiveness of controls and a conclusion on this evaluation. Based on this evaluation, our management concluded our internal control over financial reporting was not effective as at December 31, 2022 due to the following material weaknesses which are indicative of many small companies with small staff: (i) inadequate segregation of duties and effective risk assessment; (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines; (iii) inadequate security and restricted access to computer systems including insufficient disaster recovery plans; and

(iv) no written whistle-blower policy.

 

10

 

 

We plan to take steps to enhance and improve the design of our internal controls over financial reporting when our company has sufficient staff to allocate responsibilities. During the period covered by this Report, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we plan to implement the following changes once our financial resources will support the required staffing level: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; (ii) adopt sufficient written policies and procedures for accounting and financial reporting and a whistle-blower policy; and (iii) implement sufficient security and restricted access measures regarding our computer systems and implement a disaster recovery plan. The remediation efforts set out in (i) and (iii) are largely dependent upon our company securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely effected in a material manner.

 

This Report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. Our internal control over financial reporting was not subject to attestation by our independent registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit us to provide only management’s report in this Report.

 

Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake.

 

Changes In Internal Control Over Financial Reporting.

 

There were no changes in our internal control over financial reporting during the year ended December 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Item 9B. Other Information.

 

None.

 

11

 

 

PART III

 

Item 10. Directors, Executive Officers and Corporate Governance.

 

Directors and Executive Officers

 

Our directors and executive officers, their ages and their positions held with our company are as follows:

 

Name   Age   Position(s) Held with the Company
Michael Campbell   67   Chairman of the Board and Chief Executive Officer
Joel D, Stone  

53

  President and Chief Operations Officer
Dean S. Skupen   62   Chief Financial Officer
Steven Shum   53   Director
Sean Fontenot   40   Director

 

There are no arrangements between our directors and any other person pursuant to which our directors were nominated or elected for their positions. There are no family relationships among our directors or officers.

 

The following biographical information regarding our directors and executive officers.

 

Michael Campbell. Mr. Campbell became our Chief Executive Officer on September 12, 2018. For the past 20 years, Mr. Campbell has been the managing director of M1 Advisors LLC, a business advisory and consulting firm that has engineered, orchestrated and provided support and services to numerous private-to-public transitions, debt and equity financings and hyper- organic-growth and consolidation strategies in a wide range of industries. In addition, from December 2011 to February 2017, Mr. Campbell was the Chief Executive Officer and a director of NXChain, Inc., a publicly-traded start-up shell company in the cryptocurrency business that was a successor to AgriVest Americas Inc., a publicly-traded start-up shell company that sought to acquire cattle ranches in Brazil for conversion to soybean farms. Mr. Campbell spent the first 20 years of his career in the high-tech industry creating and operating various companies that included a computer retailing operation, data-storage peripheral company with three computer disk-drive manufacturing companies through joint ventures with the Russian, Chinese and Spanish governments, a specialized call-center company for telco broadband provisioning and an online broadband services ordering and order aggregation company with the Regional Bell Operating Companies.

 

Joel D. Stone. Mr. Stone became our President and Chief Operating Officer on March 28, 2023. Mr. Stone has 24 years of broad-based operations, engineering, construction, integration, transformation, and technical leadership in the data center infrastructure, sourcing, and telecommunications industries. Prior to joining our company, Mr. Stone led the Global Site Sourcing teams for Meta Platforms that supported the data center infrastructure teams from 2019 to 2022. Prior to 2019, Mr. Stone served as Senior Vice President and Chief Operating Officer of RagingWire Data Centers, an NTT communications company, where he was responsible for critical facilities engineering, design, construction, and data center operations from 2016-2018. Prior to RagingWire, Mr. Stone served as Vice President of Global Data Center Operations for CenturyLink Communications, responsible for 58 data centers around the world and a global team of 600+ people from 2011to 2016. Prior to CenturyLink, Mr. Stone was Group Operations Director at Global Switch in London, one of the largest wholesale data center providers in Europe and Asia. Mr. Stone spent nine years at Microsoft where he was responsible for all North America data center operations.  Earlier in his career, Mr. Stone built-out two state-of-the-art data centers in Silicon Valley (Santa Clara) for Cable & Wireless Communications.

 

Dean S. Skupen. Mr. Skupen became our Chief Financial Officer on September 12, 2018. Mr. Skupen is a business advisor who has provided various financial accounting services to, or acted as the Interim Chief Financial Officer for, a number of public companies since 2010. Prior to that, he was a Partner at Stonefield Josephson, Inc. (now Marcum, LLP), an accounting firm with five offices throughout California where he provided auditing and consulting services to public companies and to privately-held entrepreneurial companies transitioning to public ownership in diverse industries. Mr. Skupen graduated from the University of Southern California with a Bachelor of Science degree in Accounting. In addition, he is licensed as a Certified Public Accountant in the State of California.

 

12

 

 

Steven M. Shum. Mr. Shum has been Chief Executive Officer of INVO Bioscience (NASDAQ: INVO) since October 2019 and a member of the board of directors of INVO Bioscience since October 2017. Prior to INVO Bioscience, Mr. Shun served as Chief Financial Officer of Eastside Distilling (NASDAQ: EAST) from October 2015 to November 2019. Prior to joining Eastside, Mr. Shum was an employee and a member of the board of directors of XZERES Corp. (OTCQB:XPWR), a global renewable energy company, from October 2008 until April 2015, where he served in various officer roles, including Chief Operating Officer from September 2014 until April 2015, Chief Financial Officer, Principal Accounting Officer and Secretary from April 2010 until September 2014 (under former name, Cascade Wind Corp) and Chief Executive Officer and President from October 2008 to August 2010. Mr. Shum also serves as the managing principal of Core Fund Management, LP and the Fund Manager of Core Fund, LP. He was a founder of Revere Data LLC (now part of Factset Research Systems, Inc.) and served as its Executive Vice President for four years, heading up the product development efforts and contributing to operations, business development, and sales. He spent six years as an investment research analyst and portfolio manager of D.N.B. Capital Management, Inc. His previous employers include Red Chip Review and Laughlin Group of Companies. He earned a B.S. in Finance and a B.S. in General Management from Portland State University in 1992.

 

Sean Fontenot. Mr. Fontenot has spent 20 years as a self-employed IT and network specialist and in 2017 became an executive producer of independent films. Mr. Fontenot is a technology enthusiast and film producer that manages a 5013c foundation dedicated to (i) educating the public on the history of video, arcade, and computer gaming - including the technical aspects and the impact of games on society; (ii) fostering public interest in software development and gaming hardware to enable technological growth and inspire the next generation of developers, and (iii) developing public space for action sports’ recreation - including mentoring youths and building programs designed to help bridge the gender gap in various action sports categories as well as underserved community members.

 

Our chief executive officer, Mr. Campbell, currently serves as a consultant to our company. Mr. Stone, our President and Chief Operating Officer, is currently our only employee and devotes the majority of his time to advancing the company’s mission and executing our business plan. Management intends to spend as much time as is necessary to exercise its fiduciary duties as officers and directors of our company.

 

Involvement in Certain Legal Proceedings

 

None of our directors and executive officers have been involved in any of the following events during the past ten years:

 

1.any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time;

 

2.any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offences);

 

3.being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities;

 

4.being found by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, where the judgment has not been reversed, suspended, or vacated;

 

5.being the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of (i) any federal or state securities or commodities law or regulation; (ii) any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease- and-desist order, or removal or prohibition order; or (iii) any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or being the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Securities Exchange Act of 1934), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

 

13

 

 

Director Independence

 

Our board of directors has reviewed the composition of our board of directors and the independence of each director. Based upon information requested from and provided by each director concerning his background, employment and affiliations, including family relationships, our board of directors has determined that each of Steven Shum and Sean Fontenot is an “independent director” as defined under Rule 5605(a)(2) of the Nasdaq Marketplace Rules. In making such determinations, our board of directors considered the relationships that each such non-employee director has with our company and all other facts and circumstances our board of directors deemed relevant in determining independence, including the beneficial ownership of our capital stock by each non-employee director.

 

Board Committees

 

We do not have a standing Audit Committee. We do not believe that the lack of an Audit Committee has had or will have any adverse effect on our financial statements, based upon current operations; however, our board of directors will consider establishing an Audit Committee of independent directors as the number of directors increases. Until such time, our board of directors will perform the duties of an Audit Committee including delegating an auditor firm and interacting with them.

 

We do not have a standing Compensation Committee. Presently, our executive officers, who constitute our only employees, do not take salary or other benefits from our company. As we continue to develop our data center and commence selling colocation services, we expect to increase the size of our board to include independent directors who will approve the compensation arrangements with our executive officers.

 

We also do not have a Nominating Committee as we have not adopted any procedures by which security holders may recommend nominees to our board of directors.

 

Code of Ethics

 

Effective March 28, 2022, our Board of Directors adopted an amended Code of Business Conduct and Ethics that applies to, among other persons, members of our board of directors, our company’s officers, contractors, consultants and advisors. We will provide a copy of the Code of Business Conduct and Ethics to any person without charge, upon request. Requests can be sent to our company at the address on the cover of this Annual Report.

 

Section 16(a) Beneficial Ownership Compliance

 

Section 16(a) of the Securities Exchange Act requires our executive officers and directors, and persons who own more than 10% of our common stock, to file reports regarding ownership of, and transactions in, our securities with the Securities and Exchange Commission and to provide us with copies of those filings. Based solely on our review of the copies of such forms received by us, or written representations from certain reporting persons, and without conducting any independent investigation of our own we believe that during the fiscal year ended December 31, 2022, all filing requirements applicable to our officers, directors and greater than 10% percent beneficial owners were complied with.

 

14

 

 

Item 11. Executive Compensation.

 

The following table sets forth all compensation awarded to, earned by or paid to the executive officers of our company during the years ended December 31, 2022 and 2021. No compensation was paid to any other executive officer of our company during such periods.

 

SUMMARY COMPENSATION TABLE

 

Name and Principal Position  Fiscal Year   Salary ($)   Bonus ($)   Stock Awards ($)   Option Awards ($)   Non-Equity Incentive Plan Compensation ($)   Nonqualified Deferred Compensation Earnings
($)
   All Other Compensation ($)   Total ($) 
Michael Campbell   2022    -    -   $-    -    -    -   $200,000   $200,000(2)
Chief Executive officer (1)   2021    -    -    2,895,000(1)   -    -    -    200,064(2)   3,095,064(2)
                                              
Hyuncheol Peter Kim   2022    -    -    -    -    -    -    

140,000

    

140,000

(3)
Chief Technology Officer   2021    -    -    

19,300,000

(1)   -    -    -    

66,664

(3)   

19,366,664

(3)
                                              
Dean S. Skupen   2022    -    -    -    -    -    -    60,000(4)   60,000(4)
Chief Financial
Officer
   2021    -    -   $75,000    -    -    -   $30,000   $105,000 

 

 

  (1) Represents a restricted stock share award that was to vest upon the completion of the multiple phases of our previous chip development business plan. In August 2022, we abandoned the chip development business plan and Mr, Campbell and Mr. Kim’s consulting agreements were terminated and the associated restricted stock share awards were cancelled.
     
  (2) Represents amounts earned by Mr. Campbell under his consulting agreement.
     
 

(3)

Represents amounts earned by Mr. Kim under his consulting agreement. Mr. Kim terminated his consulting engagement in August of 2022.
     
  (4) Represents amounts earned by Mr. Skupen under his consulting agreement.

 

Consulting Agreements

 

 

Between August 17, 2021 and August 31, 2022, we had consulting agreements in place with M1 Advisors LLC, a limited liability company controlled by Michael Campbell, our Chief Executive Officer (“M1 Advisors”), and Hyuncheol Kim, pursuant to which M1 Advisors agreed to continue to provide consulting services to our company and to cause Mr. Campbell to serve as our Chief Executive Officer, and Mr. Kim agreed to provide consulting services and to serve as our Chief Technology Officer. In addition, pursuant to such consulting agreements, M1 Advisors was granted a restricted stock award of 1,500,000 shares of common stock and Mr. Kim was granted a restricted stock award of 10,000,000 shares of common stock. In August 2022, we terminated the chip development business plan and terminated the consulting agreements with M1 Advisors and Mr. Kim and canceled related restricted stock awards.

 

We are currently structuring a new consulting agreement with M1 Advisors to continue providing consulting services and for Mr. Campbell to continue serving as our Chief Executive Officer.

 

15

 

 

On October 20, 2018, we entered into a consulting agreement with DSS Consulting Corporation, a corporation controlled by Dean Skupen, our Chief Financial Officer (“DSS Consulting”), pursuant to which DSS Consulting agreed to continue to provide consulting services to our company and to cause Mr. Skupen to serve as our Chief Financial Officer. The agreement with DSS Consulting will continue until terminated by either party. Pursuant to such agreement, DSS Consulting was issued 250,000 shares of common stock in March 2019 and DSS Consulting will be paid a monthly consulting fee in the amount of $5,000.

 

Each of our consulting agreements contains customary confidentiality restrictions and work-product provisions, as well as customary non-competition covenants and non-solicitation covenants with respect to our employees, consultants and customers.

 

Equity Compensation Plan Information

 

The following table provides information as of December 31, 2022, regarding our compensation plans under which equity securities are authorized for issuance:

 

Plan category  Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights   Weighted- Average Exercise Price of Outstanding Options, Warrants and Rights  

Number of Securities Remaining Available for Future Issuance

Under Equity Compensation Plans (Excluding Securities Reflected

in Column (a))

 
   (a)   (b)   (c) 
2021 Equity compensation plan approved by security holders           2,500,000 
Equity compensation plans not approved by security holders            
Total   

   $ —    2,500,000 

 

2021 Equity Incentive Plan

 

On October 4, 2021, we adopted our 2021 Equity Incentive Plan (the “Equity Plan”) to provide an additional means to attract, motivate, retain and reward selected employees and other eligible persons. Our stockholders also approved the Equity Plan on October 4, 2021. Employees, officers, directors and consultants that provide services to us or one of our subsidiaries were eligible to receive awards under the Equity Plan. Awards under the Equity Plan are issuable in the form of incentive or nonqualified stock options, stock appreciation rights, stock bonuses, restricted stock, stock units and other forms of awards including cash awards.

 

As of December 31, 2022, no equity grants had been made under the Equity Plan, and 2,500,000 shares authorized under the Equity Plan remained available for award purposes.

 

Purpose. The purpose of the Equity Plan is to further and promote the interests of our company and its stockholders by enabling us to attract, retain and motivate employees, directors and consultants, or those who will become employees, directors or consultants, and to align the interests of those individuals with the interests of our stockholders.

 

Administration. The Equity Plan will be administered by an independent compensation committee appointed by the Board (the “Compensation Committee”), which will have general administrative authority for the Equity Plan. In the event that the Board has not appointed the Compensation Committee, then the Board shall have all the powers of the Compensation Committee under the Equity Plan. The Compensation Committee may delegate certain limited authority to one or more of our senior executive officers to grant awards to employees who are not subject to Section 16 of the Exchange Act. Additionally, the Compensation Committee may designate persons other than members of the Compensation Committee to carry out the day-to-day ministerial administration of the Equity Plan (other than with regard to the selection for participation in the Equity Plan and/or the granting of any awards to participants) under such conditions and limitations as prescribed by the Compensation Committee (the appropriate acting body, be it the Compensation Committee, the Board, or an executive officer within his or her delegated authority, is referred to herein as the “Administrator”). The Administrator’s determinations under the Equity Plan need not be uniform and may be made selectively among the Equity Plan’s participants, whether or not such participants are similarly situated.

 

16

 

 

The Administrator has broad authority under the Equity Plan with respect to award grants including, without limitation, the authority to:

 

  select the Equity Plan’s participants;
     
  make awards in such amounts and form as the Administrator shall determine;
     
  impose such restrictions, terms and conditions upon such awards as the Administrator shall deem appropriate; and
     
  correct any technical defect(s) or technical omission(s), or reconciling any technical inconsistency(ies), in the Equity Plan and/or any award agreement.

 

Eligibility. Persons eligible to receive awards under the Equity Plan include employees, directors and consultants, or those who will become employees, directors or consultants, of our company and/or its subsidiaries. Notwithstanding the above, incentive stock options may only be granted under the Equity Plan to our employees.

 

Authorized Shares. The maximum number of shares of common stock that may be initially issued or transferred pursuant to awards under the Equity Plan shall not exceed 2,500,000 shares, all of which may be issued as any type of award permitted under the Equity Plan, including, but not limited to, incentive stock options.

 

Types of Awards. The Equity Plan authorizes awards of stock options and restricted shares of common stock.

 

A stock option is the right to purchase shares of common stock at a future date at a specified price per share (the “Exercise Price”). The per share Exercise Price of an option generally may not be less than the fair market value of a share of common stock on the date of grant. The maximum term of an option is ten years from the date of grant. An option may either be an incentive stock option or a nonqualified stock option. Incentive stock option benefits are taxed differently from nonqualified stock options, as described under “Federal Income Tax Consequences of Awards Under the Plan” below. Incentive stock options are also subject to more restrictive terms and are limited in amount by the U.S. Internal Revenue Code (the “Code”) and the Equity Plan. Incentive stock options may only be granted to employees of our company or a subsidiary.

 

Restricted shares are shares of common stock granted to Equity Plan participants, subject to such restrictions, terms and conditions, if any, as the Administrator deems appropriate, including, without limitation, (a) restrictions on the sale, assignment, transfer, hypothecation or other disposition of such shares, (b) the requirement that the participant deposit such shares with our company while such shares are subject to such restrictions, and (c) the requirement that such shares be forfeited upon termination of employment or service with our company for any reason or for specified reasons within a specified period of time or for other reasons (including, without limitation, the failure to achieve designated performance goals). Upon satisfaction or lapse of the applicable restrictions, terms, and conditions, subject to applicable securities laws, the participant will receive shares of common stock in exchange for such restricted shares.

 

Dividend Equivalents; Deferrals. The Administrator may provide for the deferred payment of awards and may determine the other terms applicable to deferrals. The Administrator may provide that awards under the Equity Plan earn dividends or dividend equivalents based on the amount of dividends paid on outstanding shares of common stock.

 

Assumption and Termination of Awards. Generally, and subject to limited exceptions set forth in the Equity Plan, if we dissolve or undergo certain corporate transactions such as a merger, business combination, or other reorganization, or a sale of substantially all of its assets, all awards then-outstanding under the Equity Plan will become fully vested or paid, as applicable, and will terminate or be terminated in such circumstances, unless the Administrator provides for the assumption, substitution or other continuation of the award. The Administrator also has the discretion to establish other change in control provisions with respect to awards granted under the Equity Plan. For example, the Administrator could provide for the acceleration of vesting or payment of an award in connection with a corporate event that is not described above and provide that any such acceleration shall be automatic upon the occurrence of any such event.

 

17

 

 

Clawback. We may cancel any award under the Equity Plan, require reimbursement from a participant, and effect any other right of recoupment of equity or other compensation provided under the Equity Plan in accordance with any clawback policies adopted by us.

 

Transfer Restrictions. Subject to certain exceptions contained in the Equity Plan, awards under the Equity Plan generally are not transferable by the recipient other than by will or the laws of descent and distribution and are generally exercisable, during the recipient’s lifetime, only by the recipient. Any amounts payable or shares issuable pursuant to an award generally will be paid only to the recipient or the recipient’s beneficiary or representative. The Administrator has discretion, however, to establish written conditions and procedures for the transfer of awards to other persons or entities, provided that such transfers comply with applicable federal and state securities laws.

 

Adjustments. As is customary in incentive plans of this nature, each share limit and the number and kind of shares available under the Equity Plan and any outstanding awards, as well as the exercise or purchase prices of awards, and performance targets under certain types of performance-based awards, are subject to adjustment in the event of certain reorganizations, mergers, combinations, recapitalizations, stock splits, stock dividends, or other similar events that change the number or kind of shares outstanding, and extraordinary dividends or distributions of property to the stockholders.

 

No Limit on Other Authority. The Equity Plan does not limit the authority of the Board or any committee to grant awards or authorize any other compensation, with or without reference to the our common stock, under any other plan or authority.

 

Termination of or Changes to the Equity Plan. The Board may amend or terminate the Equity Plan at any time and in any manner. Stockholder approval for an amendment will be required only to the extent then required by applicable law or any applicable listing agency or required under Sections 422 or 424 of the Code to preserve the intended tax consequences of the plan. For example, stockholder approval will be required for any amendment that proposes to increase the maximum number of shares that may be delivered with respect to awards granted under the Equity Plan (adjustments as a result of stock splits or similar events will not, however, be considered an amendment requiring stockholder approval). Unless terminated earlier by the Board, the authority to grant new awards under the Equity Plan will terminate on October 4, 2031. Outstanding awards, as well as the Administrator’s authority with respect thereto, generally will continue following the expiration or termination of the Equity Plan. Generally speaking, outstanding awards may be amended by the Administrator (except for a repricing), but the consent of the award holder is required if the amendment (or any Equity Plan amendment) materially and adversely affects the holder.

 

Federal Income Tax Consequences of Awards under the Plan.

 

The U.S. federal income tax consequences of the Equity Plan under current federal law, which is subject to change, are summarized in the following discussion of the general tax principles applicable to the Equity Plan. This summary is not intended to be exhaustive and, among other considerations, does not describe the deferred compensation provisions of Section 409A of the Code to the extent an award is subject to and does not satisfy those rules, nor does it describe certain elections under the Code (such as an election under Code Section 83(b)), alternative minimum tax, or state, local, or international tax consequences.

 

With respect to nonqualified stock options, we are generally entitled to deduct, and the participant recognizes taxable income in an amount equal to the difference between the option exercise price and the fair market value of the shares at the time of exercise. With respect to incentive stock options, we are generally not entitled to a deduction nor does the participant recognize income at the time of exercise, although the participant may be subject to the U.S. federal alternative minimum tax. Upon a disposition of shares acquired by exercise of an incentive stock option before the end of the applicable incentive stock option holding periods, the participant generally must recognize ordinary income equal to the lesser of (i) the fair market value of the shares at the date of exercise minus the exercise price or (ii) the amount realized upon the disposition of the incentive stock option shares minus the exercise price. Otherwise, a participant’s disposition of shares acquired upon the exercise of an option (including an incentive stock option for which the incentive stock option holding periods are met) generally will result in only capital gain or loss.

 

18

 

 

With respect to restricted shares, we are generally entitled to deduct and the participant recognizes taxable income in an amount equal to the excess of the fair market value over the price paid (if any) only at the time the restrictions lapse (unless the recipient elects to accelerate recognition as of the date of grant).

 

If an award is accelerated under the Equity Plan in connection with a “change in control” (as this term is used under the Code), we may not be permitted to deduct the portion of the compensation attributable to the acceleration (“parachute payments”) if it exceeds certain threshold limits under the Code (and certain related excise taxes may be triggered).

 

We have the authority and the right to deduct or withhold, or require a participant to remit to us, an amount sufficient to satisfy any income, payroll, and other taxes (including, without limitation, pursuant to the Federal Insurance Contributions Act and the Federal Unemployment Tax Act) to the extent required by law to be withheld with respect to any taxable event concerning a participant arising as a result of an award under the Equity Plan.

 

Outstanding Equity Awards At Annual Period End

 

As of December 31, 2022, there were no awards outstanding.

 

Aggregated Option Exercises

 

There were no options exercised by any officer or director of our company during the year ended December 31, 2022.

 

Directors Compensation

 

No director compensation was paid during the years ended December 31, 2022 and 2021 in the form of cash expenses, stock awards, option awards, non-equity incentive plan compensation, pension value and nonqualified deferred compensation earnings or any other type of compensation. We do not currently pay any cash fees to our directors, nor do we pay directors’ expenses in attending board meetings.

 

Employment Agreements

 

We are not presently a party to any employment agreements.

 

19

 

 

Pension and Retirement Plans

 

Currently, we do not offer any annuity, pension or retirement benefits to be paid to any of our officers, directors or employees, in the event of retirement.

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

 

The following table sets forth, as of April 13, 2023, the names, addresses and number of shares of common stock beneficially owned by (i) all persons known to our management to be beneficial owners of more than 5% of the outstanding shares of our common stock, (ii) each director of our company, (iii) each named Executive Officer and (iv) all executive officers and directors of our company as a group (except as indicated, each beneficial owner listed exercises sole voting power and sole dispositive power over the shares beneficially owned):

 

Name and Address of Beneficial Owner 

Amount and Nature of Beneficial

Ownership

   Percent of Class(1) 
M1 Advisors LLC(2)   8,954,199    61.77%
(Michael Campbell)(2)   8,954,199    

61.77

%
Joel Stone   -    0.00%
Dean Skupen(3)   325,000    2.24%
Steven Shum   4,655    0.03%
Sean Fontenot(4)   4,620,000    24.17%
All executive officers and directors as a group          
(5 persons)   13,903,854    95.92%
5% Stockholders:          
David Unsworth (5)   1,435,000    9.90%
The Cooper Family Living Trust Dtd 7/20/98 (6)   1,079,000    7.44%

 

(1) As of April 13, 2023, there were 14,495,621 shares of common stock outstanding. Except as indicated in the footnotes to this table, we believe that all persons named in the table have sole voting and investment power with respect to all common stock shown as beneficially owned by them. In accordance with the rules of the Securities and Exchange Commission (the “Commission”), a person or entity is deemed to be the beneficial owner of common stock that can be acquired by such person or entity within sixty (60) days upon the exercise of options or warrants or other rights to acquire common stock. Each beneficial owner’s percentage ownership is determined by assuming that options and warrants that are held by such person (but not those held by any other person) and which are exercisable within sixty (60) days have been exercised. The inclusion herein of such shares listed as beneficially owned does not constitute an admission of beneficial ownership.
(2) Represents shares of common stock owned of record by M1 Advisors LLC, a company controlled by Michael Campbell. The address of Michael Campbell and M1 Advisors LLC is 11753 Willard Avenue, Tustin, CA 92782. Mr. Campbell has sole voting and investment power over the shares held by M1 Advisors LLC.
(3) Represents shares of common stock owned of record by DSS Consulting Corporation, a company controlled by Dean Skupen. DSS Consulting Corporation’s address is 2945 Townsgate Road, Suite 200, West Lake Village CA 91361. Mr. Skupen has sole voting and investment power over the shares held by DSS Consulting Corporation.
(4) Represents 3,080,000 shares of common stock issuable upon the conversion of a convertible note, and 1,540,000 shares of common stock issuable upon the exercise of warrants, owned of record by Nanosha Investments, LLC, a company controlled by Sean Fontenot. The address of Nanosha Investments, LLC is 1202 Walnut Avenue, Long Beach, CA 90813. Mr. Fontenot has sole voting and investment power over the securities held by Nanosha Investments, LLC.
(5) David Unsworth’s address is 246 Bayview Avenue, Belvedere CA 94920.
(6) Piers and Sally Cooper are the trustees of The Cooper Family Living Trust Dated 7/20/98. The address of the trust is 452 Lakeview Way, Emerald Hills, CA 94062.

 

20

 

 

Item 13. Certain Relationships and Related Transactions, and Director Independence.

 

To the best of our knowledge, except as set forth below, during the last fiscal year, there were no material transactions, or series of similar transactions, or any currently proposed transactions, or series of similar transactions, to which we were or are to be a party, in which the amount involved exceeds $120,000 or one percent of the average total assets at year end for each of the last two fiscal years, and in which any director or executive officer, or any security holder who is known by us to own of record or beneficially more than 5% of any class of our common stock, or any member of the immediate family of any of the foregoing persons, has an interest.

 

Item 14. Principal Accountant Fees And Services.

 

Audit Fees

 

The aggregate fees billed for professional services rendered by RBSM LLP, our principal accountants for the years ended December 31, 2022 and 2021, for the audit of financial statements, quarterly reviews of our interim financial statements and services normally provided by the independent accountant in connection with statutory and regulatory filings or engagements for these periods were as follows:

 

   For the Years ended December 31, 
   2022   2021 
Audit Fees and Audit Related Fees  $28,000   $50,000 
Tax Fees        
All Other Fees        
Total  $28,000   $50,000 

 

In the above table, “audit fees” are fees billed by our company’s external auditor for services provided in auditing our company’s financial statements for the periods indicated above. “Audit-related fees” are fees not included in audit fees that are billed by the auditor for assurance and related services, including quarterly reviews, that are reasonably related to the performance of the audit of our company’s financial statements. “Tax fees” are fees billed by the auditor for professional services rendered for tax compliance, tax advice and tax planning. “All other fees” are fees billed by the auditor for products and services not included in the foregoing categories.

 

Our board of directors pre-approves all services provided by our independent auditors. All of the above services and fees were reviewed and approved by our board of directors either before or after the respective services were rendered.

 

21

 

 

PART IV

 

Item.15. Exhibits, Financial Statement Schedules.

 

Exhibit    
Number   Description
     
3.1   Articles of Incorporation (incorporated by reference to Exhibit 3.1 to our Registration Statement on Form SB-2 filed on July 5, 2002).
     
3.2   Certificate of Change filed with the Nevada Secretary of State on December 20, 2005 (incorporated by reference to Exhibit 99.1 to our Current Report on Form 8-K filed on December 29, 2005).
     
3.3   Articles of Merger filed with the Nevada Secretary of State on February 6, 2006 (incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K filed on February 9, 2006).
     
3.4   Certificate of Amendment filed with the Nevada Secretary of State on November 27, 2006 (incorporated by reference from Exhibit 99.1 to Current Report on Form 8-K filed on November 30, 2006).
     
3.5   Articles of Merger filed with the Nevada Secretary of State on February 6, 2006 (incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on February 9, 2006).
     
3.6   Articles of Merger filed with the Nevada Secretary of State on July 15, 2013 (incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on July 19, 2013).
     
3.7   Certificate of Change filed with the Nevada Secretary of State on August 28, 2018 (incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on August 29, 2018).
     
3.8   Certificate of Designation of Series A Preferred Stock filed with the Nevada Secretary of State on September 12, 2018 (incorporated by reference to Exhibit 3.2 to our Current Report on Form 8-K filed on September 14, 2018).
     
3.9   Amendment to Certificate of Designation After Issuance of Class or Series filed with the Nevada Secretary of State on October 29, 2018 (incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K filed on October 29, 2018).
     
3.10   Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to our Current Report on Form 8-K filed on July 19, 2013).
     
4.10   Description of Registered Securities
     
10.1   2021 Equity Incentive Plan (incorporated by reference to Exhibit Annex A to our Schedule 14C Information Statement filed on October 21, 2021).
     
10.2   Form of OID Convertible Promissory Note due February 28, 2021 (incorporated by reference to Exhibit 10.4 to our Annual Report on Form 10-K filed on March 30, 2021).
     
10.3   Form of Series A Warrant (incorporated by reference to Exhibit 10.5 to our Annual Report on Form 10-K filed on March 30, 2021).
     
10.4   Form of OID Promissory Note dated September 15, 2021 (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed on September 21, 2021).
     
10.5   Form of Series A Warrant dated September 15, 2021 (incorporated by reference to Exhibit 4.2 to our Current Report on Form 8-K filed on September 21, 2021).

 

22

 

 

Exhibit    
Number   Description
10.6   Warrant dated September 15, 2021 of CalEthos to Mireya Lange (incorporated by reference to Exhibit 4.5 to our Current Report on Form 8-K filed on September 21, 2021).
     
10.7   Registration Rights Agreement dated as of September 15, 2021 between CalEthos Inc. and Nonosha Investments LLC (incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K filed on September 21, 2021).
     
10.8   Consulting Agreement dated as of October 10, 2018 between CalEthos Inc. and DSS Consulting Corporation.
     
14   Code of Conduct and Ethics of CalEthos Inc.
     
31.1   Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.***
     
31.2   Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.***
     
32.1   Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.***
     
101.ins**   Inline XBRL Instance Document
     
101.xsd**   Inline XBRL Taxonomy Extension Schema Document
     
101.cal**   Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
101.def**   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
101.lab**   Inline XBRL Taxonomy Extension Label Linkbase Document
     
101.pre**   Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)
     
**   Furnished. Not filed. Not incorporated by reference. Not subject to liability.
***   A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

23

 

 

SIGNATURES

 

Pursuant to the requirements of the Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on the 17 day of April 2023.

 

  CalEthos, Inc.
     
  By: /s/ Michael Campbell
  Name: Michael Campbell
  Title: Chief Executive Officer
    (Principal Executive Officer)

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Signature   Title   Date
         
/s/ Michael Campbell   Chief Executive Officer and Director   Date: April 17, 2023
Michael Campbell   (Principal Executive Officer)    
         
/s/ Dean S. Skupen   Chief Financial Officer   Date: April 17, 2023
Dean S. Skupen   (Principal Accounting Officer)    
         
/s/ Sean Fontenot   Director   Date: April 17, 2023
Sean Fontenot   (Director)    
         
/s/ Steven Shum   Director   Date: April 17, 2023
Steven Shum   (Director)    

 

24

 

 

CalEthos, Inc.

For the Years Ended December 31, 2022 and 2021

 

Index to the Consolidated Financial Statements

 

Contents Page(s)

Report of Independent Registered Public Accounting Firm PCAOB ID 587

F-2

   
Consolidated Balance Sheets as of December 31, 2022 and 2021 F-3
   
Consolidated Statements of Operations and Comprehensive Loss for the Years ended December 31, 2022 and 2021 F-4
   
Consolidated Statements of Changes in Stockholders’ Deficit for the Years ended December 31, 2022 and 2021 F-5
   
Consolidated Statements of Cash Flows for the Years ended December 31, 2022 and 2021 F-6
   
Notes to the Consolidated Financial Statements F-7

 

F-1
 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Stockholders of

CalEthos, Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of CalEthos Inc., (the “Company”) as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, stockholders’ deficit and cash flows for each of the two year period ended December 31, 2022, and the related notes and schedules (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the consolidated results of its operations and its cash flows for each of the two years in the period ended December 31, 2022 in conformity with accounting principles generally accepted in the United States of America.

 

The Company’s Ability to Continue as a Going Concern

 

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 1 to the accompanying consolidated financial statements, although the Company has net income it is primarily attributable to non-cash reversal of compensation for restricted stock units, has generated negative cash flows from operating activities, has an accumulated deficit and has stated that substantial doubt exists about Company’s ability to continue as a going concern. Management’s evaluation of the events and conditions and management’s plans regarding these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

The critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments.

 

We determined that there are no critical audit matters.

 

/s/ RBSM LLP

 

We have served as the Company’s auditor since 2018.

 

Larkspur, CA

April 17, 2023

 

F-2
 

 

CalEthos, Inc.

Consolidated Balance Sheets

As of December 31,

 

   2022   2021 
         
Assets          
Current assets          
Cash and cash equivalents  $2,067,000   $3,047,000 
Prepaid and other current expenses   4,000    7,000 
Total current assets   2,071,000    3,054,000 
           
Other assets   -    38,000 
Total assets  $2,071,000   $3,092,000 
           
Liabilities and stockholders’ deficit          
Current liabilities          
Accounts payable and accrued expenses  $540,000   $434,000 
Convertible promissory notes, net   4,613,000    3,087,000 
Notes payable   61,000    111,000 
Total current liabilities   5,214,000    3,632,000 
           
Commitments and contingencies (Note 7)   -    - 
           
Stockholders’ deficit          
Series A convertible preferred stock, par value $0.001, 3,600,000 shares authorized; no shares issued and outstanding   -    - 
Preferred stock, par value $0.001, 100,000,000 shares authorized; no shares issued and outstanding   -    - 
Common stock, par value $0.001, 100,000,000 shares authorized; 24,495,621 and 25,995,621 shares issued and outstanding   24,000    26,000 
Additional paid-in capital   11,480,000    16,269,000 
Other comprehensive income (loss)   5,000    (2,000)
Stock subscription receivable   (2,000)   (2,000)
Accumulated deficit   (14,650,000)   (16,831,000)
Total stockholders’ deficit   (3,143,000)   (540,000)
           
Total liabilities and stockholders’ deficit  $2,071,000   $3,092,000 

 

The accompanying notes are an integral part of these Consolidated Financial Statements.

 

F-3
 

 

CalEthos, Inc.

Consolidated Statements of Operations and Comprehensive Loss

For the Years Ended December 31,

 

   2022   2021 
         
Revenue  $-   $- 
           
Operating expenses          
Professional fees   667,000    1,033,000 
Restricted stock grants   (4,791,000)   5,062,000 
General and administrative expenses   52,000    57,000 
Impairment loss   154,000    - 
Total operating (income) expenses   (3,918,000)   6,152,000 
           
Income (loss) from operations   3,918,000    (6,152,000)
           
Other income (expenses)          
Interest income   7,000    - 
Financing costs   (1,744,000)   (597,000)
Total other expenses   (1,737,000)   (597,000)
           
Income (loss) before provision for income taxes   2,181,000    (6,749,000)
           
Provision for income taxes   -    - 
           
Net income (loss)  $2,181,000   $(6,749,000)
           
Net income (loss) per share, basic  $0.15   $(0.35)
Net income (loss) per share, diluted  $0.08   $(0.35)
           
Weighted average common shares outstanding – basic   14,495,621    19,482,261 
Weighted average common shares outstanding – diluted   

29,342,327

    19,482,261 
           
Comprehensive income (loss):          
Net income (loss)  $2,181,000   $(6,749,000)
Change in foreign currency translation   7,000    (2,000)
Comprehensive income (loss)  $2,188,000   $(6,751,000)

 

The accompanying notes are an integral part of these Consolidated Financial Statements.

 

F-4
 

 

CalEthos, Inc.

Consolidated Statements of Changes in Stockholders’ Deficit

For the Years Ended December 31, 2022 and 2021

 

   Shares   Amount   Shares   Amount   Capital   Receivable   Income (Loss)   Deficit   Equity 
  

Series A Convertible

Preferred Stock

   Common Stock   Additional Paid-In   Stock Subscription   Other Comprehensive   Accumulated   Total Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   Receivable   Income (Loss)   Deficit   Equity 
Balance, December 31, 2020   -   $-    16,634,951   $17,000   $8,744,000   $(2,000)  $-   $(10,082,000)  $(1,323,000)
Relative fair value of warrants issued with convertible promissory note   -    -    -    -    1,690,000    -    -    -    1,690,000 
Stock options issued for services   -    -    -    -    575,000    -    -    -    575,000 
Stock issued for debt forgiveness   -    -    75,000    -    166,000    -    -    -    166,000 
Stock issued for accrued compensation   -    -    -    -    38,000    -    -    -    38,000 
Stocks returned   -    -    (3,674,330)   (4,000)   4,000    -    -    -    - 
Stock issued on exercise of options   -    -    1,435,000    2,000    -    -    -    -    2,000 
Stock-based compensation   -    -    25,000    -    272,000    -    -    -    272,000 
Restricted common stock awards issued for compensation   -    -    11,500,000    11,000    4,780,000    -    -    -    4,791,000 
Foreign currency translation loss   -    -    -    -    -    -    (2,000)   -    (2,000)
Net loss   -    -    -    -    -    -    -    (6,749,000)   (6,749,000)
Balance, December 31, 2021   -    -    25,995,621   $26,000   $16,269,000    (2,000)  $(2,000)   (16,831,000)   (540,000)
Stock-based compensation   -    -    -    -    6,377,000    -    -    -    6,377,000 
Forfeiture of stock-based compensation   -    -    (1,500,000)   (2,000)   (11,166,000)   -    -    -    (11,168,000)
Foreign currency translation income   -    -    -    -    -    -    7,000    -    7,000 
Net income   -    -    -    -    -    -    -    2,181,000    2,181,000 
Balance, December 31, 2022   -   $-    24,495,621   $24,000   $11,480,000   $(2,000)  $5,000   $(14,650,000)  $(3,143,000)

 

The accompanying notes are an integral part of these Consolidated Financial Statements.

 

F-5
 

 

CalEthos, Inc.

Consolidated Statements of Cash Flows

For the Years Ended December 31,

 

   2022   2021 
Cash Flows From Operating Activities          
Net income (loss)  $2,181,000   $(6,749,000)
Adjustments to reconcile net income (loss) to net cash used in operating activities:          
Impairment   154,000    - 
Amortization of convertible promissory note discounts   1,526,000    524,000 
Fair value of equity-based compensation   -    846,000 
Forfeiture of restricted stock grants   (11,168,000)   - 
Accretion of compensation cost for restricted stock awards   6,377,000    4,791,000 
Changes in operating assets and liabilities          
Prepaid expenses and other current assets   3,000    (5,000)
Accounts payable and accrued expenses   107,000    28,000 
Net Cash Used in Operating Activities   (820,000)   (565,000)
           
Cash Flows From Investing Activities          
Other assets   (105,000)   (38,000)
Net Cash Used in Investing Activities   (105,000)   (38,000)
           
Cash Flows From Financing Activities          
Proceeds from the issuance of convertible promissory notes   -    3,550,000 
Proceeds from the issuance of notes payable   -    150,000 
Repayments of notes payable   (50,000)   (50,000)
Proceeds from the exercise of options   -    2,000 
Net Cash (Used in) Provided by Financing Activities   (50,000)   3,652,000 
           
Effect of exchange rate changes on cash and cash equivalents   (5,000)   (2,000)
           
Net (decrease) increase in Cash   (980,000)   3,047,000 
Cash, Beginning of Period   3,047,000    - 
Cash, End of Period  $2,067,000   $3,047,000 
           
Supplemental disclosure of cash flow information:          
Cash paid for interest  $5,407   $- 
Cash paid for income taxes  $-   $- 
           
Non-cash investing and financing activities          
Relative fair value of warrants issued with convertible promissory notes  $-   $1,690,000 
Common stock issued for accrued compensation  $-   $38,000 
Common stock issued from forgiven debt  $-   $166,000 
Original issue discount recorded on convertible promissory notes  $-   $355,000 

 

The accompanying notes are an integral part of these Consolidated Financial Statements.

 

F-6
 

 

CalEthos, Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2022 and 2021

 

Note 1 - Organization and Accounting Policies

 

CalEthos, Inc. (the “Company” or “we”) was incorporated on March 20, 2002 under the laws of the State of Nevada.

 

The Company is implementing its plan to build a clean-energy-powered, modular immersion and liquid cooled data center that provides colocation data center services to enterprise IT customers. In addition, the Company may acquire assets and all or part of other companies operating in the high-density computing industry or to invest or joint venture with other more-established companies already in the industry that would add value to the Company’s business strategy.

 

In July 2022, due to the declining state of the bitcoin mining industry and market for its planned products, the Company’s board of directors resolved to discontinue the development in South Korea of the Company’s 5 nanometer ASIC chip and containerized, immersion-cooled bitcoin mining computer system and to focus exclusively on developing the clean-energy-powered data center segment of its business strategy. The Company has suspended operations of its South Korean subsidiary and will decide in the next twelve months whether to use it to develop other products or dissolve it.

 

Incorporation of Korean entity

 

On November 5, 2021, AIQ System Inc. (“AIQ”) was incorporated in Seoul, Republic of Korea. AIQ is authorized to issue 3 million shares of common stock. At the date of incorporation, 10,000 shares were issued to the Company for 100,000,000 Korean Won or approximately $89,000 for 100% ownership of AIQ.

 

Basis of Presentation

 

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary from the formation date. All material intercompany transactions and balances have been eliminated in consolidation.

 

Going Concern and Liquidity

 

The Company incurred net income of approximately $2,181,000 for the year ended December 31, 2022, of which $4,791,000 was attributable to a noncash transaction for the reversal of compensation for restricted stock units, and had an accumulated deficit of approximately $14,650,000 as of December 31, 2022. The Company has financed its activities principally through debt and equity financing and shareholder contributions. Management expects to incur additional losses and cash outflows in the foreseeable future in connection with its operating activities.

 

The Company’s consolidated financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

 

The Company is subject to a number of risks similar to those of other similar stage companies, including dependence on key individuals; successful development, marketing and branding of products; uncertainty of product development and generation of revenues; dependence on outside sources of financing; risks associated with research and development; dependence on third-party suppliers and collaborators; protection of intellectual property; and competition with larger, better-capitalized companies. Ultimately, the attainment of profitable operations is dependent on future events, including obtaining adequate financing to fund its operations and generating a level of revenues adequate to support the Company’s cost structure.

 

The Company will need to raise debt or equity financing in the future in order to continue its operations and achieve its growth targets. However, there can be no assurance that such financing will be available in sufficient amounts and on acceptable terms, when and if needed, or at all. The precise amount and timing of the funding needs cannot be determined accurately at this time, and will depend on a number of factors, including market demand for the Company’s products and services, the success of product development efforts, the timing of receipts for customer deposits, the management of working capital, and the continuation of normal payment terms and conditions for purchase of goods and services. The Company believes its cash balances and cash flow from operations will not be sufficient to fund its operations and growth for the next twelve months from the issuance date of these financial statements. If the Company is unable to substantially increase revenues, reduce expenditures, or otherwise generate cash flows from operations, then the Company will likely need to raise additional funding from investors or through other avenues to continue as a going concern.

 

F-7
 

 

COVID-19

 

The continuing COVID-19 global pandemic has caused significant disruption to the economy and financial markets globally, and the full extent of the potential impacts of COVID-19 are not yet known. Circumstances caused by the COVID-19 pandemic are complex, uncertain and rapidly evolving. The impact of COVID-19 has not been significant to the Company’s results of operations, financial condition, and liquidity and capital resources. Although no material impairment or other effects have been identified to date, there is substantial uncertainty in the nature and degree of its continued effects over time. That uncertainty affects management’s accounting estimates and assumptions, which could result in greater variability in a variety of areas that depend on these estimates and assumptions as additional events and information become known. The Company will continue to consider the potential impact of the COVID-19 pandemic on its business operations.

 

Use of Estimates

 

The preparation of consolidated financial statements in conformity with GAAP and requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods.

 

Foreign Currency Translation

 

The financial statements of foreign subsidiaries, for which the functional currency is the local currency, are translated into U.S. dollars using the exchange rate at the consolidated balance sheet date for assets and liabilities and a weighted-average exchange rate during the year for revenue, expenses, gains and losses. Translation adjustments are recorded as other comprehensive income (loss) within shareholders’ equity (deficit). Gains or losses from foreign currency transactions are recognized in the consolidated statements of operations.

 

Fair Value Measurement

 

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Applicable accounting guidance provides an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. There are three levels of inputs that may be used to measure fair value:

 

Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 - Other inputs that are directly or indirectly observable in the marketplace.

Level 3 - Unobservable inputs which are supported by little or no market activity.

 

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

 

As of and for the year ended December 31, 2022, the Company had no assets or liabilities that require fair value measurement.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates its fair value. The Company maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (“FDIC”) in accounts that at times may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions. As of December 31, 2022 and 2021, the Company had $1,817,000 and $2,797,000 in excess of the federal insurance limit, respectively.

 

Prepaid Expense

 

Prepaid expenses are assets held by the Company, which are expected to be realized and consumed within twelve months after the reporting period.

 

Other Assets

 

Other assets consist of long-term advances paid for chip and processor design and development.

 

F-8
 

 

Related Parties

 

The Company follows Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) section 850-10 for the identification of related parties and disclosure of related party transactions.

 

Pursuant to ASC section 850-10-20 the related parties include (a.) affiliates of the Company (“Affiliate” means, with respect to any specified Person, any other Person that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the Securities Act); (b.) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option of ASC section 825–10–15, to be accounted for by the equity method by the investing entity; (c.) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; (d.) principal owners of the Company; (e.) management of the Company; (f.) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and (g.) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

 

The consolidated financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: (a.) the nature of the relationship(s) involved; (b.) a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; (c.) the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and (d.) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.

 

Commitments and Contingencies

 

The Company follows ASC section 450-20 to report accounting for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or un-asserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or un-asserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.

 

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.

 

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.

 

Debt Discounts

 

The Company accounts for debt discounts originating in connection with conversion features that remain embedded in the related notes in accordance with ASC 470-20, Debt with Conversion and Other Options. These costs are classified on the balance sheet as a direct deduction from the debt liability. The Company amortizes these costs over the term of its debt agreements as financing cost in the consolidated statement of operations and comprehensive loss.

 

Warrant Liability

 

In connection with financing arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes Merton (“BSM”) option pricing model as of the measurement date.

 

F-9
 

 

Stock-Based Compensation

 

We account for our stock-based compensation under ASC 718, “Compensation – Stock Compensation” using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges it equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments.

 

We use the fair value method for equity instruments granted to non-employees and use the BSM model for measuring the fair value of options. The stock based fair value compensation is determined as of the date of the grant (measurement date) and is recognized over the vesting periods.

 

Income Taxes

 

The Company accounts for income taxes in accordance with ASC 740, Income Taxes, deferred tax assets and liabilities are computed based on the difference between the financial reporting and income tax bases of assets and liabilities using the enacted marginal tax rate. ASC 740 requires that the net deferred tax asset be reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some portion or all of the net deferred tax asset will not be realized.

 

The Company accounts for income taxes using an asset and liability approach, which requires the recognition of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. The measurement of current and deferred tax assets and liabilities is based on provisions of enacted tax laws; the effects of future changes in tax laws or rates are not anticipated. If necessary, the measurement of deferred tax assets is reduced by the amount of any tax benefits that are not expected to be realized based on available evidence.

 

The Company has adopted guidance related to the accounting for uncertainty in income taxes which prescribes rules for recognition, measurement and classification in the financial statements of tax positions taken or expected to be taken in a tax return. The guidance prescribes a two-step approach which involves evaluating whether a tax position will be more likely than not (greater than 50 percent likelihood) sustained upon examination based on the technical merits of the position. The second step requires that any tax position that meets the more likely than not recognition threshold be measured and recognized in the financial statements at the largest amount of benefit that is a greater than 50 percent likelihood of being realized upon settlement.

 

The Company’s policy is to recognize interest and penalties, if any, related to unrecognized tax benefits in income tax expense. The Company is not currently under examination by any taxing authority nor has the Company been notified of a pending examination. The statute of limitations for which the Company is generally no longer subject to federal or state income tax examinations by tax authorities is for years before 2013.

 

Earnings Per Share

 

We use ASC 260, “Earnings Per Share” for calculating the basic and diluted earnings (loss) per share. We compute basic earnings (loss) per share by dividing net income (loss) by the weighted average number of common shares outstanding. Diluted earnings (loss) per share is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential common shares outstanding during the period using the treasury stock method. Dilutive potential common shares include outstanding stock options and warrants and stock awards. For periods with a net loss, basic and diluted loss per share is the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share.

 

Securities that could potentially dilute income (loss) per share in the future were not included in the computation of diluted income (loss) per share on December 31 because their inclusion would be anti-dilutive as follows:

   2022   2021 
Restricted stock awards   -    11,500,000 
Convertible promissory notes and accrued interest   4,125,699    3,947,394 
Series A warrants issued with convertible promissory notes   1,668,304    1,921,304 
Series B warrants to be issued upon exercise of Series A warrants   1,668,304    1,921,304 
Warrants issued for services   100,000    100,000 
Total potential future shares   7,562,307    19,390,002 

 

Recent Accounting Pronouncements

 

The Company’s management reviewed all recently issued accounting standard updates (“ASU’s”) not yet adopted by the Company and does not believe the future adoptions of any such ASU’s may be expected to cause a material impact on the Company’s condensed consolidated financial condition or the results of its operations.

 

F-10
 

 

Note 2 – Related Party Transactions

 

The Company incurred approximately $200,000 and $199,000 for years ended December 31, 2022 and 2021, and paid approximately $200,000 and $202,000, respectively, to M1 Advisors for the services of the Company’s CEO and miscellaneous operating expenses.

 

Note 3 – Intangible and Other Assets

 

On December 23, 2021, AIQ entered into a Technology Development Agreement (the “Agreement”) with PICOCEL, Co., Ltd. (the “Contractor” or “PICOCEL”) to develop a FPGA based Bitcoin mining simulation system. The Agreement was expected to be completed within 6 weeks for a total contract price of 198,000,000 Korean Won (“KRW”) or approximately $167,000. Total payments made to PICOCEL as of December 31, 2022 amounted to approximately $69,000. On March 17, 2022, the Company and PICOCEL entered into a mutual agreement to cancel and terminate the Agreement. As of the date of the termination, PICOCEL had completed the first phase of the Agreement upon delivery of the SHA-256 code and FPGA board simulator.

 

On April 5, 2022, AIQ entered into a Technology Development Agreement (the “Agreement”) with NNS, Co., Ltd. (the “Contractor” or “NNS”) to develop a FPGA based Bitcoin mining simulation system. The Agreement was expected to be completed within 9 weeks for a total contract price of 99,000,000 KRW, including 9,000,000 KRW VAT, or approximately $82,000. The payments are scheduled as follows:

 

   Amount 
   USD   KRW 
Within 5 days after signing the contract  $41,000    49,500,000 
Within 5 days after all conditions are met as stated in “Schedule B – Statement of Work”   41,000    49,500,000 
Total  $82,000    99,000,000 

 

Payment of 90,000,000 KRW or approximately $69,000 was made to NNS as of December 31, 2022, which was expensed and included in the consolidated statement of operations.

 

Impairment

 

During the six months ended June 30, 2022, the Bitcoin market was in a constant decline, and since the ASIC chip being developed by AIQ was planned to be used for Bitcoin mining machines, management believes that there is an impairment indicator. In August 2022, management discontinued the operations of AIQ.

 

Indicators of impairment include significant underperformance relative to historical or projected future operating results, significant changes in our use of the assets or in our business strategy, loss of or changes in customer relationships and significant negative industry or economic trends. When indications of impairment arise for a particular asset or group of assets, we assess the future recoverability of the carrying value of the asset (or asset group) based on an undiscounted cash flow analysis. If the carrying value exceeds projected, net, undiscounted cash flows, an additional analysis is performed to determine the asset’ (or asset group), typically a discounted cashflow analysis, and an impairment charge is recorded for the excess of carrying value over fair value.

 

As of December 31, 2022, intangibles and other assets were fully impaired. Impairment loss amounted to $154,000, inclusive of a $12,000 impairment of prepaid VAT related to the services provided by PICOCEL and NNS.

 

The table below summarizes the impairment loss for the year ended December 31, 2022:

 

   Amount   VAT   Total 
PICOCEL  $69,000   $5,000   $74,000 
NNS   69,000    5,000    74,000 
Total   138,000    10,000    148,000 
Foreign exchange loss   4,000    2,000    6,000 
Impairment loss  $142,000   $12,000   $154,000 

 

F-11
 

 

Note 4 – Accounts Payable and Accrued Expenses

 

The following table summarizes the Company’s accounts payable and accrued expense balances as of December 31:

 

   2022   2021 
Accounts payable  $186,000   $221,000 
Accrued expenses   28,000    99,000 
Accrued interest   326,000    114,000 
Accounts payable and accrued expenses  $540,000   $434,000 

 

Accrued Interest

 

The following table presents the details of accrued interest as of December 31:

 

   2022   2021 
Notes payable  $17,000   $9,000 
Convertible promissory notes   309,000    105,000 
Balance, end of the year  $326,000   $114,000 

 

Note 5 – Notes Payable

 

The table below summarizes the transactions as of December 31:

 

   2022   2021 
Balance, beginning of the year  $111,000   $11,000 
Additions       150,000 
Payments   (50,000)   (50,000)
Balance, end of the year  $61,000   $111,000 

 

On July 7, 2020, the Company issued a promissory note in the principal amount of $11,000. The note is noninterest bearing. The principal was due on or before August 7, 2020. During any event of default under the note, the interest rate shall increase to 10% per annum. Events of default include failure to pay principal or interest, breach of covenants, breach of representations and warranties, borrower’s assignment of substantial part of its property or business, any money judgment, writ, or similar process shall be entered or filed against the borrower or any subsidiary of the borrower or any of its properties or other assets for more than $100,000, bankruptcy, liquidation of business, and cessation of operations. The principal amount outstanding under this note was $11,000 as of December 31, 2022. The note principal and interest are past due, therefore in default. For the year ended December 31, 2022, the Company has accrued approximately $3,000 of default interest.

 

On February 19, 2021, the Company issued a promissory note in the principal amount of $25,000. The interest on the unpaid principal balance accrued at a rate of 10% per annum. The principal and any accrued interest was to be paid in a single installment on or before February 19, 2022. If the Company fails to pay the balance of this note in full on the due date or fails to make any payment due within 15 days of the due date, any unpaid principal shall accrue interest at the rate of 15% per annum during the default (default interest). Events of default include failure to make any payment including accrued interest when due, voluntary, or involuntary petition of bankruptcy, appointment of a receiver, custodian, trustee or similar party to take possession of the Company’s assets or property, or assignment made by the Company for the benefit of creditors. The principal amount was settled in full on January 25, 2022.

 

On April 22, 2021, the Company issued a promissory note in the principal amount of $50,000. The interest on the unpaid principal balance accrued at a rate of 10% per annum. The principal and any accrued interest was to be paid in a single installment on or before April 22, 2022. If the Company fails to pay the balance of this note in full on the date or fails to make any payments due within 15 days of the due date, any unpaid principal shall accrue interest at the rate of 15% per annum during the default. Events of default include failure to make any payment including accrued interest when due, voluntary, or involuntary petition of bankruptcy, appointment of a receiver, custodian, trustee or similar party to take possession of the Company’s assets or property, or assignment made by the Company for the benefit of creditors. The principal amount outstanding under this note was $50,000 as of December 31, 2022. The note principal and interest are past due, therefore in default. Interest accrued, including default interest, as of December 31, 2022 is $10,000.

 

F-12
 

 

On July 1, 2021, the Company issued a promissory note in the principal amount of $25,000. The interest on the unpaid principal balance accrues at a rate of 10% per annum. The principal and any accrued interest were to be paid in a single installment on or before July 1, 2022. If the Company fails to pay the balance of this note in full on the date or fails to make any payments due within 15 days of the due date, any unpaid principal shall accrue interest at the rate of 15% per annum during the default (default interest). Events of default include failure to make any payment including accrued interest when due, voluntary, or involuntary petition of bankruptcy, appointment of a receiver, custodian, trustee or similar party to take possession of the Company’s assets or property, or assignment made by the Company for the benefit of creditors. The principal amount was settled in full on November 29, 2022.

 

Interest expense on notes payable amounted to $14,000 and $8,000 for the years ended December 31, 2022 and 2021, respectively.

 

Note 6 – Convertible Promissory Notes

 

In 2021, the Company issued two convertible promissory notes amounting to $55,000 and $3,850,000 (the “Notes”), respectively. The total aggregate proceeds were $3,550,000 due to a $355,000 aggregate original issue discount. The Notes are non-interest bearing with the principal due and payable on March 1, 2022 and August 31, 2022, respectively. Any amount of unpaid principal on the date of maturity will accrue interest at rate of 10% per annum (default interest). Interest accrued as of December 31, 2022 is $133,000. The principal amount and all accrued interest are convertible into shares of the Company’s common stock, as of the date of issuance, at a rate of $1.00 and $1.25 per share (“Conversion Rate”), respectively. The Conversion Rate is adjustable if, at any time when any principal amount of the Notes remains unpaid or unconverted, the Company issues or sells any shares of the Company’s common stock for no consideration or for a consideration per share (before deduction of reasonable expenses or commissions or underwriting discounts or allowances in connection therewith), which is less than the Conversion Rate in effect on the date of such issuance (or deemed issuance) of such shares of common stock (a “Dilutive Issuance”). Immediately upon a Dilutive Issuance, the Conversion Rate will be reduced to the amount of the consideration per share received by the Company in such Dilutive Issuance. Events of default include failure to issue conversion shares, the occurrence of a breach or default under any other agreement, any money judgment, writ, or similar process entered or filed against the Company or any of its property or other assets for more than $100,000, bankruptcy filing, application for the appointment of a custodian, trustee or receiver, insolvency, the Company’s common stock delisted, or dissolution, winding up, or termination of the business of the Company. The note principal and interest are past due, therefore in default.

 

In connection with the issuance of the Notes, the Company issued to the purchasers of the Notes stock purchase warrants (the “Warrants”) to purchase an aggregate of 1,567,500 shares of the Company’s common stock for a purchase price of $1.50 to $1.87 per share, subject to adjustments. The Warrants were valued using the Black Scholes option pricing model for a total fair value of $3,004,000 based on a 3-year term, volatility of 404.91% to 405.93%, a risk-free equivalent yield of 0.27% to 0.42%, and stock price ranging from $0.10 to $1.95.

 

In accordance with ASC 470 - Debt, the Company has allocated the cash proceeds amounts of the Notes among the Notes, the Warrants and the conversion feature. The relative fair value of the Warrants issued amounted to approximately $1,690,000 and the beneficial conversion amounted to $0, which amounts are being amortized and expensed over the term of the Notes.

 

The Company determined that the conversion feature of the Notes would not be an embedded feature to be bifurcated and accounted for as a derivative in accordance with ASC 815-15 Derivatives and Hedging.

 

Financing cost recognized for the amortization of debt discount was approximately $1,526,000 and $524,000 for the years ended December 31, 2022 and 2021, respectively.

 

The convertible promissory notes consisted of the following as of December 31:

 

   2022   2021 
Principal          
Balance, beginning of year  $4,613,000   $708,000 
Additions       3,905,000 
Balance, end of year   4,613,000    4,613,000 
           
Discount          
Balance, beginning of year   1,526,000    5,000 
Additions   -    2,045,000 
Amortization   (1,526,000)   (524,000)
Balance, end of year   -    1,526,000 
Net carrying amount  $4,613,000   $3,087,000 

 

Effective interest rate used to amortize the debt discount for the years ended December 31, 2022 and 2021 ranges from 4.76% to 64.60%.

 

F-13
 

 

Potential future shares to be issued on conversion of the notes as of December 31:

 

   2022   2021 
Principal  $4,613,000   $4,613,000 
Interest   309,000    105,000 
Total   4,922,000    4,718,000 
Conversion price per share   1.001.25    1.001.25 
Potential future shares   4,125,699    3,947,394 

 

The default interest expense for the convertible promissory notes amounted to $204,000 and $65,000 for the year ended December 31, 2022, and 2021, respectively.

 

Note 7 – Commitments and contingencies

 

Litigation

 

From time to time, the Company may become subject to legal proceedings, claims and litigation arising in the ordinary course of business. In addition, the Company may receive letters alleging infringement of patent or other intellectual property rights. The Company is not currently a party to any material legal proceedings, nor is the Company aware of any pending or threatened litigation that would have a material adverse effect on the Company’s business, operating results, cash flows or financial condition should such litigation be resolved unfavorably, except as follows.

 

On January 3, 2022, a complaint was filed against our company in the Superior Court of California, County of Los Angeles titled Michael Sekula v. CalEthos Inc, Michael Campbell and Does 1-25 (Case No. 22STCV00121) for, among other matters, failure to pay wages, fraud and other wage-related claims. In the complaint, the plaintiff claimed he worked under a consulting agreement as Vice President of Brand Management of our company and was to be paid $4,000 per month and to receive an option to purchase 50,000 shares of our common stock that was to vest quarterly over the term of the agreement. In the complaint, the plaintiff alleged that, on or around March 27, 2020, the Company ceased paying the plaintiff despite the plaintiff’s continuing efforts on behalf of our company and that the Company agreed to continue to accrue his monthly retainer amount until such time that the Company received at least $100,000 in funding. Plaintiff further alleged that he continued to work for our company for 38 additional weeks in reliance on our promise of payment. The plaintiff claimed that our refusal to make the promised payments amounts to violations of the California labor laws and seeks damages in excess of $450,000.

 

On June 9, 2022, a Settlement Agreement and Mutual Release was reached by the parties in the above mentioned complaint whereby as full consideration for the plaintiff’s execution of and compliance with the agreement and plaintiff’s release of all claims against the defendants, the Company agreed to pay a gross settlement amount of $90,000. Such payment was made on June 23, 2022.

 

Note 8 – Equity

 

Shares Authorized

 

The Company is authorized to issue 200,000,000 shares of which 100,000,000 shares shall be preferred stock, par value $0.001 per share, and 100,000,000 shares shall be common stock, par value $0.001 per share.

 

Preferred Stock

 

Series A Convertible Preferred Stock

 

The Series A Convertible Preferred Stock (“Series A”) is convertible into shares of the Company’s common stock at the rate of $1.38 per share, subject to adjustments based on the Company’s future sales of financial instruments at a value less than $1.38 per share. The holders of the Series A have the right to convert any time after the date of issuance. With the issuance of the convertible promissory notes, as explained in Note 5 above, the Series A’s conversion rate adjusted to $1.00 per share. In accordance with ASC 470, the Company has calculated the effect of the conversion rate adjustment, which was approximately $36,000. The conversion rate adjustment has been treated as a deemed dividend, which has been presented in the Statement of Changes in Stockholders’ Deficit.

 

The Series A is mandatorily convertible upon (i) the closing of the sale of shares of the Company’s common stock to the public in an underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $10,000,000 of gross proceeds to the Company, (ii) the close of business on the sixtieth consecutive day on which the closing price of the Company’s common stock on the OTC Markets is at least $2.80 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, stock combination or other similar recapitalization with respect to the common stock, or (iii) the affirmative vote of the holders of at least 66⅔% of the outstanding shares of Series A, given at a meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders all outstanding shares of Series A shall automatically be converted into shares of the Company’s common stock, at the then effective conversion rate.

 

F-14
 

 

On any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Series A shall be entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of Series A held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of the Articles of Incorporation, holders of Series A shall vote together with the holders of common stock as a single class.

 

From and after the date of the issuance of any shares of Series A, a cumulative dividend on each outstanding share of Series A Preferred Stock shall accrue at a rate per annum equal to ten percent of the Series A original issue price. Accrued dividends on the Series A shall be paid in shares of the Company’s common stock, such shares to be valued for such purpose at the applicable series A conversion price.

 

On February 11, 2020, the Company converted 85,975 shares of Series A into a Convertible Promissory Notes in the principal amount approximately $147,000.

 

Common Stock

 

In January 2021, the Company’s President and a member of the Board of Directors, resigned as an officer and director of the Company (“Termination Agreement”). Part of the Termination Agreement stipulates the return of 3,674,330 shares of the Company’s common stock (“Cancelled Shares”). The Cancelled Shares were returned and cancelled on April 20, 2021.

 

In March 2021, the Company’s Chief Executive Officer (“CEO’) agreed to forgive approximately $68,000 due to him, which was treated as contributed paid in capital.

 

In March 2021, the Company’s Chief Financial Officer agreed to reduce the amounts due to him from approximately $128,000 to $30,000. For the reduction of $98,000, the Company will issue 75,000 shares of common stock. The remaining liability of $30,000 will be paid in cash.

 

In September 2021, the Company entered into a release agreement with one of its consultants. As part of the separation payment, the Company issued 25,000 shares valued at $76,000 and paid $20,000 cash in October 2021.

 

Restricted Common Stock Awards

 

On August 17, 2021, the Company entered into Restricted Share Award Agreements (the “Award Agreements”) with two consultants pursuant to which the Company issued to the consultants shares of common stock of the Company in exchange for their future services. The Awards had an initial term of one year, which was to be automatically renewed on a year-to-year basis unless either party gave a written notice of termination. The two consultants who entered into these agreements include:

 

  1) A consultant who was granted 10,000,000 restricted share awards.
  2) An entity, which is owned by the Company’s CEO and majority shareholder, was granted 1,500,000 restricted share awards.

 

The Company’s management accounted for the Award Grants as restricted stock compensation in accordance with ASC 718 – Stock Compensation (“ASC 718”). ASC 718 required the Company to estimate the service period over which the compensation cost would be recognized. Management had estimated that the first two development phases would be completed within 15 months and the Foundry Mask would be completed within 6 months for a total of 21 months service period. Compensation cost was to be recognized ratably over 21 months and in the same manner had the Company paid in cash. The estimated service period would be adjusted for changes in actual and expected completion dates. Any such change was to be recognized prospectively, and the remaining deferred compensation was to be recognized over the remaining service period.

 

The Company issued restricted stock grants totaling 10,000,000 shares (“Grant Shares”) to Hyuncheol (Peter) Kim (“CTO”), the Company’s former Chief Technology Officer, and 1,500,000 to a M1 Advisors LLC, a company owned by the Company’s chief executive officer. The value was $1.93 per share on the date of issuance (“Grant Date”) for an aggregate fair value of $22,195,000

 

The stock-based award compensation was recorded as an increase in deferred compensation expense, common stock, and additional paid-in capital in the Company’s books at the time of the grant.

 

On July 27, 2022, the Company sent the CTO, a letter notifying him that the Company’s Board of Directors had resolved to discontinue the Company’s 5 nanometer ASIC chip and bitcoin mining machine project and that his consulting agreement was to terminate at the end of August 2022. The Grant Shares issued in connection with his consulting agreement were canceled. As of the issuance date of these consolidated financial statements, the CTO had not executed the documentation required for the Company to cancel the Grant Shares; therefore, the Grant Shares are still legally outstanding, so the number of Grant Shares has not been removed from the total shares issued and outstanding. Since it is probable that the Grant Shares will not be earned, the Company has reversed the expense recognized for the fair value of the Grant Shares.

 

F-15
 

 

Also, at the end of August 2022, the Company canceled the restricted stock grant issued to M1 Advisors LLC.

 

The table below summarizes the transactions related to the Company restricted stock awards as of December 31, 2022:

 

   Shares   Deferred
compensation
 
Grant date fair value   11,500,000   $22,195,000 
Accretion   -    (11,168,000)
Canceled   (1,500,000)   (11,027,000)
Balance as of December 31, 2022   10,000,000   $- 

 

Restricted stock grant compensation expense for the year ended December 31, 2022, is as follows:

 

      
2022 Accretion expense  $6,377,000 
Reversal of 2021 accretion expense   (4,791,000)
Reversal of 2022 accretion expense   (6,377,000)
Restricted stock grant compensation  $(4,791,000)

 

Issuance of Stock Options and Warrants

 

In February 2021, the Company signed a new consulting agreement that granted one of its shareholders an option to purchase 750,000 shares of the Company’s common stock at $0.001 per share for the consultancy work provided from August 2020 to February 2021. The options were fully vested on the date of issuance. The fair value of the options was approximately $52,000, as of the grant date, of which approximately $38,000 was expensed and accrued during the year ended December 31, 2020 and $14,000 was expensed for the year ended December 31, 2021.

 

In May 2021, the Company signed a letter of understanding that granted one of its shareholders an option to purchase 300,000 shares of the Company’s common stock at $0.001 per share for the consultancy work provided during the Company’s restructuring phase from February 17, 2021 through April 30, 2021. The options were fully vested on the date of issuance. The fair value of the options was approximately $561,000, as of grant date, which was expensed during the year ended December 31, 2021.

 

In May 2021, an option holder exercised three options for 385,000, 750,000 and 300,000 shares of the Company’s common stock at an exercise price of $0.001 for each option, for total proceeds of approximately $2,000.

 

The table below summarizes the Company’s stock option activities for the years ended December 31, 2022 and 2021 (all share and per share data reflects the reverse stock split):

 

  

Number of

Stock Option

Shares

  

Exercise

Price

Range Per

Share

  

Weighted

Average

Exercise

Price

  

Relative

Fair

Value

  

Aggregate

Intrinsic

Value

 
Balance, January 1, 2021   385,000   $   $0.001   $   $7,315 
Granted   1,050,000    0.001    0.001    1.94     
Forfeited                    
Exercised   (1,435,000)   0.001    0.001         
Expired                    
Balance, December 31, 2021                    
Granted                    
Forfeited                    
Exercised                    
Expired                    
Balance, December 31, 2022      $   $   $   $ 
Vested and exercisable, December 31, 2022      $   $   $   $ 
Unvested, December 31, 2022      $   $   $   $ 

 

On September 15, 2021, the Company issued warrants to purchase 100,000 shares of the Company’s common stock. For the year ended December 31, 2021, the compensation expense, classified as professional fees in the consolidated statement of operations and comprehensive loss, was $195,000, which was calculated using the Black Scholes fair value option-pricing model with key input variables provided by management, as of the date of issuance: volatility of 359%, fair value of common stock $1.95, estimated life of 3 years, risk free rate of 0.43% and dividend rate of $0.

 

F-16
 

 

The table below summarizes the Company’s warrant activities for the years ended December 31, 2022 and 2021 (all share and per share data reflects the reverse stock split):

 

  

Number of Shares

   Weighted Average Strike Price/Share   Weighted Average Remaining Contractual Term (Years)   Weighted Average Grant Date Fair Value/Share  

Aggregate

Intrinsic

Value

 
Balance, January 1, 2021   353,804   $1.50    2.88   $0.18   $ 
Granted   1,667,500    1.86    3.00    1.67    0.11 
Forfeited                    
Exercised                    
Expired                    
Balance, December 31, 2021   2,021,304    1.80    2.98    1.14    0.17 
Vested and exercisable, December 31, 2021   2,021,304    1.80    2.98    1.14    0.17 
Unvested, December 31, 2021                    
                          
Balance, January 1, 2022   2,021,304    1.80    2.98    1.14    0.17 
Granted                    
Forfeited                    
Exercised                    
Expired   (253,000)   1.80    2.98    1.14    0.17 
Balance, December 31, 2022   1,768,304    1.84    3.00    1.49     
Vested and exercisable, December 31, 2022   1,768,304    1.84    3.00    1.49     
Unvested, December 31, 2022      $       $   $ 

 

The following table sets forth the weighted-average assumptions used to estimate the fair value of warrants granted for the year ended December 31:

 

   2022   2021 
Expected life (in years)       3 
Risk-free interest rate       0.27% - 0.42 %
Expected volatility       405% - 406%
Dividend yield       0.00%
Stock price       $ 0.101.95 

 

F-17
 

 

Note 9 – Earnings (Loss) Per Share

 

The following table sets forth the computation of basic and diluted earnings (loss) per share for the years ended December 31:

 

SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED

Numerator  2022   2021 
Net income (loss)  $2,181,000   $(6,749,000)
Effect of dilutive instruments          
Convertible notes interest expense   204,000    - 
Numerator for diluted EPS   2,385,000    (6,749,000)
           
Denominator          
Denominator - for basic EPS   14,495,621    19,482,261 
           
Effect of dilutive instruments          
Warrants   721,006    - 
Restricted stock awards   

10,000,000

    - 
Convertible notes   4,125,699    - 
Dilutive potential common shares   14,846,705    - 
           
Denominator for diluted EPS   29,342,327    19,482,261 
           
Basic EPS  $0.15   $(0.35)
Diluted EPS  $0.08   $(0.35)

 

Securities that could potentially dilute loss per share in the future were not included in the computation of diluted loss per share for the year ended December 31, 2021 because their inclusion would be anti-dilutive. Common share equivalents amounted to 3,942,608 for warrants, 3,947,394 for convertible notes and 11,500,000 for restricted stock units for total of 19,390,002 as of December 31, 2021. For the year ended December 31, 2022, the Company had 14,846,705 dilutive securities.

 

Note 10 – Deferred Tax Assets and Income Tax Provision

 

Deferred Tax Assets

 

At December 31, 2022, the Company had net operating loss (“NOL”) carry forwards for Federal income tax purposes of $3,070,000 that may be offset against future taxable income. No tax benefit has been reported with respect to these net operating loss carry-forwards in the accompanying financial statements because the Company believes that the realization of the Company’s net deferred tax assets of approximately $1,708,000 was not considered more likely than not and accordingly, the potential tax benefits of the net operating loss carry-forwards are fully offset by a full valuation allowance. Federal NOL’s have an indefinite carryover period and state NOL’s begin to expire in 2037 if not utilized by then.

 

Deferred tax assets consist primarily of the tax effect of NOL carry-forwards. The Company has provided a full valuation allowance on the deferred tax assets because of the uncertainty regarding its realization. The valuation allowance (decreased) increased by approximately $(782,000) and $2,191,000 for the reporting periods ended December 31, 2022 and 2021, respectively.

 

Components of deferred tax assets are as follows as of December 31:

 

   2022   2021 
Net deferred tax assets – Non-current:          
           
Intangible assets  $1,000   $- 
Impairment loss   38,000    - 
Interest expense limitations   802,000    - 
           
Stock-based compensation   9,000    1,488,000 
           
Expected income tax benefit from NOL carry-forwards   859,000    1,002,000 
           
Less valuation allowance   (1,709,000)   (2,490,000)
           
Deferred tax assets, net of valuation allowance  $-   $- 

 

F-18
 

 

Income Tax Provision in the Statements of Operations

 

A reconciliation of the federal statutory income tax rate and the effective income tax rate as a percentage of income before income taxes is as follows for the years ended December 31:

 

   2022   2021 
         
Federal statutory income tax rate   21.0%   21.0%
           
Change in valuation allowance on net operating loss carry-forwards   (21.0)   (21.0)
           
Effective income tax rate   0.0%   0.0%

 

Note 11 – Subsequent Events

 

The Company has evaluated all events that occurred after the balance sheet date through the date when the financial statements were issued to determine if they must be reported. The management of the Company determined the following reportable events:

 

Purchase of Land for Building a Data Center

 

On March 30, 2023, the Company signed an option agreement to acquire 80 acres of commercially zoned land in Imperial County, California (the “Option”) for $3,360,000 (“Purchase Price”). The Option expires in September 2024. The Company paid a non-refundable deposit of $84,000 on the signing of the Option. The Company is required to deposit an additional $84,000 into an escrow (“Escrow Funds”). If the Company does not exercise the Option by September 2024, the Escrow funds will be returned to the Company.

 

The Purchase Price is payable with a cash payment of $1,680,000 and the issuance of 840,000 shares of the Company’s common stock (the “Purchase Shares”). At the closing of the purchase (“Closing Date”), if the stock is trading at a value less than $1.00 per share, the Company is required to issue a promissory note in the amount of $840,000, payable on the third anniversary of the closing date, with an interest rate equal to the Secured Overnight Financing Rate plus 2.0%.

 

If the Purchase Shares are issued at the Closing Date, the Company has agreed to repurchase the Shares (the “Put Option”). The Put Option period ends on the one-year anniversary after a six-month holding period. However, if the Company’s common stock trades above $2.00 per share for 120 consecutive days, the Put Option expires. If the Company’s common stock trades below $2.00 per for 10 consecutive days, the Holder has the option for the Company to repurchase the Purchase Shares for $2.00 per share. o

 

Employment Agreement

 

On March 27, 2023, executed an offer of employment to hire an individual as the Company’s president and chief operating officer. The effective date of employment was March 28, 2023. The salary is $250,000 per year, with an increase to $300,000 annually, immediately once permits have been granted to start construction of the data center, and an increase to $350,000 annually, upon the data center being operational and contracted for 25% of the planned 100MW colocation capacity. Also, the individual is eligible for a cash annual bonus and2,000,000 shares that will be provided in an employee option or a restricted stock award, if certain milestones are accomplished. The stock grant will be included in a pending employment agreement that is planned to be completed between the Company and employee with the next couple of weeks.

 

Cancellation of Restricted Stock Awards

 

On April 10, 2023, we completed the required paperwork for our transfer agent to cancel 10,000,000 shares of restricted stock that was previously issued to Mr. Kim as our former CTO.

 

F-19

EX-4.10 2 ex4-10.htm

 

Exhibit 4.10

 

DESCRIPTION OF THE COMPANY’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

 

DESCRIPTION OF CAPITAL STOCK

 

The following description of our common stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the complete text of our Articles of Incorporation, as amended (the “Articles of Incorporation”), and our Bylaws (the “Bylaws”), each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.1 is a part. We encourage you to read our Articles of Incorporation, our Bylaws and the applicable provisions of the Nevada Revised Statutes (“NRS”) for additional information.

 

Our authorized capital stock consists of 100,000,000 shares of common stock, par value $0.0001 per share (our “common stock”), and 100,000,000 shares of preferred stock, par value $0.001 per share (our “preferred stock”).

 

As of March 31, 2023, 14,495,621 shares of common stock and no shares of preferred stock were issued and outstanding.

 

Common Stock

 

General

 

The following summary of certain provisions of our common stock does not purport to be complete. This description is summarized from, and is qualified in its entirety by reference to, our articles of incorporation and our bylaws, to which you should refer and both of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.1 is a part. The summary below is also qualified by provisions of applicable law, including Chapters 78 and 92A of the Nevada Revised Statutes (the “NRS”), as applicable to corporations.

 

Voting, Dividend and Other Rights. Each outstanding share of common stock entitles the holder to one vote on all matters presented to the shareholders for a vote. Holders of shares of common stock have no cumulative voting, pre-emptive, subscription or conversion rights. All shares of common stock to be issued pursuant to this registration statement will be duly authorized, fully paid and non-assessable. Our board of directors determines if and when distributions may be paid out of legally available funds to the holders. To date, we have not declared any dividends with respect to our common stock. Our declaration of any cash dividends in the future will depend on our board of directors’ determination as to whether, in light of our earnings, financial position, cash requirements and other relevant factors existing at the time, it appears advisable to do so. We do not anticipate paying cash dividends on the common stock in the foreseeable future.

 

Rights Upon Liquidation. Upon liquidation, subject to the right of any holders of the preferred stock to receive preferential distributions, each outstanding share of common stock may participate pro rata in the assets remaining after payment of, or adequate provision for, all our known debts and liabilities.

 

Majority Voting. The holders of a majority of the outstanding shares of common stock constitute a quorum at any meeting of the shareholders. A plurality of the votes cast at a meeting of shareholders elects our directors. The common stock does not have cumulative voting rights. Therefore, the holders of a majority of the outstanding shares of common stock can elect all of our directors. In general, a majority of the votes cast at a meeting of shareholders must authorize shareholder actions other than the election of directors. Most amendments to our articles of incorporation require the vote of the holders of a majority of all outstanding voting shares.

 

All issued and outstanding shares of common stock are fully paid and nonassessable. Shares of our common stock that may be offered, from time to time, under this prospectus will be fully paid and nonassessable.

 

Transfer Agent and Registrar

 

The transfer agent and registrar for our common stock is Nevada Agency and Transfer Company. The address of Nevada Agency and Transfer Company is 50 West Liberty Street, Suite 880, Reno, NV 89501 and its telephone number is (775) 322-0626.

 

Market for Common Stock

 

Our common stock is listed for quotation on the OTC Pink Market under the symbol “BUZZ.”

 

 

EX-31.1 3 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

 

I, Michael Campbell, certify that:

 

1. I have reviewed this Annual Report on Form 10-K of CalEthos, Inc. (the “Registrant”);
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures; and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: April 17, 2023 /s/ Michael Campbell
  Michael Campbell
 

Chief Executive Officer

  (Principal Executive Officer)

 

 

EX-31.2 4 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

 

I, Dean S. Skupen, certify that:

 

1. I have reviewed this Annual Report on Form 10-K of CalEthos, Inc. (the “Registrant”);
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures; and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: April 17, 2023 /s/ Dean S. Skupen
  Dean S. Skupen
 

Chief Financial Officer

  (Principal Financial Officer)

 

 

EX-32.1 5 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION

OF PRINCIPAL EXECUTIVE OFFICER AND

PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U. S. C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of CalEthos, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2022 (the “Report”), I, Michael Campbell, Chief Executive Officer of the Company, and I, Dean S. Skupen, Chief Financial Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and
   
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: April 17, 2023 /s/ Michael Campbell
  Michael Campbell
 

Chief Executive Officer

  (Principal Executive Officer)

 

Date: April 17, 2023 /s/ Dean S. Skupen
  Dean S. Skupen
 

Chief Financial Officer

  (Principal Financial Officer)

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed from within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

EX-101.SCH 6 buuz-20221231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - ORGANIZATION AND ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - INTANGIBLE AND OTHER ASSETS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - CONVERTIBLE PROMISSORY NOTES link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - EQUITY link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - EARNINGS (LOSS) PER SHARE link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - DEFERRED TAX ASSETS AND INCOME TAX PROVISION link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - ORGANIZATION AND ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - ORGANIZATION AND ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - INTANGIBLE AND OTHER ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - DEFERRED TAX ASSETS AND INCOME TAX PROVISION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - SCHEDULE OF INCOME AND LOSS PER SHARE ANTI-DILUTIVE (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - ORGANIZATION AND ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - SCHEDULE OF PAYMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - SCHEDULE OF IMPAIRMENT LOSS (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - INTANGIBLE AND OTHER ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - SCHEDULE OF ACCRUED INTEREST (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - SCHEDULE OF CONVERTIBLE PROMISSORY NOTES (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - SCHEDULE OF POTENTIAL FUTURE SHARES ISSUANCE OF CONVERSION NOTES (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - SCHEDULE OF COMPANY RESTRICTED STOCK AWARDS (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - SCHEDULE OF RESTRICTED STOCK GRANT COMPENSATION EXPENSE (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - SCHEDULE OF FAIR VALUE OF WARRANTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - EARNINGS (LOSS) PER SHARE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - SCHEDULE OF RECONCILIATION OF INCOME TAX (Details) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - DEFERRED TAX ASSETS AND INCOME TAX PROVISION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 buuz-20221231_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 buuz-20221231_def.xml XBRL DEFINITION FILE EX-101.LAB 9 buuz-20221231_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series A Convertible Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Stock Subscription Receivable [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Legal Entity [Axis] AIQ System Inc [Member] Investment, Name [Axis] Antidilutive Securities [Axis] Restricted Stock Award [Member] Convertible Promissory Notes And Accrued Interest [Member] Series A Warrants Issued With Convertible Promissory Notes [Member] Series B Warrants To Be Issued Upon Exercise Of Series A Warrant [Member] Warrants Issued For Services [Member] Related Party [Axis] M1 Advisors [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Technology Development Agreement [Member] PICOCEL, Co., Ltd. [Member] Related Party Transaction [Axis] AIQ [Member] NNS Co Ltd [Member] Finite-Lived Intangible Assets by Major Class [Axis] Value Added Tax [Member] Within 5 days after signing the contract [Member] Within 5 days after all conditions are met as stated in “Schedule B - Statement of Work” [Member] PICOCEL [Member] Amount [Member] NNS [Member] Debt Instrument [Axis] Promissory Note [Member] Title of Individual [Axis] Borrower [Member] Promissory Note One [Member] Promissory Note Two [Member] Convertible Promissory Note One [Member] Convertible Promissory Note Two [Member] Warrant [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Convertible Notes Payable [Member] Termination Agreement [Member] Chief Executive Officer [Member] Chief Financial Officer [Member] Consultants [Member] Chief Technology Officer [Member] New Consulting Agreement [Member] Shareholder [Member] Letter of Understanding [Member] Vesting [Axis] Share-Based Payment Arrangement, Tranche One [Member] Share-Based Payment Arrangement, Tranche Two [Member] Share-Based Payment Arrangement, Tranche Three [Member] Award Type [Axis] Restricted Stock [Member] Plan Name [Axis] Two Thousand Twenty Two Accretion Expense [Member] Reversal Two Thousand Twenty One Accretion Expense [Member] Reversal Two Thousand Twenty Two Accretion Expense [Member] Measurement Input Type [Axis] Measurement Input, Expected Term [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Price Volatility [Member] Measurement Input, Expected Dividend Rate [Member] Measurement Input, Share Price [Member] Convertible Notes [Member] Restricted Stock Units [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Variable Rate [Axis] Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] Employment Agreement [Member] Hyuncheol Peter Kim [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Auditor Firm ID Auditor Name Auditor Location Statement [Table] Statement [Line Items] Assets Current assets Cash and cash equivalents Prepaid and other current expenses Total current assets Other assets Total assets Liabilities and stockholders’ deficit Current liabilities Accounts payable and accrued expenses Convertible promissory notes, net Notes payable Total current liabilities Commitments and contingencies (Note 7) Stockholders’ deficit Preferred stock, value Common stock, par value $0.001, 100,000,000 shares authorized; 24,495,621 and 25,995,621 shares issued and outstanding Additional paid-in capital Other comprehensive income (loss) Stock subscription receivable Accumulated deficit Total stockholders’ deficit Total liabilities and stockholders’ deficit Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Operating expenses Professional fees Restricted stock grants General and administrative expenses Impairment loss Total operating (income) expenses Income (loss) from operations Other income (expenses) Interest income Financing costs Total other expenses Income (loss) before provision for income taxes Provision for income taxes Net income (loss) Net income (loss) per share, basic Net income (loss) per share, diluted Weighted average common shares outstanding – basic Weighted average common shares outstanding – diluted Comprehensive income (loss): Change in foreign currency translation Comprehensive income (loss) Beginning balance, value Beginning balance, shares Relative fair value of warrants issued with convertible promissory note Stock options issued for services Stock issued for debt forgiveness Stocks issued for debt forgiveness, shares Stock issued for accrued compensation Stocks returned Stocks returned, shares Stock issued on exercise of options Stock issued on exercise of options, shares Stock-based compensation Stock-based compensation, shares Restricted common stock awards issued for compensation Restricted common stock awards issued for compensation, shares Foreign currency translation income Net income (Loss) Forfeiture of stock-based compensation Forfeiture of stock-based compensation, shares Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] Cash Flows From Operating Activities Net income (loss) Adjustments to reconcile net income (loss) to net cash used in operating activities: Impairment Amortization of convertible promissory note discounts Fair value of equity-based compensation Forfeiture of restricted stock grants Accretion of compensation cost for restricted stock awards Changes in operating assets and liabilities Prepaid expenses and other current assets Accounts payable and accrued expenses Net Cash Used in Operating Activities Cash Flows From Investing Activities Other assets Net Cash Used in Investing Activities Cash Flows From Financing Activities Proceeds from the issuance of convertible promissory notes Proceeds from the issuance of notes payable Repayments of notes payable Proceeds from the exercise of options Net Cash (Used in) Provided by Financing Activities Effect of exchange rate changes on cash and cash equivalents Net (decrease) increase in Cash Cash, Beginning of Period Cash, End of Period Supplemental disclosure of cash flow information: Cash paid for interest Cash paid for income taxes Non-cash investing and financing activities Relative fair value of warrants issued with convertible promissory notes Common stock issued for accrued compensation Common stock issued from forgiven debt Original issue discount recorded on convertible promissory notes Accounting Policies [Abstract] ORGANIZATION AND ACCOUNTING POLICIES Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Goodwill and Intangible Assets Disclosure [Abstract] INTANGIBLE AND OTHER ASSETS Payables and Accruals [Abstract] ACCOUNTS PAYABLE AND ACCRUED EXPENSES Notes Payable NOTES PAYABLE Debt Disclosure [Abstract] CONVERTIBLE PROMISSORY NOTES Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Equity [Abstract] EQUITY Earnings Per Share [Abstract] EARNINGS (LOSS) PER SHARE Income Tax Disclosure [Abstract] DEFERRED TAX ASSETS AND INCOME TAX PROVISION Subsequent Events [Abstract] SUBSEQUENT EVENTS Incorporation of Korean entity Basis of Presentation Principles of Consolidation Going Concern and Liquidity COVID-19 Use of Estimates Foreign Currency Translation Fair Value Measurement Cash and Cash Equivalents Prepaid Expense Other Assets Related Parties Commitments and Contingencies Debt Discounts Warrant Liability Stock-Based Compensation Income Taxes Earnings Per Share Recent Accounting Pronouncements SCHEDULE OF INCOME AND LOSS PER SHARE ANTI-DILUTIVE SCHEDULE OF PAYMENTS SCHEDULE OF IMPAIRMENT LOSS SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES SCHEDULE OF ACCRUED INTEREST SCHEDULE OF NOTES PAYABLE SCHEDULE OF CONVERTIBLE PROMISSORY NOTES SCHEDULE OF POTENTIAL FUTURE SHARES ISSUANCE OF CONVERSION NOTES SCHEDULE OF COMPANY RESTRICTED STOCK AWARDS SCHEDULE OF RESTRICTED STOCK GRANT COMPENSATION EXPENSE SCHEDULE OF STOCK OPTION ACTIVITIES SCHEDULE OF WARRANTS ACTIVITY SCHEDULE OF FAIR VALUE OF WARRANTS SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS SCHEDULE OF RECONCILIATION OF INCOME TAX Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total potential future shares Common stock shares authorized Issuance of common stock, shares Issuance of common stock, value Ownership percentage Restricted stock grants Accumulated deficit Cash, FDIC Insured Amount Prepaid Insurance Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Proceeds from related party Payment to related party Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Total Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Total Foreign exchange loss Impairment loss Contract price Value added tax Accounts payable Accrued expenses Accrued interest Accounts payable and accrued expenses Notes payable Convertible promissory notes Balance, end of the year Schedule Of Notes Payable Balance, beginning of the year Additions Payments Balance, end of the year Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Debt instrument, face amount Increase in interest rate Debt instrument, periodic payment Debt instrument, interest rate Debt instrument, maturity date Interest expense, debt Balance, beginning of year Additions Balance, end of year Balance, beginning of year Additions Amortization Balance, end of year Net carrying amount Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] Principal Interest Total Conversion price per share Potential future shares Convertible promissory note Proceed from convertible debt Original issue discount Accrued interest Debt instruments, conversion price Events of default description Indebtedness for borrowed money maximum limit Issuance of warrants to purchase of common stock Issuance of warrant price per share Fair value of common stock Fair value of common stock estimated life Date of issuance volatility percentage Fair value of common stock risk free interest rate Share price Fair value of warrants Debt Instrument, Convertible, Beneficial Conversion Feature Amortization of Debt Issuance Costs and Discounts Debt Instrument, Interest Rate, Effective Percentage Interest Expense, Debt Litigation description Payments for rent Option to purchase shares vested Funds received Damages value Gross settlement amount Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Grant date fair value, shares Deferred compensation grant date fair value Accretion, shares Deferred compensation accretion Canceled, shares Deferred compensation canceled Shares, balance Deferred compensation Restricted stock grant compensation Number of Number of Stock Option Shares, Outstanding, Beginning Balance Exercise Price Range Per Share, Outstanding, Beginning Weighted Average Exercise Price, Outstanding, Beginning Relative Fair Value, Outstanding, Beginning Aggregate Intrinsic Value, Beginning Balance Number of Stock Option Shares, Granted Exercise Price Range Per Share, Granted Weighted Average Exercise Price, Granted Relative Fair Value, Granted Aggregate Intrinsic Value, Granted Number of Stock Option Shares, Forfeited Exercise Price Range Per Share, Forfeited Weighted Average Exercise Price, Forfeited Relative Fair Value, Forfeited Aggregate Intrinsic Value, Forfeited Number of Stock Option Shares, Exercised Exercise Price Range Per Share, Exercised Weighted Average Exercise Price, Exercised Relative Fair Value, Exercised Aggregate Intrinsic Value, Exercised Number of Stock Option Shares, Expired Exercise Price Range Per Share, Expired Weighted Average Exercise Price, Expired Relative Fair Value, Expired Aggregate Intrinsic Value, Expired Number of Number of Stock Option Shares, Outstanding, Beginning Balance Exercise Price Range Per Share, Outstanding, Beginning Weighted Average Exercise Price, Outstanding, Beginning Relative Fair Value, Outstanding, Beginning Aggregate Intrinsic Value, Beginning Balance Number of Stock Option, Vested and Exercisable, Ending Balance Exercise Price Range Per Share, Vested and Exercisable Weighted Average Exercise Price, Vested and Exercisable Relative Fair Value, Vested and Exercisable Aggregate Intrinsic Value, Vested and Exercisable Number of Stock Option, Unvested, Ending Balance Exercise Price Range Per Share, Unvested Weighted Average Exercise Price, Unvested Relative Fair Value, Unvested Aggregate Intrinsic Value, Unvested Number of warrants issued, Outstanding, Beginning of period Weighted Average Strike Price/Share, Outstanding, Beginning of period Weighted Average Remaining Contractual Term (Years) Weighted Average Grant Date Fair Value/Share, Ending of period Aggregate intrinsic value, Beginning of period Number of warrants issued, Granted Weighted Average Strike Price/Share, Granted Weighted Average Remaining Contractual Term (Years), Granted Weighted Average Grant Date Fair Value/Share, Granted Aggregate intrinsic value, Granted Number of warrants issued, Forfeited Weighted Average Strike Price/Share, Forfeited Weighted Average Grant Date Fair Value/Share, forfeited Aggregate intrinsic value, forfeited Number of warrants issued, Exercised Weighted Average Strike Price/Share, Exercised Weighted Average Grant Date Fair Value/Share, Exercised Aggregate intrinsic value, Exercised Number of warrants issued, Expired Weighted Average Strike Price/Share, Expired Weighted Average Grant Date Fair Value/Share, Expired Aggregate intrinsic value, Expired Number of warrants issued, Outstanding, Ending of period Weighted Average Strike Price/Share, Outstanding, ending of period Weighted Average Remaining Contractual Term (Years) Weighted Average Grant Date Fair Value/Share, ending balance Aggregate intrinsic value, ending balance Number of warrants issued, Vested and Exercisable, Ending of period Weighted Average Strike Price/Share, Vested and Exercisable, Ending of period Weighted Average Remaining Contractual Term (Years), Vested and Exercisable Weighted Average Grant Date Fair Value/Share, Vested and Exercisable, Ending of period Aggregate intrinsic value, Vested and Exercisable, Ending of period Number of warrants issued, Unvested, Ending of period Weighted Average Strike Price/Share, Unvested, Ending of period Weighted Average Grant Date Fair Value/Share, Unvested, Ending of period Aggregate intrinsic value, Unvested, Ending of period Weighted Average Remaining Contractual Term (Years) Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Warrants and rights outstanding, term Dividend yield Schedule of Stock by Class [Table] Class of Stock [Line Items] Authorized to issue shares Sale of stock shares price per share Debt Instrument, Convertible, Conversion Price Conversion rate adjustment, value Proceeds from Issuance of Common Stock Sale of Stock, Description of Transaction Conversion of shares Conversion of debt Return of shares Debt instrument decrease forgiveness Due to related parties Reduction amount Stock issued during period shares new issues Remaining cash liability Stock Issued During Period, Shares, Issued for Services Stock Issued During Period, Value, Issued for Services Payments to consultants Restricted common stock shares granted Shares Issued, Price Per Share Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Option to purchase shares Fair value of options Option expense Share-based compensation arrangement by share-based payment award, options Number of share options exercised Class of warrant exercise price Proceeds from stock options exercised Number of securities called by warrants or rights Compensation expenses Fair value assumptions, expected volatility rate Expected Term Risk Free Interest Rate Dividend payments Effect of dilutive instruments Convertible notes interest expense Numerator for diluted EPS Denominator Denominator - for basic EPS Effect of dilutive instruments Warrants Restricted stock awards Convertible notes Dilutive potential common shares Denominator for diluted EPS Basic EPS Diluted EPS Dilutive securities Intangible assets Impairment loss Interest expense limitations Stock-based compensation Expected income tax benefit from NOL carry-forwards Less valuation allowance Deferred tax assets, net of valuation allowance Federal statutory income tax rate Change in valuation allowance on net operating loss carry-forwards Effective income tax rate Net operating loss deferred tax Deferred tax assets net Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Subsequent Event [Table] Subsequent Event [Line Items] Area of Land Stock Issued During Period, Value, New Issues Non refundable deposit Escrow Deposit Issuance of common stock purchase price payable Stock issued during period, shares, new issues Promissory note Secured overnight financing, variable interest rate Shares issued, price per share Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold Construction of data center Percentage of contracted colocation capacity Cash annual bonus Cancellation of restricted stock awards AIQ [Member] Stock subscription receivable. Series A Convertible Preferred Stock [Member] Unusual Or Infrequent Items [Policy Text Block] Prepaid Expense [Policy Text Block] Other Assets [Policy Text Block] Related Parties [Policy Text Block] Financing costs. Forfeiture Of Restricted Stock Grants M1 Advisors [Member] Relative fair value of warrants issued with convertible promissory notes. Common stock issued for accrued compensation. Original issue discount recorded on convertible promissory notes. Stock Subscription Receivable [Member] Technology Development Agreement [Member] PICOCEL, Co., Ltd. [Member] Contract price. Relative fair value of warrants issued with convertible promissory notes. Within Five Days after Signing the Contract [Member] Within Five Days Afterall Conditions Are Met [Member] Value Added Tax [Member] PICOCEL [Member] Amount [Member] NNS [Member] Notes payable additions. Promissory Note [Member] Borrower [Member] Promissory Note One [Member] Promissory Note Two [Member] Convertible Promissory Note One [Member] Convertible Promissory Note Two [Member] Accrued interest. Indebtedness for borrowed money maximum limit. Share based compensation arrangement by share based payment award fair value of commonStock. Debt instrument additions. Debt instrument unamortized discount additions. Debt instrument unamortized discount amortization. The tabular disclosure of potential future shares issuance of conversion notes. Funds received. Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies. Convertible Notes [Member] Restricted Stock Units [Member] Conversion rate adjustment, value. Stock issued during period return of shares. Termination Agreement [Member] Reduction amount. Remaining liability paid for cash. Consultants [Member] Grant date fair value shares. Deferred compensation grant date fair value. Accretion Shares. Deferred compensation accretion. Schedule of Share Based Compensation Restricted Stock Grant [Table Text Block] New Consulting Agreement [Member] Shareholder [Member] Letter of Understanding [Member] Exercise Price Range Per Share, Outstanding, Beginning Relative Fair Value, Outstanding, Beginning. Exercise Price Range Per Share, Granted. Relative Fair Value, Granted. Share based compensation arrangement by share based payment award options granted intrinsic value. Sharebased compensation arrangements by ShareBased payment award options in period exercise price range per share forfeited. Sharebased compensation arrangements by ShareBased payment award options in period exercises in period relative fair value forfeited. ShareBased compensation arrangement By ShareBased payment award options grants in period forfeited intrinsic value. Exercise Price Range Per Share, Exercised. Relative Fair Value, Exercised Share based compensation arrangement by share based payment award options in period exercisedintrinsic value. Exercise Price Range Per Share, Expired. Relative Fair Value, Expired. Share based compensation arrangement by share based payment award options in period expired intrinsic value. Share based compensation arrangement by share based payment award options vested and exercisable ending balance. Share based compensation arrangements by share based payment award Optionsexercisable in period exercise price range per share vested and exercisable. Share based compensation arrangement by share based payment award options outstanding weighted average exercise price vested and exercisable. Share based compensation arrangements by share based payment award options exercisable in period relative fair value vested and exercisable. Number of Stock Option Unvested, Ending Balance. Exercise Price Range Per Share, Unvested. Weighted Average Exercise Price, Unvested. Relative Fair Value, Unvested. Aggregate Intrinsic Value, Unvested Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan. Share based compensation arrangement by share based paymentaward non option equity instruments weighted average Remaining ContractualTerm. Share based compensation arrangement by share based payment award non option equity instruments weighted average grant fair value. Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Aggregate Intrinsic Value. Share based compensation arrangement by share based payment award non option equity instruments grants in period aggregate intrinsic value granted. Weighted average per share amount at which grantees can acquire shares of common stock by exercise of non-option equity. Share Based compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Remaining Contractual Term Share based compensation arrangement by share based payment award non option equity instruments weighted average grant fair value. Weighted average price at which grantees could have acquired the underlying shares with respect to stock non options that were terminated. ShareBased compensation arrangement by shareBased payment award non option equity instruments grants in period weighted average grant fair value forfeited. ShareBased compensation arangement by shareBased payment award non option equity instruments grants in period aggregate intrinsic forfeited. Weighted Average Exercise Price, Warrants exercised. Share based compensation arrangement by share based payment award non option equity instruments weighted average grant fair value exercised. Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Aggregate Intrinsic Value Exercised Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expired Share based compensation arrangements by share based payment award non options expired in period weighted average exercise price. Share based compensation arrangement by share based payment award non option equity instruments weighted average grant fair value expired. Share based compensation arrangement by share based payment award non option equity instruments grants in period aggregate intrinsic value expired. Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Vested And Exercisable Share based compensation arrangements by share based payment award non options expired in period weighted average price vested and exerciable. Share based compensation arrangement by share based payment award non option equity instruments weighted average grant fair value vested and exercisable. Weighted average remaining contractual term unvested and exercisable. Share based compensation arrangement by share based payment award non option equity instruments aggregate intrinsic value vested and exercisable. Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Vested And Exercisable Share based compensation arrangement by share based paymentaward non option equity instruments weighted average price vested. Share based compensation arrangement by share based payment award non option equity instruments weighted average grant fair value vested. Share based compensation arrangement by share based payment award non option equity instruments aggregate intrinsic value vested. Going Concern And Liquidity [PolicyTextBlock] Restricted Stock Grants. Warrant Liability [PolicyTextBlock] Schedule Of Payments [Table Text Block] Notes Payable Disclosure [Text Block] Chief Technology Officer [Membe] Forfeiture Shares. Deferred Compensation Forfeiture. Share based compensation arrangement by share based paymentaward non option equity instruments weighted average Remaining ContractualTerm. Share Based compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expired In Period Weighted Average Remaining Contractual Term. AIQ System Inc [Member] NNS Co Ltd [Member] Payments to consultants. Effect of Dilutive Instruments [Abstract] Convertible notes interest expense. Numerator for Diluted Earning Per Share Amount. Convertible promissory note. Non refundable deposit. Cash annual bonus. Deferred compensation canceled. Canceled shares. Hyuncheol Peter Kim [Member] Assets, Current Assets [Default Label] Liabilities, Current Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Shares, Outstanding Shares Issued, Value, Share-Based Payment Arrangement, Forfeited Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited ForfeitureOfRestrictedStockGrants Increase (Decrease) in Prepaid Expense Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Other Productive Assets Net Cash Provided by (Used in) Investing Activities Repayments of Notes Payable Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Finite-Lived Intangible Assets, Net Impairment of Intangible Assets (Excluding Goodwill) Notes Payable, Current DebtInstrumentAdditions DebtInstrumentUnamortizedDiscountAdditions Convertible Notes Payable, Current Debt Conversion, Converted Instrument, Amount AccruedInterest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceRangePerShareOutstandingBeginning Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRelativeFairValueOutstandingBeginning Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableEndingBalance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedEndingBalance ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAggregateIntrinsicValueUnvested Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantFairValue ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageRemainingContractualTerm Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net EX-101.PRE 10 buuz-20221231_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover - USD ($)
12 Months Ended
Dec. 31, 2022
Apr. 13, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2022    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2022    
Current Fiscal Year End Date --12-31    
Entity File Number 000-50331    
Entity Registrant Name CALETHOS, INC.    
Entity Central Index Key 0001174891    
Entity Tax Identification Number 98-0371433    
Entity Incorporation, State or Country Code NV    
Entity Address, Address Line One 11753 Willard Avenue    
Entity Address, City or Town Tustin    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 92782    
City Area Code (714)    
Local Phone Number 352-5315    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 13,041,055
Entity Common Stock, Shares Outstanding   14,495,621  
ICFR Auditor Attestation Flag false    
Auditor Firm ID 587    
Auditor Name RBSM LLP    
Auditor Location Larkspur, CA    
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Current assets    
Cash and cash equivalents $ 2,067,000 $ 3,047,000
Prepaid and other current expenses 4,000 7,000
Total current assets 2,071,000 3,054,000
Other assets 38,000
Total assets 2,071,000 3,092,000
Current liabilities    
Accounts payable and accrued expenses 540,000 434,000
Convertible promissory notes, net 4,613,000 3,087,000
Notes payable 61,000 111,000
Total current liabilities 5,214,000 3,632,000
Commitments and contingencies (Note 7)
Stockholders’ deficit    
Preferred stock, value
Common stock, par value $0.001, 100,000,000 shares authorized; 24,495,621 and 25,995,621 shares issued and outstanding 24,000 26,000
Additional paid-in capital 11,480,000 16,269,000
Other comprehensive income (loss) 5,000 (2,000)
Stock subscription receivable (2,000) (2,000)
Accumulated deficit (14,650,000) (16,831,000)
Total stockholders’ deficit (3,143,000) (540,000)
Total liabilities and stockholders’ deficit 2,071,000 3,092,000
Series A Convertible Preferred Stock [Member]    
Stockholders’ deficit    
Preferred stock, value
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2022
Dec. 31, 2021
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 100,000,000 100,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 24,495,621 25,995,621
Common stock, shares outstanding 24,495,621 25,995,621
Series A Convertible Preferred Stock [Member]    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 3,600,000 3,600,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]    
Revenue
Operating expenses    
Professional fees 667,000 1,033,000
Restricted stock grants (4,791,000) 5,062,000
General and administrative expenses 52,000 57,000
Impairment loss 154,000
Total operating (income) expenses (3,918,000) 6,152,000
Income (loss) from operations 3,918,000 (6,152,000)
Other income (expenses)    
Interest income 7,000
Financing costs (1,744,000) (597,000)
Total other expenses (1,737,000) (597,000)
Income (loss) before provision for income taxes 2,181,000 (6,749,000)
Provision for income taxes
Net income (loss) $ 2,181,000 $ (6,749,000)
Net income (loss) per share, basic $ 0.15 $ (0.35)
Net income (loss) per share, diluted $ 0.08 $ (0.35)
Weighted average common shares outstanding – basic 14,495,621 19,482,261
Weighted average common shares outstanding – diluted 29,342,327 19,482,261
Comprehensive income (loss):    
Change in foreign currency translation $ 7,000 $ (2,000)
Comprehensive income (loss) $ 2,188,000 $ (6,751,000)
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Changes in Stockholders' Deficit - USD ($)
Preferred Stock [Member]
Series A Convertible Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Stock Subscription Receivable [Member]
AOCI Attributable to Parent [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2020 $ 17,000 $ 8,744,000 $ (2,000) $ (10,082,000) $ (1,323,000)
Beginning balance, shares at Dec. 31, 2020 16,634,951          
Relative fair value of warrants issued with convertible promissory note 1,690,000 1,690,000
Stock options issued for services 575,000 575,000
Stock issued for debt forgiveness 166,000 166,000
Stocks issued for debt forgiveness, shares   75,000          
Stock issued for accrued compensation 38,000 38,000
Stocks returned $ (4,000) 4,000
Stocks returned, shares   (3,674,330)          
Stock issued on exercise of options $ 2,000 $ 2,000
Stock issued on exercise of options, shares   1,435,000         1,435,000
Stock-based compensation 272,000 $ 272,000
Stock-based compensation, shares   25,000          
Restricted common stock awards issued for compensation $ 11,000 4,780,000 4,791,000
Restricted common stock awards issued for compensation, shares   11,500,000          
Foreign currency translation income (2,000) (2,000)
Net income (Loss) (6,749,000) (6,749,000)
Ending balance, value at Dec. 31, 2021 $ 26,000 16,269,000 (2,000) (2,000) (16,831,000) $ (540,000)
Ending balance, shares at Dec. 31, 2021 25,995,621          
Stock issued on exercise of options, shares            
Stock-based compensation 6,377,000 $ 6,377,000
Foreign currency translation income 7,000 7,000
Net income (Loss) 2,181,000 2,181,000
Forfeiture of stock-based compensation $ (2,000) (11,166,000) (11,168,000)
Forfeiture of stock-based compensation, shares   (1,500,000)          
Ending balance, value at Dec. 31, 2022 $ 24,000 $ 11,480,000 $ (2,000) $ 5,000 $ (14,650,000) $ (3,143,000)
Ending balance, shares at Dec. 31, 2022 24,495,621          
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended 24 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2022
Cash Flows From Operating Activities      
Net income (loss) $ 2,181,000 $ (6,749,000)  
Adjustments to reconcile net income (loss) to net cash used in operating activities:      
Impairment 154,000  
Amortization of convertible promissory note discounts 1,526,000 524,000  
Fair value of equity-based compensation 846,000  
Forfeiture of restricted stock grants (11,168,000)  
Accretion of compensation cost for restricted stock awards 6,377,000 4,791,000  
Changes in operating assets and liabilities      
Prepaid expenses and other current assets 3,000 (5,000)  
Accounts payable and accrued expenses 107,000 28,000  
Net Cash Used in Operating Activities (820,000) (565,000)  
Cash Flows From Investing Activities      
Other assets (105,000) (38,000)  
Net Cash Used in Investing Activities (105,000) (38,000)  
Cash Flows From Financing Activities      
Proceeds from the issuance of convertible promissory notes 3,550,000  
Proceeds from the issuance of notes payable 150,000  
Repayments of notes payable (50,000) (50,000)  
Proceeds from the exercise of options 2,000  
Net Cash (Used in) Provided by Financing Activities (50,000) 3,652,000  
Effect of exchange rate changes on cash and cash equivalents (5,000) (2,000)  
Net (decrease) increase in Cash (980,000) 3,047,000  
Cash, Beginning of Period 3,047,000
Cash, End of Period 2,067,000 3,047,000 $ 2,067,000
Supplemental disclosure of cash flow information:      
Cash paid for interest 5,407  
Cash paid for income taxes  
Non-cash investing and financing activities      
Relative fair value of warrants issued with convertible promissory notes 1,690,000  
Common stock issued for accrued compensation 38,000  
Common stock issued from forgiven debt 166,000  
Original issue discount recorded on convertible promissory notes $ 355,000  
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.1
ORGANIZATION AND ACCOUNTING POLICIES
12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
ORGANIZATION AND ACCOUNTING POLICIES

Note 1 - Organization and Accounting Policies

 

CalEthos, Inc. (the “Company” or “we”) was incorporated on March 20, 2002 under the laws of the State of Nevada.

 

The Company is implementing its plan to build a clean-energy-powered, modular immersion and liquid cooled data center that provides colocation data center services to enterprise IT customers. In addition, the Company may acquire assets and all or part of other companies operating in the high-density computing industry or to invest or joint venture with other more-established companies already in the industry that would add value to the Company’s business strategy.

 

In July 2022, due to the declining state of the bitcoin mining industry and market for its planned products, the Company’s board of directors resolved to discontinue the development in South Korea of the Company’s 5 nanometer ASIC chip and containerized, immersion-cooled bitcoin mining computer system and to focus exclusively on developing the clean-energy-powered data center segment of its business strategy. The Company has suspended operations of its South Korean subsidiary and will decide in the next twelve months whether to use it to develop other products or dissolve it.

 

Incorporation of Korean entity

 

On November 5, 2021, AIQ System Inc. (“AIQ”) was incorporated in Seoul, Republic of Korea. AIQ is authorized to issue 3 million shares of common stock. At the date of incorporation, 10,000 shares were issued to the Company for 100,000,000 Korean Won or approximately $89,000 for 100% ownership of AIQ.

 

Basis of Presentation

 

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary from the formation date. All material intercompany transactions and balances have been eliminated in consolidation.

 

Going Concern and Liquidity

 

The Company incurred net income of approximately $2,181,000 for the year ended December 31, 2022, of which $4,791,000 was attributable to a noncash transaction for the reversal of compensation for restricted stock units, and had an accumulated deficit of approximately $14,650,000 as of December 31, 2022. The Company has financed its activities principally through debt and equity financing and shareholder contributions. Management expects to incur additional losses and cash outflows in the foreseeable future in connection with its operating activities.

 

The Company’s consolidated financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

 

The Company is subject to a number of risks similar to those of other similar stage companies, including dependence on key individuals; successful development, marketing and branding of products; uncertainty of product development and generation of revenues; dependence on outside sources of financing; risks associated with research and development; dependence on third-party suppliers and collaborators; protection of intellectual property; and competition with larger, better-capitalized companies. Ultimately, the attainment of profitable operations is dependent on future events, including obtaining adequate financing to fund its operations and generating a level of revenues adequate to support the Company’s cost structure.

 

The Company will need to raise debt or equity financing in the future in order to continue its operations and achieve its growth targets. However, there can be no assurance that such financing will be available in sufficient amounts and on acceptable terms, when and if needed, or at all. The precise amount and timing of the funding needs cannot be determined accurately at this time, and will depend on a number of factors, including market demand for the Company’s products and services, the success of product development efforts, the timing of receipts for customer deposits, the management of working capital, and the continuation of normal payment terms and conditions for purchase of goods and services. The Company believes its cash balances and cash flow from operations will not be sufficient to fund its operations and growth for the next twelve months from the issuance date of these financial statements. If the Company is unable to substantially increase revenues, reduce expenditures, or otherwise generate cash flows from operations, then the Company will likely need to raise additional funding from investors or through other avenues to continue as a going concern.

 

 

COVID-19

 

The continuing COVID-19 global pandemic has caused significant disruption to the economy and financial markets globally, and the full extent of the potential impacts of COVID-19 are not yet known. Circumstances caused by the COVID-19 pandemic are complex, uncertain and rapidly evolving. The impact of COVID-19 has not been significant to the Company’s results of operations, financial condition, and liquidity and capital resources. Although no material impairment or other effects have been identified to date, there is substantial uncertainty in the nature and degree of its continued effects over time. That uncertainty affects management’s accounting estimates and assumptions, which could result in greater variability in a variety of areas that depend on these estimates and assumptions as additional events and information become known. The Company will continue to consider the potential impact of the COVID-19 pandemic on its business operations.

 

Use of Estimates

 

The preparation of consolidated financial statements in conformity with GAAP and requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods.

 

Foreign Currency Translation

 

The financial statements of foreign subsidiaries, for which the functional currency is the local currency, are translated into U.S. dollars using the exchange rate at the consolidated balance sheet date for assets and liabilities and a weighted-average exchange rate during the year for revenue, expenses, gains and losses. Translation adjustments are recorded as other comprehensive income (loss) within shareholders’ equity (deficit). Gains or losses from foreign currency transactions are recognized in the consolidated statements of operations.

 

Fair Value Measurement

 

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Applicable accounting guidance provides an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. There are three levels of inputs that may be used to measure fair value:

 

Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 - Other inputs that are directly or indirectly observable in the marketplace.

Level 3 - Unobservable inputs which are supported by little or no market activity.

 

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

 

As of and for the year ended December 31, 2022, the Company had no assets or liabilities that require fair value measurement.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates its fair value. The Company maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (“FDIC”) in accounts that at times may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions. As of December 31, 2022 and 2021, the Company had $1,817,000 and $2,797,000 in excess of the federal insurance limit, respectively.

 

Prepaid Expense

 

Prepaid expenses are assets held by the Company, which are expected to be realized and consumed within twelve months after the reporting period.

 

Other Assets

 

Other assets consist of long-term advances paid for chip and processor design and development.

 

 

Related Parties

 

The Company follows Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) section 850-10 for the identification of related parties and disclosure of related party transactions.

 

Pursuant to ASC section 850-10-20 the related parties include (a.) affiliates of the Company (“Affiliate” means, with respect to any specified Person, any other Person that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the Securities Act); (b.) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option of ASC section 825–10–15, to be accounted for by the equity method by the investing entity; (c.) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; (d.) principal owners of the Company; (e.) management of the Company; (f.) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and (g.) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

 

The consolidated financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: (a.) the nature of the relationship(s) involved; (b.) a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; (c.) the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and (d.) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.

 

Commitments and Contingencies

 

The Company follows ASC section 450-20 to report accounting for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or un-asserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or un-asserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.

 

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.

 

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.

 

Debt Discounts

 

The Company accounts for debt discounts originating in connection with conversion features that remain embedded in the related notes in accordance with ASC 470-20, Debt with Conversion and Other Options. These costs are classified on the balance sheet as a direct deduction from the debt liability. The Company amortizes these costs over the term of its debt agreements as financing cost in the consolidated statement of operations and comprehensive loss.

 

Warrant Liability

 

In connection with financing arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes Merton (“BSM”) option pricing model as of the measurement date.

 

 

Stock-Based Compensation

 

We account for our stock-based compensation under ASC 718, “Compensation – Stock Compensation” using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges it equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments.

 

We use the fair value method for equity instruments granted to non-employees and use the BSM model for measuring the fair value of options. The stock based fair value compensation is determined as of the date of the grant (measurement date) and is recognized over the vesting periods.

 

Income Taxes

 

The Company accounts for income taxes in accordance with ASC 740, Income Taxes, deferred tax assets and liabilities are computed based on the difference between the financial reporting and income tax bases of assets and liabilities using the enacted marginal tax rate. ASC 740 requires that the net deferred tax asset be reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some portion or all of the net deferred tax asset will not be realized.

 

The Company accounts for income taxes using an asset and liability approach, which requires the recognition of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. The measurement of current and deferred tax assets and liabilities is based on provisions of enacted tax laws; the effects of future changes in tax laws or rates are not anticipated. If necessary, the measurement of deferred tax assets is reduced by the amount of any tax benefits that are not expected to be realized based on available evidence.

 

The Company has adopted guidance related to the accounting for uncertainty in income taxes which prescribes rules for recognition, measurement and classification in the financial statements of tax positions taken or expected to be taken in a tax return. The guidance prescribes a two-step approach which involves evaluating whether a tax position will be more likely than not (greater than 50 percent likelihood) sustained upon examination based on the technical merits of the position. The second step requires that any tax position that meets the more likely than not recognition threshold be measured and recognized in the financial statements at the largest amount of benefit that is a greater than 50 percent likelihood of being realized upon settlement.

 

The Company’s policy is to recognize interest and penalties, if any, related to unrecognized tax benefits in income tax expense. The Company is not currently under examination by any taxing authority nor has the Company been notified of a pending examination. The statute of limitations for which the Company is generally no longer subject to federal or state income tax examinations by tax authorities is for years before 2013.

 

Earnings Per Share

 

We use ASC 260, “Earnings Per Share” for calculating the basic and diluted earnings (loss) per share. We compute basic earnings (loss) per share by dividing net income (loss) by the weighted average number of common shares outstanding. Diluted earnings (loss) per share is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential common shares outstanding during the period using the treasury stock method. Dilutive potential common shares include outstanding stock options and warrants and stock awards. For periods with a net loss, basic and diluted loss per share is the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share.

 

Securities that could potentially dilute income (loss) per share in the future were not included in the computation of diluted income (loss) per share on December 31 because their inclusion would be anti-dilutive as follows:

   2022   2021 
Restricted stock awards   -    11,500,000 
Convertible promissory notes and accrued interest   4,125,699    3,947,394 
Series A warrants issued with convertible promissory notes   1,668,304    1,921,304 
Series B warrants to be issued upon exercise of Series A warrants   1,668,304    1,921,304 
Warrants issued for services   100,000    100,000 
Total potential future shares   7,562,307    19,390,002 

 

Recent Accounting Pronouncements

 

The Company’s management reviewed all recently issued accounting standard updates (“ASU’s”) not yet adopted by the Company and does not believe the future adoptions of any such ASU’s may be expected to cause a material impact on the Company’s condensed consolidated financial condition or the results of its operations.

 

 

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTY TRANSACTIONS
12 Months Ended
Dec. 31, 2022
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

Note 2 – Related Party Transactions

 

The Company incurred approximately $200,000 and $199,000 for years ended December 31, 2022 and 2021, and paid approximately $200,000 and $202,000, respectively, to M1 Advisors for the services of the Company’s CEO and miscellaneous operating expenses.

 

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.1
INTANGIBLE AND OTHER ASSETS
12 Months Ended
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE AND OTHER ASSETS

Note 3 – Intangible and Other Assets

 

On December 23, 2021, AIQ entered into a Technology Development Agreement (the “Agreement”) with PICOCEL, Co., Ltd. (the “Contractor” or “PICOCEL”) to develop a FPGA based Bitcoin mining simulation system. The Agreement was expected to be completed within 6 weeks for a total contract price of 198,000,000 Korean Won (“KRW”) or approximately $167,000. Total payments made to PICOCEL as of December 31, 2022 amounted to approximately $69,000. On March 17, 2022, the Company and PICOCEL entered into a mutual agreement to cancel and terminate the Agreement. As of the date of the termination, PICOCEL had completed the first phase of the Agreement upon delivery of the SHA-256 code and FPGA board simulator.

 

On April 5, 2022, AIQ entered into a Technology Development Agreement (the “Agreement”) with NNS, Co., Ltd. (the “Contractor” or “NNS”) to develop a FPGA based Bitcoin mining simulation system. The Agreement was expected to be completed within 9 weeks for a total contract price of 99,000,000 KRW, including 9,000,000 KRW VAT, or approximately $82,000. The payments are scheduled as follows:

 

   Amount 
   USD   KRW 
Within 5 days after signing the contract  $41,000    49,500,000 
Within 5 days after all conditions are met as stated in “Schedule B – Statement of Work”   41,000    49,500,000 
Total  $82,000    99,000,000 

 

Payment of 90,000,000 KRW or approximately $69,000 was made to NNS as of December 31, 2022, which was expensed and included in the consolidated statement of operations.

 

Impairment

 

During the six months ended June 30, 2022, the Bitcoin market was in a constant decline, and since the ASIC chip being developed by AIQ was planned to be used for Bitcoin mining machines, management believes that there is an impairment indicator. In August 2022, management discontinued the operations of AIQ.

 

Indicators of impairment include significant underperformance relative to historical or projected future operating results, significant changes in our use of the assets or in our business strategy, loss of or changes in customer relationships and significant negative industry or economic trends. When indications of impairment arise for a particular asset or group of assets, we assess the future recoverability of the carrying value of the asset (or asset group) based on an undiscounted cash flow analysis. If the carrying value exceeds projected, net, undiscounted cash flows, an additional analysis is performed to determine the asset’ (or asset group), typically a discounted cashflow analysis, and an impairment charge is recorded for the excess of carrying value over fair value.

 

As of December 31, 2022, intangibles and other assets were fully impaired. Impairment loss amounted to $154,000, inclusive of a $12,000 impairment of prepaid VAT related to the services provided by PICOCEL and NNS.

 

The table below summarizes the impairment loss for the year ended December 31, 2022:

 

   Amount   VAT   Total 
PICOCEL  $69,000   $5,000   $74,000 
NNS   69,000    5,000    74,000 
Total   138,000    10,000    148,000 
Foreign exchange loss   4,000    2,000    6,000 
Impairment loss  $142,000   $12,000   $154,000 

 

 

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.1
ACCOUNTS PAYABLE AND ACCRUED EXPENSES
12 Months Ended
Dec. 31, 2022
Payables and Accruals [Abstract]  
ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Note 4 – Accounts Payable and Accrued Expenses

 

The following table summarizes the Company’s accounts payable and accrued expense balances as of December 31:

 

   2022   2021 
Accounts payable  $186,000   $221,000 
Accrued expenses   28,000    99,000 
Accrued interest   326,000    114,000 
Accounts payable and accrued expenses  $540,000   $434,000 

 

Accrued Interest

 

The following table presents the details of accrued interest as of December 31:

 

   2022   2021 
Notes payable  $17,000   $9,000 
Convertible promissory notes   309,000    105,000 
Balance, end of the year  $326,000   $114,000 

 

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.1
NOTES PAYABLE
12 Months Ended
Dec. 31, 2022
Notes Payable  
NOTES PAYABLE

Note 5 – Notes Payable

 

The table below summarizes the transactions as of December 31:

 

   2022   2021 
Balance, beginning of the year  $111,000   $11,000 
Additions       150,000 
Payments   (50,000)   (50,000)
Balance, end of the year  $61,000   $111,000 

 

On July 7, 2020, the Company issued a promissory note in the principal amount of $11,000. The note is noninterest bearing. The principal was due on or before August 7, 2020. During any event of default under the note, the interest rate shall increase to 10% per annum. Events of default include failure to pay principal or interest, breach of covenants, breach of representations and warranties, borrower’s assignment of substantial part of its property or business, any money judgment, writ, or similar process shall be entered or filed against the borrower or any subsidiary of the borrower or any of its properties or other assets for more than $100,000, bankruptcy, liquidation of business, and cessation of operations. The principal amount outstanding under this note was $11,000 as of December 31, 2022. The note principal and interest are past due, therefore in default. For the year ended December 31, 2022, the Company has accrued approximately $3,000 of default interest.

 

On February 19, 2021, the Company issued a promissory note in the principal amount of $25,000. The interest on the unpaid principal balance accrued at a rate of 10% per annum. The principal and any accrued interest was to be paid in a single installment on or before February 19, 2022. If the Company fails to pay the balance of this note in full on the due date or fails to make any payment due within 15 days of the due date, any unpaid principal shall accrue interest at the rate of 15% per annum during the default (default interest). Events of default include failure to make any payment including accrued interest when due, voluntary, or involuntary petition of bankruptcy, appointment of a receiver, custodian, trustee or similar party to take possession of the Company’s assets or property, or assignment made by the Company for the benefit of creditors. The principal amount was settled in full on January 25, 2022.

 

On April 22, 2021, the Company issued a promissory note in the principal amount of $50,000. The interest on the unpaid principal balance accrued at a rate of 10% per annum. The principal and any accrued interest was to be paid in a single installment on or before April 22, 2022. If the Company fails to pay the balance of this note in full on the date or fails to make any payments due within 15 days of the due date, any unpaid principal shall accrue interest at the rate of 15% per annum during the default. Events of default include failure to make any payment including accrued interest when due, voluntary, or involuntary petition of bankruptcy, appointment of a receiver, custodian, trustee or similar party to take possession of the Company’s assets or property, or assignment made by the Company for the benefit of creditors. The principal amount outstanding under this note was $50,000 as of December 31, 2022. The note principal and interest are past due, therefore in default. Interest accrued, including default interest, as of December 31, 2022 is $10,000.

 

 

On July 1, 2021, the Company issued a promissory note in the principal amount of $25,000. The interest on the unpaid principal balance accrues at a rate of 10% per annum. The principal and any accrued interest were to be paid in a single installment on or before July 1, 2022. If the Company fails to pay the balance of this note in full on the date or fails to make any payments due within 15 days of the due date, any unpaid principal shall accrue interest at the rate of 15% per annum during the default (default interest). Events of default include failure to make any payment including accrued interest when due, voluntary, or involuntary petition of bankruptcy, appointment of a receiver, custodian, trustee or similar party to take possession of the Company’s assets or property, or assignment made by the Company for the benefit of creditors. The principal amount was settled in full on November 29, 2022.

 

Interest expense on notes payable amounted to $14,000 and $8,000 for the years ended December 31, 2022 and 2021, respectively.

 

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.1
CONVERTIBLE PROMISSORY NOTES
12 Months Ended
Dec. 31, 2022
Debt Disclosure [Abstract]  
CONVERTIBLE PROMISSORY NOTES

Note 6 – Convertible Promissory Notes

 

In 2021, the Company issued two convertible promissory notes amounting to $55,000 and $3,850,000 (the “Notes”), respectively. The total aggregate proceeds were $3,550,000 due to a $355,000 aggregate original issue discount. The Notes are non-interest bearing with the principal due and payable on March 1, 2022 and August 31, 2022, respectively. Any amount of unpaid principal on the date of maturity will accrue interest at rate of 10% per annum (default interest). Interest accrued as of December 31, 2022 is $133,000. The principal amount and all accrued interest are convertible into shares of the Company’s common stock, as of the date of issuance, at a rate of $1.00 and $1.25 per share (“Conversion Rate”), respectively. The Conversion Rate is adjustable if, at any time when any principal amount of the Notes remains unpaid or unconverted, the Company issues or sells any shares of the Company’s common stock for no consideration or for a consideration per share (before deduction of reasonable expenses or commissions or underwriting discounts or allowances in connection therewith), which is less than the Conversion Rate in effect on the date of such issuance (or deemed issuance) of such shares of common stock (a “Dilutive Issuance”). Immediately upon a Dilutive Issuance, the Conversion Rate will be reduced to the amount of the consideration per share received by the Company in such Dilutive Issuance. Events of default include failure to issue conversion shares, the occurrence of a breach or default under any other agreement, any money judgment, writ, or similar process entered or filed against the Company or any of its property or other assets for more than $100,000, bankruptcy filing, application for the appointment of a custodian, trustee or receiver, insolvency, the Company’s common stock delisted, or dissolution, winding up, or termination of the business of the Company. The note principal and interest are past due, therefore in default.

 

In connection with the issuance of the Notes, the Company issued to the purchasers of the Notes stock purchase warrants (the “Warrants”) to purchase an aggregate of 1,567,500 shares of the Company’s common stock for a purchase price of $1.50 to $1.87 per share, subject to adjustments. The Warrants were valued using the Black Scholes option pricing model for a total fair value of $3,004,000 based on a 3-year term, volatility of 404.91% to 405.93%, a risk-free equivalent yield of 0.27% to 0.42%, and stock price ranging from $0.10 to $1.95.

 

In accordance with ASC 470 - Debt, the Company has allocated the cash proceeds amounts of the Notes among the Notes, the Warrants and the conversion feature. The relative fair value of the Warrants issued amounted to approximately $1,690,000 and the beneficial conversion amounted to $0, which amounts are being amortized and expensed over the term of the Notes.

 

The Company determined that the conversion feature of the Notes would not be an embedded feature to be bifurcated and accounted for as a derivative in accordance with ASC 815-15 Derivatives and Hedging.

 

Financing cost recognized for the amortization of debt discount was approximately $1,526,000 and $524,000 for the years ended December 31, 2022 and 2021, respectively.

 

The convertible promissory notes consisted of the following as of December 31:

 

   2022   2021 
Principal          
Balance, beginning of year  $4,613,000   $708,000 
Additions       3,905,000 
Balance, end of year   4,613,000    4,613,000 
           
Discount          
Balance, beginning of year   1,526,000    5,000 
Additions   -    2,045,000 
Amortization   (1,526,000)   (524,000)
Balance, end of year   -    1,526,000 
Net carrying amount  $4,613,000   $3,087,000 

 

Effective interest rate used to amortize the debt discount for the years ended December 31, 2022 and 2021 ranges from 4.76% to 64.60%.

 

 

Potential future shares to be issued on conversion of the notes as of December 31:

 

   2022   2021 
Principal  $4,613,000   $4,613,000 
Interest   309,000    105,000 
Total   4,922,000    4,718,000 
Conversion price per share   1.001.25    1.001.25 
Potential future shares   4,125,699    3,947,394 

 

The default interest expense for the convertible promissory notes amounted to $204,000 and $65,000 for the year ended December 31, 2022, and 2021, respectively.

 

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES
12 Months Ended
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

Note 7 – Commitments and contingencies

 

Litigation

 

From time to time, the Company may become subject to legal proceedings, claims and litigation arising in the ordinary course of business. In addition, the Company may receive letters alleging infringement of patent or other intellectual property rights. The Company is not currently a party to any material legal proceedings, nor is the Company aware of any pending or threatened litigation that would have a material adverse effect on the Company’s business, operating results, cash flows or financial condition should such litigation be resolved unfavorably, except as follows.

 

On January 3, 2022, a complaint was filed against our company in the Superior Court of California, County of Los Angeles titled Michael Sekula v. CalEthos Inc, Michael Campbell and Does 1-25 (Case No. 22STCV00121) for, among other matters, failure to pay wages, fraud and other wage-related claims. In the complaint, the plaintiff claimed he worked under a consulting agreement as Vice President of Brand Management of our company and was to be paid $4,000 per month and to receive an option to purchase 50,000 shares of our common stock that was to vest quarterly over the term of the agreement. In the complaint, the plaintiff alleged that, on or around March 27, 2020, the Company ceased paying the plaintiff despite the plaintiff’s continuing efforts on behalf of our company and that the Company agreed to continue to accrue his monthly retainer amount until such time that the Company received at least $100,000 in funding. Plaintiff further alleged that he continued to work for our company for 38 additional weeks in reliance on our promise of payment. The plaintiff claimed that our refusal to make the promised payments amounts to violations of the California labor laws and seeks damages in excess of $450,000.

 

On June 9, 2022, a Settlement Agreement and Mutual Release was reached by the parties in the above mentioned complaint whereby as full consideration for the plaintiff’s execution of and compliance with the agreement and plaintiff’s release of all claims against the defendants, the Company agreed to pay a gross settlement amount of $90,000. Such payment was made on June 23, 2022.

 

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.1
EQUITY
12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
EQUITY

Note 8 – Equity

 

Shares Authorized

 

The Company is authorized to issue 200,000,000 shares of which 100,000,000 shares shall be preferred stock, par value $0.001 per share, and 100,000,000 shares shall be common stock, par value $0.001 per share.

 

Preferred Stock

 

Series A Convertible Preferred Stock

 

The Series A Convertible Preferred Stock (“Series A”) is convertible into shares of the Company’s common stock at the rate of $1.38 per share, subject to adjustments based on the Company’s future sales of financial instruments at a value less than $1.38 per share. The holders of the Series A have the right to convert any time after the date of issuance. With the issuance of the convertible promissory notes, as explained in Note 5 above, the Series A’s conversion rate adjusted to $1.00 per share. In accordance with ASC 470, the Company has calculated the effect of the conversion rate adjustment, which was approximately $36,000. The conversion rate adjustment has been treated as a deemed dividend, which has been presented in the Statement of Changes in Stockholders’ Deficit.

 

The Series A is mandatorily convertible upon (i) the closing of the sale of shares of the Company’s common stock to the public in an underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $10,000,000 of gross proceeds to the Company, (ii) the close of business on the sixtieth consecutive day on which the closing price of the Company’s common stock on the OTC Markets is at least $2.80 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, stock combination or other similar recapitalization with respect to the common stock, or (iii) the affirmative vote of the holders of at least 66⅔% of the outstanding shares of Series A, given at a meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders all outstanding shares of Series A shall automatically be converted into shares of the Company’s common stock, at the then effective conversion rate.

 

 

On any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Series A shall be entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of Series A held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of the Articles of Incorporation, holders of Series A shall vote together with the holders of common stock as a single class.

 

From and after the date of the issuance of any shares of Series A, a cumulative dividend on each outstanding share of Series A Preferred Stock shall accrue at a rate per annum equal to ten percent of the Series A original issue price. Accrued dividends on the Series A shall be paid in shares of the Company’s common stock, such shares to be valued for such purpose at the applicable series A conversion price.

 

On February 11, 2020, the Company converted 85,975 shares of Series A into a Convertible Promissory Notes in the principal amount approximately $147,000.

 

Common Stock

 

In January 2021, the Company’s President and a member of the Board of Directors, resigned as an officer and director of the Company (“Termination Agreement”). Part of the Termination Agreement stipulates the return of 3,674,330 shares of the Company’s common stock (“Cancelled Shares”). The Cancelled Shares were returned and cancelled on April 20, 2021.

 

In March 2021, the Company’s Chief Executive Officer (“CEO’) agreed to forgive approximately $68,000 due to him, which was treated as contributed paid in capital.

 

In March 2021, the Company’s Chief Financial Officer agreed to reduce the amounts due to him from approximately $128,000 to $30,000. For the reduction of $98,000, the Company will issue 75,000 shares of common stock. The remaining liability of $30,000 will be paid in cash.

 

In September 2021, the Company entered into a release agreement with one of its consultants. As part of the separation payment, the Company issued 25,000 shares valued at $76,000 and paid $20,000 cash in October 2021.

 

Restricted Common Stock Awards

 

On August 17, 2021, the Company entered into Restricted Share Award Agreements (the “Award Agreements”) with two consultants pursuant to which the Company issued to the consultants shares of common stock of the Company in exchange for their future services. The Awards had an initial term of one year, which was to be automatically renewed on a year-to-year basis unless either party gave a written notice of termination. The two consultants who entered into these agreements include:

 

  1) A consultant who was granted 10,000,000 restricted share awards.
  2) An entity, which is owned by the Company’s CEO and majority shareholder, was granted 1,500,000 restricted share awards.

 

The Company’s management accounted for the Award Grants as restricted stock compensation in accordance with ASC 718 – Stock Compensation (“ASC 718”). ASC 718 required the Company to estimate the service period over which the compensation cost would be recognized. Management had estimated that the first two development phases would be completed within 15 months and the Foundry Mask would be completed within 6 months for a total of 21 months service period. Compensation cost was to be recognized ratably over 21 months and in the same manner had the Company paid in cash. The estimated service period would be adjusted for changes in actual and expected completion dates. Any such change was to be recognized prospectively, and the remaining deferred compensation was to be recognized over the remaining service period.

 

The Company issued restricted stock grants totaling 10,000,000 shares (“Grant Shares”) to Hyuncheol (Peter) Kim (“CTO”), the Company’s former Chief Technology Officer, and 1,500,000 to a M1 Advisors LLC, a company owned by the Company’s chief executive officer. The value was $1.93 per share on the date of issuance (“Grant Date”) for an aggregate fair value of $22,195,000

 

The stock-based award compensation was recorded as an increase in deferred compensation expense, common stock, and additional paid-in capital in the Company’s books at the time of the grant.

 

On July 27, 2022, the Company sent the CTO, a letter notifying him that the Company’s Board of Directors had resolved to discontinue the Company’s 5 nanometer ASIC chip and bitcoin mining machine project and that his consulting agreement was to terminate at the end of August 2022. The Grant Shares issued in connection with his consulting agreement were canceled. As of the issuance date of these consolidated financial statements, the CTO had not executed the documentation required for the Company to cancel the Grant Shares; therefore, the Grant Shares are still legally outstanding, so the number of Grant Shares has not been removed from the total shares issued and outstanding. Since it is probable that the Grant Shares will not be earned, the Company has reversed the expense recognized for the fair value of the Grant Shares.

 

 

Also, at the end of August 2022, the Company canceled the restricted stock grant issued to M1 Advisors LLC.

 

The table below summarizes the transactions related to the Company restricted stock awards as of December 31, 2022:

 

   Shares   Deferred
compensation
 
Grant date fair value   11,500,000   $22,195,000 
Accretion   -    (11,168,000)
Canceled   (1,500,000)   (11,027,000)
Balance as of December 31, 2022   10,000,000   $- 

 

Restricted stock grant compensation expense for the year ended December 31, 2022, is as follows:

 

      
2022 Accretion expense  $6,377,000 
Reversal of 2021 accretion expense   (4,791,000)
Reversal of 2022 accretion expense   (6,377,000)
Restricted stock grant compensation  $(4,791,000)

 

Issuance of Stock Options and Warrants

 

In February 2021, the Company signed a new consulting agreement that granted one of its shareholders an option to purchase 750,000 shares of the Company’s common stock at $0.001 per share for the consultancy work provided from August 2020 to February 2021. The options were fully vested on the date of issuance. The fair value of the options was approximately $52,000, as of the grant date, of which approximately $38,000 was expensed and accrued during the year ended December 31, 2020 and $14,000 was expensed for the year ended December 31, 2021.

 

In May 2021, the Company signed a letter of understanding that granted one of its shareholders an option to purchase 300,000 shares of the Company’s common stock at $0.001 per share for the consultancy work provided during the Company’s restructuring phase from February 17, 2021 through April 30, 2021. The options were fully vested on the date of issuance. The fair value of the options was approximately $561,000, as of grant date, which was expensed during the year ended December 31, 2021.

 

In May 2021, an option holder exercised three options for 385,000, 750,000 and 300,000 shares of the Company’s common stock at an exercise price of $0.001 for each option, for total proceeds of approximately $2,000.

 

The table below summarizes the Company’s stock option activities for the years ended December 31, 2022 and 2021 (all share and per share data reflects the reverse stock split):

 

  

Number of

Stock Option

Shares

  

Exercise

Price

Range Per

Share

  

Weighted

Average

Exercise

Price

  

Relative

Fair

Value

  

Aggregate

Intrinsic

Value

 
Balance, January 1, 2021   385,000   $   $0.001   $   $7,315 
Granted   1,050,000    0.001    0.001    1.94     
Forfeited                    
Exercised   (1,435,000)   0.001    0.001         
Expired                    
Balance, December 31, 2021                    
Granted                    
Forfeited                    
Exercised                    
Expired                    
Balance, December 31, 2022      $   $   $   $ 
Vested and exercisable, December 31, 2022      $   $   $   $ 
Unvested, December 31, 2022      $   $   $   $ 

 

On September 15, 2021, the Company issued warrants to purchase 100,000 shares of the Company’s common stock. For the year ended December 31, 2021, the compensation expense, classified as professional fees in the consolidated statement of operations and comprehensive loss, was $195,000, which was calculated using the Black Scholes fair value option-pricing model with key input variables provided by management, as of the date of issuance: volatility of 359%, fair value of common stock $1.95, estimated life of 3 years, risk free rate of 0.43% and dividend rate of $0.

 

 

The table below summarizes the Company’s warrant activities for the years ended December 31, 2022 and 2021 (all share and per share data reflects the reverse stock split):

 

  

Number of Shares

   Weighted Average Strike Price/Share   Weighted Average Remaining Contractual Term (Years)   Weighted Average Grant Date Fair Value/Share  

Aggregate

Intrinsic

Value

 
Balance, January 1, 2021   353,804   $1.50    2.88   $0.18   $ 
Granted   1,667,500    1.86    3.00    1.67    0.11 
Forfeited                    
Exercised                    
Expired                    
Balance, December 31, 2021   2,021,304    1.80    2.98    1.14    0.17 
Vested and exercisable, December 31, 2021   2,021,304    1.80    2.98    1.14    0.17 
Unvested, December 31, 2021                    
                          
Balance, January 1, 2022   2,021,304    1.80    2.98    1.14    0.17 
Granted                    
Forfeited                    
Exercised                    
Expired   (253,000)   1.80    2.98    1.14    0.17 
Balance, December 31, 2022   1,768,304    1.84    3.00    1.49     
Vested and exercisable, December 31, 2022   1,768,304    1.84    3.00    1.49     
Unvested, December 31, 2022      $       $   $ 

 

The following table sets forth the weighted-average assumptions used to estimate the fair value of warrants granted for the year ended December 31:

 

   2022   2021 
Expected life (in years)       3 
Risk-free interest rate       0.27% - 0.42 %
Expected volatility       405% - 406%
Dividend yield       0.00%
Stock price       $ 0.101.95 

 

 

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.1
EARNINGS (LOSS) PER SHARE
12 Months Ended
Dec. 31, 2022
Earnings Per Share [Abstract]  
EARNINGS (LOSS) PER SHARE

Note 9 – Earnings (Loss) Per Share

 

The following table sets forth the computation of basic and diluted earnings (loss) per share for the years ended December 31:

 

SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED

Numerator  2022   2021 
Net income (loss)  $2,181,000   $(6,749,000)
Effect of dilutive instruments          
Convertible notes interest expense   204,000    - 
Numerator for diluted EPS   2,385,000    (6,749,000)
           
Denominator          
Denominator - for basic EPS   14,495,621    19,482,261 
           
Effect of dilutive instruments          
Warrants   721,006    - 
Restricted stock awards   

10,000,000

    - 
Convertible notes   4,125,699    - 
Dilutive potential common shares   14,846,705    - 
           
Denominator for diluted EPS   29,342,327    19,482,261 
           
Basic EPS  $0.15   $(0.35)
Diluted EPS  $0.08   $(0.35)

 

Securities that could potentially dilute loss per share in the future were not included in the computation of diluted loss per share for the year ended December 31, 2021 because their inclusion would be anti-dilutive. Common share equivalents amounted to 3,942,608 for warrants, 3,947,394 for convertible notes and 11,500,000 for restricted stock units for total of 19,390,002 as of December 31, 2021. For the year ended December 31, 2022, the Company had 14,846,705 dilutive securities.

 

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.1
DEFERRED TAX ASSETS AND INCOME TAX PROVISION
12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
DEFERRED TAX ASSETS AND INCOME TAX PROVISION

Note 10 – Deferred Tax Assets and Income Tax Provision

 

Deferred Tax Assets

 

At December 31, 2022, the Company had net operating loss (“NOL”) carry forwards for Federal income tax purposes of $3,070,000 that may be offset against future taxable income. No tax benefit has been reported with respect to these net operating loss carry-forwards in the accompanying financial statements because the Company believes that the realization of the Company’s net deferred tax assets of approximately $1,708,000 was not considered more likely than not and accordingly, the potential tax benefits of the net operating loss carry-forwards are fully offset by a full valuation allowance. Federal NOL’s have an indefinite carryover period and state NOL’s begin to expire in 2037 if not utilized by then.

 

Deferred tax assets consist primarily of the tax effect of NOL carry-forwards. The Company has provided a full valuation allowance on the deferred tax assets because of the uncertainty regarding its realization. The valuation allowance (decreased) increased by approximately $(782,000) and $2,191,000 for the reporting periods ended December 31, 2022 and 2021, respectively.

 

Components of deferred tax assets are as follows as of December 31:

 

   2022   2021 
Net deferred tax assets – Non-current:          
           
Intangible assets  $1,000   $- 
Impairment loss   38,000    - 
Interest expense limitations   802,000    - 
           
Stock-based compensation   9,000    1,488,000 
           
Expected income tax benefit from NOL carry-forwards   859,000    1,002,000 
           
Less valuation allowance   (1,709,000)   (2,490,000)
           
Deferred tax assets, net of valuation allowance  $-   $- 

 

 

Income Tax Provision in the Statements of Operations

 

A reconciliation of the federal statutory income tax rate and the effective income tax rate as a percentage of income before income taxes is as follows for the years ended December 31:

 

   2022   2021 
         
Federal statutory income tax rate   21.0%   21.0%
           
Change in valuation allowance on net operating loss carry-forwards   (21.0)   (21.0)
           
Effective income tax rate   0.0%   0.0%

 

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.1
SUBSEQUENT EVENTS
12 Months Ended
Dec. 31, 2022
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

Note 11 – Subsequent Events

 

The Company has evaluated all events that occurred after the balance sheet date through the date when the financial statements were issued to determine if they must be reported. The management of the Company determined the following reportable events:

 

Purchase of Land for Building a Data Center

 

On March 30, 2023, the Company signed an option agreement to acquire 80 acres of commercially zoned land in Imperial County, California (the “Option”) for $3,360,000 (“Purchase Price”). The Option expires in September 2024. The Company paid a non-refundable deposit of $84,000 on the signing of the Option. The Company is required to deposit an additional $84,000 into an escrow (“Escrow Funds”). If the Company does not exercise the Option by September 2024, the Escrow funds will be returned to the Company.

 

The Purchase Price is payable with a cash payment of $1,680,000 and the issuance of 840,000 shares of the Company’s common stock (the “Purchase Shares”). At the closing of the purchase (“Closing Date”), if the stock is trading at a value less than $1.00 per share, the Company is required to issue a promissory note in the amount of $840,000, payable on the third anniversary of the closing date, with an interest rate equal to the Secured Overnight Financing Rate plus 2.0%.

 

If the Purchase Shares are issued at the Closing Date, the Company has agreed to repurchase the Shares (the “Put Option”). The Put Option period ends on the one-year anniversary after a six-month holding period. However, if the Company’s common stock trades above $2.00 per share for 120 consecutive days, the Put Option expires. If the Company’s common stock trades below $2.00 per for 10 consecutive days, the Holder has the option for the Company to repurchase the Purchase Shares for $2.00 per share. o

 

Employment Agreement

 

On March 27, 2023, executed an offer of employment to hire an individual as the Company’s president and chief operating officer. The effective date of employment was March 28, 2023. The salary is $250,000 per year, with an increase to $300,000 annually, immediately once permits have been granted to start construction of the data center, and an increase to $350,000 annually, upon the data center being operational and contracted for 25% of the planned 100MW colocation capacity. Also, the individual is eligible for a cash annual bonus and2,000,000 shares that will be provided in an employee option or a restricted stock award, if certain milestones are accomplished. The stock grant will be included in a pending employment agreement that is planned to be completed between the Company and employee with the next couple of weeks.

 

Cancellation of Restricted Stock Awards

 

On April 10, 2023, we completed the required paperwork for our transfer agent to cancel 10,000,000 shares of restricted stock that was previously issued to Mr. Kim as our former CTO.

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.1
ORGANIZATION AND ACCOUNTING POLICIES (Policies)
12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Incorporation of Korean entity

Incorporation of Korean entity

 

On November 5, 2021, AIQ System Inc. (“AIQ”) was incorporated in Seoul, Republic of Korea. AIQ is authorized to issue 3 million shares of common stock. At the date of incorporation, 10,000 shares were issued to the Company for 100,000,000 Korean Won or approximately $89,000 for 100% ownership of AIQ.

 

Basis of Presentation

Basis of Presentation

 

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

 

Principles of Consolidation

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary from the formation date. All material intercompany transactions and balances have been eliminated in consolidation.

 

Going Concern and Liquidity

Going Concern and Liquidity

 

The Company incurred net income of approximately $2,181,000 for the year ended December 31, 2022, of which $4,791,000 was attributable to a noncash transaction for the reversal of compensation for restricted stock units, and had an accumulated deficit of approximately $14,650,000 as of December 31, 2022. The Company has financed its activities principally through debt and equity financing and shareholder contributions. Management expects to incur additional losses and cash outflows in the foreseeable future in connection with its operating activities.

 

The Company’s consolidated financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

 

The Company is subject to a number of risks similar to those of other similar stage companies, including dependence on key individuals; successful development, marketing and branding of products; uncertainty of product development and generation of revenues; dependence on outside sources of financing; risks associated with research and development; dependence on third-party suppliers and collaborators; protection of intellectual property; and competition with larger, better-capitalized companies. Ultimately, the attainment of profitable operations is dependent on future events, including obtaining adequate financing to fund its operations and generating a level of revenues adequate to support the Company’s cost structure.

 

The Company will need to raise debt or equity financing in the future in order to continue its operations and achieve its growth targets. However, there can be no assurance that such financing will be available in sufficient amounts and on acceptable terms, when and if needed, or at all. The precise amount and timing of the funding needs cannot be determined accurately at this time, and will depend on a number of factors, including market demand for the Company’s products and services, the success of product development efforts, the timing of receipts for customer deposits, the management of working capital, and the continuation of normal payment terms and conditions for purchase of goods and services. The Company believes its cash balances and cash flow from operations will not be sufficient to fund its operations and growth for the next twelve months from the issuance date of these financial statements. If the Company is unable to substantially increase revenues, reduce expenditures, or otherwise generate cash flows from operations, then the Company will likely need to raise additional funding from investors or through other avenues to continue as a going concern.

 

 

COVID-19

COVID-19

 

The continuing COVID-19 global pandemic has caused significant disruption to the economy and financial markets globally, and the full extent of the potential impacts of COVID-19 are not yet known. Circumstances caused by the COVID-19 pandemic are complex, uncertain and rapidly evolving. The impact of COVID-19 has not been significant to the Company’s results of operations, financial condition, and liquidity and capital resources. Although no material impairment or other effects have been identified to date, there is substantial uncertainty in the nature and degree of its continued effects over time. That uncertainty affects management’s accounting estimates and assumptions, which could result in greater variability in a variety of areas that depend on these estimates and assumptions as additional events and information become known. The Company will continue to consider the potential impact of the COVID-19 pandemic on its business operations.

 

Use of Estimates

Use of Estimates

 

The preparation of consolidated financial statements in conformity with GAAP and requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods.

 

Foreign Currency Translation

Foreign Currency Translation

 

The financial statements of foreign subsidiaries, for which the functional currency is the local currency, are translated into U.S. dollars using the exchange rate at the consolidated balance sheet date for assets and liabilities and a weighted-average exchange rate during the year for revenue, expenses, gains and losses. Translation adjustments are recorded as other comprehensive income (loss) within shareholders’ equity (deficit). Gains or losses from foreign currency transactions are recognized in the consolidated statements of operations.

 

Fair Value Measurement

Fair Value Measurement

 

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Applicable accounting guidance provides an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. There are three levels of inputs that may be used to measure fair value:

 

Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 - Other inputs that are directly or indirectly observable in the marketplace.

Level 3 - Unobservable inputs which are supported by little or no market activity.

 

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

 

As of and for the year ended December 31, 2022, the Company had no assets or liabilities that require fair value measurement.

 

Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates its fair value. The Company maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (“FDIC”) in accounts that at times may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions. As of December 31, 2022 and 2021, the Company had $1,817,000 and $2,797,000 in excess of the federal insurance limit, respectively.

 

Prepaid Expense

Prepaid Expense

 

Prepaid expenses are assets held by the Company, which are expected to be realized and consumed within twelve months after the reporting period.

 

Other Assets

Other Assets

 

Other assets consist of long-term advances paid for chip and processor design and development.

 

 

Related Parties

Related Parties

 

The Company follows Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) section 850-10 for the identification of related parties and disclosure of related party transactions.

 

Pursuant to ASC section 850-10-20 the related parties include (a.) affiliates of the Company (“Affiliate” means, with respect to any specified Person, any other Person that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the Securities Act); (b.) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option of ASC section 825–10–15, to be accounted for by the equity method by the investing entity; (c.) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; (d.) principal owners of the Company; (e.) management of the Company; (f.) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and (g.) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

 

The consolidated financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: (a.) the nature of the relationship(s) involved; (b.) a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; (c.) the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and (d.) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.

 

Commitments and Contingencies

Commitments and Contingencies

 

The Company follows ASC section 450-20 to report accounting for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or un-asserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or un-asserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.

 

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.

 

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.

 

Debt Discounts

Debt Discounts

 

The Company accounts for debt discounts originating in connection with conversion features that remain embedded in the related notes in accordance with ASC 470-20, Debt with Conversion and Other Options. These costs are classified on the balance sheet as a direct deduction from the debt liability. The Company amortizes these costs over the term of its debt agreements as financing cost in the consolidated statement of operations and comprehensive loss.

 

Warrant Liability

Warrant Liability

 

In connection with financing arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes Merton (“BSM”) option pricing model as of the measurement date.

 

 

Stock-Based Compensation

Stock-Based Compensation

 

We account for our stock-based compensation under ASC 718, “Compensation – Stock Compensation” using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges it equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments.

 

We use the fair value method for equity instruments granted to non-employees and use the BSM model for measuring the fair value of options. The stock based fair value compensation is determined as of the date of the grant (measurement date) and is recognized over the vesting periods.

 

Income Taxes

Income Taxes

 

The Company accounts for income taxes in accordance with ASC 740, Income Taxes, deferred tax assets and liabilities are computed based on the difference between the financial reporting and income tax bases of assets and liabilities using the enacted marginal tax rate. ASC 740 requires that the net deferred tax asset be reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some portion or all of the net deferred tax asset will not be realized.

 

The Company accounts for income taxes using an asset and liability approach, which requires the recognition of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. The measurement of current and deferred tax assets and liabilities is based on provisions of enacted tax laws; the effects of future changes in tax laws or rates are not anticipated. If necessary, the measurement of deferred tax assets is reduced by the amount of any tax benefits that are not expected to be realized based on available evidence.

 

The Company has adopted guidance related to the accounting for uncertainty in income taxes which prescribes rules for recognition, measurement and classification in the financial statements of tax positions taken or expected to be taken in a tax return. The guidance prescribes a two-step approach which involves evaluating whether a tax position will be more likely than not (greater than 50 percent likelihood) sustained upon examination based on the technical merits of the position. The second step requires that any tax position that meets the more likely than not recognition threshold be measured and recognized in the financial statements at the largest amount of benefit that is a greater than 50 percent likelihood of being realized upon settlement.

 

The Company’s policy is to recognize interest and penalties, if any, related to unrecognized tax benefits in income tax expense. The Company is not currently under examination by any taxing authority nor has the Company been notified of a pending examination. The statute of limitations for which the Company is generally no longer subject to federal or state income tax examinations by tax authorities is for years before 2013.

 

Earnings Per Share

Earnings Per Share

 

We use ASC 260, “Earnings Per Share” for calculating the basic and diluted earnings (loss) per share. We compute basic earnings (loss) per share by dividing net income (loss) by the weighted average number of common shares outstanding. Diluted earnings (loss) per share is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential common shares outstanding during the period using the treasury stock method. Dilutive potential common shares include outstanding stock options and warrants and stock awards. For periods with a net loss, basic and diluted loss per share is the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share.

 

Securities that could potentially dilute income (loss) per share in the future were not included in the computation of diluted income (loss) per share on December 31 because their inclusion would be anti-dilutive as follows:

   2022   2021 
Restricted stock awards   -    11,500,000 
Convertible promissory notes and accrued interest   4,125,699    3,947,394 
Series A warrants issued with convertible promissory notes   1,668,304    1,921,304 
Series B warrants to be issued upon exercise of Series A warrants   1,668,304    1,921,304 
Warrants issued for services   100,000    100,000 
Total potential future shares   7,562,307    19,390,002 

 

Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

The Company’s management reviewed all recently issued accounting standard updates (“ASU’s”) not yet adopted by the Company and does not believe the future adoptions of any such ASU’s may be expected to cause a material impact on the Company’s condensed consolidated financial condition or the results of its operations.

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.1
ORGANIZATION AND ACCOUNTING POLICIES (Tables)
12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
SCHEDULE OF INCOME AND LOSS PER SHARE ANTI-DILUTIVE

Securities that could potentially dilute income (loss) per share in the future were not included in the computation of diluted income (loss) per share on December 31 because their inclusion would be anti-dilutive as follows:

   2022   2021 
Restricted stock awards   -    11,500,000 
Convertible promissory notes and accrued interest   4,125,699    3,947,394 
Series A warrants issued with convertible promissory notes   1,668,304    1,921,304 
Series B warrants to be issued upon exercise of Series A warrants   1,668,304    1,921,304 
Warrants issued for services   100,000    100,000 
Total potential future shares   7,562,307    19,390,002 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.1
INTANGIBLE AND OTHER ASSETS (Tables)
12 Months Ended
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
SCHEDULE OF PAYMENTS

 

   Amount 
   USD   KRW 
Within 5 days after signing the contract  $41,000    49,500,000 
Within 5 days after all conditions are met as stated in “Schedule B – Statement of Work”   41,000    49,500,000 
Total  $82,000    99,000,000 
SCHEDULE OF IMPAIRMENT LOSS

The table below summarizes the impairment loss for the year ended December 31, 2022:

 

   Amount   VAT   Total 
PICOCEL  $69,000   $5,000   $74,000 
NNS   69,000    5,000    74,000 
Total   138,000    10,000    148,000 
Foreign exchange loss   4,000    2,000    6,000 
Impairment loss  $142,000   $12,000   $154,000 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.1
ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)
12 Months Ended
Dec. 31, 2022
Payables and Accruals [Abstract]  
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES

The following table summarizes the Company’s accounts payable and accrued expense balances as of December 31:

 

   2022   2021 
Accounts payable  $186,000   $221,000 
Accrued expenses   28,000    99,000 
Accrued interest   326,000    114,000 
Accounts payable and accrued expenses  $540,000   $434,000 
SCHEDULE OF ACCRUED INTEREST

The following table presents the details of accrued interest as of December 31:

 

   2022   2021 
Notes payable  $17,000   $9,000 
Convertible promissory notes   309,000    105,000 
Balance, end of the year  $326,000   $114,000 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.1
NOTES PAYABLE (Tables)
12 Months Ended
Dec. 31, 2022
Notes Payable  
SCHEDULE OF NOTES PAYABLE

The table below summarizes the transactions as of December 31:

 

   2022   2021 
Balance, beginning of the year  $111,000   $11,000 
Additions       150,000 
Payments   (50,000)   (50,000)
Balance, end of the year  $61,000   $111,000 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.1
CONVERTIBLE PROMISSORY NOTES (Tables)
12 Months Ended
Dec. 31, 2022
Debt Disclosure [Abstract]  
SCHEDULE OF CONVERTIBLE PROMISSORY NOTES

The convertible promissory notes consisted of the following as of December 31:

 

   2022   2021 
Principal          
Balance, beginning of year  $4,613,000   $708,000 
Additions       3,905,000 
Balance, end of year   4,613,000    4,613,000 
           
Discount          
Balance, beginning of year   1,526,000    5,000 
Additions   -    2,045,000 
Amortization   (1,526,000)   (524,000)
Balance, end of year   -    1,526,000 
Net carrying amount  $4,613,000   $3,087,000 
SCHEDULE OF POTENTIAL FUTURE SHARES ISSUANCE OF CONVERSION NOTES

Potential future shares to be issued on conversion of the notes as of December 31:

 

   2022   2021 
Principal  $4,613,000   $4,613,000 
Interest   309,000    105,000 
Total   4,922,000    4,718,000 
Conversion price per share   1.001.25    1.001.25 
Potential future shares   4,125,699    3,947,394 
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.1
EQUITY (Tables)
12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
SCHEDULE OF COMPANY RESTRICTED STOCK AWARDS

The table below summarizes the transactions related to the Company restricted stock awards as of December 31, 2022:

 

   Shares   Deferred
compensation
 
Grant date fair value   11,500,000   $22,195,000 
Accretion   -    (11,168,000)
Canceled   (1,500,000)   (11,027,000)
Balance as of December 31, 2022   10,000,000   $- 
SCHEDULE OF RESTRICTED STOCK GRANT COMPENSATION EXPENSE

Restricted stock grant compensation expense for the year ended December 31, 2022, is as follows:

 

      
2022 Accretion expense  $6,377,000 
Reversal of 2021 accretion expense   (4,791,000)
Reversal of 2022 accretion expense   (6,377,000)
Restricted stock grant compensation  $(4,791,000)
SCHEDULE OF STOCK OPTION ACTIVITIES

The table below summarizes the Company’s stock option activities for the years ended December 31, 2022 and 2021 (all share and per share data reflects the reverse stock split):

 

  

Number of

Stock Option

Shares

  

Exercise

Price

Range Per

Share

  

Weighted

Average

Exercise

Price

  

Relative

Fair

Value

  

Aggregate

Intrinsic

Value

 
Balance, January 1, 2021   385,000   $   $0.001   $   $7,315 
Granted   1,050,000    0.001    0.001    1.94     
Forfeited                    
Exercised   (1,435,000)   0.001    0.001         
Expired                    
Balance, December 31, 2021                    
Granted                    
Forfeited                    
Exercised                    
Expired                    
Balance, December 31, 2022      $   $   $   $ 
Vested and exercisable, December 31, 2022      $   $   $   $ 
Unvested, December 31, 2022      $   $   $   $ 
SCHEDULE OF WARRANTS ACTIVITY

The table below summarizes the Company’s warrant activities for the years ended December 31, 2022 and 2021 (all share and per share data reflects the reverse stock split):

 

  

Number of Shares

   Weighted Average Strike Price/Share   Weighted Average Remaining Contractual Term (Years)   Weighted Average Grant Date Fair Value/Share  

Aggregate

Intrinsic

Value

 
Balance, January 1, 2021   353,804   $1.50    2.88   $0.18   $ 
Granted   1,667,500    1.86    3.00    1.67    0.11 
Forfeited                    
Exercised                    
Expired                    
Balance, December 31, 2021   2,021,304    1.80    2.98    1.14    0.17 
Vested and exercisable, December 31, 2021   2,021,304    1.80    2.98    1.14    0.17 
Unvested, December 31, 2021                    
                          
Balance, January 1, 2022   2,021,304    1.80    2.98    1.14    0.17 
Granted                    
Forfeited                    
Exercised                    
Expired   (253,000)   1.80    2.98    1.14    0.17 
Balance, December 31, 2022   1,768,304    1.84    3.00    1.49     
Vested and exercisable, December 31, 2022   1,768,304    1.84    3.00    1.49     
Unvested, December 31, 2022      $       $   $ 
SCHEDULE OF FAIR VALUE OF WARRANTS

The following table sets forth the weighted-average assumptions used to estimate the fair value of warrants granted for the year ended December 31:

 

   2022   2021 
Expected life (in years)       3 
Risk-free interest rate       0.27% - 0.42 %
Expected volatility       405% - 406%
Dividend yield       0.00%
Stock price       $ 0.101.95 
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.1
EARNINGS (LOSS) PER SHARE (Tables)
12 Months Ended
Dec. 31, 2022
Earnings Per Share [Abstract]  
SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED

The following table sets forth the computation of basic and diluted earnings (loss) per share for the years ended December 31:

 

SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED

Numerator  2022   2021 
Net income (loss)  $2,181,000   $(6,749,000)
Effect of dilutive instruments          
Convertible notes interest expense   204,000    - 
Numerator for diluted EPS   2,385,000    (6,749,000)
           
Denominator          
Denominator - for basic EPS   14,495,621    19,482,261 
           
Effect of dilutive instruments          
Warrants   721,006    - 
Restricted stock awards   

10,000,000

    - 
Convertible notes   4,125,699    - 
Dilutive potential common shares   14,846,705    - 
           
Denominator for diluted EPS   29,342,327    19,482,261 
           
Basic EPS  $0.15   $(0.35)
Diluted EPS  $0.08   $(0.35)

XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.1
DEFERRED TAX ASSETS AND INCOME TAX PROVISION (Tables)
12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS

Components of deferred tax assets are as follows as of December 31:

 

   2022   2021 
Net deferred tax assets – Non-current:          
           
Intangible assets  $1,000   $- 
Impairment loss   38,000    - 
Interest expense limitations   802,000    - 
           
Stock-based compensation   9,000    1,488,000 
           
Expected income tax benefit from NOL carry-forwards   859,000    1,002,000 
           
Less valuation allowance   (1,709,000)   (2,490,000)
           
Deferred tax assets, net of valuation allowance  $-   $- 
SCHEDULE OF RECONCILIATION OF INCOME TAX

A reconciliation of the federal statutory income tax rate and the effective income tax rate as a percentage of income before income taxes is as follows for the years ended December 31:

 

   2022   2021 
         
Federal statutory income tax rate   21.0%   21.0%
           
Change in valuation allowance on net operating loss carry-forwards   (21.0)   (21.0)
           
Effective income tax rate   0.0%   0.0%
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF INCOME AND LOSS PER SHARE ANTI-DILUTIVE (Details) - shares
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potential future shares 7,562,307 19,390,002
Restricted Stock Award [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potential future shares 11,500,000
Convertible Promissory Notes And Accrued Interest [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potential future shares 4,125,699 3,947,394
Series A Warrants Issued With Convertible Promissory Notes [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potential future shares 1,668,304 1,921,304
Series B Warrants To Be Issued Upon Exercise Of Series A Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potential future shares 1,668,304 1,921,304
Warrants Issued For Services [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potential future shares 100,000 100,000
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.1
ORGANIZATION AND ACCOUNTING POLICIES (Details Narrative)
12 Months Ended
Nov. 05, 2021
USD ($)
shares
Nov. 05, 2021
KRW (₩)
shares
Dec. 31, 2022
USD ($)
shares
Dec. 31, 2021
USD ($)
shares
Common stock shares authorized | shares     100,000,000 100,000,000
Issuance of common stock, value      
Net income (loss)     $ 2,181,000 (6,749,000)
Restricted stock grants     4,791,000 (5,062,000)
Accumulated deficit     14,650,000 16,831,000
Cash, FDIC Insured Amount     250,000  
Prepaid Insurance     $ 1,817,000 $ 2,797,000
AIQ System Inc [Member]        
Ownership percentage 100.00% 100.00%    
AIQ System Inc [Member]        
Common stock shares authorized | shares 3,000,000 3,000,000    
Issuance of common stock, shares | shares 10,000 10,000    
Issuance of common stock, value $ 89,000 ₩ 100,000,000    
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTY TRANSACTIONS (Details Narrative) - M1 Advisors [Member] - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Related Party Transaction [Line Items]    
Proceeds from related party $ 200,000 $ 199,000
Payment to related party $ 200,000 $ 202,000
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF PAYMENTS (Details) - Apr. 05, 2022
USD ($)
KRW (₩)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Total $ 82,000 ₩ 99,000,000
Within 5 days after signing the contract [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Total 41,000 49,500,000
Within 5 days after all conditions are met as stated in “Schedule B - Statement of Work” [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Total $ 41,000 ₩ 49,500,000
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF IMPAIRMENT LOSS (Details)
12 Months Ended
Dec. 31, 2022
USD ($)
Finite-Lived Intangible Assets [Line Items]  
Total $ 148,000
Foreign exchange loss 6,000
Impairment loss 154,000
Amount [Member]  
Finite-Lived Intangible Assets [Line Items]  
Total 138,000
Foreign exchange loss 4,000
Impairment loss 142,000
Value Added Tax [Member]  
Finite-Lived Intangible Assets [Line Items]  
Total 10,000
Foreign exchange loss 2,000
Impairment loss 12,000
PICOCEL [Member]  
Finite-Lived Intangible Assets [Line Items]  
Total 74,000
PICOCEL [Member] | Amount [Member]  
Finite-Lived Intangible Assets [Line Items]  
Total 69,000
PICOCEL [Member] | Value Added Tax [Member]  
Finite-Lived Intangible Assets [Line Items]  
Total 5,000
NNS [Member]  
Finite-Lived Intangible Assets [Line Items]  
Total 74,000
NNS [Member] | Amount [Member]  
Finite-Lived Intangible Assets [Line Items]  
Total 69,000
NNS [Member] | Value Added Tax [Member]  
Finite-Lived Intangible Assets [Line Items]  
Total $ 5,000
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.1
INTANGIBLE AND OTHER ASSETS (Details Narrative)
12 Months Ended
Dec. 31, 2022
USD ($)
Dec. 31, 2022
KRW (₩)
Apr. 05, 2022
USD ($)
Apr. 05, 2022
KRW (₩)
Dec. 23, 2021
USD ($)
Dec. 23, 2021
KRW (₩)
Finite-Lived Intangible Assets [Line Items]            
Contract price     $ 82,000 ₩ 99,000,000    
Impairment loss $ 154,000          
Value Added Tax [Member]            
Finite-Lived Intangible Assets [Line Items]            
Impairment loss 12,000          
AIQ [Member]            
Finite-Lived Intangible Assets [Line Items]            
Contract price     $ 82,000 99,000,000    
Value added tax | ₩       ₩ 9,000,000    
Technology Development Agreement [Member] | PICOCEL, Co., Ltd. [Member]            
Finite-Lived Intangible Assets [Line Items]            
Contract price         $ 167,000 ₩ 198,000,000
Payment to related party 69,000          
Technology Development Agreement [Member] | NNS Co Ltd [Member]            
Finite-Lived Intangible Assets [Line Items]            
Payment to related party $ 69,000 ₩ 90,000,000        
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Payables and Accruals [Abstract]    
Accounts payable $ 186,000 $ 221,000
Accrued expenses 28,000 99,000
Accrued interest 326,000 114,000
Accounts payable and accrued expenses $ 540,000 $ 434,000
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF ACCRUED INTEREST (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Payables and Accruals [Abstract]    
Notes payable $ 17,000 $ 9,000
Convertible promissory notes 309,000 105,000
Balance, end of the year $ 326,000 $ 114,000
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF NOTES PAYABLE (Details) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Notes Payable    
Balance, beginning of the year $ 111,000 $ 11,000
Additions 150,000
Payments (50,000) (50,000)
Balance, end of the year $ 61,000 $ 111,000
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.1
NOTES PAYABLE (Details Narrative) - USD ($)
12 Months Ended
Jul. 01, 2021
Apr. 22, 2021
Feb. 19, 2021
Jul. 07, 2020
Dec. 31, 2022
Dec. 31, 2021
Short-Term Debt [Line Items]            
Accrued interest         $ 326,000 $ 114,000
Interest expense, debt         204,000 65,000
Promissory Note [Member]            
Short-Term Debt [Line Items]            
Debt instrument, face amount     $ 25,000 $ 11,000 11,000  
Increase in interest rate     15.00% 10.00%    
Accrued interest         3,000  
Debt instrument, interest rate     10.00%      
Debt instrument, maturity date     Feb. 19, 2022      
Interest expense, debt         14,000 $ 8,000
Promissory Note [Member] | Borrower [Member]            
Short-Term Debt [Line Items]            
Debt instrument, periodic payment       $ 100,000    
Promissory Note One [Member]            
Short-Term Debt [Line Items]            
Debt instrument, face amount   $ 50,000     50,000  
Increase in interest rate   15.00%        
Accrued interest         $ 10,000  
Debt instrument, interest rate   10.00%        
Debt instrument, maturity date   Apr. 22, 2022        
Promissory Note Two [Member]            
Short-Term Debt [Line Items]            
Debt instrument, face amount $ 25,000          
Increase in interest rate 15.00%          
Debt instrument, interest rate 10.00%          
Debt instrument, maturity date Jul. 01, 2022          
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF CONVERTIBLE PROMISSORY NOTES (Details) - Convertible Notes Payable [Member] - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Short-Term Debt [Line Items]    
Balance, beginning of year $ 4,613,000 $ 708,000
Additions 3,905,000
Balance, end of year 4,613,000 4,613,000
Balance, beginning of year 1,526,000 5,000
Additions 2,045,000
Amortization (1,526,000) (524,000)
Balance, end of year 1,526,000
Net carrying amount $ 4,613,000 $ 3,087,000
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF POTENTIAL FUTURE SHARES ISSUANCE OF CONVERSION NOTES (Details) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Debt Instrument [Line Items]    
Principal $ 4,613,000 $ 4,613,000
Interest 309,000 105,000
Total $ 4,922,000 $ 4,718,000
Potential future shares 4,125,699 3,947,394
Minimum [Member]    
Debt Instrument [Line Items]    
Conversion price per share $ 1.00 $ 1.00
Maximum [Member]    
Debt Instrument [Line Items]    
Conversion price per share $ 1.25 $ 1.25
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.1
CONVERTIBLE PROMISSORY NOTES (Details Narrative) - USD ($)
12 Months Ended 24 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2022
Sep. 15, 2021
May 31, 2021
Dec. 31, 2020
Short-Term Debt [Line Items]            
Proceed from convertible debt $ 3,550,000        
Accrued interest $ 133,000          
Events of default description Immediately upon a Dilutive Issuance, the Conversion Rate will be reduced to the amount of the consideration per share received by the Company in such Dilutive Issuance. Events of default include failure to issue conversion shares, the occurrence of a breach or default under any other agreement, any money judgment, writ, or similar process entered or filed against the Company or any of its property or other assets for more than $100,000, bankruptcy filing, application for the appointment of a custodian, trustee or receiver, insolvency, the Company’s common stock delisted, or dissolution, winding up, or termination of the business of the Company          
Indebtedness for borrowed money maximum limit $ 100,000   $ 100,000      
Issuance of warrants to purchase of common stock       100,000    
Issuance of warrant price per share         $ 0.001  
Fair value of common stock estimated life   3 years        
Date of issuance volatility percentage   359.00%        
Fair value of common stock risk free interest rate   43.00%        
Share price   $ 1.95        
Fair value of warrants 1,690,000          
Debt Instrument, Convertible, Beneficial Conversion Feature 0          
Amortization of Debt Issuance Costs and Discounts 1,526,000 $ 524,000        
Interest Expense, Debt $ 204,000 $ 65,000        
Minimum [Member]            
Short-Term Debt [Line Items]            
Debt instruments, conversion price $ 1.00 $ 1.00 $ 1.00      
Maximum [Member]            
Short-Term Debt [Line Items]            
Debt instruments, conversion price $ 1.25 $ 1.25 $ 1.25      
Warrant [Member]            
Short-Term Debt [Line Items]            
Issuance of warrants to purchase of common stock 1,567,500   1,567,500      
Fair value of common stock $ 3,004,000          
Fair value of common stock estimated life 3 years          
Warrant [Member] | Minimum [Member]            
Short-Term Debt [Line Items]            
Issuance of warrant price per share $ 1.50   $ 1.50      
Date of issuance volatility percentage 404.91%          
Fair value of common stock risk free interest rate 0.27%          
Share price $ 0.10   0.10      
Warrant [Member] | Maximum [Member]            
Short-Term Debt [Line Items]            
Issuance of warrant price per share $ 1.87   1.87      
Date of issuance volatility percentage 405.93%          
Fair value of common stock risk free interest rate 0.42%          
Share price $ 1.95   $ 1.95      
Convertible Promissory Note One [Member]            
Short-Term Debt [Line Items]            
Convertible promissory note   $ 55,000        
Debt instrument, maturity date   Mar. 01, 2022        
Debt instruments, conversion price   $ 1.00        
Convertible Promissory Note Two [Member]            
Short-Term Debt [Line Items]            
Convertible promissory note   $ 3,850,000        
Proceed from convertible debt     $ 3,550,000      
Original issue discount   $ 355,000        
Debt instrument, maturity date   Aug. 31, 2022        
Increase in interest rate   10.00%        
Debt instruments, conversion price   $ 1.25        
Convertible Notes Payable [Member]            
Short-Term Debt [Line Items]            
Original issue discount $ 1,526,000     $ 5,000
Convertible Notes Payable [Member] | Minimum [Member]            
Short-Term Debt [Line Items]            
Debt Instrument, Interest Rate, Effective Percentage 4.76% 4.76% 4.76%      
Convertible Notes Payable [Member] | Maximum [Member]            
Short-Term Debt [Line Items]            
Debt Instrument, Interest Rate, Effective Percentage 64.60% 64.60% 64.60%      
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
Jan. 03, 2022
Jun. 09, 2022
Commitments and Contingencies Disclosure [Abstract]    
Litigation description In the complaint, the plaintiff claimed he worked under a consulting agreement as Vice President of Brand Management of our company and was to be paid $4,000 per month and to receive an option to purchase 50,000 shares of our common stock that was to vest quarterly over the term of the agreement. In the complaint, the plaintiff alleged that, on or around March 27, 2020, the Company ceased paying the plaintiff despite the plaintiff’s continuing efforts on behalf of our company and that the Company agreed to continue to accrue his monthly retainer amount until such time that the Company received at least $100,000 in funding. Plaintiff further alleged that he continued to work for our company for 38 additional weeks in reliance on our promise of payment. The plaintiff claimed that our refusal to make the promised payments amounts to violations of the California labor laws and seeks damages in excess of $450,000  
Payments for rent $ 4,000  
Option to purchase shares vested 50,000  
Funds received $ 100,000  
Damages value $ 450,000  
Gross settlement amount   $ 90,000
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF COMPANY RESTRICTED STOCK AWARDS (Details) - Restricted Stock [Member]
Dec. 31, 2022
USD ($)
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Grant date fair value, shares | shares 11,500,000
Deferred compensation grant date fair value | $ $ 22,195,000
Accretion, shares | shares
Deferred compensation accretion | $ $ (11,168,000)
Canceled, shares | shares (1,500,000)
Deferred compensation canceled | $ $ (11,027,000)
Shares, balance | shares 10,000,000
Deferred compensation | $
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF RESTRICTED STOCK GRANT COMPENSATION EXPENSE (Details)
12 Months Ended
Dec. 31, 2022
USD ($)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Restricted stock grant compensation $ (4,791,000)
Two Thousand Twenty Two Accretion Expense [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Restricted stock grant compensation 6,377,000
Reversal Two Thousand Twenty One Accretion Expense [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Restricted stock grant compensation (4,791,000)
Reversal Two Thousand Twenty Two Accretion Expense [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Restricted stock grant compensation $ (6,377,000)
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF STOCK OPTION ACTIVITIES (Details) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Equity [Abstract]    
Number of Number of Stock Option Shares, Outstanding, Beginning Balance 385,000
Exercise Price Range Per Share, Outstanding, Beginning
Weighted Average Exercise Price, Outstanding, Beginning 0.001
Relative Fair Value, Outstanding, Beginning
Aggregate Intrinsic Value, Beginning Balance $ 7,315
Number of Stock Option Shares, Granted 1,050,000
Exercise Price Range Per Share, Granted $ 0.001
Weighted Average Exercise Price, Granted 0.001
Relative Fair Value, Granted 1.94
Aggregate Intrinsic Value, Granted
Number of Stock Option Shares, Forfeited
Exercise Price Range Per Share, Forfeited
Weighted Average Exercise Price, Forfeited
Relative Fair Value, Forfeited
Aggregate Intrinsic Value, Forfeited
Number of Stock Option Shares, Exercised (1,435,000)
Exercise Price Range Per Share, Exercised $ 0.001
Weighted Average Exercise Price, Exercised 0.001
Relative Fair Value, Exercised
Aggregate Intrinsic Value, Exercised
Number of Stock Option Shares, Expired
Exercise Price Range Per Share, Expired
Weighted Average Exercise Price, Expired
Relative Fair Value, Expired
Aggregate Intrinsic Value, Expired
Number of Number of Stock Option Shares, Outstanding, Beginning Balance
Exercise Price Range Per Share, Outstanding, Beginning
Weighted Average Exercise Price, Outstanding, Beginning
Relative Fair Value, Outstanding, Beginning
Aggregate Intrinsic Value, Beginning Balance
Number of Stock Option, Vested and Exercisable, Ending Balance  
Exercise Price Range Per Share, Vested and Exercisable  
Weighted Average Exercise Price, Vested and Exercisable  
Relative Fair Value, Vested and Exercisable  
Aggregate Intrinsic Value, Vested and Exercisable  
Number of Stock Option, Unvested, Ending Balance  
Exercise Price Range Per Share, Unvested  
Weighted Average Exercise Price, Unvested  
Relative Fair Value, Unvested  
Aggregate Intrinsic Value, Unvested  
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF WARRANTS ACTIVITY (Details) - $ / shares
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Equity [Abstract]    
Number of warrants issued, Outstanding, Beginning of period 2,021,304 353,804
Weighted Average Strike Price/Share, Outstanding, Beginning of period $ 1.80 $ 1.50
Weighted Average Remaining Contractual Term (Years) 2 years 11 months 23 days 2 years 10 months 17 days
Weighted Average Grant Date Fair Value/Share, Ending of period $ 1.14 $ 0.18
Aggregate intrinsic value, Beginning of period $ 0.17
Number of warrants issued, Granted 1,667,500
Weighted Average Strike Price/Share, Granted $ 1.86
Weighted Average Remaining Contractual Term (Years), Granted 3 years
Weighted Average Grant Date Fair Value/Share, Granted $ 1.67
Aggregate intrinsic value, Granted $ 0.11
Number of warrants issued, Forfeited
Weighted Average Strike Price/Share, Forfeited
Weighted Average Grant Date Fair Value/Share, forfeited
Aggregate intrinsic value, forfeited
Number of warrants issued, Exercised
Weighted Average Strike Price/Share, Exercised
Weighted Average Grant Date Fair Value/Share, Exercised
Aggregate intrinsic value, Exercised
Number of warrants issued, Expired (253,000)
Weighted Average Strike Price/Share, Expired $ 1.80
Weighted Average Grant Date Fair Value/Share, Expired 1.14
Aggregate intrinsic value, Expired $ 0.17
Number of warrants issued, Outstanding, Ending of period 1,768,304 2,021,304
Weighted Average Strike Price/Share, Outstanding, ending of period $ 1.84 $ 1.80
Weighted Average Remaining Contractual Term (Years) 3 years 2 years 11 months 23 days
Weighted Average Grant Date Fair Value/Share, ending balance $ 1.49 $ 1.14
Aggregate intrinsic value, ending balance $ 0.17
Number of warrants issued, Vested and Exercisable, Ending of period 1,768,304 2,021,304
Weighted Average Strike Price/Share, Vested and Exercisable, Ending of period 1.84 1.80
Weighted Average Remaining Contractual Term (Years), Vested and Exercisable 3 years 2 years 11 months 23 days
Weighted Average Grant Date Fair Value/Share, Vested and Exercisable, Ending of period 1.49 1.14
Aggregate intrinsic value, Vested and Exercisable, Ending of period 0.17
Number of warrants issued, Unvested, Ending of period
Weighted Average Strike Price/Share, Unvested, Ending of period
Weighted Average Grant Date Fair Value/Share, Unvested, Ending of period
Aggregate intrinsic value, Unvested, Ending of period  
Weighted Average Remaining Contractual Term (Years) 2 years 11 months 23 days  
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF FAIR VALUE OF WARRANTS (Details)
Dec. 31, 2022
$ / shares
Dec. 31, 2021
$ / shares
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Share price   $ 1.95
Measurement Input, Expected Term [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants and rights outstanding, term 3 years
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Dividend yield   0.27
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Dividend yield   0.42
Measurement Input, Price Volatility [Member] | Minimum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Dividend yield   405
Measurement Input, Price Volatility [Member] | Maximum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Dividend yield   406
Measurement Input, Expected Dividend Rate [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Dividend yield   0.00
Measurement Input, Share Price [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Share price  
Measurement Input, Share Price [Member] | Minimum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Share price   $ 0.10
Measurement Input, Share Price [Member] | Maximum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Share price   $ 1.95
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.1
EQUITY (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Aug. 17, 2021
Feb. 11, 2020
Oct. 31, 2021
May 31, 2021
Mar. 31, 2021
Feb. 28, 2021
Jan. 31, 2021
Mar. 31, 2021
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Sep. 15, 2021
Class of Stock [Line Items]                        
Authorized to issue shares                 200,000,000      
Preferred stock, shares authorized                 100,000,000 100,000,000    
Preferred stock, par value                 $ 0.001 $ 0.001    
Common stock, shares authorized                 100,000,000 100,000,000    
Common stock, par value                 $ 0.001 $ 0.001    
Proceeds from Issuance of Common Stock                 $ 10,000,000      
Sale of Stock, Description of Transaction                 the close of business on the sixtieth consecutive day on which the closing price of the Company’s common stock on the OTC Markets is at least $2.80 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, stock combination or other similar recapitalization with respect to the common stock, or (iii) the affirmative vote of the holders of at least 66⅔% of the outstanding shares of Series A, given at a meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders all outstanding shares of Series A shall automatically be converted into shares of the Company’s common stock, at the then effective conversion rate      
Conversion of debt                 $ 4,613,000 $ 4,613,000    
Remaining cash liability         $ 30,000     $ 30,000        
Stock Issued During Period, Value, Issued for Services                   $ 575,000    
Option to purchase shares                 1,050,000    
Share price                   $ 1.95    
Share-based compensation arrangement by share-based payment award, options                   $ 561,000    
Number of share options exercised                 1,435,000    
Class of warrant exercise price       $ 0.001                
Proceeds from stock options exercised       $ 2,000         $ 2,000    
Number of securities called by warrants or rights                       100,000
Compensation expenses                   $ 195,000    
Fair value assumptions, expected volatility rate                   359.00%    
Expected Term                   3 years    
Risk Free Interest Rate                   43.00%    
Dividend payments                   $ 0    
Share-Based Payment Arrangement, Tranche One [Member]                        
Class of Stock [Line Items]                        
Number of share options exercised       385,000                
Share-Based Payment Arrangement, Tranche Two [Member]                        
Class of Stock [Line Items]                        
Number of share options exercised       750,000                
Share-Based Payment Arrangement, Tranche Three [Member]                        
Class of Stock [Line Items]                        
Number of share options exercised       300,000                
Minimum [Member]                        
Class of Stock [Line Items]                        
Debt Instrument, Convertible, Conversion Price                 $ 1.00 $ 1.00    
Maximum [Member]                        
Class of Stock [Line Items]                        
Debt Instrument, Convertible, Conversion Price                 $ 1.25 $ 1.25    
Chief Executive Officer [Member]                        
Class of Stock [Line Items]                        
Debt instrument decrease forgiveness               68,000        
Restricted common stock shares granted 1,500,000                      
Chief Financial Officer [Member]                        
Class of Stock [Line Items]                        
Reduction amount               $ 98,000        
Stock issued during period shares new issues               75,000        
Chief Financial Officer [Member] | Minimum [Member]                        
Class of Stock [Line Items]                        
Due to related parties         128,000              
Chief Financial Officer [Member] | Maximum [Member]                        
Class of Stock [Line Items]                        
Due to related parties         $ 30,000              
Consultants [Member]                        
Class of Stock [Line Items]                        
Stock Issued During Period, Shares, Issued for Services     25,000                  
Stock Issued During Period, Value, Issued for Services     $ 76,000                  
Payments to consultants     $ 20,000                  
Restricted common stock shares granted 10,000,000               10,000,000      
Shares Issued, Price Per Share                 $ 1.93      
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures                 $ 22,195,000      
Chief Technology Officer [Member]                        
Class of Stock [Line Items]                        
Restricted common stock shares granted                 1,500,000      
Termination Agreement [Member]                        
Class of Stock [Line Items]                        
Return of shares             3,674,330          
New Consulting Agreement [Member] | Shareholder [Member]                        
Class of Stock [Line Items]                        
Option to purchase shares           750,000            
Share price           $ 0.001            
Fair value of options           $ 52,000            
Option expense                   $ 14,000 $ 38,000  
Letter of Understanding [Member]                        
Class of Stock [Line Items]                        
Common stock, shares authorized       300,000                
Common stock, par value       $ 0.001                
Series A Convertible Preferred Stock [Member]                        
Class of Stock [Line Items]                        
Preferred stock, shares authorized                 3,600,000 3,600,000    
Preferred stock, par value                 $ 0.001 $ 0.001    
Sale of stock shares price per share                 1.38      
Debt Instrument, Convertible, Conversion Price                 $ 1.00      
Conversion rate adjustment, value                 $ 36,000      
Conversion of shares   85,975                    
Conversion of debt   $ 147,000                    
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED (Details) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Earnings Per Share [Abstract]    
Net income (loss) $ 2,181,000 $ (6,749,000)
Effect of dilutive instruments    
Convertible notes interest expense 204,000
Numerator for diluted EPS $ 2,385,000 $ (6,749,000)
Denominator    
Denominator - for basic EPS 14,495,621 19,482,261
Effect of dilutive instruments    
Warrants 721,006
Restricted stock awards 10,000,000
Convertible notes 4,125,699
Dilutive potential common shares 14,846,705
Denominator for diluted EPS 29,342,327 19,482,261
Basic EPS $ 0.15 $ (0.35)
Diluted EPS $ 0.08 $ (0.35)
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.1
EARNINGS (LOSS) PER SHARE (Details Narrative) - shares
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Dilutive securities 7,562,307 19,390,002
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Dilutive securities   3,942,608
Convertible Notes [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Dilutive securities   3,947,394
Restricted Stock Units [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Dilutive securities   11,500,000
Common Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Dilutive securities 14,846,705 19,390,002
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Intangible assets $ 1,000
Impairment loss 38,000
Interest expense limitations 802,000
Stock-based compensation 9,000 1,488,000
Expected income tax benefit from NOL carry-forwards 859,000 1,002,000
Less valuation allowance (1,709,000) (2,490,000)
Deferred tax assets, net of valuation allowance
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF RECONCILIATION OF INCOME TAX (Details)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Federal statutory income tax rate 21.00% 21.00%
Change in valuation allowance on net operating loss carry-forwards (21.00%) (21.00%)
Effective income tax rate 0.00% 0.00%
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.23.1
DEFERRED TAX ASSETS AND INCOME TAX PROVISION (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Net operating loss deferred tax $ 3,070,000  
Deferred tax assets net 1,708,000  
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount $ (782,000) $ 2,191,000
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.23.1
SUBSEQUENT EVENTS (Details Narrative)
12 Months Ended
Apr. 10, 2023
shares
Mar. 30, 2023
USD ($)
a
$ / shares
shares
Mar. 27, 2023
USD ($)
shares
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
$ / shares
Dec. 31, 2020
USD ($)
Subsequent Event [Line Items]            
Stock Issued During Period, Value, New Issues          
Issuance of common stock purchase price payable       $ 10,000,000    
Share price | $ / shares         $ 1.95  
Promissory note       $ 61,000 $ 111,000 $ 11,000
Subsequent Event [Member]            
Subsequent Event [Line Items]            
Area of Land | a   80        
Stock Issued During Period, Value, New Issues   $ 3,360,000        
Non refundable deposit   84,000        
Escrow Deposit   84,000        
Issuance of common stock purchase price payable   $ 1,680,000        
Stock issued during period, shares, new issues | shares   840,000        
Share price | $ / shares   $ 1.00        
Promissory note   $ 840,000        
Shares issued, price per share | $ / shares   $ 2.00        
Subsequent Event [Member] | Restricted Stock [Member] | Hyuncheol Peter Kim [Member]            
Subsequent Event [Line Items]            
Cancellation of restricted stock awards | shares 10,000,000          
Subsequent Event [Member] | Employment Agreement [Member]            
Subsequent Event [Line Items]            
Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold     $ 250,000      
Construction of data center     $ 350,000      
Percentage of contracted colocation capacity     25.00%      
Cash annual bonus | shares     2,000,000      
Subsequent Event [Member] | Employment Agreement [Member] | Maximum [Member]            
Subsequent Event [Line Items]            
Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold     $ 300,000      
Subsequent Event [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]            
Subsequent Event [Line Items]            
Secured overnight financing, variable interest rate   2.00%        
XML 63 form10-k_htm.xml IDEA: XBRL DOCUMENT 0001174891 2022-01-01 2022-12-31 0001174891 2022-06-30 0001174891 2023-04-13 0001174891 2022-12-31 0001174891 2021-12-31 0001174891 BUUZ:SeriesAConvertiblePreferredStockMember 2022-12-31 0001174891 BUUZ:SeriesAConvertiblePreferredStockMember 2021-12-31 0001174891 2021-01-01 2021-12-31 0001174891 BUUZ:SeriesAConvertiblePreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001174891 us-gaap:CommonStockMember 2020-12-31 0001174891 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001174891 BUUZ:StockSubscriptionReceivableMember 2020-12-31 0001174891 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001174891 us-gaap:RetainedEarningsMember 2020-12-31 0001174891 2020-12-31 0001174891 BUUZ:SeriesAConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001174891 us-gaap:CommonStockMember 2021-12-31 0001174891 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001174891 BUUZ:StockSubscriptionReceivableMember 2021-12-31 0001174891 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001174891 us-gaap:RetainedEarningsMember 2021-12-31 0001174891 BUUZ:SeriesAConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001174891 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001174891 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001174891 BUUZ:StockSubscriptionReceivableMember 2021-01-01 2021-12-31 0001174891 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001174891 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001174891 BUUZ:SeriesAConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001174891 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001174891 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001174891 BUUZ:StockSubscriptionReceivableMember 2022-01-01 2022-12-31 0001174891 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001174891 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001174891 BUUZ:SeriesAConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001174891 us-gaap:CommonStockMember 2022-12-31 0001174891 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001174891 BUUZ:StockSubscriptionReceivableMember 2022-12-31 0001174891 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001174891 us-gaap:RetainedEarningsMember 2022-12-31 0001174891 BUUZ:AIQSystemIncMember 2021-11-05 0001174891 BUUZ:AIQSystemIncMember 2021-11-04 2021-11-05 0001174891 BUUZ:AIQSystemIncMember 2021-11-05 0001174891 BUUZ:RestrictedStockAwardMember 2022-01-01 2022-12-31 0001174891 BUUZ:RestrictedStockAwardMember 2021-01-01 2021-12-31 0001174891 BUUZ:ConvertiblePromissoryNotesAndAccruedInterestMember 2022-01-01 2022-12-31 0001174891 BUUZ:ConvertiblePromissoryNotesAndAccruedInterestMember 2021-01-01 2021-12-31 0001174891 BUUZ:SeriesAWarrantsIssuedWithConvertiblePromissoryNotesMember 2022-01-01 2022-12-31 0001174891 BUUZ:SeriesAWarrantsIssuedWithConvertiblePromissoryNotesMember 2021-01-01 2021-12-31 0001174891 BUUZ:SeriesBWarrantsToBeIssuedUponExerciseOfSeriesAWarrantMember 2022-01-01 2022-12-31 0001174891 BUUZ:SeriesBWarrantsToBeIssuedUponExerciseOfSeriesAWarrantMember 2021-01-01 2021-12-31 0001174891 BUUZ:WarrantsIssuedForServicesMember 2022-01-01 2022-12-31 0001174891 BUUZ:WarrantsIssuedForServicesMember 2021-01-01 2021-12-31 0001174891 BUUZ:MOneAdvisorsMember 2022-01-01 2022-12-31 0001174891 BUUZ:MOneAdvisorsMember 2021-01-01 2021-12-31 0001174891 BUUZ:TechnologyDevelopmentAgreementMember BUUZ:PICOCELCoLtdMember 2021-12-23 0001174891 BUUZ:TechnologyDevelopmentAgreementMember BUUZ:PICOCELCoLtdMember 2022-01-01 2022-12-31 0001174891 BUUZ:AIQMember 2022-04-05 0001174891 BUUZ:TechnologyDevelopmentAgreementMember BUUZ:NNSCoLtdMember 2022-01-01 2022-12-31 0001174891 BUUZ:ValueAddedTaxMember 2022-01-01 2022-12-31 0001174891 BUUZ:WithinFiveDaysAfterSigningTheContractMember 2022-04-05 0001174891 BUUZ:WithinFiveDaysAfterallConditionsAreMetMember 2022-04-05 0001174891 2022-04-05 0001174891 BUUZ:AmountMember BUUZ:PICOCELMember 2022-12-31 0001174891 BUUZ:ValueAddedTaxMember BUUZ:PICOCELMember 2022-12-31 0001174891 BUUZ:PICOCELMember 2022-12-31 0001174891 BUUZ:AmountMember BUUZ:NNSMember 2022-12-31 0001174891 BUUZ:ValueAddedTaxMember BUUZ:NNSMember 2022-12-31 0001174891 BUUZ:NNSMember 2022-12-31 0001174891 BUUZ:AmountMember 2022-12-31 0001174891 BUUZ:ValueAddedTaxMember 2022-12-31 0001174891 BUUZ:AmountMember 2022-01-01 2022-12-31 0001174891 BUUZ:PromissoryNoteMember 2020-07-07 0001174891 BUUZ:PromissoryNoteMember 2020-07-06 2020-07-07 0001174891 BUUZ:BorrowerMember BUUZ:PromissoryNoteMember 2020-07-06 2020-07-07 0001174891 BUUZ:PromissoryNoteMember 2022-12-31 0001174891 BUUZ:PromissoryNoteMember 2021-02-19 0001174891 BUUZ:PromissoryNoteMember 2021-02-18 2021-02-19 0001174891 BUUZ:PromissoryNoteOneMember 2021-04-22 0001174891 BUUZ:PromissoryNoteOneMember 2021-04-20 2021-04-22 0001174891 BUUZ:PromissoryNoteOneMember 2022-12-31 0001174891 BUUZ:PromissoryNoteTwoMember 2021-07-01 0001174891 BUUZ:PromissoryNoteTwoMember 2021-06-29 2021-07-01 0001174891 BUUZ:PromissoryNoteMember 2022-01-01 2022-12-31 0001174891 BUUZ:PromissoryNoteMember 2021-01-01 2021-12-31 0001174891 BUUZ:ConvertiblePromissoryNoteOneMember 2021-12-31 0001174891 BUUZ:ConvertiblePromissoryNoteTwoMember 2021-12-31 0001174891 BUUZ:ConvertiblePromissoryNoteTwoMember 2021-01-01 2022-12-31 0001174891 BUUZ:ConvertiblePromissoryNoteOneMember 2021-01-01 2021-12-31 0001174891 BUUZ:ConvertiblePromissoryNoteTwoMember 2021-01-01 2021-12-31 0001174891 us-gaap:WarrantMember 2022-12-31 0001174891 srt:MinimumMember us-gaap:WarrantMember 2022-12-31 0001174891 srt:MaximumMember us-gaap:WarrantMember 2022-12-31 0001174891 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001174891 srt:MinimumMember us-gaap:WarrantMember 2022-01-01 2022-12-31 0001174891 srt:MaximumMember us-gaap:WarrantMember 2022-01-01 2022-12-31 0001174891 srt:MinimumMember us-gaap:ConvertibleNotesPayableMember 2022-12-31 0001174891 srt:MinimumMember us-gaap:ConvertibleNotesPayableMember 2021-12-31 0001174891 srt:MaximumMember us-gaap:ConvertibleNotesPayableMember 2022-12-31 0001174891 srt:MaximumMember us-gaap:ConvertibleNotesPayableMember 2021-12-31 0001174891 us-gaap:ConvertibleNotesPayableMember 2021-12-31 0001174891 us-gaap:ConvertibleNotesPayableMember 2020-12-31 0001174891 us-gaap:ConvertibleNotesPayableMember 2022-01-01 2022-12-31 0001174891 us-gaap:ConvertibleNotesPayableMember 2021-01-01 2021-12-31 0001174891 us-gaap:ConvertibleNotesPayableMember 2022-12-31 0001174891 srt:MinimumMember 2022-12-31 0001174891 srt:MaximumMember 2022-12-31 0001174891 srt:MinimumMember 2021-12-31 0001174891 srt:MaximumMember 2021-12-31 0001174891 2022-01-02 2022-01-03 0001174891 2022-06-09 0001174891 BUUZ:SeriesAConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001174891 BUUZ:SeriesAConvertiblePreferredStockMember 2020-02-10 2020-02-11 0001174891 BUUZ:TerminationAgreementMember 2021-01-01 2021-01-31 0001174891 srt:ChiefExecutiveOfficerMember 2021-01-01 2021-03-31 0001174891 srt:MinimumMember srt:ChiefFinancialOfficerMember 2021-03-01 2021-03-31 0001174891 srt:MaximumMember srt:ChiefFinancialOfficerMember 2021-03-01 2021-03-31 0001174891 srt:ChiefFinancialOfficerMember 2021-01-01 2021-03-31 0001174891 2021-03-31 0001174891 BUUZ:ConsultantsMember 2021-10-01 2021-10-31 0001174891 BUUZ:ConsultantsMember 2021-08-16 2021-08-17 0001174891 srt:ChiefExecutiveOfficerMember 2021-08-16 2021-08-17 0001174891 BUUZ:ConsultantsMember 2022-01-01 2022-12-31 0001174891 BUUZ:ChiefTechnologyOfficerMember 2022-01-01 2022-12-31 0001174891 BUUZ:ConsultantsMember 2022-12-31 0001174891 BUUZ:ShareholderMember BUUZ:NewConsultingAgreementMember 2021-02-01 2021-02-28 0001174891 BUUZ:ShareholderMember BUUZ:NewConsultingAgreementMember 2021-02-28 0001174891 BUUZ:ShareholderMember BUUZ:NewConsultingAgreementMember 2020-01-01 2020-12-31 0001174891 BUUZ:ShareholderMember BUUZ:NewConsultingAgreementMember 2021-01-01 2021-12-31 0001174891 BUUZ:LetterofUnderstandingMember 2021-05-31 0001174891 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-05-01 2021-05-31 0001174891 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-05-01 2021-05-31 0001174891 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2021-05-01 2021-05-31 0001174891 2021-05-31 0001174891 2021-05-01 2021-05-31 0001174891 2021-09-15 0001174891 us-gaap:RestrictedStockMember 2022-12-31 0001174891 BUUZ:TwoThousandTwentyTwoAccretionExpenseMember 2022-01-01 2022-12-31 0001174891 BUUZ:ReversalTwoThousandTwentyOneAccretionExpenseMember 2022-01-01 2022-12-31 0001174891 BUUZ:ReversalTwoThousandTwentyTwoAccretionExpenseMember 2022-01-01 2022-12-31 0001174891 us-gaap:MeasurementInputExpectedTermMember 2022-12-31 0001174891 us-gaap:MeasurementInputExpectedTermMember 2021-12-31 0001174891 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001174891 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001174891 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001174891 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001174891 us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001174891 us-gaap:MeasurementInputSharePriceMember 2022-12-31 0001174891 srt:MinimumMember us-gaap:MeasurementInputSharePriceMember 2021-12-31 0001174891 srt:MaximumMember us-gaap:MeasurementInputSharePriceMember 2021-12-31 0001174891 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001174891 BUUZ:ConvertibleNotesMember 2021-01-01 2021-12-31 0001174891 BUUZ:RestrictedStockUnitsMember 2021-01-01 2021-12-31 0001174891 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001174891 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001174891 us-gaap:SubsequentEventMember 2023-03-30 0001174891 us-gaap:SubsequentEventMember 2023-03-29 2023-03-30 0001174891 us-gaap:SubsequentEventMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-03-30 0001174891 us-gaap:SubsequentEventMember BUUZ:EmploymentAgreementMember 2023-03-26 2023-03-27 0001174891 srt:MaximumMember us-gaap:SubsequentEventMember BUUZ:EmploymentAgreementMember 2023-03-26 2023-03-27 0001174891 BUUZ:HyuncheolPeterKimMember us-gaap:RestrictedStockMember us-gaap:SubsequentEventMember 2023-04-07 2023-04-10 iso4217:USD shares iso4217:USD shares iso4217:KRW pure utr:acre 0001174891 false FY 10-K true 2022-12-31 --12-31 2022 false 000-50331 CALETHOS, INC. NV 98-0371433 11753 Willard Avenue Tustin CA 92782 (714) 352-5315 No No Yes Yes Non-accelerated Filer true false false false 13041055 14495621 587 RBSM LLP Larkspur, CA 2067000 3047000 4000 7000 2071000 3054000 38000 2071000 3092000 540000 434000 4613000 3087000 61000 111000 5214000 3632000 0.001 0.001 3600000 3600000 0 0 0 0 0.001 0.001 100000000 100000000 0 0 0 0 0.001 0.001 100000000 100000000 24495621 24495621 25995621 25995621 24000 26000 11480000 16269000 5000 -2000 -2000 -2000 -14650000 -16831000 -3143000 -540000 2071000 3092000 667000 1033000 4791000 -5062000 52000 57000 154000 -3918000 6152000 3918000 -6152000 7000 -1744000 -597000 -1737000 -597000 2181000 -6749000 2181000 -6749000 0.15 -0.35 0.08 -0.35 14495621 19482261 29342327 19482261 2181000 -6749000 7000 -2000 2188000 -6751000 16634951 17000 8744000 -2000 -10082000 -1323000 1690000 1690000 575000 575000 75000 166000 166000 38000 38000 3674330 -4000 4000 1435000 2000 2000 25000 272000 272000 11500000 11000 4780000 4791000 -2000 -2000 -6749000 -6749000 25995621 26000 16269000 -2000 -2000 -16831000 -540000 6377000 6377000 1500000 2000 11166000 11168000 7000 7000 2181000 2181000 2181000 2181000 24495621 24000 11480000 -2000 5000 -14650000 -3143000 2181000 -6749000 154000 1526000 524000 846000 11168000 6377000 4791000 -3000 5000 107000 28000 -820000 -565000 105000 38000 -105000 -38000 3550000 150000 50000 50000 2000 -50000 3652000 -5000 -2000 -980000 3047000 3047000 2067000 3047000 5407 1690000 38000 166000 355000 <p id="xdx_808_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zeYPQz3Q8K01" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 - <span>Organization and Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> <span id="xdx_82E_zz3whidNUBAi" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">ORGANIZATION AND ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CalEthos, Inc. (the “Company” or “we”) was incorporated on March 20, 2002 under the laws of the State of Nevada.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is implementing its plan to build a clean-energy-powered, modular immersion and liquid cooled data center that provides colocation data center services to enterprise IT customers. In addition, the Company may acquire assets and all or part of other companies operating in the high-density computing industry or to invest or joint venture with other more-established companies already in the industry that would add value to the Company’s business strategy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2022, due to the declining state of the bitcoin mining industry and market for its planned products, the Company’s board of directors resolved to discontinue the development in South Korea of the Company’s 5 nanometer ASIC chip and containerized, immersion-cooled bitcoin mining computer system and to focus exclusively on developing the clean-energy-powered data center segment of its business strategy. The Company has suspended operations of its South Korean subsidiary and will decide in the next twelve months whether to use it to develop other products or dissolve it.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--BusinessCombinationsPolicy_zE2qDmjCfi94" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zzH1N6GrHYxi">Incorporation of Korean entity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 5, 2021, AIQ System Inc. (“AIQ”) was incorporated in Seoul, Republic of Korea. AIQ is authorized to issue <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_pp6n6_c20211105__dei--LegalEntityAxis__custom--AIQSystemIncMember_zaOoW9QK4QA7" title="Common stock shares authorized">3</span> million shares of common stock. At the date of incorporation, <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211104__20211105__dei--LegalEntityAxis__custom--AIQSystemIncMember_zAzhVOWByCBg" title="Issuance of common stock, shares">10,000</span> shares were issued to the Company for <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_uSouthKoreanWon_c20211104__20211105__dei--LegalEntityAxis__custom--AIQSystemIncMember_z1JOFegZbd94" title="Issuance of common stock, value">100,000,000</span> Korean Won or approximately $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20211104__20211105__dei--LegalEntityAxis__custom--AIQSystemIncMember_zcO7m3CmRUw5" title="Issuance of common stock, value">89,000</span> for <span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20211105__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AIQSystemIncMember_zp6kvrMKYzD7" title="Ownership percentage">100</span>% ownership of AIQ.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zEN2NoO9MpVe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zfICp7LqHLX">Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--ConsolidationPolicyTextBlock_zFOlRbtyKK6l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zI4ge9PCPE2g">Principles of Consolidation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary from the formation date. All material intercompany transactions and balances have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_ecustom--GoingConcernAndLiquidityPolicyTextBlock_zmMOMdaNZU0j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zIlnuvtqBre5">Going Concern and Liquidity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company incurred net income of approximately $<span id="xdx_908_eus-gaap--NetIncomeLoss_c20220101__20221231_z5HsSiyf4Hkg" title="Net income (loss)">2,181,000</span> for the year ended December 31, 2022, of which $<span id="xdx_902_ecustom--RestrictedStockGrants_c20220101__20221231_zSUoJvkCU1Z8" title="Restricted stock grants">4,791,000</span> was attributable to a noncash transaction for the reversal of compensation for restricted stock units, and had an accumulated deficit of approximately $<span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20221231_zUBrgGBTw4n" title="Accumulated deficit">14,650,000</span> as of December 31, 2022. The Company has financed its activities principally through debt and equity financing and shareholder contributions. Management expects to incur additional losses and cash outflows in the foreseeable future in connection with its operating activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s consolidated financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to a number of risks similar to those of other similar stage companies, including dependence on key individuals; successful development, marketing and branding of products; uncertainty of product development and generation of revenues; dependence on outside sources of financing; risks associated with research and development; dependence on third-party suppliers and collaborators; protection of intellectual property; and competition with larger, better-capitalized companies. Ultimately, the attainment of profitable operations is dependent on future events, including obtaining adequate financing to fund its operations and generating a level of revenues adequate to support the Company’s cost structure.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company will need to raise debt or equity financing in the future in order to continue its operations and achieve its growth targets. However, there can be no assurance that such financing will be available in sufficient amounts and on acceptable terms, when and if needed, or at all. The precise amount and timing of the funding needs cannot be determined accurately at this time, and will depend on a number of factors, including market demand for the Company’s products and services, the success of product development efforts, the timing of receipts for customer deposits, the management of working capital, and the continuation of normal payment terms and conditions for purchase of goods and services. The Company believes its cash balances and cash flow from operations will not be sufficient to fund its operations and growth for the next twelve months from the issuance date of these financial statements. If the Company is unable to substantially increase revenues, reduce expenditures, or otherwise generate cash flows from operations, then the Company will likely need to raise additional funding from investors or through other avenues to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_ecustom--UnusualOrInfrequentItemsPolicyTextBlock_zH8hhddTIVXi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zxpoHTMtVBab">COVID-19</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The continuing COVID-19 global pandemic has caused significant disruption to the economy and financial markets globally, and the full extent of the potential impacts of COVID-19 are not yet known. Circumstances caused by the COVID-19 pandemic are complex, uncertain and rapidly evolving. The impact of COVID-19 has not been significant to the Company’s results of operations, financial condition, and liquidity and capital resources. Although no material impairment or other effects have been identified to date, there is substantial uncertainty in the nature and degree of its continued effects over time. That uncertainty affects management’s accounting estimates and assumptions, which could result in greater variability in a variety of areas that depend on these estimates and assumptions as additional events and information become known. The Company will continue to consider the potential impact of the COVID-19 pandemic on its business operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--UseOfEstimates_zjWAlxwh07M2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zbZfVQNXBSLh">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with GAAP and requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zfUgyWizQdk4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zkQLs8YORdq9">Foreign Currency Translation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements of foreign subsidiaries, for which the functional currency is the local currency, are translated into U.S. dollars using the exchange rate at the consolidated balance sheet date for assets and liabilities and a weighted-average exchange rate during the year for revenue, expenses, gains and losses. Translation adjustments are recorded as other comprehensive income (loss) within shareholders’ equity (deficit). Gains or losses from foreign currency transactions are recognized in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zcV8epyjuhw6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_z4dLQlyQeNX7">Fair Value Measurement</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Applicable accounting guidance provides an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. There are three levels of inputs that may be used to measure fair value:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 - Other inputs that are directly or indirectly observable in the marketplace.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 - Unobservable inputs which are supported by little or no market activity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of and for the year ended December 31, 2022, the Company had no assets or liabilities that require fair value measurement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zqW2o8baRqu3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_z4EShVyShSWd">Cash and Cash Equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates its fair value. The Company maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (“FDIC”) in accounts that at times may be in excess of the federally insured limit of $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_c20221231_z0VNPNjKVbx">250,000</span> per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions. As of December 31, 2022 and 2021, the Company had $<span id="xdx_906_eus-gaap--PrepaidInsurance_iI_c20221231_zTqnvCSCpSy2">1,817,000</span> and $<span id="xdx_90B_eus-gaap--PrepaidInsurance_iI_c20211231_zMbhM7HMR4s4">2,797,000</span> in excess of the federal insurance limit, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_ecustom--PrepaidExpensePolicyTextBlock_zy6ZkQUYbTw7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zCAlFnZSSe57">Prepaid Expense</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses are assets held by the Company, which are expected to be realized and consumed within twelve months after the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_ecustom--OtherAssetsPolicyTextBlock_zvyS8IAiwE1l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zL5To355xcjc">Other Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other assets consist of long-term advances paid for chip and processor design and development.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_ecustom--RelatedPartiesPolicyTextBlock_zTXXo4TcBXDc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zNLClHrFAbwi">Related Parties</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) section 850-10 for the identification of related parties and disclosure of related party transactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to ASC section 850-10-20 the related parties include (a.) affiliates of the Company (“Affiliate” means, with respect to any specified Person, any other Person that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the Securities Act); (b.) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option of ASC section 825–10–15, to be accounted for by the equity method by the investing entity; (c.) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; (d.) principal owners of the Company; (e.) management of the Company; (f.) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and (g.) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: (a.) the nature of the relationship(s) involved; (b.) a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; (c.) the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and (d.) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zazGHsz67Zr8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zZriflsYuPDh">Commitments and Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows ASC section 450-20 to report accounting for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or un-asserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or un-asserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--DebtPolicyTextBlock_zIBQuzWvME0l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zVT9HMiU0H7c">Debt Discounts</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for debt discounts originating in connection with conversion features that remain embedded in the related notes in accordance with ASC 470-20, <i>Debt with Conversion and Other Options</i>. These costs are classified on the balance sheet as a direct deduction from the debt liability. The Company amortizes these costs over the term of its debt agreements as financing cost in the consolidated statement of operations and comprehensive loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_ecustom--WarrantLiabilityPolicyTextBlock_zpReyO1LFd29" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zRMtKV0bMosg">Warrant Liability</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with financing arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes Merton (“BSM”) option pricing model as of the measurement date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zulfVTb2cFu2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_ztplEUuEHcDf">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We account for our stock-based compensation under ASC 718, “<i>Compensation – Stock Compensation</i>” using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges it equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We use the fair value method for equity instruments granted to non-employees and use the BSM model for measuring the fair value of options. The stock based fair value compensation is determined as of the date of the grant (measurement date) and is recognized over the vesting periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--IncomeTaxPolicyTextBlock_z9UexeE1gZJ9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zoNd3ae50Kqk">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes in accordance with ASC 740, <i>Income Taxes</i>, deferred tax assets and liabilities are computed based on the difference between the financial reporting and income tax bases of assets and liabilities using the enacted marginal tax rate. ASC 740 requires that the net deferred tax asset be reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some portion or all of the net deferred tax asset will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes using an asset and liability approach, which requires the recognition of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. The measurement of current and deferred tax assets and liabilities is based on provisions of enacted tax laws; the effects of future changes in tax laws or rates are not anticipated. If necessary, the measurement of deferred tax assets is reduced by the amount of any tax benefits that are not expected to be realized based on available evidence.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has adopted guidance related to the accounting for uncertainty in income taxes which prescribes rules for recognition, measurement and classification in the financial statements of tax positions taken or expected to be taken in a tax return. The guidance prescribes a two-step approach which involves evaluating whether a tax position will be more likely than not (greater than 50 percent likelihood) sustained upon examination based on the technical merits of the position. The second step requires that any tax position that meets the more likely than not recognition threshold be measured and recognized in the financial statements at the largest amount of benefit that is a greater than 50 percent likelihood of being realized upon settlement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s policy is to recognize interest and penalties, if any, related to unrecognized tax benefits in income tax expense. The Company is not currently under examination by any taxing authority nor has the Company been notified of a pending examination. The statute of limitations for which the Company is generally no longer subject to federal or state income tax examinations by tax authorities is for years before 2013.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zH5PcrqbJkki" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zA1y4YlbPIBl">Earnings Per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We use ASC 260, “<i>Earnings Per Share</i>” for calculating the basic and diluted earnings (loss) per share. We compute basic earnings (loss) per share by dividing net income (loss) by the weighted average number of common shares outstanding. Diluted earnings (loss) per share is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential common shares outstanding during the period using the treasury stock method. Dilutive potential common shares include outstanding stock options and warrants and stock awards. For periods with a net loss, basic and diluted loss per share is the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zqkHI8ipemLd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities that could potentially dilute income (loss) per share in the future were not included in the computation of diluted income (loss) per share on December 31 because their inclusion would be anti-dilutive as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="xdx_8B7_zd4h46oC8aI8" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF INCOME AND LOSS PER SHARE ANTI-DILUTIVE</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20220101__20221231_zxeVc8VJWWGe" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20210101__20211231_zod1vfjZuxUk" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockAwardMember_zWrAPNZavqMf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Restricted stock awards</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0562">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">11,500,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePromissoryNotesAndAccruedInterestMember_zYmBJSRqG3E5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Convertible promissory notes and accrued interest</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,125,699</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,947,394</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAWarrantsIssuedWithConvertiblePromissoryNotesMember_zoN7qy4JMNBc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Series A warrants issued with convertible promissory notes</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,668,304</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,921,304</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBWarrantsToBeIssuedUponExerciseOfSeriesAWarrantMember_zJ3TmS0wz2n9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Series B warrants to be issued upon exercise of Series A warrants</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,668,304</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,921,304</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsIssuedForServicesMember_zb49xvOrOERa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Warrants issued for services</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zipK15uNeLie" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total potential future shares</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7,562,307</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">19,390,002</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zLNSDI3ULxT6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zvTG5Pd2zaDb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z61QcHR4kGyk">Recent Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s management reviewed all recently issued accounting standard updates (“ASU’s”) not yet adopted by the Company and does not believe the future adoptions of any such ASU’s may be expected to cause a material impact on the Company’s condensed consolidated financial condition or the results of its operations.</span></p> <p id="xdx_856_zAcW0ChTV6ki" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--BusinessCombinationsPolicy_zE2qDmjCfi94" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zzH1N6GrHYxi">Incorporation of Korean entity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 5, 2021, AIQ System Inc. (“AIQ”) was incorporated in Seoul, Republic of Korea. AIQ is authorized to issue <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_pp6n6_c20211105__dei--LegalEntityAxis__custom--AIQSystemIncMember_zaOoW9QK4QA7" title="Common stock shares authorized">3</span> million shares of common stock. At the date of incorporation, <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211104__20211105__dei--LegalEntityAxis__custom--AIQSystemIncMember_zAzhVOWByCBg" title="Issuance of common stock, shares">10,000</span> shares were issued to the Company for <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_uSouthKoreanWon_c20211104__20211105__dei--LegalEntityAxis__custom--AIQSystemIncMember_z1JOFegZbd94" title="Issuance of common stock, value">100,000,000</span> Korean Won or approximately $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20211104__20211105__dei--LegalEntityAxis__custom--AIQSystemIncMember_zcO7m3CmRUw5" title="Issuance of common stock, value">89,000</span> for <span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20211105__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AIQSystemIncMember_zp6kvrMKYzD7" title="Ownership percentage">100</span>% ownership of AIQ.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 3000000 10000 100000000 89000 1 <p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zEN2NoO9MpVe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zfICp7LqHLX">Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--ConsolidationPolicyTextBlock_zFOlRbtyKK6l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zI4ge9PCPE2g">Principles of Consolidation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary from the formation date. All material intercompany transactions and balances have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_ecustom--GoingConcernAndLiquidityPolicyTextBlock_zmMOMdaNZU0j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zIlnuvtqBre5">Going Concern and Liquidity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company incurred net income of approximately $<span id="xdx_908_eus-gaap--NetIncomeLoss_c20220101__20221231_z5HsSiyf4Hkg" title="Net income (loss)">2,181,000</span> for the year ended December 31, 2022, of which $<span id="xdx_902_ecustom--RestrictedStockGrants_c20220101__20221231_zSUoJvkCU1Z8" title="Restricted stock grants">4,791,000</span> was attributable to a noncash transaction for the reversal of compensation for restricted stock units, and had an accumulated deficit of approximately $<span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20221231_zUBrgGBTw4n" title="Accumulated deficit">14,650,000</span> as of December 31, 2022. The Company has financed its activities principally through debt and equity financing and shareholder contributions. Management expects to incur additional losses and cash outflows in the foreseeable future in connection with its operating activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s consolidated financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to a number of risks similar to those of other similar stage companies, including dependence on key individuals; successful development, marketing and branding of products; uncertainty of product development and generation of revenues; dependence on outside sources of financing; risks associated with research and development; dependence on third-party suppliers and collaborators; protection of intellectual property; and competition with larger, better-capitalized companies. Ultimately, the attainment of profitable operations is dependent on future events, including obtaining adequate financing to fund its operations and generating a level of revenues adequate to support the Company’s cost structure.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company will need to raise debt or equity financing in the future in order to continue its operations and achieve its growth targets. However, there can be no assurance that such financing will be available in sufficient amounts and on acceptable terms, when and if needed, or at all. The precise amount and timing of the funding needs cannot be determined accurately at this time, and will depend on a number of factors, including market demand for the Company’s products and services, the success of product development efforts, the timing of receipts for customer deposits, the management of working capital, and the continuation of normal payment terms and conditions for purchase of goods and services. The Company believes its cash balances and cash flow from operations will not be sufficient to fund its operations and growth for the next twelve months from the issuance date of these financial statements. If the Company is unable to substantially increase revenues, reduce expenditures, or otherwise generate cash flows from operations, then the Company will likely need to raise additional funding from investors or through other avenues to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2181000 4791000 -14650000 <p id="xdx_84B_ecustom--UnusualOrInfrequentItemsPolicyTextBlock_zH8hhddTIVXi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zxpoHTMtVBab">COVID-19</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The continuing COVID-19 global pandemic has caused significant disruption to the economy and financial markets globally, and the full extent of the potential impacts of COVID-19 are not yet known. Circumstances caused by the COVID-19 pandemic are complex, uncertain and rapidly evolving. The impact of COVID-19 has not been significant to the Company’s results of operations, financial condition, and liquidity and capital resources. Although no material impairment or other effects have been identified to date, there is substantial uncertainty in the nature and degree of its continued effects over time. That uncertainty affects management’s accounting estimates and assumptions, which could result in greater variability in a variety of areas that depend on these estimates and assumptions as additional events and information become known. The Company will continue to consider the potential impact of the COVID-19 pandemic on its business operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--UseOfEstimates_zjWAlxwh07M2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zbZfVQNXBSLh">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with GAAP and requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zfUgyWizQdk4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zkQLs8YORdq9">Foreign Currency Translation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements of foreign subsidiaries, for which the functional currency is the local currency, are translated into U.S. dollars using the exchange rate at the consolidated balance sheet date for assets and liabilities and a weighted-average exchange rate during the year for revenue, expenses, gains and losses. Translation adjustments are recorded as other comprehensive income (loss) within shareholders’ equity (deficit). Gains or losses from foreign currency transactions are recognized in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zcV8epyjuhw6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_z4dLQlyQeNX7">Fair Value Measurement</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Applicable accounting guidance provides an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. There are three levels of inputs that may be used to measure fair value:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 - Other inputs that are directly or indirectly observable in the marketplace.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 - Unobservable inputs which are supported by little or no market activity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of and for the year ended December 31, 2022, the Company had no assets or liabilities that require fair value measurement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zqW2o8baRqu3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_z4EShVyShSWd">Cash and Cash Equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates its fair value. The Company maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (“FDIC”) in accounts that at times may be in excess of the federally insured limit of $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_c20221231_z0VNPNjKVbx">250,000</span> per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions. As of December 31, 2022 and 2021, the Company had $<span id="xdx_906_eus-gaap--PrepaidInsurance_iI_c20221231_zTqnvCSCpSy2">1,817,000</span> and $<span id="xdx_90B_eus-gaap--PrepaidInsurance_iI_c20211231_zMbhM7HMR4s4">2,797,000</span> in excess of the federal insurance limit, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 250000 1817000 2797000 <p id="xdx_84E_ecustom--PrepaidExpensePolicyTextBlock_zy6ZkQUYbTw7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zCAlFnZSSe57">Prepaid Expense</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses are assets held by the Company, which are expected to be realized and consumed within twelve months after the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_ecustom--OtherAssetsPolicyTextBlock_zvyS8IAiwE1l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zL5To355xcjc">Other Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other assets consist of long-term advances paid for chip and processor design and development.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_ecustom--RelatedPartiesPolicyTextBlock_zTXXo4TcBXDc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zNLClHrFAbwi">Related Parties</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) section 850-10 for the identification of related parties and disclosure of related party transactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to ASC section 850-10-20 the related parties include (a.) affiliates of the Company (“Affiliate” means, with respect to any specified Person, any other Person that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the Securities Act); (b.) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option of ASC section 825–10–15, to be accounted for by the equity method by the investing entity; (c.) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; (d.) principal owners of the Company; (e.) management of the Company; (f.) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and (g.) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: (a.) the nature of the relationship(s) involved; (b.) a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; (c.) the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and (d.) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zazGHsz67Zr8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zZriflsYuPDh">Commitments and Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows ASC section 450-20 to report accounting for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or un-asserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or un-asserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--DebtPolicyTextBlock_zIBQuzWvME0l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zVT9HMiU0H7c">Debt Discounts</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for debt discounts originating in connection with conversion features that remain embedded in the related notes in accordance with ASC 470-20, <i>Debt with Conversion and Other Options</i>. These costs are classified on the balance sheet as a direct deduction from the debt liability. The Company amortizes these costs over the term of its debt agreements as financing cost in the consolidated statement of operations and comprehensive loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_ecustom--WarrantLiabilityPolicyTextBlock_zpReyO1LFd29" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zRMtKV0bMosg">Warrant Liability</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with financing arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes Merton (“BSM”) option pricing model as of the measurement date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zulfVTb2cFu2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_ztplEUuEHcDf">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We account for our stock-based compensation under ASC 718, “<i>Compensation – Stock Compensation</i>” using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges it equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We use the fair value method for equity instruments granted to non-employees and use the BSM model for measuring the fair value of options. The stock based fair value compensation is determined as of the date of the grant (measurement date) and is recognized over the vesting periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--IncomeTaxPolicyTextBlock_z9UexeE1gZJ9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zoNd3ae50Kqk">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes in accordance with ASC 740, <i>Income Taxes</i>, deferred tax assets and liabilities are computed based on the difference between the financial reporting and income tax bases of assets and liabilities using the enacted marginal tax rate. ASC 740 requires that the net deferred tax asset be reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some portion or all of the net deferred tax asset will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes using an asset and liability approach, which requires the recognition of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. The measurement of current and deferred tax assets and liabilities is based on provisions of enacted tax laws; the effects of future changes in tax laws or rates are not anticipated. If necessary, the measurement of deferred tax assets is reduced by the amount of any tax benefits that are not expected to be realized based on available evidence.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has adopted guidance related to the accounting for uncertainty in income taxes which prescribes rules for recognition, measurement and classification in the financial statements of tax positions taken or expected to be taken in a tax return. The guidance prescribes a two-step approach which involves evaluating whether a tax position will be more likely than not (greater than 50 percent likelihood) sustained upon examination based on the technical merits of the position. The second step requires that any tax position that meets the more likely than not recognition threshold be measured and recognized in the financial statements at the largest amount of benefit that is a greater than 50 percent likelihood of being realized upon settlement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s policy is to recognize interest and penalties, if any, related to unrecognized tax benefits in income tax expense. The Company is not currently under examination by any taxing authority nor has the Company been notified of a pending examination. The statute of limitations for which the Company is generally no longer subject to federal or state income tax examinations by tax authorities is for years before 2013.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zH5PcrqbJkki" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zA1y4YlbPIBl">Earnings Per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We use ASC 260, “<i>Earnings Per Share</i>” for calculating the basic and diluted earnings (loss) per share. We compute basic earnings (loss) per share by dividing net income (loss) by the weighted average number of common shares outstanding. Diluted earnings (loss) per share is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential common shares outstanding during the period using the treasury stock method. Dilutive potential common shares include outstanding stock options and warrants and stock awards. For periods with a net loss, basic and diluted loss per share is the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zqkHI8ipemLd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities that could potentially dilute income (loss) per share in the future were not included in the computation of diluted income (loss) per share on December 31 because their inclusion would be anti-dilutive as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="xdx_8B7_zd4h46oC8aI8" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF INCOME AND LOSS PER SHARE ANTI-DILUTIVE</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20220101__20221231_zxeVc8VJWWGe" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20210101__20211231_zod1vfjZuxUk" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockAwardMember_zWrAPNZavqMf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Restricted stock awards</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0562">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">11,500,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePromissoryNotesAndAccruedInterestMember_zYmBJSRqG3E5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Convertible promissory notes and accrued interest</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,125,699</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,947,394</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAWarrantsIssuedWithConvertiblePromissoryNotesMember_zoN7qy4JMNBc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Series A warrants issued with convertible promissory notes</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,668,304</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,921,304</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBWarrantsToBeIssuedUponExerciseOfSeriesAWarrantMember_zJ3TmS0wz2n9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Series B warrants to be issued upon exercise of Series A warrants</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,668,304</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,921,304</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsIssuedForServicesMember_zb49xvOrOERa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Warrants issued for services</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zipK15uNeLie" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total potential future shares</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7,562,307</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">19,390,002</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zLNSDI3ULxT6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zqkHI8ipemLd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities that could potentially dilute income (loss) per share in the future were not included in the computation of diluted income (loss) per share on December 31 because their inclusion would be anti-dilutive as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="xdx_8B7_zd4h46oC8aI8" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF INCOME AND LOSS PER SHARE ANTI-DILUTIVE</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20220101__20221231_zxeVc8VJWWGe" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20210101__20211231_zod1vfjZuxUk" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockAwardMember_zWrAPNZavqMf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Restricted stock awards</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0562">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">11,500,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePromissoryNotesAndAccruedInterestMember_zYmBJSRqG3E5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Convertible promissory notes and accrued interest</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,125,699</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,947,394</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAWarrantsIssuedWithConvertiblePromissoryNotesMember_zoN7qy4JMNBc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Series A warrants issued with convertible promissory notes</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,668,304</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,921,304</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBWarrantsToBeIssuedUponExerciseOfSeriesAWarrantMember_zJ3TmS0wz2n9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Series B warrants to be issued upon exercise of Series A warrants</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,668,304</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,921,304</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsIssuedForServicesMember_zb49xvOrOERa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Warrants issued for services</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zipK15uNeLie" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total potential future shares</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7,562,307</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">19,390,002</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 11500000 4125699 3947394 1668304 1921304 1668304 1921304 100000 100000 7562307 19390002 <p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zvTG5Pd2zaDb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z61QcHR4kGyk">Recent Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s management reviewed all recently issued accounting standard updates (“ASU’s”) not yet adopted by the Company and does not believe the future adoptions of any such ASU’s may be expected to cause a material impact on the Company’s condensed consolidated financial condition or the results of its operations.</span></p> <p id="xdx_80C_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zJYHRYO74Iz5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note 2 – <span>Related Party Transactions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_827_zJskVGc6Othi" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">RELATED PARTY TRANSACTIONS</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company incurred approximately $<span id="xdx_906_eus-gaap--ProceedsFromRelatedPartyDebt_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MOneAdvisorsMember_zxxLMlRHzaAj" title="Proceeds from related party">200,000</span> and $<span id="xdx_901_eus-gaap--ProceedsFromRelatedPartyDebt_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MOneAdvisorsMember_zNl5lDLyX4Ni" title="Proceeds from related party">199,000</span> for years ended December 31, 2022 and 2021, and paid approximately $<span id="xdx_903_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MOneAdvisorsMember_zqF0XmgzyoA2" title="Payment to related party">200,000</span> and $<span id="xdx_90D_eus-gaap--RepaymentsOfRelatedPartyDebt_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MOneAdvisorsMember_zW0HeIdJBVEl" title="Payment to related party">202,000</span>, respectively, to M1 Advisors for the services of the Company’s CEO and miscellaneous operating expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b> </b></span></p> 200000 199000 200000 202000 <p id="xdx_80C_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zVXu4Gl85Ni4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note 3 – <span>Intangible and Other Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_82B_zPR89hHxDuIl" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">INTANGIBLE AND OTHER ASSETS</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 23, 2021, AIQ entered into a Technology Development Agreement (the “Agreement”) with PICOCEL, Co., Ltd. (the “Contractor” or “PICOCEL”) to develop a FPGA based Bitcoin mining simulation system. The Agreement was expected to be completed within 6 weeks for a total contract price of <span id="xdx_905_ecustom--ContractPrice_iI_uSouthKoreanWon_c20211223__us-gaap--TypeOfArrangementAxis__custom--TechnologyDevelopmentAgreementMember__dei--LegalEntityAxis__custom--PICOCELCoLtdMember_z0XBPtr2Ame2">198,000,000</span> Korean Won (“KRW”) or approximately $<span id="xdx_908_ecustom--ContractPrice_iI_c20211223__us-gaap--TypeOfArrangementAxis__custom--TechnologyDevelopmentAgreementMember__dei--LegalEntityAxis__custom--PICOCELCoLtdMember_zUTKFJq7Ja91" title="Contract price">167,000</span>. Total payments made to PICOCEL as of December 31, 2022 amounted to approximately $<span id="xdx_90E_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TechnologyDevelopmentAgreementMember__dei--LegalEntityAxis__custom--PICOCELCoLtdMember_z65i1uDOqZLb" title="Payment to related party">69,000</span>. On March 17, 2022, the Company and PICOCEL entered into a mutual agreement to cancel and terminate the Agreement. As of the date of the termination, PICOCEL had completed the first phase of the Agreement upon delivery of the SHA-256 code and FPGA board simulator.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 5, 2022, AIQ entered into a Technology Development Agreement (the “Agreement”) with NNS, Co., Ltd. (the “Contractor” or “NNS”) to develop a FPGA based Bitcoin mining simulation system. The Agreement was expected to be completed within 9 weeks for a total contract price of <span id="xdx_90E_ecustom--ContractPrice_iI_uSouthKoreanWon_c20220405__us-gaap--RelatedPartyTransactionAxis__custom--AIQMember_zI8yi8uAmZbl" title="Contract price">99,000,000</span> KRW, including <span id="xdx_901_eus-gaap--ValueAddedTaxReceivableCurrent_iI_uSouthKoreanWon_c20220405__us-gaap--RelatedPartyTransactionAxis__custom--AIQMember_z3rBmLxI58Ob" title="Value added tax">9,000,000</span> KRW VAT, or approximately $<span id="xdx_90C_ecustom--ContractPrice_iI_c20220405__us-gaap--RelatedPartyTransactionAxis__custom--AIQMember_z7cK5Vx969Y1" title="Contract price">82,000</span>. The payments are scheduled as follows:</span></p> <p id="xdx_89A_ecustom--ScheduleOfPaymentsTableTextBlock_zFCLaL2q5l8k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zZvp7D3vXuuk" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF PAYMENTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">USD</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">KRW</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Within 5 days after signing the contract</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--ContractPrice_iI_c20220405__us-gaap--TypeOfArrangementAxis__custom--WithinFiveDaysAfterSigningTheContractMember_zzkUHbH1abFd" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Contract price">41,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_981_ecustom--ContractPrice_iI_uSouthKoreanWon_c20220405__us-gaap--TypeOfArrangementAxis__custom--WithinFiveDaysAfterSigningTheContractMember_zb7BavIjxCub" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Contract price">49,500,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Within 5 days after all conditions are met as stated in “Schedule B – Statement of Work”</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_ecustom--ContractPrice_iI_c20220405__us-gaap--TypeOfArrangementAxis__custom--WithinFiveDaysAfterallConditionsAreMetMember_z5Zd11cHXV1h" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Contract price">41,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_ecustom--ContractPrice_iI_uSouthKoreanWon_c20220405__us-gaap--TypeOfArrangementAxis__custom--WithinFiveDaysAfterallConditionsAreMetMember_zqrHJDkGrsO4" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Contract price">49,500,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_ecustom--ContractPrice_iI_c20220405_zH26M0Ua8Wxk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">82,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_ecustom--ContractPrice_iI_uSouthKoreanWon_c20220405_zQrtH5fdZ056" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">99,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zRu0BvqVJvs4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment of <span id="xdx_90E_eus-gaap--RepaymentsOfRelatedPartyDebt_uSouthKoreanWon_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TechnologyDevelopmentAgreementMember__dei--LegalEntityAxis__custom--NNSCoLtdMember_zNsyBBMtPN64" title="Payment to related party">90,000,000</span> KRW or approximately $<span id="xdx_903_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--TechnologyDevelopmentAgreementMember__dei--LegalEntityAxis__custom--NNSCoLtdMember_zxohFjNhAp1i" title="Payment to related party">69,000</span> was made to NNS as of December 31, 2022, which was expensed and included in the consolidated statement of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impairment</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2022, the Bitcoin market was in a constant decline, and since the ASIC chip being developed by AIQ was planned to be used for Bitcoin mining machines, management believes that there is an impairment indicator. In August 2022, management discontinued the operations of AIQ.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicators of impairment include significant underperformance relative to historical or projected future operating results, significant changes in our use of the assets or in our business strategy, loss of or changes in customer relationships and significant negative industry or economic trends. When indications of impairment arise for a particular asset or group of assets, we assess the future recoverability of the carrying value of the asset (or asset group) based on an undiscounted cash flow analysis. If the carrying value exceeds projected, net, undiscounted cash flows, an additional analysis is performed to determine the asset’ (or asset group), typically a discounted cashflow analysis, and an impairment charge is recorded for the excess of carrying value over fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, intangibles and other assets were fully impaired. Impairment loss amounted to $<span id="xdx_90D_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_c20220101__20221231_zatPcuawMSkk">154,000</span>, inclusive of a $<span id="xdx_90D_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ValueAddedTaxMember_z9nNZ1toa3oi" title="Impairment loss">12,000</span> impairment of prepaid VAT related to the services provided by PICOCEL and NNS.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfImpairedIntangibleAssetsTextBlock_zRiQyL1Op0h1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below summarizes the impairment loss for the year ended December 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zVjaNNWqGQxk" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF IMPAIRMENT LOSS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">VAT</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 52%">PICOCEL</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231__dei--LegalEntityAxis__custom--PICOCELMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmountMember_zrmV5CEKpqw9" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total">69,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231__dei--LegalEntityAxis__custom--PICOCELMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ValueAddedTaxMember_zgOw34PgKtdf" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total">5,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231__dei--LegalEntityAxis__custom--PICOCELMember_zj5wRcKaxYKe" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total">74,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">NNS</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231__dei--LegalEntityAxis__custom--NNSMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmountMember_zxw6VGy1HKCl" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">69,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231__dei--LegalEntityAxis__custom--NNSMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ValueAddedTaxMember_zNYzeR4BfmLh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">5,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231__dei--LegalEntityAxis__custom--NNSMember_zB7M6kItSSV4" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">74,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Total</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmountMember_zZedXtesMk7a" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">138,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ValueAddedTaxMember_z38HhLKUnxN8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">10,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231_zkcokgypLzT4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">148,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Foreign exchange loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmountMember_zHulCRpwQGWe" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Foreign exchange loss">4,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ValueAddedTaxMember_zQwSWGx52of2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Foreign exchange loss">2,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_pp0p0_c20220101__20221231_zArO1qykOSna" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Foreign exchange loss">6,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Impairment loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmountMember_zANxuHwMni14" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Impairment loss">142,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ValueAddedTaxMember_zMBGZGft0Pdh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Impairment loss">12,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pp0p0_c20220101__20221231_ziIqQCgDgiDd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Impairment loss">154,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zYksEUTktsnl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b> </b></span></p> 198000000 167000 69000 99000000 9000000 82000 <p id="xdx_89A_ecustom--ScheduleOfPaymentsTableTextBlock_zFCLaL2q5l8k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zZvp7D3vXuuk" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF PAYMENTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">USD</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">KRW</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Within 5 days after signing the contract</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--ContractPrice_iI_c20220405__us-gaap--TypeOfArrangementAxis__custom--WithinFiveDaysAfterSigningTheContractMember_zzkUHbH1abFd" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Contract price">41,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_981_ecustom--ContractPrice_iI_uSouthKoreanWon_c20220405__us-gaap--TypeOfArrangementAxis__custom--WithinFiveDaysAfterSigningTheContractMember_zb7BavIjxCub" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Contract price">49,500,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Within 5 days after all conditions are met as stated in “Schedule B – Statement of Work”</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_ecustom--ContractPrice_iI_c20220405__us-gaap--TypeOfArrangementAxis__custom--WithinFiveDaysAfterallConditionsAreMetMember_z5Zd11cHXV1h" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Contract price">41,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_ecustom--ContractPrice_iI_uSouthKoreanWon_c20220405__us-gaap--TypeOfArrangementAxis__custom--WithinFiveDaysAfterallConditionsAreMetMember_zqrHJDkGrsO4" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Contract price">49,500,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_ecustom--ContractPrice_iI_c20220405_zH26M0Ua8Wxk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">82,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_ecustom--ContractPrice_iI_uSouthKoreanWon_c20220405_zQrtH5fdZ056" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">99,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 41000 49500000 41000 49500000 82000 99000000 90000000 69000 154000 12000 <p id="xdx_89F_eus-gaap--ScheduleOfImpairedIntangibleAssetsTextBlock_zRiQyL1Op0h1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below summarizes the impairment loss for the year ended December 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zVjaNNWqGQxk" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF IMPAIRMENT LOSS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">VAT</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 52%">PICOCEL</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231__dei--LegalEntityAxis__custom--PICOCELMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmountMember_zrmV5CEKpqw9" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total">69,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231__dei--LegalEntityAxis__custom--PICOCELMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ValueAddedTaxMember_zgOw34PgKtdf" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total">5,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231__dei--LegalEntityAxis__custom--PICOCELMember_zj5wRcKaxYKe" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total">74,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">NNS</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231__dei--LegalEntityAxis__custom--NNSMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmountMember_zxw6VGy1HKCl" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">69,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231__dei--LegalEntityAxis__custom--NNSMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ValueAddedTaxMember_zNYzeR4BfmLh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">5,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231__dei--LegalEntityAxis__custom--NNSMember_zB7M6kItSSV4" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">74,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Total</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmountMember_zZedXtesMk7a" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">138,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ValueAddedTaxMember_z38HhLKUnxN8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">10,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231_zkcokgypLzT4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">148,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Foreign exchange loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmountMember_zHulCRpwQGWe" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Foreign exchange loss">4,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ValueAddedTaxMember_zQwSWGx52of2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Foreign exchange loss">2,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_pp0p0_c20220101__20221231_zArO1qykOSna" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Foreign exchange loss">6,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Impairment loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmountMember_zANxuHwMni14" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Impairment loss">142,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ValueAddedTaxMember_zMBGZGft0Pdh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Impairment loss">12,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pp0p0_c20220101__20221231_ziIqQCgDgiDd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Impairment loss">154,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 69000 5000 74000 69000 5000 74000 138000 10000 148000 4000 2000 6000 142000 12000 154000 <p id="xdx_803_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zEBYfmViXyCj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note 4 – <span>Accounts Payable and Accrued Expenses</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> <span id="xdx_826_zNH5KgnmGS2i" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></p> <p id="xdx_89D_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zm1ZDZEvYU76" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the Company’s accounts payable and accrued expense balances as of December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_z1how6bxQQg3" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20221231_zGdcYajovWlf" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20211231_zu08wqUBCFI7" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40F_eus-gaap--AccountsPayableCurrent_iI_pp0p0_maAPAALzA7W_zGLF25OXkYF5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Accounts payable</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">186,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">221,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_maAPAALzA7W_zOt4Jx0OBRK9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued expenses</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">99,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--InterestPayableCurrent_iI_pp0p0_maAPAALzA7W_zPKkAcXT0SM5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Accrued interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">326,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">114,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_pp0p0_mtAPAALzA7W_zxzUVQea6uJe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Accounts payable and accrued expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">540,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">434,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zqj9YMpYa2Oa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accrued Interest</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zUXzJWTg1sx7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the details of accrued interest as of December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zVkWbt8aadNg" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF ACCRUED INTEREST</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Notes payable</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20221231_zf2hO7pOn655" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Notes payable">17,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20211231_zIJI1JNPBRUd" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Notes payable">9,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Convertible promissory notes</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--ConvertibleDebtCurrent_iI_pp0p0_c20221231_zDThBR4Hmrpf" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Convertible promissory notes">309,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ConvertibleDebtCurrent_iI_pp0p0_c20211231_ziZx4XoEVTNd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Convertible promissory notes">105,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Balance, end of the year</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--InterestPayableCurrent_iI_pp0p0_c20221231_zEj80anDCwth" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, end of the year">326,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--InterestPayableCurrent_c20211231_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, end of the year">114,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zcrXjbRsH57i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-variant: small-caps"><b> </b></span></span></p> <p id="xdx_89D_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zm1ZDZEvYU76" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the Company’s accounts payable and accrued expense balances as of December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_z1how6bxQQg3" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20221231_zGdcYajovWlf" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20211231_zu08wqUBCFI7" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40F_eus-gaap--AccountsPayableCurrent_iI_pp0p0_maAPAALzA7W_zGLF25OXkYF5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Accounts payable</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">186,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">221,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_maAPAALzA7W_zOt4Jx0OBRK9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued expenses</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">99,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--InterestPayableCurrent_iI_pp0p0_maAPAALzA7W_zPKkAcXT0SM5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Accrued interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">326,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">114,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_pp0p0_mtAPAALzA7W_zxzUVQea6uJe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Accounts payable and accrued expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">540,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">434,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 186000 221000 28000 99000 326000 114000 540000 434000 <p id="xdx_894_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zUXzJWTg1sx7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the details of accrued interest as of December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zVkWbt8aadNg" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF ACCRUED INTEREST</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Notes payable</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20221231_zf2hO7pOn655" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Notes payable">17,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20211231_zIJI1JNPBRUd" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Notes payable">9,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Convertible promissory notes</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--ConvertibleDebtCurrent_iI_pp0p0_c20221231_zDThBR4Hmrpf" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Convertible promissory notes">309,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ConvertibleDebtCurrent_iI_pp0p0_c20211231_ziZx4XoEVTNd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Convertible promissory notes">105,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Balance, end of the year</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--InterestPayableCurrent_iI_pp0p0_c20221231_zEj80anDCwth" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, end of the year">326,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--InterestPayableCurrent_c20211231_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, end of the year">114,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 17000 9000 309000 105000 326000 114000 <p id="xdx_80D_ecustom--NotesPayableDisclosureTextBlock_zVeSZ3JETmJf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note 5 – Notes Payable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_821_zMCI6sBbUTG2" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES PAYABLE</span></span></p> <p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_zi9uInnmvFhg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below summarizes the transactions as of December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_z48G36k1Asme" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF NOTES PAYABLE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Balance, beginning of the year</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--NotesPayable_iS_c20220101__20221231_zOmcAaHvV4o" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Balance, beginning of the year">111,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--NotesPayable_iS_pp0p0_c20210101__20211231_zsuHE81btyia" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Balance, beginning of the year">11,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Additions</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_ecustom--NotesPayableAdditions_c20220101__20221231_zPUF4Wu9Su8e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additions"><span style="-sec-ix-hidden: xdx2ixbrl0696">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--NotesPayableAdditions_pp0p0_c20210101__20211231_zVSqG5GU6We2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additions">150,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Payments</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--RepaymentsOfNotesPayable_iN_di_c20220101__20221231_zrP6xGO6Pi25" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Payments">(50,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--RepaymentsOfNotesPayable_iN_pp0p0_di_c20210101__20211231_zGnERke9he6i" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Payments">(50,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Balance, end of the year</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--NotesPayable_iE_c20220101__20221231_ztAXn1In2As5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, end of the year">61,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--NotesPayable_iE_pp0p0_c20210101__20211231_zbeYxmDDfVmg" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, end of the year">111,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_ztE1efaIX4T1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 7, 2020, the Company issued a promissory note in the principal amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20200707__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zFOyBtaCDlld" title="Debt instrument face amount">11,000</span>. The note is noninterest bearing. The principal was due on or before August 7, 2020. During any event of default under the note, the interest rate shall increase to <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPure_c20200706__20200707__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zaUZL2RWb6Gk" title="Debt instrument interest rate increase decrease">10</span>% per annum. Events of default include failure to pay principal or interest, breach of covenants, breach of representations and warranties, borrower’s assignment of substantial part of its property or business, any money judgment, writ, or similar process shall be entered or filed against the borrower or any subsidiary of the borrower or any of its properties or other assets for more than $<span id="xdx_90D_eus-gaap--DebtInstrumentPeriodicPayment_c20200706__20200707__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--BorrowerMember_zX8Qa2VMHSSg" title="Debt instrument, periodic payment">100,000</span>, bankruptcy, liquidation of business, and cessation of operations. The principal amount outstanding under this note was $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zbmHpD0UOaW8" title="Debt instrument face amount">11,000</span> as of December 31, 2022. The note principal and interest are past due, therefore in default. For the year ended December 31, 2022, the Company has accrued approximately $<span id="xdx_909_eus-gaap--InterestPayableCurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z0C4uBmpakMd" title="Interest payable current">3,000</span> of default interest.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 19, 2021, the Company issued a promissory note in the principal amount of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20210219__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zwXaLHz9wjM2" title="Debt instrument face amount">25,000</span>. The interest on the unpaid principal balance accrued at a rate of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210219__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z0BX6MACPrfa" title="Debt instrument interest rate stated percentage">10</span>% per annum. The principal and any accrued interest was to be paid in a single installment on or before <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20210218__20210219__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z9gQ75D26IA4" title="Maturity date">February 19, 2022</span>. If the Company fails to pay the balance of this note in full on the due date or fails to make any payment due within 15 days of the due date, any unpaid principal shall accrue interest at the rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPure_c20210218__20210219__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zGCKfauE7N1h" title="Debt instrument interest rateIncrease decrease">15</span>% per annum during the default (default interest). Events of default include failure to make any payment including accrued interest when due, voluntary, or involuntary petition of bankruptcy, appointment of a receiver, custodian, trustee or similar party to take possession of the Company’s assets or property, or assignment made by the Company for the benefit of creditors. The principal amount was settled in full on January 25, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 22, 2021, the Company issued a promissory note in the principal amount of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20210422__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zaJcSnWbYD72" title="Debt instrument, face amount">50,000</span>. The interest on the unpaid principal balance accrued at a rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210422__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_z4uCE98S9E29" title="Debt instrument, interest rate">10</span>% per annum. The principal and any accrued interest was to be paid in a single installment on or before <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20210420__20210422__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_z73UlmmQtLwa" title="Debt instrument, maturity date">April 22, 2022</span>. If the Company fails to pay the balance of this note in full on the date or fails to make any payments due within 15 days of the due date, any unpaid principal shall accrue interest at the rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPure_c20210420__20210422__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zKFzGL60Dxpl" title="Increase in interest rate">15</span>% per annum during the default. Events of default include failure to make any payment including accrued interest when due, voluntary, or involuntary petition of bankruptcy, appointment of a receiver, custodian, trustee or similar party to take possession of the Company’s assets or property, or assignment made by the Company for the benefit of creditors. The principal amount outstanding under this note was $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zaanXjOQTVii" title="Debt instrument, face amount">50,000</span> as of December 31, 2022. The note principal and interest are past due, therefore in default. Interest accrued, including default interest, as of December 31, 2022 is $<span id="xdx_900_eus-gaap--InterestPayableCurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zGGOo7v21jid" title="Accrued interest">10,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 1, 2021, the Company issued a promissory note in the principal amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20210701__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_zRx5OOQlSlNi" title="Debt instrument, face amount">25,000</span>. The interest on the unpaid principal balance accrues at a rate of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210701__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_zcpx6YPkCnkj" title="Debt instrument, interest rate">10</span>% per annum. The principal and any accrued interest were to be paid in a single installment on or before <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20210629__20210701__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_zPC9viR5Bio1" title="Debt instrument, maturity date">July 1, 2022</span>. If the Company fails to pay the balance of this note in full on the date or fails to make any payments due within 15 days of the due date, any unpaid principal shall accrue interest at the rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPure_c20210629__20210701__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_zIwwHu0dDhcc" title="Increase in interest rate">15</span>% per annum during the default (default interest). Events of default include failure to make any payment including accrued interest when due, voluntary, or involuntary petition of bankruptcy, appointment of a receiver, custodian, trustee or similar party to take possession of the Company’s assets or property, or assignment made by the Company for the benefit of creditors. The principal amount was settled in full on November 29, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense on notes payable amounted to $<span id="xdx_902_eus-gaap--InterestExpenseDebt_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zyDkDFsIdJY6" title="Interest expense, debt">14,000</span> and $<span id="xdx_907_eus-gaap--InterestExpenseDebt_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zQwo3wLTH3R7" title="Interest expense, debt">8,000</span> for the years ended December 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_zi9uInnmvFhg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below summarizes the transactions as of December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_z48G36k1Asme" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF NOTES PAYABLE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Balance, beginning of the year</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--NotesPayable_iS_c20220101__20221231_zOmcAaHvV4o" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Balance, beginning of the year">111,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--NotesPayable_iS_pp0p0_c20210101__20211231_zsuHE81btyia" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Balance, beginning of the year">11,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Additions</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_ecustom--NotesPayableAdditions_c20220101__20221231_zPUF4Wu9Su8e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additions"><span style="-sec-ix-hidden: xdx2ixbrl0696">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--NotesPayableAdditions_pp0p0_c20210101__20211231_zVSqG5GU6We2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additions">150,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Payments</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--RepaymentsOfNotesPayable_iN_di_c20220101__20221231_zrP6xGO6Pi25" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Payments">(50,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--RepaymentsOfNotesPayable_iN_pp0p0_di_c20210101__20211231_zGnERke9he6i" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Payments">(50,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Balance, end of the year</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--NotesPayable_iE_c20220101__20221231_ztAXn1In2As5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, end of the year">61,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--NotesPayable_iE_pp0p0_c20210101__20211231_zbeYxmDDfVmg" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance, end of the year">111,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 111000 11000 150000 50000 50000 61000 111000 11000 0.10 100000 11000 3000 25000 0.10 2022-02-19 0.15 50000 0.10 2022-04-22 0.15 50000 10000 25000 0.10 2022-07-01 0.15 14000 8000 <p id="xdx_80D_eus-gaap--DebtDisclosureTextBlock_z860jKFbtaT9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note 6 – Convertible Promissory Notes</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_82D_zsLQtP4sfOxa" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">CONVERTIBLE PROMISSORY NOTES</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2021, the Company issued two convertible promissory notes amounting to $<span id="xdx_90F_ecustom--ConvertiblePromissoryNote_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteOneMember_zf6un4xMiZYk" title="Convertible promissory note">55,000</span> and $<span id="xdx_90B_ecustom--ConvertiblePromissoryNote_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteTwoMember_z3CEKe4vWYf1" title="Convertible promissory note">3,850,000</span> (the “Notes”), respectively. The total aggregate proceeds were $<span id="xdx_901_eus-gaap--ProceedsFromConvertibleDebt_c20210101__20221231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteTwoMember_ziURNk27lcj5" title="Proceed from convertible debt">3,550,000</span> due to a $<span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteTwoMember_zp3ScvPGBUre" title="Original issue discount">355,000</span> aggregate original issue discount. The Notes are non-interest bearing with the principal due and payable on <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteOneMember_zvY63jGJc9o1" title="Debt instrument, maturity date">March 1, 2022</span> and <span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteTwoMember_znn1h5VUc8j1" title="Debt instrument, maturity date">August 31, 2022</span>, respectively. Any amount of unpaid principal on the date of maturity will accrue interest at rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPure_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteTwoMember_zOtCNeE2JjXd" title="Increase in interest rate">10</span>% per annum (default interest). Interest accrued as of December 31, 2022 is $<span id="xdx_908_ecustom--AccruedInterest_c20220101__20221231_zGNNJg0lBUvg" title="Accrued interest">133,000</span>. The principal amount and all accrued interest are convertible into shares of the Company’s common stock, as of the date of issuance, at a rate of $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteOneMember_z3mroldZ3asg" title="Debt instruments, conversion price">1.00</span> and $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteTwoMember_zkQMw0gyrhug" title="Debt instruments, conversion price">1.25</span> per share (“Conversion Rate”), respectively. The Conversion Rate is adjustable if, at any time when any principal amount of the Notes remains unpaid or unconverted, the Company issues or sells any shares of the Company’s common stock for no consideration or for a consideration per share (before deduction of reasonable expenses or commissions or underwriting discounts or allowances in connection therewith), which is less than the Conversion Rate in effect on the date of such issuance (or deemed issuance) of such shares of common stock (a “Dilutive Issuance”). <span id="xdx_900_eus-gaap--DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault_c20220101__20221231_zPmObeHCYvIa" title="Events of default description">Immediately upon a Dilutive Issuance, the Conversion Rate will be reduced to the amount of the consideration per share received by the Company in such Dilutive Issuance. Events of default include failure to issue conversion shares, the occurrence of a breach or default under any other agreement, any money judgment, writ, or similar process entered or filed against the Company or any of its property or other assets for more than $<span id="xdx_904_ecustom--IndebtednessForBorrowedMoneyMaximumLimit_iI_c20221231_z9NlpP5mowz8" title="Indebtedness for borrowed money maximum limit">100,000</span>, bankruptcy filing, application for the appointment of a custodian, trustee or receiver, insolvency, the Company’s common stock delisted, or dissolution, winding up, or termination of the business of the Company</span>. The note principal and interest are past due, therefore in default.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the issuance of the Notes, the Company issued to the purchasers of the Notes stock purchase warrants (the “Warrants”) to purchase an aggregate of <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHs6IZsMWAvb" title="Issuance of warrants to purchase of common stock">1,567,500</span> shares of the Company’s common stock for a purchase price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zKLiJoTZGjH" title="Issuance of warrant price per share">1.50</span> to $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z6Mw6iBCNZD2" title="Issuance of warrant price per share">1.87</span> per share, subject to adjustments. The Warrants were valued using the Black Scholes option pricing model for a total fair value of $<span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonStock_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA4UX8tUcfF8" title="Fair value of common stock">3,004,000</span> based on a <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zk7ResU6Z3zj" title="Fair value of common stock estimated life">3</span>-year term, volatility of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zY6urTjyoIbi" title="Date of issuance volatility percentage">404.91</span>% to <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z6Ln8vO0wvVj" title="Date of issuance volatility percentage">405.93</span>%, a risk-free equivalent yield of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zEmjrP0wexY5" title="Fair value of common stock risk free interest rate">0.27</span>% to <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zNWQJXC8fDj1" title="Fair value of common stock risk free interest rate">0.42</span>%, and stock price ranging from $<span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zzj8VYzmIQvk" title="Share price">0.10</span> to $<span id="xdx_90E_eus-gaap--SharePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_ziydeWe0XoOk" title="Share price">1.95</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 470 - Debt, the Company has allocated the cash proceeds amounts of the Notes among the Notes, the Warrants and the conversion feature. The relative fair value of the Warrants issued amounted to approximately $<span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231_zlIBccvbeYd7" title="Fair value of warrants">1,690,000</span> and the beneficial conversion amounted to $<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20220101__20221231_zivl0oHY2rda" title="Debt Instrument, Convertible, Beneficial Conversion Feature">0</span>, which amounts are being amortized and expensed over the term of the Notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company determined that the conversion feature of the Notes would not be an embedded feature to be bifurcated and accounted for as a derivative in accordance with ASC 815-15 <i>Derivatives and Hedging</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financing cost recognized for the amortization of debt discount was approximately $<span id="xdx_909_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20220101__20221231_z0Nhepyl7Tw7">1,526,000</span> and $<span id="xdx_908_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20210101__20211231_zJK0t1Vsoip4">524,000</span> for the years ended December 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ConvertibleDebtTableTextBlock_zwfWpJUwjDqc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The convertible promissory notes consisted of the following as of December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zJXOiCnwHm0f" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF CONVERTIBLE PROMISSORY NOTES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20220101__20221231_zjxSqtiUuKG" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20210101__20211231_zdlmbrlCVGOh" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif">Principal</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DebtInstrumentFaceAmount_iS_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zAoJ2zjjzLH8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Balance, beginning of year</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">4,613,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">708,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--DebtInstrumentAdditions_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zwTLyQ6YmBWe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Additions</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0809">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,905,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DebtInstrumentFaceAmount_iE_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zrd5jHnsYjLg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Balance, end of year</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,613,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,613,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif">Discount</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DebtInstrumentUnamortizedDiscount_iS_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zlkkt9rlrkT1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Balance, beginning of year</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,526,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--DebtInstrumentUnamortizedDiscountAdditions_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zijwPyndzMM1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Additions</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0818">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,045,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--DebtInstrumentUnamortizedDiscountAmortization_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zkfdsgDc5YWg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Amortization</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,526,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(524,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--DebtInstrumentUnamortizedDiscount_iE_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zHVgxGQN7uac" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Balance, end of year</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0824">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,526,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ConvertibleNotesPayableCurrent_iE_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_z9nDhZHRiuK2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net carrying amount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,613,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,087,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zLkPVsnmfoml" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective interest rate used to amortize the debt discount for the years ended December 31, 2022 and 2021 ranges from <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__srt--RangeAxis__srt--MinimumMember_zWOiNxnhbEd2"><span id="xdx_900_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20211231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__srt--RangeAxis__srt--MinimumMember_zxttHlAkvhba">4.76</span></span>% to <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__srt--RangeAxis__srt--MaximumMember_zbyET0739k98"><span id="xdx_909_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20211231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__srt--RangeAxis__srt--MaximumMember_zyXst3WlDtK2">64.60</span></span>%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_ecustom--ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesTableTextBlock_zcmqDjYRHeX6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential future shares to be issued on conversion of the notes as of December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zdAzVBaKHDf6" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF POTENTIAL FUTURE SHARES ISSUANCE OF CONVERSION NOTES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20220101__20221231_z6xjSG2ucKYe" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20210101__20211231_zmDTRojT4Oia" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40F_eus-gaap--DebtConversionOriginalDebtAmount1_z2ywNp8i97di" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%">Principal</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">4,613,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">4,613,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InterestAndDebtExpense_zEs2zay6K0Mh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">309,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">105,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DebtConversionConvertedInstrumentAmount1_iT_zLtExoZIb2Hc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Total</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,922,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,718,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Conversion price per share</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20221231__srt--RangeAxis__srt--MinimumMember_z0Sx5m5LuKni" title="Conversion price per share">1.00</span> – <span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20221231__srt--RangeAxis__srt--MaximumMember_zoy0SOvkH4m1" title="Conversion price per share">1.25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20211231__srt--RangeAxis__srt--MinimumMember_zQ6kI51RsARc" title="Conversion price per share">1.00</span> – <span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20211231__srt--RangeAxis__srt--MaximumMember_zzAY9U5brMHl" title="Conversion price per share">1.25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_zv4QTxvPp0m5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Potential future shares</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,125,699</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,947,394</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zXe9UKxCuRHl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The default interest expense for the convertible promissory notes amounted to $<span id="xdx_907_eus-gaap--InterestExpenseDebt_c20220101__20221231_zrdt5JkZNln8">204,000</span> and $<span id="xdx_906_eus-gaap--InterestExpenseDebt_c20210101__20211231_zynt468cF9Ga">65,000</span> for the year ended December 31, 2022, and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 55000 3850000 3550000 355000 2022-03-01 2022-08-31 0.10 133000 1.00 1.25 Immediately upon a Dilutive Issuance, the Conversion Rate will be reduced to the amount of the consideration per share received by the Company in such Dilutive Issuance. Events of default include failure to issue conversion shares, the occurrence of a breach or default under any other agreement, any money judgment, writ, or similar process entered or filed against the Company or any of its property or other assets for more than $100,000, bankruptcy filing, application for the appointment of a custodian, trustee or receiver, insolvency, the Company’s common stock delisted, or dissolution, winding up, or termination of the business of the Company 100000 1567500 1.50 1.87 3004000 P3Y 4.0491 4.0593 0.0027 0.0042 0.10 1.95 1690000 0 1526000 524000 <p id="xdx_892_eus-gaap--ConvertibleDebtTableTextBlock_zwfWpJUwjDqc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The convertible promissory notes consisted of the following as of December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zJXOiCnwHm0f" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF CONVERTIBLE PROMISSORY NOTES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20220101__20221231_zjxSqtiUuKG" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20210101__20211231_zdlmbrlCVGOh" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif">Principal</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DebtInstrumentFaceAmount_iS_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zAoJ2zjjzLH8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Balance, beginning of year</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">4,613,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">708,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--DebtInstrumentAdditions_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zwTLyQ6YmBWe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Additions</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0809">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,905,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DebtInstrumentFaceAmount_iE_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zrd5jHnsYjLg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Balance, end of year</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,613,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,613,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif">Discount</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DebtInstrumentUnamortizedDiscount_iS_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zlkkt9rlrkT1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Balance, beginning of year</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,526,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--DebtInstrumentUnamortizedDiscountAdditions_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zijwPyndzMM1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Additions</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0818">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,045,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--DebtInstrumentUnamortizedDiscountAmortization_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zkfdsgDc5YWg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Amortization</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,526,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(524,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--DebtInstrumentUnamortizedDiscount_iE_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zHVgxGQN7uac" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Balance, end of year</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0824">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,526,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ConvertibleNotesPayableCurrent_iE_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_z9nDhZHRiuK2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net carrying amount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,613,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,087,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 4613000 708000 3905000 4613000 4613000 1526000 5000 2045000 -1526000 -524000 1526000 4613000 3087000 0.0476 0.0476 0.6460 0.6460 <p id="xdx_898_ecustom--ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesTableTextBlock_zcmqDjYRHeX6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential future shares to be issued on conversion of the notes as of December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zdAzVBaKHDf6" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF POTENTIAL FUTURE SHARES ISSUANCE OF CONVERSION NOTES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20220101__20221231_z6xjSG2ucKYe" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20210101__20211231_zmDTRojT4Oia" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40F_eus-gaap--DebtConversionOriginalDebtAmount1_z2ywNp8i97di" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%">Principal</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">4,613,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">4,613,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InterestAndDebtExpense_zEs2zay6K0Mh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">309,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">105,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DebtConversionConvertedInstrumentAmount1_iT_zLtExoZIb2Hc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Total</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,922,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,718,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Conversion price per share</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20221231__srt--RangeAxis__srt--MinimumMember_z0Sx5m5LuKni" title="Conversion price per share">1.00</span> – <span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20221231__srt--RangeAxis__srt--MaximumMember_zoy0SOvkH4m1" title="Conversion price per share">1.25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20211231__srt--RangeAxis__srt--MinimumMember_zQ6kI51RsARc" title="Conversion price per share">1.00</span> – <span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20211231__srt--RangeAxis__srt--MaximumMember_zzAY9U5brMHl" title="Conversion price per share">1.25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_zv4QTxvPp0m5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Potential future shares</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,125,699</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,947,394</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 4613000 4613000 309000 105000 4922000 4718000 1.00 1.25 1.00 1.25 4125699 3947394 204000 65000 <p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zOV7rM7bCdVk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note 7 – Commitments and contingencies</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> <span id="xdx_828_zK9E2TSBEd7l" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">COMMITMENTS AND CONTINGENCIES</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Litigation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, the Company may become subject to legal proceedings, claims and litigation arising in the ordinary course of business. In addition, the Company may receive letters alleging infringement of patent or other intellectual property rights. The Company is not currently a party to any material legal proceedings, nor is the Company aware of any pending or threatened litigation that would have a material adverse effect on the Company’s business, operating results, cash flows or financial condition should such litigation be resolved unfavorably, except as follows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 3, 2022, a complaint was filed against our company in the Superior Court of California, County of Los Angeles titled <i>Michael Sekula v. CalEthos Inc, Michael Campbell and Does 1-25</i> (Case No. 22STCV00121) for, among other matters, failure to pay wages, fraud and other wage-related claims. <span id="xdx_90F_eus-gaap--LossContingencyDomicileOfLitigation_c20220102__20220103_zwvCT8GncSHf" title="Litigation description">In the complaint, the plaintiff claimed he worked under a consulting agreement as Vice President of Brand Management of our company and was to be paid $<span id="xdx_90E_eus-gaap--PaymentsForRent_c20220102__20220103_zr9HDoO9560l" title="Payments for rent">4,000</span> per month and to receive an option to purchase <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20220102__20220103_zHy3yIwMW2Bj" title="Option to purchase shares vested">50,000</span> shares of our common stock that was to vest quarterly over the term of the agreement. In the complaint, the plaintiff alleged that, on or around March 27, 2020, the Company ceased paying the plaintiff despite the plaintiff’s continuing efforts on behalf of our company and that the Company agreed to continue to accrue his monthly retainer amount until such time that the Company received at least $<span id="xdx_906_ecustom--FundsReceived_c20220102__20220103_zdDyCjxZELSg" title="Funds received">100,000</span> in funding. Plaintiff further alleged that he continued to work for our company for 38 additional weeks in reliance on our promise of payment. The plaintiff claimed that our refusal to make the promised payments amounts to violations of the California labor laws and seeks damages in excess of $<span id="xdx_906_eus-gaap--LossContingencyDamagesSoughtValue_c20220102__20220103_zKAo3Ujdz6x6" title="Damages value">450,000</span></span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 9, 2022, a Settlement Agreement and Mutual Release was reached by the parties in the above mentioned complaint whereby as full consideration for the plaintiff’s execution of and compliance with the agreement and plaintiff’s release of all claims against the defendants, the Company agreed to pay a gross settlement amount of $<span id="xdx_900_eus-gaap--BusinessAcquisitionPreacquisitionContingencyAmountOfSettlement_iI_c20220609_z2KXs7Em9Xh5" title="Gross settlement amount">90,000</span>. Such payment was made on June 23, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> In the complaint, the plaintiff claimed he worked under a consulting agreement as Vice President of Brand Management of our company and was to be paid $4,000 per month and to receive an option to purchase 50,000 shares of our common stock that was to vest quarterly over the term of the agreement. In the complaint, the plaintiff alleged that, on or around March 27, 2020, the Company ceased paying the plaintiff despite the plaintiff’s continuing efforts on behalf of our company and that the Company agreed to continue to accrue his monthly retainer amount until such time that the Company received at least $100,000 in funding. Plaintiff further alleged that he continued to work for our company for 38 additional weeks in reliance on our promise of payment. The plaintiff claimed that our refusal to make the promised payments amounts to violations of the California labor laws and seeks damages in excess of $450,000 4000 50000 100000 450000 90000 <p id="xdx_80F_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zaOBcZSPKJw1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note 8 – Equity </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> <span id="xdx_822_zsziacfhBj55" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">EQUITY</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Shares Authorized</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is authorized to issue <span id="xdx_907_ecustom--AuthorizedToIssueShares_iI_c20221231_zWHt7zPvZRrj" title="Authorized to issue shares">200,000,000</span> shares of which <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zqKmKbBhvPK8" title="Preferred stock, shares authorized">100,000,000</span> shares shall be preferred stock, par value $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231_z2PHblv9jxF1" title="Preferred stock, par value">0.001</span> per share, and <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zRB7gm21zF21" title="Common stock, shares authorized">100,000,000</span> shares shall be common stock, par value $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231_zzI1dvquGdql" title="Common stock, par value">0.001</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series A Convertible Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series A Convertible Preferred Stock (“Series A”) is convertible into shares of the Company’s common stock at the rate of $<span id="xdx_90E_eus-gaap--SaleOfStockPricePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_ztFXDsF7cN2k" title="Sale of stock shares price per share">1.38</span> per share, subject to adjustments based on the Company’s future sales of financial instruments at a value less than $<span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zAVFLPWCzfgj" title="Sale of stock shares price per share">1.38</span> per share. The holders of the Series A have the right to convert any time after the date of issuance. With the issuance of the convertible promissory notes, as explained in Note 5 above, the Series A’s conversion rate adjusted to $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zukVAb7jFerd">1.00</span> per share. In accordance with ASC 470, the Company has calculated the effect of the conversion rate adjustment, which was approximately $<span id="xdx_90E_ecustom--ConversionRateAdjustmentValue_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zxq1fn6P6Jz7" title="Conversion rate adjustment, value">36,000</span>. The conversion rate adjustment has been treated as a deemed dividend, which has been presented in the Statement of Changes in Stockholders’ Deficit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series A is mandatorily convertible upon (i) the closing of the sale of shares of the Company’s common stock to the public in an underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20220101__20221231_zlDW4WK5gTs3">10,000,000</span> of gross proceeds to the Company, (ii) <span id="xdx_908_eus-gaap--SaleOfStockDescriptionOfTransaction_c20220101__20221231_zgZlw7AG8MF8">the close of business on the sixtieth consecutive day on which the closing price of the Company’s common stock on the OTC Markets is at least $2.80 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, stock combination or other similar recapitalization with respect to the common stock, or (iii) the affirmative vote of the holders of at least 66⅔% of the outstanding shares of Series A, given at a meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders all outstanding shares of Series A shall automatically be converted into shares of the Company’s common stock, at the then effective conversion rate</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Series A shall be entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of Series A held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of the Articles of Incorporation, holders of Series A shall vote together with the holders of common stock as a single class.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From and after the date of the issuance of any shares of Series A, a cumulative dividend on each outstanding share of Series A Preferred Stock shall accrue at a rate per annum equal to ten percent of the Series A original issue price. Accrued dividends on the Series A shall be paid in shares of the Company’s common stock, such shares to be valued for such purpose at the applicable series A conversion price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 11, 2020, the Company converted <span id="xdx_90D_eus-gaap--ConversionOfStockSharesIssued1_c20200210__20200211__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zQIAwbA7oZQ1" title="Conversion of shares">85,975</span> shares of Series A into a Convertible Promissory Notes in the principal amount approximately $<span id="xdx_907_eus-gaap--DebtConversionOriginalDebtAmount1_c20200210__20200211__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zXNjyIta7wWa" title="Conversion of debt">147,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2021, the Company’s President and a member of the Board of Directors, resigned as an officer and director of the Company (“Termination Agreement”). Part of the Termination Agreement stipulates the return of <span id="xdx_900_ecustom--StockIssuedDuringPeriodReturnOfShares_c20210101__20210131__us-gaap--TypeOfArrangementAxis__custom--TerminationAgreementMember_z0AN7KqYwDfh" title="Return of shares">3,674,330</span> shares of the Company’s common stock (“Cancelled Shares”). The Cancelled Shares were returned and cancelled on April 20, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2021, the Company’s Chief Executive Officer (“CEO’) agreed to forgive approximately $<span id="xdx_908_eus-gaap--DebtInstrumentDecreaseForgiveness_pp0p0_c20210101__20210331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zOTI5YDnlCki" title="Debt instrument decrease forgiveness">68,000</span> due to him, which was treated as contributed paid in capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2021, the Company’s Chief Financial Officer agreed to reduce the amounts due to him from approximately $<span id="xdx_905_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pp0p0_c20210301__20210331__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__srt--RangeAxis__srt--MinimumMember_zAVQIckDEFnl" title="Due to related parties">128,000</span> to $<span id="xdx_90E_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pp0p0_c20210301__20210331__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__srt--RangeAxis__srt--MaximumMember_zXP6yYeYemU9" title="Due to related parties">30,000</span>. For the reduction of $<span id="xdx_906_ecustom--ReductionAmount_pp0p0_c20210101__20210331__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zYWzIm189soa" title="Reduction amount">98,000</span>, the Company will issue <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20210331__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zBz8J803f1Sl" title="Stock issued during period shares new issues">75,000</span> shares of common stock. The remaining liability of $<span id="xdx_90D_ecustom--RemainingLiabilityPaidForCash_iI_pp0p0_c20210331_zRJUPl0AYkek" title="Remaining cash liability">30,000</span> will be paid in cash.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2021, the Company entered into a release agreement with one of its consultants. As part of the separation payment, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20211001__20211031__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zCYdM2cblHDg">25,000</span> shares valued at $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20211001__20211031__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zmfHgsNnS3Qg">76,000</span> and paid $<span id="xdx_902_ecustom--PaymentsToConsultants_c20211001__20211031__srt--TitleOfIndividualAxis__custom--ConsultantsMember_z4GhoBKpA1Wb" title="Payments to consultants">20,000</span> cash in October 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted Common Stock Awards</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 17, 2021, the Company entered into Restricted Share Award Agreements (the “Award Agreements”) with two consultants pursuant to which the Company issued to the consultants shares of common stock of the Company in exchange for their future services. The Awards had an initial term of one year, which was to be automatically renewed on a year-to-year basis unless either party gave a written notice of termination. The two consultants who entered into these agreements include:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A consultant who was granted <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_pid_uShares_c20210816__20210817__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zIkkCEipUVkf" title="Restricted common stock shares granted">10,000,000</span> restricted share awards.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An entity, which is owned by the Company’s CEO and majority shareholder, was granted <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_pid_uShares_c20210816__20210817__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zASfMWaZ6yFk" title="Restricted common stock shares granted">1,500,000</span> restricted share awards. </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s management accounted for the Award Grants as restricted stock compensation in accordance with ASC 718 – Stock Compensation (“ASC 718”). ASC 718 required the Company to estimate the service period over which the compensation cost would be recognized. Management had estimated that the first two development phases would be completed within 15 months and the Foundry Mask would be completed within 6 months for a total of 21 months service period. Compensation cost was to be recognized ratably over 21 months and in the same manner had the Company paid in cash. The estimated service period would be adjusted for changes in actual and expected completion dates. Any such change was to be recognized prospectively, and the remaining deferred compensation was to be recognized over the remaining service period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company issued restricted stock grants totaling <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_pid_uShares_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zEn5cOnITpP1">10,000,000</span> shares (“Grant Shares”) to Hyuncheol (Peter) Kim (“CTO”), the Company’s former Chief Technology Officer, and <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_pid_uShares_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ChiefTechnologyOfficerMember_zJ5Z0udrVwbf">1,500,000</span> to a M1 Advisors LLC, a company owned by the Company’s chief executive officer. The value was $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_c20221231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_z4O6IyWvYtib">1.93</span> per share on the date of issuance (“Grant Date”) for an aggregate fair value of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_uUSD_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_ziyJQGceqkUk">22,195,000</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The stock-based award compensation was recorded as an increase in deferred compensation expense, common stock, and additional paid-in capital in the Company’s books at the time of the grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 27, 2022, the Company sent the CTO, a letter notifying him that the Company’s Board of Directors had resolved to discontinue the Company’s 5 nanometer ASIC chip and bitcoin mining machine project and that his consulting agreement was to terminate at the end of August 2022. The Grant Shares issued in connection with his consulting agreement were canceled. As of the issuance date of these consolidated financial statements, the CTO had not executed the documentation required for the Company to cancel the Grant Shares; therefore, the Grant Shares are still legally outstanding, so the number of Grant Shares has not been removed from the total shares issued and outstanding. Since it is probable that the Grant Shares will not be earned, the Company has reversed the expense recognized for the fair value of the Grant Shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also, at the end of August 2022, the Company canceled the restricted stock grant issued to M1 Advisors LLC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_z58QAr77Uzff" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below summarizes the transactions related to the Company restricted stock awards as of December 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zKKYGBhFDUb4" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF COMPANY RESTRICTED STOCK AWARDS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Deferred <br/> compensation</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Grant date fair value</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_983_ecustom--GrantDateFairValueShares_iI_pid_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zzUqMOyfCgb7" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Grant date fair value, shares">11,500,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--DeferredCompensationGrantDateFairValue_iI_uUSD_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjE0tOqOt8vd" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Deferred compensation grant date fair value">22,195,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Accretion</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_ecustom--AccretionShares_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z7y7Ar1TgRF4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accretion, shares"><span style="-sec-ix-hidden: xdx2ixbrl0929">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_ecustom--DeferredCompensationAccretion_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zFfvEx4JZmYl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred compensation accretion">(11,168,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Canceled</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--CanceledShares_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zzPr7VJzG1h7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Canceled, shares">(1,500,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--DeferredCompensationCanceled_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z71KSV8OC6h2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred compensation canceled">(11,027,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance as of December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z64iCU2EUzmi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, balance">10,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--DeferredCompensationShareBasedArrangementsLiabilityCurrent_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zGDndz6Wgxkg" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred compensation"><span style="-sec-ix-hidden: xdx2ixbrl0939">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zzcPlqrWnT4a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_ecustom--ScheduleOfShareBasedCompensationRestrictedStockGrantTableTextBlock_zuka4H4tcZo3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted stock grant compensation expense for the year ended December 31, 2022, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zx7hXeNS0ng7" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF RESTRICTED STOCK GRANT COMPENSATION EXPENSE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49E_20220101__20221231_zxNW6zfbOGce" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoAccretionExpenseMember_z0n08cWcQF65" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left">2022 Accretion expense</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">6,377,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--PlanNameAxis__custom--ReversalTwoThousandTwentyOneAccretionExpenseMember_zvqTCVJBAxDi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Reversal of 2021 accretion expense</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(4,791,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--PlanNameAxis__custom--ReversalTwoThousandTwentyTwoAccretionExpenseMember_zgZpKCHqLDR2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Reversal of 2022 accretion expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(6,377,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--AllocatedShareBasedCompensationExpense_ziMQs99altja" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Restricted stock grant compensation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,791,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8A9_zbCuoMfEcqO4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Issuance of Stock Options and Warrants</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2021, the Company signed a new consulting agreement that granted one of its shareholders an option to purchase <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210201__20210228__us-gaap--TypeOfArrangementAxis__custom--NewConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ShareholderMember_zgmrCCb0XCta" title="Option to purchase shares">750,000</span> shares of the Company’s common stock at $<span id="xdx_905_eus-gaap--SharePrice_iI_c20210228__us-gaap--TypeOfArrangementAxis__custom--NewConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ShareholderMember_zsTdddzT65J3" title="Share price">0.001</span> per share for the consultancy work provided from August 2020 to February 2021. The options were fully vested on the date of issuance. The fair value of the options was approximately $<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20210201__20210228__us-gaap--TypeOfArrangementAxis__custom--NewConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ShareholderMember_z7j0xwULh9m6" title="Fair value of options">52,000</span>, as of the grant date, of which approximately $<span id="xdx_90F_eus-gaap--StockOptionPlanExpense_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--NewConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ShareholderMember_zEEB62DT12H8" title="Option expense">38,000</span> was expensed and accrued during the year ended December 31, 2020 and $<span id="xdx_905_eus-gaap--StockOptionPlanExpense_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--NewConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ShareholderMember_z24zFh2YD84j" title="Option expense">14,000</span> was expensed for the year ended December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2021, the Company signed a letter of understanding that granted one of its shareholders an option to purchase <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20210531__us-gaap--TypeOfArrangementAxis__custom--LetterofUnderstandingMember_zX4wpujtjXH9" title="Common stock, shares authorized">300,000</span> shares of the Company’s common stock at $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210531__us-gaap--TypeOfArrangementAxis__custom--LetterofUnderstandingMember_zxDPAYw0Au6h" title="Common stock, par value">0.001</span> per share for the consultancy work provided during the Company’s restructuring phase from February 17, 2021 through April 30, 2021. The options were fully vested on the date of issuance. The fair value of the options was approximately $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20210101__20211231_zKY5G0HzRT81" title="Share-based compensation arrangement by share-based payment award, options">561,000</span>, as of grant date, which was expensed during the year ended December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2021, an option holder exercised three options for <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210501__20210531__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zVdtfKSvnDH7" title="Number of share options exercised">385,000</span>, <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210501__20210531__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zQMX3tp0QDA7" title="Number of share options exercised">750,000</span> and <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210501__20210531__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_zvybL4AvQEK4" title="Number of share options exercised">300,000</span> shares of the Company’s common stock at an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210531_zo1LqVKYUvMi" title="Class of warrant exercise price">0.001</span> for each option, for total proceeds of approximately $<span id="xdx_907_eus-gaap--ProceedsFromStockOptionsExercised_c20210501__20210531_zJU6TQIwUH2" title="Proceeds from stock options exercised">2,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zekUCwOIkeyf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below summarizes the Company’s stock option activities for the years ended December 31, 2022 and 2021 (all share and per share data reflects the reverse stock split):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zM6Lpu4bRWQ7" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF STOCK OPTION ACTIVITIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Option</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range Per</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relative</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 35%">Balance, January 1, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zfb8f6TnxzR" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Number of Number of Stock Option Shares, Outstanding, Beginning Balance">385,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceRangePerShareOutstandingBeginning_iS_c20210101__20211231_zdCOHZ1uwew1" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Exercise Price Range Per Share, Outstanding, Beginning"><span style="-sec-ix-hidden: xdx2ixbrl0981">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zokrci5jJa91" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning">0.001</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRelativeFairValueOutstandingBeginning_iS_c20210101__20211231_zYd2Vcl49XFl" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Relative Fair Value, Outstanding, Beginning"><span style="-sec-ix-hidden: xdx2ixbrl0985">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pdp0_c20210101__20211231_zJdXikrAHwd6" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Aggregate Intrinsic Value, Beginning Balance">7,315</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zwLuWs9qzEi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Stock Option Shares, Granted">1,050,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInExercisePriceRangePerShareGranted_c20210101__20211231_zdOtTlaWSi56" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Range Per Share, Granted">0.001</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zt9leAWPPZ7k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted">0.001</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodRelativeFairValueGranted_c20210101__20211231_znb3tMcIsdij" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Relative Fair Value, Granted">1.94</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue_c20210101__20211231_zJtrjiBwcVM8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0997">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210101__20211231_zpNT6P5B9R4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Stock Option Shares, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0999">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsInPeriodExercisePriceRangePerShareForfeited_c20210101__20211231_zODHjuOdTrvb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Range Per Share, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1001">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_zXkvBQ1on9l" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1003">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodRelativeFairValueForfeited_c20210101__20211231_zuKtxNcljvgg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Relative Fair Value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1005">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodForfeitedIntrinsicValue_c20210101__20211231_zMAxxisjqWu4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1007">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210101__20211231_z3aTKyfo1SSi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Stock Option Shares, Exercised">(1,435,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodExercisePriceRangePerShareExercised_c20210101__20211231_zQEFXRzvDYCa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Range Per Share, Exercised">0.001</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231_zKdfAehFKVLj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised">0.001</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodRelativeFairValueExercised_c20210101__20211231_zqI1SfNNddL7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Relative Fair Value, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1015">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInPeriodExercisedIntrinsicValue_c20210101__20211231_zAnz1wBM906f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1017">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Expired</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20210101__20211231_z6K53gVUYPzg" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Stock Option Shares, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1019">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePriceRangePerShareExpired_c20210101__20211231_zaZBznrUmIwh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Range Per Share, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1021">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zr5KcFf3YuT4" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1023">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodRelativeFairValueExpired_c20210101__20211231_z74S9K8VIz9c" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Relative Fair Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1025">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInPeriodExpiredIntrinsicValue_c20210101__20211231_zRXiyVFolFZ2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1027">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Balance, December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zFCjh8k4fuS1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Number of Stock Option Shares, Outstanding, Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1029">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceRangePerShareOutstandingBeginning_iS_c20220101__20221231_zTRYv4CPPSs4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Range Per Share, Outstanding, Beginning"><span style="-sec-ix-hidden: xdx2ixbrl1031">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zPObti2DwO8h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning"><span style="-sec-ix-hidden: xdx2ixbrl1033">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRelativeFairValueOutstandingBeginning_iS_c20220101__20221231_zCdFhR3MWo2d" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Relative Fair Value, Outstanding, Beginning"><span style="-sec-ix-hidden: xdx2ixbrl1035">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pdp0_c20220101__20221231_zTy615g4bVbg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1037">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_z1tawgIdWxL2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Stock Option Shares, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1039">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInExercisePriceRangePerShareGranted_c20220101__20221231_zwlkmp1iGKxd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Range Per Share, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1041">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zBUh6LYwsKE8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1043">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodRelativeFairValueGranted_c20220101__20221231_z4ufIaAItsR8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Relative Fair Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1045">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue_c20220101__20221231_zLWSh6I4rkOb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1047">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20220101__20221231_zuTfJilZfvv6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Stock Option Shares, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1049">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsInPeriodExercisePriceRangePerShareForfeited_c20220101__20221231_zUO8gWRN51Dc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Range Per Share, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1051">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20221231_zZyX7z9Tjzz9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1053">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodRelativeFairValueForfeited_c20220101__20221231_ztSJA9RuVVuc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Relative Fair Value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1055">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodForfeitedIntrinsicValue_c20220101__20221231_zFEN866NtXld" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1057">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220101__20221231_zv1LZuxsj3q5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Stock Option Shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1059">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodExercisePriceRangePerShareExercised_c20220101__20221231_zYwgQwdKnN43" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Range Per Share, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1061">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231_zUWt5DyurlN4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1063">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodRelativeFairValueExercised_c20220101__20221231_zvpXwlpDDBLh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Relative Fair Value, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1065">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInPeriodExercisedIntrinsicValue_c20220101__20221231_zgZzycTh3Wac" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1067">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Expired</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20220101__20221231_zL2FLKezaKF" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Stock Option Shares, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1069">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePriceRangePerShareExpired_c20220101__20221231_zuT7ifCoZuwd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Range Per Share, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1071">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zy2ilxgH65v3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1073">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodRelativeFairValueExpired_c20220101__20221231_ztAOuGcf3QB1" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Relative Fair Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1075">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInPeriodExpiredIntrinsicValue_c20220101__20221231_zziRoprpKEhg" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1077">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zhZhTVmzEai9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Number of Stock Option Shares, Outstanding, Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1079">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceRangePerShareOutstandingBeginning_iE_c20220101__20221231_zEtmXQ2okTq1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Range Per Share, Outstanding, Beginning"><span style="-sec-ix-hidden: xdx2ixbrl1081">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zrS8KFqDxxJ1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning"><span style="-sec-ix-hidden: xdx2ixbrl1083">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRelativeFairValueOutstandingBeginning_iE_c20220101__20221231_zGXBsJKbj0H6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Relative Fair Value, Outstanding, Beginning"><span style="-sec-ix-hidden: xdx2ixbrl1085">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pdp0_c20220101__20221231_zeHEAcIeq0q8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1087">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Vested and exercisable, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableEndingBalance_iE_c20220101__20221231_zrla6Q4nFEx1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Stock Option, Vested and Exercisable, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1089">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodExercisePriceRangePerShareVestedAndExercisable_c20220101__20221231_zL87LLCzsu44" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Range Per Share, Vested and Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1091">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceVestedAndExercisable_c20220101__20221231_zgo8qcHROgV2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Vested and Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1093">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodRelativeFairValueVestedAndExercisable_c20220101__20221231_zuNlByx3dckc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Relative Fair Value, Vested and Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1095">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pdp0_c20220101__20221231_zUKMaQoeUICa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Vested and Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1097">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Unvested, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedEndingBalance_iE_c20220101__20221231_z2d6ECfpG1w1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Stock Option, Unvested, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1099">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsInPeriodExercisePriceRangePerShareUnvested_c20220101__20221231_zzdClPDre70f" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Range Per Share, Unvested"><span style="-sec-ix-hidden: xdx2ixbrl1101">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iI_c20221231_zO7PSzJZMOde" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Unvested"><span style="-sec-ix-hidden: xdx2ixbrl1103">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsUnvestedInPeriodRelativeFairValueUnvested_c20220101__20221231_zDBO26TenNTj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Relative Fair Value, Unvested"><span style="-sec-ix-hidden: xdx2ixbrl1105">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAggregateIntrinsicValueUnvested_iE_pdp0_c20220101__20221231_zJLd6LNzJ5Cb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Unvested"><span style="-sec-ix-hidden: xdx2ixbrl1107">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zPTTvHCcrQbl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 15, 2021, the Company issued warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210915_zbwfZZmE3Dvd" title=" Number of securities called by warrants or rights">100,000</span> shares of the Company’s common stock. For the year ended December 31, 2021, the compensation expense, classified as professional fees in the consolidated statement of operations and comprehensive loss, was $<span id="xdx_906_eus-gaap--ShareBasedCompensation_c20210101__20211231_zRW3yV38tF53" title="Compensation expenses">195,000</span>, which was calculated using the Black Scholes fair value option-pricing model with key input variables provided by management, as of the date of issuance: volatility of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_z9NJesl7dII4" title=" Fair value assumptions, expected volatility rate">359</span>%, fair value of common stock $<span id="xdx_90E_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20211231_zQw3Ghetus78" title="Share price">1.95</span>, estimated life of <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zUqqTwHCxbV4" title=" Expected Term">3</span> years, risk free rate of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_uPure_c20210101__20211231_zX9GlSq1gR1i" title="Risk Free Interest Rate">0.43</span>% and dividend rate of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20210101__20211231_zOfBsN9UFWQ9" title="Dividend payments">0</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zQ53SHJPa3C" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below summarizes the Company’s warrant activities for the years ended December 31, 2022 and 2021 (all share and per share data reflects the reverse stock split):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zYV82oU5FE5a" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF WARRANTS ACTIVITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of </b></span><b>Shares</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Strike Price/Share</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Remaining Contractual Term (Years)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Grant Date Fair Value/Share</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 35%">Balance, January 1, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231_zoJ4YlPQZ97g" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Number of warrants issued, Outstanding, Beginning of period">353,804</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zQDMerB3RXRc" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Weighted Average Strike Price/Share, Outstanding, Beginning of period">1.50</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_z8V9hFd9TP6d" title="Weighted Average Remaining Contractual Term (Years), ending of period">2.88</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantFairValue_iS_c20210101__20211231_zmtPfIyHiJR6" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Weighted Average Grant Date Fair Value/Share, beginning balance">0.18</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue_iS_c20210101__20211231_zR1xxBSBJ8lb" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Aggregate intrinsic value, beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1133">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231_zTfEGlAccDFh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants issued, Granted">1,667,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_ze5m36fljJDc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share, Granted">1.86</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231_zgzBcTbdU6P3" title="Weighted Average Remaining Contractual Term (Years), Granted">3.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValue_c20210101__20211231_zrRfrflh5Bsg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share, Granted">1.67</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueGranted_c20210101__20211231_zvCsqVA5kime" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic, Granted">0.11</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20211231_zIgypDqhDu8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants issued, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1145">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_zRqpgoXTrjv4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1147">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">–</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueForfeited_c20210101__20211231_zzDrBiByXlIf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1149">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicForfeited_c20210101__20211231_zcthyWsF5elk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1151">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20211231_z1bY1EIiD7dg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants issued, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1153">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExerciseInPeriodWeightedAverageExercisePrice_c20210101__20211231_zTjXtkvEgUm8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1155">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">–</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueExercised_c20210101__20211231_ztgBl2cQFIM5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1157">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueExercised_c20210101__20211231_znAvy0Hled45" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value exercised"><span style="-sec-ix-hidden: xdx2ixbrl1159">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Expired</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpired_c20210101__20211231_zkUFOMn28LTf" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants issued, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1161">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20211231_zbXrvxtuIGdb" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1163">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">–</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueExpired_c20210101__20211231_zvN9RCYfYEil" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share, expired"><span style="-sec-ix-hidden: xdx2ixbrl1165">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueExpired_c20210101__20211231_zTbMeZ64grn1" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value expired"><span style="-sec-ix-hidden: xdx2ixbrl1167">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance, December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231_zTRaoAIB15Ba" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants issued, Outstanding, Ending of period">2,021,304</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_zCZ1UrIekPei" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share, Outstanding, ending of period">1.80</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231_zka1rO5513dh" title="Weighted Average Remaining Contractual Term (Years)">2.98</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantFairValue_iE_c20210101__20211231_zZi3X6GvnoJk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share, ending balance">1.14</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue_iE_c20210101__20211231_ze54kh8Jqfk1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, ending balance">0.17</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Vested and exercisable, December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExercisable_iI_c20211231_zgpiUOHSkZRe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Non option equity instruments vested and exercisable, ending of period">2,021,304</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceVestedAndExercisable_iI_c20211231_zfQP1Wt5ZtIe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share vested and exercisable, ending of period">1.80</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingContractualTermUnvestedAndExercisable_dtY_c20210101__20211231_zmOyMxEmsOb8" title="Weighted Average Remaining Contractual Term (Years), vested and exercisable">2.98</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantFairValueVestedAndExercisable_iI_c20211231_zXfT0tYCLgl5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share vested and exercisable, ending of period">1.14</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVestedAndExercisable_iI_c20211231_zFI2mJYbGpw3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value vested and exercisable, ending of period">0.17</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Unvested, December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested_iI_c20211231_zY8GkRO0G586" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Non option equity instruments Unvested, ending of period"><span style="-sec-ix-hidden: xdx2ixbrl1189">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceVested_iI_c20211231_zM11kHCBBQP9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share unvested"><span style="-sec-ix-hidden: xdx2ixbrl1191">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">–</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantFairValueVested_iI_c20211231_zSE8sse9FIfe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share Unvested, Ending of period"><span style="-sec-ix-hidden: xdx2ixbrl1193">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVested_iI_c20211231_zF5gEq2Fn8m8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value Unvested, ending of period"><span style="-sec-ix-hidden: xdx2ixbrl1195">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Balance, January 1, 2022</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231_zmiRJQHCOsR" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants issued, Outstanding, Beginning of period">2,021,304</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zHbuvzQDzrI1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share, Outstanding, Beginning of period">1.80</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_z72c2KJnqAig" title="Weighted Average Remaining Contractual Term (Years)">2.98</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantFairValue_iS_c20220101__20221231_zBgJV9L7JuXg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share, Ending of period">1.14</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue_iS_c20220101__20221231_zBeffeGxRDA5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, Beginning of period">0.17</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231_zFOvg2qFv97f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants issued, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1207">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zONaB3l9d2Ok" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1209">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231_zuGCMUOzRXB" title="Weighted Average Remaining Contractual Term (Years), Granted"><span style="-sec-ix-hidden: xdx2ixbrl1211">–</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValue_c20220101__20221231_zxMfXd1EWpwd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1213">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueGranted_c20220101__20221231_zm3yxcFKKAM2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1215">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231_zuRIicJ1BmIa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants issued, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1217">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20221231_zCkAcqsqQmE2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1219">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">–</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueForfeited_c20220101__20221231_zupwYYyJ1Bwc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1221">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicForfeited_c20220101__20221231_z4jy30TFBask" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1223">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20221231_z3W7U6jxSDJa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants issued, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1225">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExerciseInPeriodWeightedAverageExercisePrice_c20220101__20221231_zxOsmqqkUOI6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1227">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">–</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueExercised_c20220101__20221231_zusf3ecfpjcc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1229">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueExercised_c20220101__20221231_zugtUgCm7k9j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1231">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Expired</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpired_c20220101__20221231_zI40SmzHgYXd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants issued, Expired">(253,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231_zbqyuGRTJ4md" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share, Expired">1.80</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231_zUH6bqUVMma" title="Weighted Average Remaining Contractual Term (Years)">2.98</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueExpired_c20220101__20221231_zt2rXiALuq" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share, Expired">1.14</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueExpired_c20220101__20221231_z2ImZyIdCoki" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, Expired">0.17</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231_zsjjkos9EH76" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants issued, Outstanding, Ending of period">1,768,304</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zs7Vja1LWYN3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share, Outstanding, ending of period">1.84</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231_zcq4o0zR6bii" title="Weighted Average Remaining Contractual Term (Years)">3.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantFairValue_iE_c20220101__20221231_zv01Vpg5cMD6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share, ending balance">1.49</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue_iE_c20220101__20221231_zzYfGD577r62" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1251">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Vested and exercisable, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExercisable_iI_c20221231_zfsKu2hZgyXj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants issued, Vested and Exercisable, Ending of period">1,768,304</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceVestedAndExercisable_iI_c20221231_zUk16WHrgbF" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share, Vested and Exercisable, Ending of period">1.84</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingContractualTermUnvestedAndExercisable_dtY_c20220101__20221231_zrVVohMWfXRk" title="Weighted Average Remaining Contractual Term (Years), Vested and Exercisable">3.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantFairValueVestedAndExercisable_iI_c20221231_zJTsIuIrughf" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share, Vested and Exercisable, Ending of period">1.49</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVestedAndExercisable_iI_c20221231_zr0Q2r5TKUH3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, Vested and Exercisable, Ending of period"><span style="-sec-ix-hidden: xdx2ixbrl1261">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Unvested, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested_iI_c20221231_zpE69sJDkmOh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants issued, Unvested, Ending of period"><span style="-sec-ix-hidden: xdx2ixbrl1263">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceVested_iI_c20221231_zAqzdWUF2pA5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share, Unvested, Ending of period"><span style="-sec-ix-hidden: xdx2ixbrl1265">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">–</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantFairValueVested_iI_c20221231_z2bfkyo1Hfwh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share, Unvested, Ending of period"><span style="-sec-ix-hidden: xdx2ixbrl1267">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVested_iI_c20211231_zmnVrEO3jawc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, Unvested, Ending of period"><span style="-sec-ix-hidden: xdx2ixbrl1269">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zMb0z6w6ESKg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zvByQPnBeUJ5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the weighted-average assumptions used to estimate the fair value of warrants granted for the year ended December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zSbxVwVmLlbi" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF FAIR VALUE OF WARRANTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Expected life (in years)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z2PNRO2wAU1l" title="Warrants and rights outstanding, term"><span style="-sec-ix-hidden: xdx2ixbrl1273">–</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zzsjlMJ4KkWi" title="Warrants and rights outstanding, term">3</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z0VY4c6u8bec" title="Risk free interest rate">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_z2lWIfpD2mOe" title="Risk free interest rate">0.27</span>% - <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zhDxzRe8FLIa" title="Risk free interest rate">0.42</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zM87efvVwia1" title="Expected volatility">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_z3i6ydiE43oj" title="Expected volatility">405</span>% - <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zwxK55NwXDi1" title="Expected volatility">406</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zn7YkVcxSZl3" title="Dividend yield">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zTZCgm32Exjc" title="Dividend yield">0.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Stock price</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--SharePrice_iI_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zrEpiHbkFyF4" title="Share price"><span style="-sec-ix-hidden: xdx2ixbrl1293">–</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ <span id="xdx_90D_eus-gaap--SharePrice_iI_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_z7CtbCWEPM6f" title="Share price">0.10</span> – <span id="xdx_90E_eus-gaap--SharePrice_iI_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zWaWTDddIyka" title="Share price">1.95</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zPLAayUVk3Mj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b> </b></span></p> 200000000 100000000 0.001 100000000 0.001 1.38 1.38 1.00 36000 10000000 the close of business on the sixtieth consecutive day on which the closing price of the Company’s common stock on the OTC Markets is at least $2.80 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, stock combination or other similar recapitalization with respect to the common stock, or (iii) the affirmative vote of the holders of at least 66⅔% of the outstanding shares of Series A, given at a meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders all outstanding shares of Series A shall automatically be converted into shares of the Company’s common stock, at the then effective conversion rate 85975 147000 3674330 68000 128000 30000 98000 75000 30000 25000 76000 20000 10000000 1500000 10000000 1500000 1.93 22195000 <p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_z58QAr77Uzff" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below summarizes the transactions related to the Company restricted stock awards as of December 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zKKYGBhFDUb4" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF COMPANY RESTRICTED STOCK AWARDS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Deferred <br/> compensation</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Grant date fair value</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_983_ecustom--GrantDateFairValueShares_iI_pid_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zzUqMOyfCgb7" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Grant date fair value, shares">11,500,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--DeferredCompensationGrantDateFairValue_iI_uUSD_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjE0tOqOt8vd" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Deferred compensation grant date fair value">22,195,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Accretion</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_ecustom--AccretionShares_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z7y7Ar1TgRF4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accretion, shares"><span style="-sec-ix-hidden: xdx2ixbrl0929">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_ecustom--DeferredCompensationAccretion_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zFfvEx4JZmYl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred compensation accretion">(11,168,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Canceled</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--CanceledShares_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zzPr7VJzG1h7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Canceled, shares">(1,500,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--DeferredCompensationCanceled_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z71KSV8OC6h2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred compensation canceled">(11,027,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance as of December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z64iCU2EUzmi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, balance">10,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--DeferredCompensationShareBasedArrangementsLiabilityCurrent_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zGDndz6Wgxkg" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred compensation"><span style="-sec-ix-hidden: xdx2ixbrl0939">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 11500000 22195000 -11168000 -1500000 -11027000 10000000 <p id="xdx_899_ecustom--ScheduleOfShareBasedCompensationRestrictedStockGrantTableTextBlock_zuka4H4tcZo3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted stock grant compensation expense for the year ended December 31, 2022, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zx7hXeNS0ng7" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF RESTRICTED STOCK GRANT COMPENSATION EXPENSE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49E_20220101__20221231_zxNW6zfbOGce" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoAccretionExpenseMember_z0n08cWcQF65" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left">2022 Accretion expense</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">6,377,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--PlanNameAxis__custom--ReversalTwoThousandTwentyOneAccretionExpenseMember_zvqTCVJBAxDi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Reversal of 2021 accretion expense</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(4,791,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--PlanNameAxis__custom--ReversalTwoThousandTwentyTwoAccretionExpenseMember_zgZpKCHqLDR2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Reversal of 2022 accretion expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(6,377,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--AllocatedShareBasedCompensationExpense_ziMQs99altja" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Restricted stock grant compensation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,791,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 6377000 -4791000 -6377000 -4791000 750000 0.001 52000 38000 14000 300000 0.001 561000 385000 750000 300000 0.001 2000 <p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zekUCwOIkeyf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below summarizes the Company’s stock option activities for the years ended December 31, 2022 and 2021 (all share and per share data reflects the reverse stock split):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zM6Lpu4bRWQ7" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF STOCK OPTION ACTIVITIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Option</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range Per</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relative</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 35%">Balance, January 1, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zfb8f6TnxzR" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Number of Number of Stock Option Shares, Outstanding, Beginning Balance">385,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceRangePerShareOutstandingBeginning_iS_c20210101__20211231_zdCOHZ1uwew1" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Exercise Price Range Per Share, Outstanding, Beginning"><span style="-sec-ix-hidden: xdx2ixbrl0981">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zokrci5jJa91" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning">0.001</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRelativeFairValueOutstandingBeginning_iS_c20210101__20211231_zYd2Vcl49XFl" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Relative Fair Value, Outstanding, Beginning"><span style="-sec-ix-hidden: xdx2ixbrl0985">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pdp0_c20210101__20211231_zJdXikrAHwd6" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Aggregate Intrinsic Value, Beginning Balance">7,315</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zwLuWs9qzEi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Stock Option Shares, Granted">1,050,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInExercisePriceRangePerShareGranted_c20210101__20211231_zdOtTlaWSi56" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Range Per Share, Granted">0.001</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zt9leAWPPZ7k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted">0.001</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodRelativeFairValueGranted_c20210101__20211231_znb3tMcIsdij" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Relative Fair Value, Granted">1.94</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue_c20210101__20211231_zJtrjiBwcVM8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0997">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210101__20211231_zpNT6P5B9R4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Stock Option Shares, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0999">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsInPeriodExercisePriceRangePerShareForfeited_c20210101__20211231_zODHjuOdTrvb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Range Per Share, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1001">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_zXkvBQ1on9l" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1003">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodRelativeFairValueForfeited_c20210101__20211231_zuKtxNcljvgg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Relative Fair Value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1005">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodForfeitedIntrinsicValue_c20210101__20211231_zMAxxisjqWu4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1007">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210101__20211231_z3aTKyfo1SSi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Stock Option Shares, Exercised">(1,435,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodExercisePriceRangePerShareExercised_c20210101__20211231_zQEFXRzvDYCa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Range Per Share, Exercised">0.001</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231_zKdfAehFKVLj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised">0.001</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodRelativeFairValueExercised_c20210101__20211231_zqI1SfNNddL7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Relative Fair Value, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1015">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInPeriodExercisedIntrinsicValue_c20210101__20211231_zAnz1wBM906f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1017">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Expired</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20210101__20211231_z6K53gVUYPzg" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Stock Option Shares, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1019">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePriceRangePerShareExpired_c20210101__20211231_zaZBznrUmIwh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Range Per Share, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1021">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zr5KcFf3YuT4" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1023">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodRelativeFairValueExpired_c20210101__20211231_z74S9K8VIz9c" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Relative Fair Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1025">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInPeriodExpiredIntrinsicValue_c20210101__20211231_zRXiyVFolFZ2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1027">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Balance, December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zFCjh8k4fuS1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Number of Stock Option Shares, Outstanding, Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1029">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceRangePerShareOutstandingBeginning_iS_c20220101__20221231_zTRYv4CPPSs4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Range Per Share, Outstanding, Beginning"><span style="-sec-ix-hidden: xdx2ixbrl1031">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zPObti2DwO8h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning"><span style="-sec-ix-hidden: xdx2ixbrl1033">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRelativeFairValueOutstandingBeginning_iS_c20220101__20221231_zCdFhR3MWo2d" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Relative Fair Value, Outstanding, Beginning"><span style="-sec-ix-hidden: xdx2ixbrl1035">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pdp0_c20220101__20221231_zTy615g4bVbg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1037">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_z1tawgIdWxL2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Stock Option Shares, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1039">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInExercisePriceRangePerShareGranted_c20220101__20221231_zwlkmp1iGKxd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Range Per Share, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1041">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zBUh6LYwsKE8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1043">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodRelativeFairValueGranted_c20220101__20221231_z4ufIaAItsR8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Relative Fair Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1045">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue_c20220101__20221231_zLWSh6I4rkOb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1047">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20220101__20221231_zuTfJilZfvv6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Stock Option Shares, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1049">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsInPeriodExercisePriceRangePerShareForfeited_c20220101__20221231_zUO8gWRN51Dc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Range Per Share, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1051">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20221231_zZyX7z9Tjzz9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1053">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodRelativeFairValueForfeited_c20220101__20221231_ztSJA9RuVVuc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Relative Fair Value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1055">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodForfeitedIntrinsicValue_c20220101__20221231_zFEN866NtXld" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1057">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220101__20221231_zv1LZuxsj3q5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Stock Option Shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1059">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodExercisePriceRangePerShareExercised_c20220101__20221231_zYwgQwdKnN43" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Range Per Share, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1061">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231_zUWt5DyurlN4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1063">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodRelativeFairValueExercised_c20220101__20221231_zvpXwlpDDBLh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Relative Fair Value, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1065">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInPeriodExercisedIntrinsicValue_c20220101__20221231_zgZzycTh3Wac" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1067">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Expired</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20220101__20221231_zL2FLKezaKF" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Stock Option Shares, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1069">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePriceRangePerShareExpired_c20220101__20221231_zuT7ifCoZuwd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Range Per Share, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1071">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zy2ilxgH65v3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1073">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodRelativeFairValueExpired_c20220101__20221231_ztAOuGcf3QB1" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Relative Fair Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1075">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInPeriodExpiredIntrinsicValue_c20220101__20221231_zziRoprpKEhg" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1077">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zhZhTVmzEai9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Number of Stock Option Shares, Outstanding, Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1079">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceRangePerShareOutstandingBeginning_iE_c20220101__20221231_zEtmXQ2okTq1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Range Per Share, Outstanding, Beginning"><span style="-sec-ix-hidden: xdx2ixbrl1081">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zrS8KFqDxxJ1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning"><span style="-sec-ix-hidden: xdx2ixbrl1083">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRelativeFairValueOutstandingBeginning_iE_c20220101__20221231_zGXBsJKbj0H6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Relative Fair Value, Outstanding, Beginning"><span style="-sec-ix-hidden: xdx2ixbrl1085">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pdp0_c20220101__20221231_zeHEAcIeq0q8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1087">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Vested and exercisable, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableEndingBalance_iE_c20220101__20221231_zrla6Q4nFEx1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Stock Option, Vested and Exercisable, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1089">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodExercisePriceRangePerShareVestedAndExercisable_c20220101__20221231_zL87LLCzsu44" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Range Per Share, Vested and Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1091">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceVestedAndExercisable_c20220101__20221231_zgo8qcHROgV2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Vested and Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1093">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodRelativeFairValueVestedAndExercisable_c20220101__20221231_zuNlByx3dckc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Relative Fair Value, Vested and Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1095">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pdp0_c20220101__20221231_zUKMaQoeUICa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Vested and Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1097">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Unvested, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedEndingBalance_iE_c20220101__20221231_z2d6ECfpG1w1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Stock Option, Unvested, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1099">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsInPeriodExercisePriceRangePerShareUnvested_c20220101__20221231_zzdClPDre70f" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise Price Range Per Share, Unvested"><span style="-sec-ix-hidden: xdx2ixbrl1101">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iI_c20221231_zO7PSzJZMOde" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Unvested"><span style="-sec-ix-hidden: xdx2ixbrl1103">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsUnvestedInPeriodRelativeFairValueUnvested_c20220101__20221231_zDBO26TenNTj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Relative Fair Value, Unvested"><span style="-sec-ix-hidden: xdx2ixbrl1105">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAggregateIntrinsicValueUnvested_iE_pdp0_c20220101__20221231_zJLd6LNzJ5Cb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Unvested"><span style="-sec-ix-hidden: xdx2ixbrl1107">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 385000 0.001 7315 1050000 0.001 0.001 1.94 1435000 0.001 0.001 100000 195000 3.59 1.95 P3Y 0.43 0 <p id="xdx_89A_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zQ53SHJPa3C" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below summarizes the Company’s warrant activities for the years ended December 31, 2022 and 2021 (all share and per share data reflects the reverse stock split):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zYV82oU5FE5a" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF WARRANTS ACTIVITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of </b></span><b>Shares</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Strike Price/Share</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Remaining Contractual Term (Years)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Grant Date Fair Value/Share</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 35%">Balance, January 1, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231_zoJ4YlPQZ97g" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Number of warrants issued, Outstanding, Beginning of period">353,804</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zQDMerB3RXRc" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Weighted Average Strike Price/Share, Outstanding, Beginning of period">1.50</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_z8V9hFd9TP6d" title="Weighted Average Remaining Contractual Term (Years), ending of period">2.88</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantFairValue_iS_c20210101__20211231_zmtPfIyHiJR6" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Weighted Average Grant Date Fair Value/Share, beginning balance">0.18</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue_iS_c20210101__20211231_zR1xxBSBJ8lb" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Aggregate intrinsic value, beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1133">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231_zTfEGlAccDFh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants issued, Granted">1,667,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_ze5m36fljJDc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share, Granted">1.86</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231_zgzBcTbdU6P3" title="Weighted Average Remaining Contractual Term (Years), Granted">3.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValue_c20210101__20211231_zrRfrflh5Bsg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share, Granted">1.67</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueGranted_c20210101__20211231_zvCsqVA5kime" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic, Granted">0.11</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20211231_zIgypDqhDu8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants issued, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1145">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_zRqpgoXTrjv4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1147">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">–</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueForfeited_c20210101__20211231_zzDrBiByXlIf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1149">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicForfeited_c20210101__20211231_zcthyWsF5elk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1151">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20211231_z1bY1EIiD7dg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants issued, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1153">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExerciseInPeriodWeightedAverageExercisePrice_c20210101__20211231_zTjXtkvEgUm8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1155">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">–</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueExercised_c20210101__20211231_ztgBl2cQFIM5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1157">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueExercised_c20210101__20211231_znAvy0Hled45" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value exercised"><span style="-sec-ix-hidden: xdx2ixbrl1159">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Expired</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpired_c20210101__20211231_zkUFOMn28LTf" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants issued, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1161">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20211231_zbXrvxtuIGdb" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1163">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">–</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueExpired_c20210101__20211231_zvN9RCYfYEil" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share, expired"><span style="-sec-ix-hidden: xdx2ixbrl1165">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueExpired_c20210101__20211231_zTbMeZ64grn1" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value expired"><span style="-sec-ix-hidden: xdx2ixbrl1167">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance, December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231_zTRaoAIB15Ba" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants issued, Outstanding, Ending of period">2,021,304</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_zCZ1UrIekPei" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share, Outstanding, ending of period">1.80</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231_zka1rO5513dh" title="Weighted Average Remaining Contractual Term (Years)">2.98</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantFairValue_iE_c20210101__20211231_zZi3X6GvnoJk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share, ending balance">1.14</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue_iE_c20210101__20211231_ze54kh8Jqfk1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, ending balance">0.17</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Vested and exercisable, December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExercisable_iI_c20211231_zgpiUOHSkZRe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Non option equity instruments vested and exercisable, ending of period">2,021,304</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceVestedAndExercisable_iI_c20211231_zfQP1Wt5ZtIe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share vested and exercisable, ending of period">1.80</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingContractualTermUnvestedAndExercisable_dtY_c20210101__20211231_zmOyMxEmsOb8" title="Weighted Average Remaining Contractual Term (Years), vested and exercisable">2.98</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantFairValueVestedAndExercisable_iI_c20211231_zXfT0tYCLgl5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share vested and exercisable, ending of period">1.14</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVestedAndExercisable_iI_c20211231_zFI2mJYbGpw3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value vested and exercisable, ending of period">0.17</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Unvested, December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested_iI_c20211231_zY8GkRO0G586" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Non option equity instruments Unvested, ending of period"><span style="-sec-ix-hidden: xdx2ixbrl1189">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceVested_iI_c20211231_zM11kHCBBQP9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share unvested"><span style="-sec-ix-hidden: xdx2ixbrl1191">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">–</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantFairValueVested_iI_c20211231_zSE8sse9FIfe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share Unvested, Ending of period"><span style="-sec-ix-hidden: xdx2ixbrl1193">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVested_iI_c20211231_zF5gEq2Fn8m8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value Unvested, ending of period"><span style="-sec-ix-hidden: xdx2ixbrl1195">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Balance, January 1, 2022</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231_zmiRJQHCOsR" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants issued, Outstanding, Beginning of period">2,021,304</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zHbuvzQDzrI1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share, Outstanding, Beginning of period">1.80</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_z72c2KJnqAig" title="Weighted Average Remaining Contractual Term (Years)">2.98</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantFairValue_iS_c20220101__20221231_zBgJV9L7JuXg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share, Ending of period">1.14</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue_iS_c20220101__20221231_zBeffeGxRDA5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, Beginning of period">0.17</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231_zFOvg2qFv97f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants issued, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1207">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zONaB3l9d2Ok" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1209">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231_zuGCMUOzRXB" title="Weighted Average Remaining Contractual Term (Years), Granted"><span style="-sec-ix-hidden: xdx2ixbrl1211">–</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValue_c20220101__20221231_zxMfXd1EWpwd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1213">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueGranted_c20220101__20221231_zm3yxcFKKAM2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1215">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231_zuRIicJ1BmIa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants issued, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1217">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20221231_zCkAcqsqQmE2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1219">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">–</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueForfeited_c20220101__20221231_zupwYYyJ1Bwc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1221">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicForfeited_c20220101__20221231_z4jy30TFBask" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1223">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20221231_z3W7U6jxSDJa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants issued, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1225">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExerciseInPeriodWeightedAverageExercisePrice_c20220101__20221231_zxOsmqqkUOI6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1227">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">–</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueExercised_c20220101__20221231_zusf3ecfpjcc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1229">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueExercised_c20220101__20221231_zugtUgCm7k9j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1231">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Expired</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpired_c20220101__20221231_zI40SmzHgYXd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants issued, Expired">(253,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231_zbqyuGRTJ4md" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share, Expired">1.80</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231_zUH6bqUVMma" title="Weighted Average Remaining Contractual Term (Years)">2.98</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueExpired_c20220101__20221231_zt2rXiALuq" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share, Expired">1.14</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueExpired_c20220101__20221231_z2ImZyIdCoki" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, Expired">0.17</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231_zsjjkos9EH76" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants issued, Outstanding, Ending of period">1,768,304</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zs7Vja1LWYN3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share, Outstanding, ending of period">1.84</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231_zcq4o0zR6bii" title="Weighted Average Remaining Contractual Term (Years)">3.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantFairValue_iE_c20220101__20221231_zv01Vpg5cMD6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share, ending balance">1.49</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue_iE_c20220101__20221231_zzYfGD577r62" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1251">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Vested and exercisable, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExercisable_iI_c20221231_zfsKu2hZgyXj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants issued, Vested and Exercisable, Ending of period">1,768,304</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceVestedAndExercisable_iI_c20221231_zUk16WHrgbF" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share, Vested and Exercisable, Ending of period">1.84</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingContractualTermUnvestedAndExercisable_dtY_c20220101__20221231_zrVVohMWfXRk" title="Weighted Average Remaining Contractual Term (Years), Vested and Exercisable">3.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantFairValueVestedAndExercisable_iI_c20221231_zJTsIuIrughf" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share, Vested and Exercisable, Ending of period">1.49</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVestedAndExercisable_iI_c20221231_zr0Q2r5TKUH3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, Vested and Exercisable, Ending of period"><span style="-sec-ix-hidden: xdx2ixbrl1261">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Unvested, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested_iI_c20221231_zpE69sJDkmOh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of warrants issued, Unvested, Ending of period"><span style="-sec-ix-hidden: xdx2ixbrl1263">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceVested_iI_c20221231_zAqzdWUF2pA5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Strike Price/Share, Unvested, Ending of period"><span style="-sec-ix-hidden: xdx2ixbrl1265">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">–</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantFairValueVested_iI_c20221231_z2bfkyo1Hfwh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value/Share, Unvested, Ending of period"><span style="-sec-ix-hidden: xdx2ixbrl1267">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVested_iI_c20211231_zmnVrEO3jawc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, Unvested, Ending of period"><span style="-sec-ix-hidden: xdx2ixbrl1269">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 353804 1.50 P2Y10M17D 0.18 1667500 1.86 P3Y 1.67 0.11 2021304 1.80 P2Y11M23D 1.14 0.17 2021304 1.80 P2Y11M23D 1.14 0.17 2021304 1.80 P2Y11M23D 1.14 0.17 -253000 1.80 P2Y11M23D 1.14 0.17 1768304 1.84 P3Y 1.49 1768304 1.84 P3Y 1.49 <p id="xdx_896_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zvByQPnBeUJ5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the weighted-average assumptions used to estimate the fair value of warrants granted for the year ended December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zSbxVwVmLlbi" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF FAIR VALUE OF WARRANTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Expected life (in years)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z2PNRO2wAU1l" title="Warrants and rights outstanding, term"><span style="-sec-ix-hidden: xdx2ixbrl1273">–</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zzsjlMJ4KkWi" title="Warrants and rights outstanding, term">3</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z0VY4c6u8bec" title="Risk free interest rate">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_z2lWIfpD2mOe" title="Risk free interest rate">0.27</span>% - <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zhDxzRe8FLIa" title="Risk free interest rate">0.42</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zM87efvVwia1" title="Expected volatility">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_z3i6ydiE43oj" title="Expected volatility">405</span>% - <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zwxK55NwXDi1" title="Expected volatility">406</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zn7YkVcxSZl3" title="Dividend yield">–</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dtY_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zTZCgm32Exjc" title="Dividend yield">0.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Stock price</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--SharePrice_iI_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zrEpiHbkFyF4" title="Share price"><span style="-sec-ix-hidden: xdx2ixbrl1293">–</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ <span id="xdx_90D_eus-gaap--SharePrice_iI_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_z7CtbCWEPM6f" title="Share price">0.10</span> – <span id="xdx_90E_eus-gaap--SharePrice_iI_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zWaWTDddIyka" title="Share price">1.95</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> P3Y 0.27 0.42 405 406 0.00 0.10 1.95 <p id="xdx_800_eus-gaap--EarningsPerShareTextBlock_zh2DKsQR7zG6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note 9 – <span>Earnings (Loss) Per Share <span id="xdx_82B_zVjdNXSxBtFe" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">EARNINGS (LOSS) PER SHARE </span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="display: none"/></p> <p id="xdx_895_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zxLmrVCHsjw6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the computation of basic and diluted earnings (loss) per share for the years ended December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zRQ36DfTMS01">SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Numerator</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220101__20221231_zZTIbsMWhw46" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20210101__20211231_zuq4T0gkGPT" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLoss_zG7szgV2z6Ld" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Net income (loss)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">2,181,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">(6,749,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--EffectOfDilutiveInstrumentsAbstract_iB_zHixyashhZlc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Effect of dilutive instruments</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--ConvertibleNotesInterestExpense_zKxZgbURJVX" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Convertible notes interest expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">204,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1310">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--NumeratorForDilutedEarningPerShareAmount_zUMyssI1JQF8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Numerator for diluted EPS</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Numerator for diluted EPS">2,385,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Numerator for diluted EPS">(6,749,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zfeMQ4FO8TBk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Denominator</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zQkf6VJE0Pyl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Denominator - for basic EPS</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,495,621</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">19,482,261</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_iB_zGsDuRPtuDOj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Effect of dilutive instruments</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_i01_zEnA7agfqUy5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Warrants</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">721,006</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1325">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_i01_zjAMRVdGgXK9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Restricted stock awards</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">10,000,000</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1328">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--IncrementalCommonSharesAttributableToConversionOfDebtSecurities_i01_zeWtAGT25654" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Convertible notes</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,125,699</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1331">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_i01_zDyK41Xo6Uog" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Dilutive potential common shares</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,846,705</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1334">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zOcfzrdrsZZe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Denominator for diluted EPS</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">29,342,327</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">19,482,261</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--EarningsPerShareBasic_zenpd7QHKfIf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Basic EPS</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">0.15</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.35</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--EarningsPerShareDiluted_zn0l4vZNWiU6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Diluted EPS</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">0.08</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.35</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8AF_zYFf5sgQGBRg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities that could potentially dilute loss per share in the future were not included in the computation of diluted loss per share for the year ended December 31, 2021 because their inclusion would be anti-dilutive. Common share equivalents amounted to <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zvA5nPIJjkE9">3,942,608</span> for warrants, <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zoMIl3BuKxJf">3,947,394</span> for convertible notes and <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsMember_zoG8bgSJwtPi" title="Potentially dilute loss">11,500,000</span> for restricted stock units for total of <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--CommonStockMember_zonp5BlefOg7" title="Dilutive securities">19,390,002 </span> as of December 31, 2021. For the year ended December 31, 2022, the Company had <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--CommonStockMember_znqY9wF2Wx85" title="Dilutive securities">14,846,705 </span> dilutive securities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zxLmrVCHsjw6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the computation of basic and diluted earnings (loss) per share for the years ended December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zRQ36DfTMS01">SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Numerator</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220101__20221231_zZTIbsMWhw46" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20210101__20211231_zuq4T0gkGPT" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLoss_zG7szgV2z6Ld" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Net income (loss)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">2,181,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">(6,749,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--EffectOfDilutiveInstrumentsAbstract_iB_zHixyashhZlc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Effect of dilutive instruments</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--ConvertibleNotesInterestExpense_zKxZgbURJVX" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Convertible notes interest expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">204,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1310">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--NumeratorForDilutedEarningPerShareAmount_zUMyssI1JQF8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Numerator for diluted EPS</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Numerator for diluted EPS">2,385,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Numerator for diluted EPS">(6,749,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zfeMQ4FO8TBk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Denominator</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zQkf6VJE0Pyl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Denominator - for basic EPS</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,495,621</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">19,482,261</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_iB_zGsDuRPtuDOj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Effect of dilutive instruments</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_i01_zEnA7agfqUy5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Warrants</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">721,006</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1325">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_i01_zjAMRVdGgXK9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Restricted stock awards</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">10,000,000</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1328">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--IncrementalCommonSharesAttributableToConversionOfDebtSecurities_i01_zeWtAGT25654" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Convertible notes</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,125,699</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1331">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_i01_zDyK41Xo6Uog" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Dilutive potential common shares</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,846,705</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1334">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zOcfzrdrsZZe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Denominator for diluted EPS</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">29,342,327</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">19,482,261</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--EarningsPerShareBasic_zenpd7QHKfIf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Basic EPS</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">0.15</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.35</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--EarningsPerShareDiluted_zn0l4vZNWiU6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Diluted EPS</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">0.08</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.35</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 2181000 -6749000 204000 2385000 -6749000 14495621 19482261 721006 10000000 4125699 14846705 29342327 19482261 0.15 -0.35 0.08 -0.35 3942608 3947394 11500000 19390002 14846705 <p id="xdx_808_eus-gaap--IncomeTaxDisclosureTextBlock_zXCjKlzbv0T7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note 10 – <span>Deferred Tax Assets and Income Tax Provision</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b> <span id="xdx_82A_zUOYoFEdmdq8" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">DEFERRED TAX ASSETS AND INCOME TAX PROVISION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Deferred Tax Assets</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2022, the Company had net operating loss (“NOL”) carry forwards for Federal income tax purposes of $<span id="xdx_905_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_c20221231_zsTlLEWgRDB3" title="Net operating loss deferred tax">3,070,000</span> that may be offset against future taxable income. No tax benefit has been reported with respect to these net operating loss carry-forwards in the accompanying financial statements because the Company believes that the realization of the Company’s net deferred tax assets of approximately $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsNet_iI_c20221231_zKFtqx16qb49" title="Deferred tax assets net">1,708,000</span> was not considered more likely than not and accordingly, the potential tax benefits of the net operating loss carry-forwards are fully offset by a full valuation allowance. Federal NOL’s have an indefinite carryover period and state NOL’s begin to expire in 2037 if not utilized by then.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets consist primarily of the tax effect of NOL carry-forwards. The Company has provided a full valuation allowance on the deferred tax assets because of the uncertainty regarding its realization. The valuation allowance (decreased) increased by approximately $<span id="xdx_901_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20220101__20221231_z0KL2HLoBZ29">(782,000)</span> and $<span id="xdx_904_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20210101__20211231_zcsX8SCVlRNe">2,191,000</span> for the reporting periods ended December 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zXcFzNyOgca9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Components of deferred tax assets are as follows as of December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zxBPLUAdW0d7" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20221231_zLlHNmb8MQvk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20211231_zxlAlOQEEqB4" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net deferred tax assets – Non-current:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_maDTALNzypl_zcUfRDYEZdDd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Intangible assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">1,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1364">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_iI_maDTALNzypl_zJTISkZWXn4i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Impairment loss</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">38,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1367">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOther_iI_maDTALNzypl_z5ilmxNUbyI" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest expense limitations</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">802,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1370">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTALNzypl_zcs5RB7D0EMi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,488,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTALNzypl_z3xmN7obM557" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected income tax benefit from NOL carry-forwards</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">859,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,002,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTALNzypl_zJf39EMq7m3j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,709,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,490,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzypl_zl7bDafDlr2b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Deferred tax assets, net of valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1381">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1382">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zTU78zkwYYAh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Income Tax Provision in the Statements of Operations</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zRvyI4uGM4E6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the federal statutory income tax rate and the effective income tax rate as a percentage of income before income taxes is as follows for the years ended December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zXCYzPhZmHU9" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF RECONCILIATION OF INCOME TAX</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; display: none; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Federal statutory income tax rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_c20220101__20221231_zUJXqxQXbFAe" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Federal statutory income tax rate">21.0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_c20210101__20211231_zCLyCSFCAUWh" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Federal statutory income tax rate">21.0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Change in valuation allowance on net operating loss carry-forwards</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_c20220101__20221231_zy0ZmqlR8NY8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in valuation allowance on net operating loss carry-forwards">(21.0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_c20210101__20211231_zKscuP9RhyB1" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in valuation allowance on net operating loss carry-forwards">(21.0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Effective income tax rate</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_uPure_c20220101__20221231_zhMwMgI7OtC6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Effective income tax rate">0.0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_uPure_c20210101__20211231_zOzmpaZVzMEa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Effective income tax rate">0.0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> <p id="xdx_8A9_zaHV28ioBKTi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b> </b></span></p> 3070000 1708000 -782000 2191000 <p id="xdx_893_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zXcFzNyOgca9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Components of deferred tax assets are as follows as of December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zxBPLUAdW0d7" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20221231_zLlHNmb8MQvk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20211231_zxlAlOQEEqB4" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net deferred tax assets – Non-current:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_maDTALNzypl_zcUfRDYEZdDd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Intangible assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">1,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1364">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_iI_maDTALNzypl_zJTISkZWXn4i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Impairment loss</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">38,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1367">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOther_iI_maDTALNzypl_z5ilmxNUbyI" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest expense limitations</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">802,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1370">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTALNzypl_zcs5RB7D0EMi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,488,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTALNzypl_z3xmN7obM557" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected income tax benefit from NOL carry-forwards</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">859,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,002,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTALNzypl_zJf39EMq7m3j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,709,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,490,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzypl_zl7bDafDlr2b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Deferred tax assets, net of valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1381">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1382">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1000 38000 802000 9000 1488000 859000 1002000 1709000 2490000 <p id="xdx_899_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zRvyI4uGM4E6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the federal statutory income tax rate and the effective income tax rate as a percentage of income before income taxes is as follows for the years ended December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zXCYzPhZmHU9" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF RECONCILIATION OF INCOME TAX</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; display: none; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Federal statutory income tax rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_c20220101__20221231_zUJXqxQXbFAe" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Federal statutory income tax rate">21.0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_c20210101__20211231_zCLyCSFCAUWh" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Federal statutory income tax rate">21.0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Change in valuation allowance on net operating loss carry-forwards</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_c20220101__20221231_zy0ZmqlR8NY8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in valuation allowance on net operating loss carry-forwards">(21.0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_c20210101__20211231_zKscuP9RhyB1" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in valuation allowance on net operating loss carry-forwards">(21.0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Effective income tax rate</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_uPure_c20220101__20221231_zhMwMgI7OtC6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Effective income tax rate">0.0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_uPure_c20210101__20211231_zOzmpaZVzMEa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Effective income tax rate">0.0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> 0.210 0.210 -0.210 -0.210 0.000 0.000 <p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_zlsiZcwRuLQ6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note 11 – Subsequent Events</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_825_zp8PnNHX20Wl" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SUBSEQUENT EVENTS</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has evaluated all events that occurred after the balance sheet date through the date when the financial statements were issued to determine if they must be reported. The management of the Company determined the following reportable events:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Purchase of Land for Building a Data Center</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 20pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 30, 2023, the Company signed an option agreement to acquire <span id="xdx_90B_eus-gaap--AreaOfLand_iI_pid_uAcre_c20230330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgU3sVz7Enlc">80</span> acres of commercially zoned land in Imperial County, California (the “Option”) for $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230329__20230330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zZkJklWxcoEl">3,360,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(“Purchase Price”). The Option expires in September 2024. The Company paid a non-refundable deposit of $<span id="xdx_901_ecustom--NonRefundableDeposit_iI_c20230330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zx5haygvLPr5" title="Non refundable deposit">84,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on the signing of the Option. The Company is required to deposit an additional $<span id="xdx_90E_eus-gaap--EscrowDeposit_iI_c20230330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMFxfRfGL7Qe">84,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">into an escrow (“Escrow Funds”). If the Company does not exercise the Option by September 2024, the Escrow funds will be returned to the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Purchase Price is payable with a cash payment of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230329__20230330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zcmbISmacKN5" title="Issuance of common stock purchase price payable">1,680,000</span> and the issuance of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230329__20230330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhp021Xp8yc6" title="Stock issued during period, shares, new issues">840,000</span> shares of the Company’s common stock (the “Purchase Shares”). At the closing of the purchase (“Closing Date”), if the stock is trading at a value less than $<span id="xdx_90C_eus-gaap--SharePrice_iI_c20230330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUpuYoKjp916" title="Share price">1.00 </span>per share, the Company is required to issue a promissory note in the amount of $<span id="xdx_90B_eus-gaap--NotesPayable_iI_c20230330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zmuitRIyAlS5" title="Promissory note">840,000</span>, payable on the third anniversary of the closing date, with an interest rate equal to the Secured Overnight Financing Rate plus <span id="xdx_907_eus-gaap--DerivativeVariableInterestRate_iI_pid_dp_uPure_c20230330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--VariableRateAxis__us-gaap--SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_zeWM2dHUZ4Q6" title="Secured overnight financing, variable interest rate">2.0%</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Purchase Shares are issued at the Closing Date, the Company has agreed to repurchase the Shares (the “Put Option”). The Put Option period ends on the one-year anniversary after a six-month holding period. However, if the Company’s common stock trades above $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20230330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHVqpoc8PCxf" title="Shares issued, price per share">2.00</span> per share for 120 consecutive days, the Put Option expires. If the Company’s common stock trades below $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_c20230330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zDdKp3eDmSd9" title="Shares issued, price per share">2.00</span> per for 10 consecutive days, the Holder has the option for the Company to repurchase the Purchase Shares for $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_c20230330__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3A35CAHc2r3" title="Shares issued, price per share">2.00</span> per share. o</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Employment Agreement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 27, 2023, executed an offer of employment to hire an individual as the Company’s president and chief operating officer. The effective date of employment was March 28, 2023. The salary is $<span id="xdx_906_eus-gaap--SalariesAndWages_c20230326__20230327__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zpCQjoWPZRRh">250,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per year, with an increase to $<span id="xdx_904_eus-gaap--SalariesAndWages_c20230326__20230327__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zcI52rrE8pu7">300,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">annually, immediately once permits have been granted to start construction of the data center, and an increase to $<span id="xdx_90C_ecustom--ConstructionOfDataCenter_c20230326__20230327__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zlvkZNQ2hHjk" title="Construction of data center">350,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">annually, upon the data center being operational and contracted for <span id="xdx_903_ecustom--PercentageOfContractedColocationCapacity_pid_dp_uPure_c20230326__20230327__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zjPMGxttt81" title="Percentage of contracted colocation capacity">25% </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of the planned 100MW colocation capacity. Also, the individual is eligible for a cash annual bonus and<span id="xdx_909_ecustom--CashAnnualBonus_c20230326__20230327__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zmpiTOo86o2" title="Cash annual bonus">2,000,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares that will be provided in an employee option or a restricted stock award, if certain milestones are accomplished. The stock grant will be included in a pending employment agreement that is planned to be completed between the Company and employee with the next couple of weeks.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancellation of Restricted Stock Awards</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 10, 2023, we completed the required paperwork for our transfer agent to cancel <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230407__20230410__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--HyuncheolPeterKimMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zehyJRXISMA3" title="Cancellation of restricted stock awards">10,000,000</span> shares of restricted stock that was previously issued to Mr. Kim as our former CTO.</span></p> 80 3360000 84000 84000 1680000 840000 1.00 840000 0.020 2.00 2.00 2.00 250000 300000 350000 0.25 2000000 10000000 EXCEL 64 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 66 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 67 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 160 344 1 false 63 0 false 6 false false R1.htm 00000001 - Document - Cover Sheet http://calethos.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://calethos.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://calethos.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit Sheet http://calethos.com/role/StatementsOfChangesInStockholdersDeficit Consolidated Statements of Changes in Stockholders' Deficit Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows Sheet http://calethos.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - ORGANIZATION AND ACCOUNTING POLICIES Sheet http://calethos.com/role/OrganizationAndAccountingPolicies ORGANIZATION AND ACCOUNTING POLICIES Notes 7 false false R8.htm 00000008 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://calethos.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 8 false false R9.htm 00000009 - Disclosure - INTANGIBLE AND OTHER ASSETS Sheet http://calethos.com/role/IntangibleAndOtherAssets INTANGIBLE AND OTHER ASSETS Notes 9 false false R10.htm 00000010 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES Sheet http://calethos.com/role/AccountsPayableAndAccruedExpenses ACCOUNTS PAYABLE AND ACCRUED EXPENSES Notes 10 false false R11.htm 00000011 - Disclosure - NOTES PAYABLE Notes http://calethos.com/role/NotesPayable NOTES PAYABLE Notes 11 false false R12.htm 00000012 - Disclosure - CONVERTIBLE PROMISSORY NOTES Notes http://calethos.com/role/ConvertiblePromissoryNotes CONVERTIBLE PROMISSORY NOTES Notes 12 false false R13.htm 00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://calethos.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 13 false false R14.htm 00000014 - Disclosure - EQUITY Sheet http://calethos.com/role/Equity EQUITY Notes 14 false false R15.htm 00000015 - Disclosure - EARNINGS (LOSS) PER SHARE Sheet http://calethos.com/role/EarningsLossPerShare EARNINGS (LOSS) PER SHARE Notes 15 false false R16.htm 00000016 - Disclosure - DEFERRED TAX ASSETS AND INCOME TAX PROVISION Sheet http://calethos.com/role/DeferredTaxAssetsAndIncomeTaxProvision DEFERRED TAX ASSETS AND INCOME TAX PROVISION Notes 16 false false R17.htm 00000017 - Disclosure - SUBSEQUENT EVENTS Sheet http://calethos.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 17 false false R18.htm 00000018 - Disclosure - ORGANIZATION AND ACCOUNTING POLICIES (Policies) Sheet http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies ORGANIZATION AND ACCOUNTING POLICIES (Policies) Policies 18 false false R19.htm 00000019 - Disclosure - ORGANIZATION AND ACCOUNTING POLICIES (Tables) Sheet http://calethos.com/role/OrganizationAndAccountingPoliciesTables ORGANIZATION AND ACCOUNTING POLICIES (Tables) Tables http://calethos.com/role/OrganizationAndAccountingPolicies 19 false false R20.htm 00000020 - Disclosure - INTANGIBLE AND OTHER ASSETS (Tables) Sheet http://calethos.com/role/IntangibleAndOtherAssetsTables INTANGIBLE AND OTHER ASSETS (Tables) Tables http://calethos.com/role/IntangibleAndOtherAssets 20 false false R21.htm 00000021 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) Sheet http://calethos.com/role/AccountsPayableAndAccruedExpensesTables ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) Tables http://calethos.com/role/AccountsPayableAndAccruedExpenses 21 false false R22.htm 00000022 - Disclosure - NOTES PAYABLE (Tables) Notes http://calethos.com/role/NotesPayableTables NOTES PAYABLE (Tables) Tables http://calethos.com/role/NotesPayable 22 false false R23.htm 00000023 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Tables) Notes http://calethos.com/role/ConvertiblePromissoryNotesTables CONVERTIBLE PROMISSORY NOTES (Tables) Tables http://calethos.com/role/ConvertiblePromissoryNotes 23 false false R24.htm 00000024 - Disclosure - EQUITY (Tables) Sheet http://calethos.com/role/EquityTables EQUITY (Tables) Tables http://calethos.com/role/Equity 24 false false R25.htm 00000025 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables) Sheet http://calethos.com/role/EarningsLossPerShareTables EARNINGS (LOSS) PER SHARE (Tables) Tables http://calethos.com/role/EarningsLossPerShare 25 false false R26.htm 00000026 - Disclosure - DEFERRED TAX ASSETS AND INCOME TAX PROVISION (Tables) Sheet http://calethos.com/role/DeferredTaxAssetsAndIncomeTaxProvisionTables DEFERRED TAX ASSETS AND INCOME TAX PROVISION (Tables) Tables http://calethos.com/role/DeferredTaxAssetsAndIncomeTaxProvision 26 false false R27.htm 00000027 - Disclosure - SCHEDULE OF INCOME AND LOSS PER SHARE ANTI-DILUTIVE (Details) Sheet http://calethos.com/role/ScheduleOfIncomeAndLossPerShareAnti-dilutiveDetails SCHEDULE OF INCOME AND LOSS PER SHARE ANTI-DILUTIVE (Details) Details 27 false false R28.htm 00000028 - Disclosure - ORGANIZATION AND ACCOUNTING POLICIES (Details Narrative) Sheet http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative ORGANIZATION AND ACCOUNTING POLICIES (Details Narrative) Details http://calethos.com/role/OrganizationAndAccountingPoliciesTables 28 false false R29.htm 00000029 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://calethos.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://calethos.com/role/RelatedPartyTransactions 29 false false R30.htm 00000030 - Disclosure - SCHEDULE OF PAYMENTS (Details) Sheet http://calethos.com/role/ScheduleOfPaymentsDetails SCHEDULE OF PAYMENTS (Details) Details 30 false false R31.htm 00000031 - Disclosure - SCHEDULE OF IMPAIRMENT LOSS (Details) Sheet http://calethos.com/role/ScheduleOfImpairmentLossDetails SCHEDULE OF IMPAIRMENT LOSS (Details) Details 31 false false R32.htm 00000032 - Disclosure - INTANGIBLE AND OTHER ASSETS (Details Narrative) Sheet http://calethos.com/role/IntangibleAndOtherAssetsDetailsNarrative INTANGIBLE AND OTHER ASSETS (Details Narrative) Details http://calethos.com/role/IntangibleAndOtherAssetsTables 32 false false R33.htm 00000033 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) Sheet http://calethos.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) Details 33 false false R34.htm 00000034 - Disclosure - SCHEDULE OF ACCRUED INTEREST (Details) Sheet http://calethos.com/role/ScheduleOfAccruedInterestDetails SCHEDULE OF ACCRUED INTEREST (Details) Details 34 false false R35.htm 00000035 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) Notes http://calethos.com/role/ScheduleOfNotesPayableDetails SCHEDULE OF NOTES PAYABLE (Details) Details 35 false false R36.htm 00000036 - Disclosure - NOTES PAYABLE (Details Narrative) Notes http://calethos.com/role/NotesPayableDetailsNarrative NOTES PAYABLE (Details Narrative) Details http://calethos.com/role/NotesPayableTables 36 false false R37.htm 00000037 - Disclosure - SCHEDULE OF CONVERTIBLE PROMISSORY NOTES (Details) Notes http://calethos.com/role/ScheduleOfConvertiblePromissoryNotesDetails SCHEDULE OF CONVERTIBLE PROMISSORY NOTES (Details) Details 37 false false R38.htm 00000038 - Disclosure - SCHEDULE OF POTENTIAL FUTURE SHARES ISSUANCE OF CONVERSION NOTES (Details) Notes http://calethos.com/role/ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesDetails SCHEDULE OF POTENTIAL FUTURE SHARES ISSUANCE OF CONVERSION NOTES (Details) Details 38 false false R39.htm 00000039 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details Narrative) Notes http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative CONVERTIBLE PROMISSORY NOTES (Details Narrative) Details http://calethos.com/role/ConvertiblePromissoryNotesTables 39 false false R40.htm 00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://calethos.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://calethos.com/role/CommitmentsAndContingencies 40 false false R41.htm 00000041 - Disclosure - SCHEDULE OF COMPANY RESTRICTED STOCK AWARDS (Details) Sheet http://calethos.com/role/ScheduleOfCompanyRestrictedStockAwardsDetails SCHEDULE OF COMPANY RESTRICTED STOCK AWARDS (Details) Details 41 false false R42.htm 00000042 - Disclosure - SCHEDULE OF RESTRICTED STOCK GRANT COMPENSATION EXPENSE (Details) Sheet http://calethos.com/role/ScheduleOfRestrictedStockGrantCompensationExpenseDetails SCHEDULE OF RESTRICTED STOCK GRANT COMPENSATION EXPENSE (Details) Details 42 false false R43.htm 00000043 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITIES (Details) Sheet http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails SCHEDULE OF STOCK OPTION ACTIVITIES (Details) Details 43 false false R44.htm 00000044 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details) Sheet http://calethos.com/role/ScheduleOfWarrantsActivityDetails SCHEDULE OF WARRANTS ACTIVITY (Details) Details 44 false false R45.htm 00000045 - Disclosure - SCHEDULE OF FAIR VALUE OF WARRANTS (Details) Sheet http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails SCHEDULE OF FAIR VALUE OF WARRANTS (Details) Details 45 false false R46.htm 00000046 - Disclosure - EQUITY (Details Narrative) Sheet http://calethos.com/role/EquityDetailsNarrative EQUITY (Details Narrative) Details http://calethos.com/role/EquityTables 46 false false R47.htm 00000047 - Disclosure - SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED (Details) Sheet http://calethos.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED (Details) Details 47 false false R48.htm 00000048 - Disclosure - EARNINGS (LOSS) PER SHARE (Details Narrative) Sheet http://calethos.com/role/EarningsLossPerShareDetailsNarrative EARNINGS (LOSS) PER SHARE (Details Narrative) Details http://calethos.com/role/EarningsLossPerShareTables 48 false false R49.htm 00000049 - Disclosure - SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS (Details) Sheet http://calethos.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS (Details) Details 49 false false R50.htm 00000050 - Disclosure - SCHEDULE OF RECONCILIATION OF INCOME TAX (Details) Sheet http://calethos.com/role/ScheduleOfReconciliationOfIncomeTaxDetails SCHEDULE OF RECONCILIATION OF INCOME TAX (Details) Details 50 false false R51.htm 00000051 - Disclosure - DEFERRED TAX ASSETS AND INCOME TAX PROVISION (Details Narrative) Sheet http://calethos.com/role/DeferredTaxAssetsAndIncomeTaxProvisionDetailsNarrative DEFERRED TAX ASSETS AND INCOME TAX PROVISION (Details Narrative) Details http://calethos.com/role/DeferredTaxAssetsAndIncomeTaxProvisionTables 51 false false R52.htm 00000052 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://calethos.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://calethos.com/role/SubsequentEvents 52 false false All Reports Book All Reports form10-k.htm buuz-20221231.xsd buuz-20221231_cal.xml buuz-20221231_def.xml buuz-20221231_lab.xml buuz-20221231_pre.xml ex31-1.htm ex31-2.htm ex32-1.htm ex4-10.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 69 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-k.htm": { "axisCustom": 0, "axisStandard": 18, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 608, "http://xbrl.sec.gov/dei/2022": 33 }, "contextCount": 160, "dts": { "calculationLink": { "local": [ "buuz-20221231_cal.xml" ] }, "definitionLink": { "local": [ "buuz-20221231_def.xml" ] }, "inline": { "local": [ "form10-k.htm" ] }, "labelLink": { "local": [ "buuz-20221231_lab.xml" ] }, "presentationLink": { "local": [ "buuz-20221231_pre.xml" ] }, "schema": { "local": [ "buuz-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 525, "entityCount": 1, "hidden": { "http://calethos.com/20221231": 81, "http://fasb.org/us-gaap/2022": 138, "http://xbrl.sec.gov/dei/2022": 3, "total": 222 }, "keyCustom": 98, "keyStandard": 246, "memberCustom": 38, "memberStandard": 22, "nsprefix": "BUUZ", "nsuri": "http://calethos.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://calethos.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES", "menuCat": "Notes", "order": "10", "role": "http://calethos.com/role/AccountsPayableAndAccruedExpenses", "shortName": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "BUUZ:NotesPayableDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - NOTES PAYABLE", "menuCat": "Notes", "order": "11", "role": "http://calethos.com/role/NotesPayable", "shortName": "NOTES PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "BUUZ:NotesPayableDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - CONVERTIBLE PROMISSORY NOTES", "menuCat": "Notes", "order": "12", "role": "http://calethos.com/role/ConvertiblePromissoryNotes", "shortName": "CONVERTIBLE PROMISSORY NOTES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES", "menuCat": "Notes", "order": "13", "role": "http://calethos.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - EQUITY", "menuCat": "Notes", "order": "14", "role": "http://calethos.com/role/Equity", "shortName": "EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - EARNINGS (LOSS) PER SHARE", "menuCat": "Notes", "order": "15", "role": "http://calethos.com/role/EarningsLossPerShare", "shortName": "EARNINGS (LOSS) PER SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - DEFERRED TAX ASSETS AND INCOME TAX PROVISION", "menuCat": "Notes", "order": "16", "role": "http://calethos.com/role/DeferredTaxAssetsAndIncomeTaxProvision", "shortName": "DEFERRED TAX ASSETS AND INCOME TAX PROVISION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "17", "role": "http://calethos.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationsPolicy", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - ORGANIZATION AND ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "18", "role": "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies", "shortName": "ORGANIZATION AND ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationsPolicy", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - ORGANIZATION AND ACCOUNTING POLICIES (Tables)", "menuCat": "Tables", "order": "19", "role": "http://calethos.com/role/OrganizationAndAccountingPoliciesTables", "shortName": "ORGANIZATION AND ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://calethos.com/role/BalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "BUUZ:ScheduleOfPaymentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - INTANGIBLE AND OTHER ASSETS (Tables)", "menuCat": "Tables", "order": "20", "role": "http://calethos.com/role/IntangibleAndOtherAssetsTables", "shortName": "INTANGIBLE AND OTHER ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "BUUZ:ScheduleOfPaymentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)", "menuCat": "Tables", "order": "21", "role": "http://calethos.com/role/AccountsPayableAndAccruedExpensesTables", "shortName": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "BUUZ:NotesPayableDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - NOTES PAYABLE (Tables)", "menuCat": "Tables", "order": "22", "role": "http://calethos.com/role/NotesPayableTables", "shortName": "NOTES PAYABLE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "BUUZ:NotesPayableDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Tables)", "menuCat": "Tables", "order": "23", "role": "http://calethos.com/role/ConvertiblePromissoryNotesTables", "shortName": "CONVERTIBLE PROMISSORY NOTES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - EQUITY (Tables)", "menuCat": "Tables", "order": "24", "role": "http://calethos.com/role/EquityTables", "shortName": "EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)", "menuCat": "Tables", "order": "25", "role": "http://calethos.com/role/EarningsLossPerShareTables", "shortName": "EARNINGS (LOSS) PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - DEFERRED TAX ASSETS AND INCOME TAX PROVISION (Tables)", "menuCat": "Tables", "order": "26", "role": "http://calethos.com/role/DeferredTaxAssetsAndIncomeTaxProvisionTables", "shortName": "DEFERRED TAX ASSETS AND INCOME TAX PROVISION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - SCHEDULE OF INCOME AND LOSS PER SHARE ANTI-DILUTIVE (Details)", "menuCat": "Details", "order": "27", "role": "http://calethos.com/role/ScheduleOfIncomeAndLossPerShareAnti-dilutiveDetails", "shortName": "SCHEDULE OF INCOME AND LOSS PER SHARE ANTI-DILUTIVE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31_custom_RestrictedStockAwardMember", "decimals": "INF", "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesAuthorized", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - ORGANIZATION AND ACCOUNTING POLICIES (Details Narrative)", "menuCat": "Details", "order": "28", "role": "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative", "shortName": "ORGANIZATION AND ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:CashFDICInsuredAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_custom_MOneAdvisorsMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromRelatedPartyDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "menuCat": "Details", "order": "29", "role": "http://calethos.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_custom_MOneAdvisorsMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromRelatedPartyDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://calethos.com/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesIssued", "span", "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "BUUZ:ScheduleOfPaymentsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-04-05", "decimals": "0", "first": true, "lang": null, "name": "BUUZ:ContractPrice", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - SCHEDULE OF PAYMENTS (Details)", "menuCat": "Details", "order": "30", "role": "http://calethos.com/role/ScheduleOfPaymentsDetails", "shortName": "SCHEDULE OF PAYMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "BUUZ:ScheduleOfPaymentsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-04-05_custom_WithinFiveDaysAfterSigningTheContractMember", "decimals": "0", "lang": null, "name": "BUUZ:ContractPrice", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - SCHEDULE OF IMPAIRMENT LOSS (Details)", "menuCat": "Details", "order": "31", "role": "http://calethos.com/role/ScheduleOfImpairmentLossDetails", "shortName": "SCHEDULE OF IMPAIRMENT LOSS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "BUUZ:ScheduleOfPaymentsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-04-05", "decimals": "0", "first": true, "lang": null, "name": "BUUZ:ContractPrice", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - INTANGIBLE AND OTHER ASSETS (Details Narrative)", "menuCat": "Details", "order": "32", "role": "http://calethos.com/role/IntangibleAndOtherAssetsDetailsNarrative", "shortName": "INTANGIBLE AND OTHER ASSETS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-04-05_custom_AIQMember", "decimals": "0", "lang": null, "name": "BUUZ:ContractPrice", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)", "menuCat": "Details", "order": "33", "role": "http://calethos.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails", "shortName": "SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - SCHEDULE OF ACCRUED INTEREST (Details)", "menuCat": "Details", "order": "34", "role": "http://calethos.com/role/ScheduleOfAccruedInterestDetails", "shortName": "SCHEDULE OF ACCRUED INTEREST (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details)", "menuCat": "Details", "order": "35", "role": "http://calethos.com/role/ScheduleOfNotesPayableDetails", "shortName": "SCHEDULE OF NOTES PAYABLE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "BUUZ:NotesPayableDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31", "decimals": "0", "lang": null, "name": "BUUZ:NotesPayableAdditions", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestPayableCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - NOTES PAYABLE (Details Narrative)", "menuCat": "Details", "order": "36", "role": "http://calethos.com/role/NotesPayableDetailsNarrative", "shortName": "NOTES PAYABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "BUUZ:NotesPayableDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-02-19_custom_PromissoryNoteMember", "decimals": "0", "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_us-gaap_ConvertibleNotesPayableMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - SCHEDULE OF CONVERTIBLE PROMISSORY NOTES (Details)", "menuCat": "Details", "order": "37", "role": "http://calethos.com/role/ScheduleOfConvertiblePromissoryNotesDetails", "shortName": "SCHEDULE OF CONVERTIBLE PROMISSORY NOTES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_ConvertibleNotesPayableMember", "decimals": "0", "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "BUUZ:ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtConversionOriginalDebtAmount1", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - SCHEDULE OF POTENTIAL FUTURE SHARES ISSUANCE OF CONVERSION NOTES (Details)", "menuCat": "Details", "order": "38", "role": "http://calethos.com/role/ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesDetails", "shortName": "SCHEDULE OF POTENTIAL FUTURE SHARES ISSUANCE OF CONVERSION NOTES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "BUUZ:ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:InterestAndDebtExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromConvertibleDebt", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details Narrative)", "menuCat": "Details", "order": "39", "role": "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "shortName": "CONVERTIBLE PROMISSORY NOTES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "lang": null, "name": "BUUZ:AccruedInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfessionalFees", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "menuCat": "Statements", "order": "4", "role": "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfessionalFees", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-022022-01-03", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyDomicileOfLitigation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "menuCat": "Details", "order": "40", "role": "http://calethos.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-022022-01-03", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyDomicileOfLitigation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_us-gaap_RestrictedStockMember", "decimals": "INF", "first": true, "lang": null, "name": "BUUZ:GrantDateFairValueShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - SCHEDULE OF COMPANY RESTRICTED STOCK AWARDS (Details)", "menuCat": "Details", "order": "41", "role": "http://calethos.com/role/ScheduleOfCompanyRestrictedStockAwardsDetails", "shortName": "SCHEDULE OF COMPANY RESTRICTED STOCK AWARDS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_us-gaap_RestrictedStockMember", "decimals": "INF", "first": true, "lang": null, "name": "BUUZ:GrantDateFairValueShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "BUUZ:ScheduleOfShareBasedCompensationRestrictedStockGrantTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - SCHEDULE OF RESTRICTED STOCK GRANT COMPENSATION EXPENSE (Details)", "menuCat": "Details", "order": "42", "role": "http://calethos.com/role/ScheduleOfRestrictedStockGrantCompensationExpenseDetails", "shortName": "SCHEDULE OF RESTRICTED STOCK GRANT COMPENSATION EXPENSE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "BUUZ:ScheduleOfShareBasedCompensationRestrictedStockGrantTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITIES (Details)", "menuCat": "Details", "order": "43", "role": "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails", "shortName": "SCHEDULE OF STOCK OPTION ACTIVITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)", "menuCat": "Details", "order": "44", "role": "http://calethos.com/role/ScheduleOfWarrantsActivityDetails", "shortName": "SCHEDULE OF WARRANTS ACTIVITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - SCHEDULE OF FAIR VALUE OF WARRANTS (Details)", "menuCat": "Details", "order": "45", "role": "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails", "shortName": "SCHEDULE OF FAIR VALUE OF WARRANTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_us-gaap_MeasurementInputExpectedTermMember", "decimals": null, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "BUUZ:AuthorizedToIssueShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - EQUITY (Details Narrative)", "menuCat": "Details", "order": "46", "role": "http://calethos.com/role/EquityDetailsNarrative", "shortName": "EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "BUUZ:AuthorizedToIssueShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED (Details)", "menuCat": "Details", "order": "47", "role": "http://calethos.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails", "shortName": "SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "lang": null, "name": "BUUZ:ConvertibleNotesInterestExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - EARNINGS (LOSS) PER SHARE (Details Narrative)", "menuCat": "Details", "order": "48", "role": "http://calethos.com/role/EarningsLossPerShareDetailsNarrative", "shortName": "EARNINGS (LOSS) PER SHARE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_WarrantMember", "decimals": "INF", "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS (Details)", "menuCat": "Details", "order": "49", "role": "http://calethos.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails", "shortName": "SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit", "menuCat": "Statements", "order": "5", "role": "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit", "shortName": "Consolidated Statements of Changes in Stockholders' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - SCHEDULE OF RECONCILIATION OF INCOME TAX (Details)", "menuCat": "Details", "order": "50", "role": "http://calethos.com/role/ScheduleOfReconciliationOfIncomeTaxDetails", "shortName": "SCHEDULE OF RECONCILIATION OF INCOME TAX (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000051 - Disclosure - DEFERRED TAX ASSETS AND INCOME TAX PROVISION (Details Narrative)", "menuCat": "Details", "order": "51", "role": "http://calethos.com/role/DeferredTaxAssetsAndIncomeTaxProvisionDetailsNarrative", "shortName": "DEFERRED TAX ASSETS AND INCOME TAX PROVISION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000052 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "menuCat": "Details", "order": "52", "role": "http://calethos.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2023-03-30_us-gaap_SubsequentEventMember", "decimals": "INF", "lang": null, "name": "us-gaap:AreaOfLand", "reportCount": 1, "unique": true, "unitRef": "Acre", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "6", "role": "http://calethos.com/role/StatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:AmortizationOfDebtDiscountPremium", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - ORGANIZATION AND ACCOUNTING POLICIES", "menuCat": "Notes", "order": "7", "role": "http://calethos.com/role/OrganizationAndAccountingPolicies", "shortName": "ORGANIZATION AND ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - RELATED PARTY TRANSACTIONS", "menuCat": "Notes", "order": "8", "role": "http://calethos.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - INTANGIBLE AND OTHER ASSETS", "menuCat": "Notes", "order": "9", "role": "http://calethos.com/role/IntangibleAndOtherAssets", "shortName": "INTANGIBLE AND OTHER ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 63, "tag": { "BUUZ_AIQMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AIQ [Member]", "label": "AIQ [Member]" } } }, "localname": "AIQMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/IntangibleAndOtherAssetsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_AIQSystemIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AIQ System Inc [Member]", "label": "AIQ System Inc [Member]" } } }, "localname": "AIQSystemIncMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_AccretionShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accretion Shares.", "label": "Accretion, shares" } } }, "localname": "AccretionShares", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfCompanyRestrictedStockAwardsDetails" ], "xbrltype": "sharesItemType" }, "BUUZ_AccruedInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accrued interest.", "label": "AccruedInterest", "verboseLabel": "Accrued interest" } } }, "localname": "AccruedInterest", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BUUZ_AdjustmentsToAdditionalPaidInCapitalRelativeFairValueOfWarrantsIssuedWithConvertiblePromissoryNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Relative fair value of warrants issued with convertible promissory notes.", "label": "Relative fair value of warrants issued with convertible promissory note" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalRelativeFairValueOfWarrantsIssuedWithConvertiblePromissoryNotes", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "BUUZ_AmountMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount [Member]", "label": "Amount [Member]" } } }, "localname": "AmountMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfImpairmentLossDetails" ], "xbrltype": "domainItemType" }, "BUUZ_AuthorizedToIssueShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.", "label": "Authorized to issue shares" } } }, "localname": "AuthorizedToIssueShares", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "BUUZ_BorrowerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrower [Member]", "label": "Borrower [Member]" } } }, "localname": "BorrowerMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_CanceledShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Canceled shares.", "label": "Canceled, shares" } } }, "localname": "CanceledShares", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfCompanyRestrictedStockAwardsDetails" ], "xbrltype": "sharesItemType" }, "BUUZ_CashAnnualBonus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash annual bonus.", "label": "Cash annual bonus" } } }, "localname": "CashAnnualBonus", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "BUUZ_ChiefTechnologyOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Chief Technology Officer [Membe]", "label": "Chief Technology Officer [Member]" } } }, "localname": "ChiefTechnologyOfficerMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_CommonStockIssuedForAccruedCompensation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock issued for accrued compensation.", "label": "Common stock issued for accrued compensation" } } }, "localname": "CommonStockIssuedForAccruedCompensation", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BUUZ_ConstructionOfDataCenter": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Construction of data center" } } }, "localname": "ConstructionOfDataCenter", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BUUZ_ConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consultants [Member]", "label": "Consultants [Member]" } } }, "localname": "ConsultantsMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_ContractPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract price.", "label": "Total", "verboseLabel": "Contract price" } } }, "localname": "ContractPrice", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/IntangibleAndOtherAssetsDetailsNarrative", "http://calethos.com/role/ScheduleOfPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "BUUZ_ConversionRateAdjustmentValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Conversion rate adjustment, value.", "label": "Conversion rate adjustment, value" } } }, "localname": "ConversionRateAdjustmentValue", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BUUZ_ConvertibleNotesInterestExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Convertible notes interest expense.", "label": "Convertible notes interest expense" } } }, "localname": "ConvertibleNotesInterestExpense", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "monetaryItemType" }, "BUUZ_ConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Notes [Member]", "label": "Convertible Notes [Member]" } } }, "localname": "ConvertibleNotesMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/EarningsLossPerShareDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_ConvertiblePromissoryNote": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Convertible promissory note.", "label": "Convertible promissory note" } } }, "localname": "ConvertiblePromissoryNote", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BUUZ_ConvertiblePromissoryNoteOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Promissory Note One [Member]", "label": "Convertible Promissory Note One [Member]" } } }, "localname": "ConvertiblePromissoryNoteOneMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_ConvertiblePromissoryNoteTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Promissory Note Two [Member]", "label": "Convertible Promissory Note Two [Member]" } } }, "localname": "ConvertiblePromissoryNoteTwoMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_ConvertiblePromissoryNotesAndAccruedInterestMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Promissory Notes And Accrued Interest [Member]" } } }, "localname": "ConvertiblePromissoryNotesAndAccruedInterestMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfIncomeAndLossPerShareAnti-dilutiveDetails" ], "xbrltype": "domainItemType" }, "BUUZ_DebtInstrumentAdditions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt instrument additions.", "label": "DebtInstrumentAdditions", "verboseLabel": "Additions" } } }, "localname": "DebtInstrumentAdditions", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "BUUZ_DebtInstrumentUnamortizedDiscountAdditions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt instrument unamortized discount additions.", "label": "DebtInstrumentUnamortizedDiscountAdditions", "verboseLabel": "Additions" } } }, "localname": "DebtInstrumentUnamortizedDiscountAdditions", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "BUUZ_DebtInstrumentUnamortizedDiscountAmortization": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt instrument unamortized discount amortization.", "label": "Amortization" } } }, "localname": "DebtInstrumentUnamortizedDiscountAmortization", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "BUUZ_DeferredCompensationAccretion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred compensation accretion.", "label": "Deferred compensation accretion" } } }, "localname": "DeferredCompensationAccretion", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfCompanyRestrictedStockAwardsDetails" ], "xbrltype": "monetaryItemType" }, "BUUZ_DeferredCompensationCanceled": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred compensation canceled.", "label": "Deferred compensation canceled" } } }, "localname": "DeferredCompensationCanceled", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfCompanyRestrictedStockAwardsDetails" ], "xbrltype": "monetaryItemType" }, "BUUZ_DeferredCompensationGrantDateFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred compensation grant date fair value.", "label": "Deferred compensation grant date fair value" } } }, "localname": "DeferredCompensationGrantDateFairValue", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfCompanyRestrictedStockAwardsDetails" ], "xbrltype": "monetaryItemType" }, "BUUZ_DisclosureNotesPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Payable", "verboseLabel": "Schedule Of Notes Payable" } } }, "localname": "DisclosureNotesPayableAbstract", "nsuri": "http://calethos.com/20221231", "xbrltype": "stringItemType" }, "BUUZ_EffectOfDilutiveInstrumentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effect of Dilutive Instruments [Abstract]", "label": "Effect of dilutive instruments" } } }, "localname": "EffectOfDilutiveInstrumentsAbstract", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "stringItemType" }, "BUUZ_EmploymentAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employment Agreement [Member]" } } }, "localname": "EmploymentAgreementMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_FinancingCosts": { "auth_ref": [], "calculation": { "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financing costs.", "label": "Financing costs" } } }, "localname": "FinancingCosts", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "BUUZ_ForfeitureOfRestrictedStockGrants": { "auth_ref": [], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Forfeiture Of Restricted Stock Grants", "label": "ForfeitureOfRestrictedStockGrants", "negatedLabel": "Forfeiture of restricted stock grants" } } }, "localname": "ForfeitureOfRestrictedStockGrants", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BUUZ_FundsReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Funds received.", "label": "Funds received" } } }, "localname": "FundsReceived", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BUUZ_GoingConcernAndLiquidityPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Going Concern And Liquidity [PolicyTextBlock]", "label": "Going Concern and Liquidity" } } }, "localname": "GoingConcernAndLiquidityPolicyTextBlock", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "BUUZ_GrantDateFairValueShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Grant date fair value shares.", "label": "Grant date fair value, shares" } } }, "localname": "GrantDateFairValueShares", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfCompanyRestrictedStockAwardsDetails" ], "xbrltype": "sharesItemType" }, "BUUZ_HyuncheolPeterKimMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hyuncheol Peter Kim [Member]", "label": "Hyuncheol Peter Kim [Member]" } } }, "localname": "HyuncheolPeterKimMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_IndebtednessForBorrowedMoneyMaximumLimit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Indebtedness for borrowed money maximum limit.", "label": "Indebtedness for borrowed money maximum limit" } } }, "localname": "IndebtednessForBorrowedMoneyMaximumLimit", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BUUZ_LetterofUnderstandingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Letter of Understanding [Member]", "label": "Letter of Understanding [Member]" } } }, "localname": "LetterofUnderstandingMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_MOneAdvisorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "M1 Advisors [Member]", "label": "M1 Advisors [Member]" } } }, "localname": "MOneAdvisorsMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_NNSCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NNS Co Ltd [Member]", "label": "NNS Co Ltd [Member]" } } }, "localname": "NNSCoLtdMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/IntangibleAndOtherAssetsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_NNSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NNS [Member]", "label": "NNS [Member]" } } }, "localname": "NNSMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfImpairmentLossDetails" ], "xbrltype": "domainItemType" }, "BUUZ_NewConsultingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Consulting Agreement [Member]", "label": "New Consulting Agreement [Member]" } } }, "localname": "NewConsultingAgreementMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_NonRefundableDeposit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non refundable deposit.", "label": "Non refundable deposit" } } }, "localname": "NonRefundableDeposit", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BUUZ_NotesPayableAdditions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Notes payable additions.", "label": "Additions" } } }, "localname": "NotesPayableAdditions", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "BUUZ_NotesPayableDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes Payable Disclosure [Text Block]", "label": "NOTES PAYABLE" } } }, "localname": "NotesPayableDisclosureTextBlock", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/NotesPayable" ], "xbrltype": "textBlockItemType" }, "BUUZ_NumeratorForDilutedEarningPerShareAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Numerator for Diluted Earning Per Share Amount.", "label": "Numerator for diluted EPS" } } }, "localname": "NumeratorForDilutedEarningPerShareAmount", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "monetaryItemType" }, "BUUZ_OriginalIssueDiscountRecordedOnConvertiblePromissoryNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Original issue discount recorded on convertible promissory notes.", "label": "Original issue discount recorded on convertible promissory notes" } } }, "localname": "OriginalIssueDiscountRecordedOnConvertiblePromissoryNotes", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BUUZ_OtherAssetsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Assets [Policy Text Block]", "label": "Other Assets" } } }, "localname": "OtherAssetsPolicyTextBlock", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "BUUZ_PICOCELCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PICOCEL, Co., Ltd. [Member]", "label": "PICOCEL, Co., Ltd. [Member]" } } }, "localname": "PICOCELCoLtdMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/IntangibleAndOtherAssetsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_PICOCELMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PICOCEL [Member]", "label": "PICOCEL [Member]" } } }, "localname": "PICOCELMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfImpairmentLossDetails" ], "xbrltype": "domainItemType" }, "BUUZ_PaymentsToConsultants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments to consultants.", "label": "Payments to consultants" } } }, "localname": "PaymentsToConsultants", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BUUZ_PercentageOfContractedColocationCapacity": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Percentage of contracted colocation capacity" } } }, "localname": "PercentageOfContractedColocationCapacity", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "percentItemType" }, "BUUZ_PrepaidExpensePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepaid Expense [Policy Text Block]", "label": "Prepaid Expense" } } }, "localname": "PrepaidExpensePolicyTextBlock", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "BUUZ_PromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note [Member]", "label": "Promissory Note [Member]" } } }, "localname": "PromissoryNoteMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_PromissoryNoteOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note One [Member]", "label": "Promissory Note One [Member]" } } }, "localname": "PromissoryNoteOneMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_PromissoryNoteTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note Two [Member]", "label": "Promissory Note Two [Member]" } } }, "localname": "PromissoryNoteTwoMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_ReductionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reduction amount.", "label": "Reduction amount" } } }, "localname": "ReductionAmount", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BUUZ_RelatedPartiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Parties [Policy Text Block]", "label": "Related Parties" } } }, "localname": "RelatedPartiesPolicyTextBlock", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "BUUZ_RelativeFairValueOfWarrantsIssuedWithConvertiblePromissoryNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Relative fair value of warrants issued with convertible promissory notes.", "label": "Relative fair value of warrants issued with convertible promissory notes" } } }, "localname": "RelativeFairValueOfWarrantsIssuedWithConvertiblePromissoryNotes", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BUUZ_RemainingLiabilityPaidForCash": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Remaining liability paid for cash.", "label": "Remaining cash liability" } } }, "localname": "RemainingLiabilityPaidForCash", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BUUZ_RestrictedStockAwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted Stock Award [Member]" } } }, "localname": "RestrictedStockAwardMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfIncomeAndLossPerShareAnti-dilutiveDetails" ], "xbrltype": "domainItemType" }, "BUUZ_RestrictedStockGrants": { "auth_ref": [], "calculation": { "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Restricted Stock Grants.", "label": "Restricted stock grants", "negatedLabel": "Restricted stock grants" } } }, "localname": "RestrictedStockGrants", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative", "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "BUUZ_RestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Stock Units [Member]", "label": "Restricted Stock Units [Member]" } } }, "localname": "RestrictedStockUnitsMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/EarningsLossPerShareDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_ReversalTwoThousandTwentyOneAccretionExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reversal Two Thousand Twenty One Accretion Expense [Member]" } } }, "localname": "ReversalTwoThousandTwentyOneAccretionExpenseMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfRestrictedStockGrantCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "BUUZ_ReversalTwoThousandTwentyTwoAccretionExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reversal Two Thousand Twenty Two Accretion Expense [Member]" } } }, "localname": "ReversalTwoThousandTwentyTwoAccretionExpenseMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfRestrictedStockGrantCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "BUUZ_ScheduleOfPaymentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Payments [Table Text Block]", "label": "SCHEDULE OF PAYMENTS" } } }, "localname": "ScheduleOfPaymentsTableTextBlock", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/IntangibleAndOtherAssetsTables" ], "xbrltype": "textBlockItemType" }, "BUUZ_ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of potential future shares issuance of conversion notes.", "label": "SCHEDULE OF POTENTIAL FUTURE SHARES ISSUANCE OF CONVERSION NOTES" } } }, "localname": "ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesTableTextBlock", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesTables" ], "xbrltype": "textBlockItemType" }, "BUUZ_ScheduleOfShareBasedCompensationRestrictedStockGrantTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Share Based Compensation Restricted Stock Grant [Table Text Block]", "label": "SCHEDULE OF RESTRICTED STOCK GRANT COMPENSATION EXPENSE" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockGrantTableTextBlock", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "BUUZ_SeriesAConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A Convertible Preferred Stock [Member]", "label": "Series A Convertible Preferred Stock [Member]" } } }, "localname": "SeriesAConvertiblePreferredStockMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/BalanceSheets", "http://calethos.com/role/BalanceSheetsParenthetical", "http://calethos.com/role/EquityDetailsNarrative", "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "BUUZ_SeriesAWarrantsIssuedWithConvertiblePromissoryNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A Warrants Issued With Convertible Promissory Notes [Member]" } } }, "localname": "SeriesAWarrantsIssuedWithConvertiblePromissoryNotesMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfIncomeAndLossPerShareAnti-dilutiveDetails" ], "xbrltype": "domainItemType" }, "BUUZ_SeriesBWarrantsToBeIssuedUponExerciseOfSeriesAWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series B Warrants To Be Issued Upon Exercise Of Series A Warrant [Member]" } } }, "localname": "SeriesBWarrantsToBeIssuedUponExerciseOfSeriesAWarrantMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfIncomeAndLossPerShareAnti-dilutiveDetails" ], "xbrltype": "domainItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award fair value of commonStock.", "label": "Fair value of common stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonStock", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments aggregate intrinsic value vested.", "label": "Aggregate intrinsic value, Unvested, Ending of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVested", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVestedAndExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments aggregate intrinsic value vested and exercisable.", "label": "Aggregate intrinsic value, Vested and Exercisable, Ending of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVestedAndExercisable", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expired", "label": "Number of warrants issued, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpired", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expired In Period Weighted Average Remaining Contractual Term.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageRemainingContractualTerm", "verboseLabel": "Weighted Average Remaining Contractual Term (Years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageRemainingContractualTerm", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "durationItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ShareBased compensation arangement by shareBased payment award non option equity instruments grants in period aggregate intrinsic forfeited.", "label": "Aggregate intrinsic value, forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicForfeited", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Aggregate Intrinsic Value Exercised", "label": "Aggregate intrinsic value, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueExercised", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments grants in period aggregate intrinsic value expired.", "label": "Aggregate intrinsic value, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueExpired", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments grants in period aggregate intrinsic value granted.", "label": "Aggregate intrinsic value, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodAggregateIntrinsicValueGranted", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of non-option equity.", "label": "Weighted Average Strike Price/Share, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments weighted average grant fair value.", "label": "Weighted Average Grant Date Fair Value/Share, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValue", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments weighted average grant fair value exercised.", "label": "Weighted Average Grant Date Fair Value/Share, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueExercised", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments weighted average grant fair value expired.", "label": "Weighted Average Grant Date Fair Value/Share, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueExpired", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ShareBased compensation arrangement by shareBased payment award non option equity instruments grants in period weighted average grant fair value forfeited.", "label": "Weighted Average Grant Date Fair Value/Share, forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantFairValueForfeited", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Remaining Contractual Term", "label": "Weighted Average Remaining Contractual Term (Years), Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageRemainingContractualTerm", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "durationItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Aggregate Intrinsic Value.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue", "periodEndLabel": "Aggregate intrinsic value, ending balance", "periodStartLabel": "Aggregate intrinsic value, Beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Weighted Average Strike Price/Share, Outstanding, ending of period", "periodStartLabel": "Weighted Average Strike Price/Share, Outstanding, Beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments weighted average grant fair value.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantFairValue", "periodEndLabel": "Weighted Average Grant Date Fair Value/Share, ending balance", "periodStartLabel": "Weighted Average Grant Date Fair Value/Share, Ending of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantFairValue", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based paymentaward non option equity instruments weighted average Remaining ContractualTerm.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm", "verboseLabel": "Weighted Average Remaining Contractual Term (Years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "durationItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based paymentaward non option equity instruments weighted average Remaining ContractualTerm.", "label": "Weighted Average Remaining Contractual Term (Years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "durationItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Vested And Exercisable", "label": "Number of warrants issued, Unvested, Ending of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Vested And Exercisable", "label": "Number of warrants issued, Vested and Exercisable, Ending of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExercisable", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantFairValueVested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments weighted average grant fair value vested.", "label": "Weighted Average Grant Date Fair Value/Share, Unvested, Ending of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantFairValueVested", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantFairValueVestedAndExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments weighted average grant fair value vested and exercisable.", "label": "Weighted Average Grant Date Fair Value/Share, Vested and Exercisable, Ending of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantFairValueVestedAndExercisable", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceVested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based paymentaward non option equity instruments weighted average price vested.", "label": "Weighted Average Strike Price/Share, Unvested, Ending of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceVested", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceVestedAndExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangements by share based payment award non options expired in period weighted average price vested and exerciable.", "label": "Weighted Average Strike Price/Share, Vested and Exercisable, Ending of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceVestedAndExercisable", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingContractualTermUnvestedAndExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term unvested and exercisable.", "label": "Weighted Average Remaining Contractual Term (Years), Vested and Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingContractualTermUnvestedAndExercisable", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "durationItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceRangePerShareOutstandingBeginning": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Per Share, Outstanding, Beginning", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceRangePerShareOutstandingBeginning", "periodEndLabel": "Exercise Price Range Per Share, Outstanding, Beginning", "periodStartLabel": "Exercise Price Range Per Share, Outstanding, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceRangePerShareOutstandingBeginning", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options granted intrinsic value.", "label": "Aggregate Intrinsic Value, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodForfeitedIntrinsicValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ShareBased compensation arrangement By ShareBased payment award options grants in period forfeited intrinsic value.", "label": "Aggregate Intrinsic Value, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodForfeitedIntrinsicValue", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInPeriodExercisedIntrinsicValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options in period exercisedintrinsic value.", "label": "Aggregate Intrinsic Value, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInPeriodExercisedIntrinsicValue", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInPeriodExpiredIntrinsicValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options in period expired intrinsic value.", "label": "Aggregate Intrinsic Value, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInPeriodExpiredIntrinsicValue", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAggregateIntrinsicValueUnvested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate Intrinsic Value, Unvested", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAggregateIntrinsicValueUnvested", "periodEndLabel": "Aggregate Intrinsic Value, Unvested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAggregateIntrinsicValueUnvested", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRelativeFairValueOutstandingBeginning": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Relative Fair Value, Outstanding, Beginning.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRelativeFairValueOutstandingBeginning", "periodEndLabel": "Relative Fair Value, Outstanding, Beginning", "periodStartLabel": "Relative Fair Value, Outstanding, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRelativeFairValueOutstandingBeginning", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Exercise Price, Unvested.", "label": "Weighted Average Exercise Price, Unvested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceVestedAndExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options outstanding weighted average exercise price vested and exercisable.", "label": "Weighted Average Exercise Price, Vested and Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceVestedAndExercisable", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedEndingBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Stock Option Unvested, Ending Balance.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedEndingBalance", "periodEndLabel": "Number of Stock Option, Unvested, Ending Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedEndingBalance", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "sharesItemType" }, "BUUZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableEndingBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options vested and exercisable ending balance.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableEndingBalance", "periodEndLabel": "Number of Stock Option, Vested and Exercisable, Ending Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableEndingBalance", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "sharesItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExerciseInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Exercise Price, Warrants exercised.", "label": "Weighted Average Strike Price/Share, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExerciseInPeriodWeightedAverageExercisePrice", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangements by share based payment award non options expired in period weighted average exercise price.", "label": "Weighted Average Strike Price/Share, Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock non options that were terminated.", "label": "Weighted Average Strike Price/Share, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodExercisePriceRangePerShareVestedAndExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangements by share based payment award Optionsexercisable in period exercise price range per share vested and exercisable.", "label": "Exercise Price Range Per Share, Vested and Exercisable" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodExercisePriceRangePerShareVestedAndExercisable", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodRelativeFairValueVestedAndExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangements by share based payment award options exercisable in period relative fair value vested and exercisable.", "label": "Relative Fair Value, Vested and Exercisable" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodRelativeFairValueVestedAndExercisable", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodExercisePriceRangePerShareExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Per Share, Exercised.", "label": "Exercise Price Range Per Share, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodExercisePriceRangePerShareExercised", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodRelativeFairValueExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Relative Fair Value, Exercised", "label": "Relative Fair Value, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodRelativeFairValueExercised", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodRelativeFairValueForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sharebased compensation arrangements by ShareBased payment award options in period exercises in period relative fair value forfeited.", "label": "Relative Fair Value, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodRelativeFairValueForfeited", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePriceRangePerShareExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Per Share, Expired.", "label": "Exercise Price Range Per Share, Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodExercisePriceRangePerShareExpired", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodRelativeFairValueExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Relative Fair Value, Expired.", "label": "Relative Fair Value, Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodRelativeFairValueExpired", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInExercisePriceRangePerShareGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Per Share, Granted.", "label": "Exercise Price Range Per Share, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInExercisePriceRangePerShareGranted", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodRelativeFairValueGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Relative Fair Value, Granted.", "label": "Relative Fair Value, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodRelativeFairValueGranted", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsInPeriodExercisePriceRangePerShareForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sharebased compensation arrangements by ShareBased payment award options in period exercise price range per share forfeited.", "label": "Exercise Price Range Per Share, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsInPeriodExercisePriceRangePerShareForfeited", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsInPeriodExercisePriceRangePerShareUnvested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Per Share, Unvested.", "label": "Exercise Price Range Per Share, Unvested" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsInPeriodExercisePriceRangePerShareUnvested", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsUnvestedInPeriodRelativeFairValueUnvested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Relative Fair Value, Unvested.", "label": "Relative Fair Value, Unvested" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsUnvestedInPeriodRelativeFairValueUnvested", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "BUUZ_ShareholderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shareholder [Member]", "label": "Shareholder [Member]" } } }, "localname": "ShareholderMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_StockIssuedDuringPeriodReturnOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period return of shares.", "label": "Return of shares" } } }, "localname": "StockIssuedDuringPeriodReturnOfShares", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "BUUZ_StockSubscriptionReceivable": { "auth_ref": [], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock subscription receivable.", "label": "Stock subscription receivable" } } }, "localname": "StockSubscriptionReceivable", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "BUUZ_StockSubscriptionReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Subscription Receivable [Member]", "label": "Stock Subscription Receivable [Member]" } } }, "localname": "StockSubscriptionReceivableMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "BUUZ_TechnologyDevelopmentAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Technology Development Agreement [Member]", "label": "Technology Development Agreement [Member]" } } }, "localname": "TechnologyDevelopmentAgreementMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/IntangibleAndOtherAssetsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_TerminationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination Agreement [Member]", "label": "Termination Agreement [Member]" } } }, "localname": "TerminationAgreementMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "BUUZ_TwoThousandTwentyTwoAccretionExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Two Thousand Twenty Two Accretion Expense [Member]" } } }, "localname": "TwoThousandTwentyTwoAccretionExpenseMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfRestrictedStockGrantCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "BUUZ_UnusualOrInfrequentItemsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unusual Or Infrequent Items [Policy Text Block]", "label": "COVID-19" } } }, "localname": "UnusualOrInfrequentItemsPolicyTextBlock", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "BUUZ_ValueAddedTaxMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Value Added Tax [Member]", "label": "Value Added Tax [Member]" } } }, "localname": "ValueAddedTaxMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/IntangibleAndOtherAssetsDetailsNarrative", "http://calethos.com/role/ScheduleOfImpairmentLossDetails" ], "xbrltype": "domainItemType" }, "BUUZ_WarrantLiabilityPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant Liability [PolicyTextBlock]", "label": "Warrant Liability" } } }, "localname": "WarrantLiabilityPolicyTextBlock", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "BUUZ_WarrantsIssuedForServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants Issued For Services [Member]" } } }, "localname": "WarrantsIssuedForServicesMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfIncomeAndLossPerShareAnti-dilutiveDetails" ], "xbrltype": "domainItemType" }, "BUUZ_WithinFiveDaysAfterSigningTheContractMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Within Five Days after Signing the Contract [Member]", "label": "Within 5 days after signing the contract [Member]" } } }, "localname": "WithinFiveDaysAfterSigningTheContractMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfPaymentsDetails" ], "xbrltype": "domainItemType" }, "BUUZ_WithinFiveDaysAfterallConditionsAreMetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Within Five Days Afterall Conditions Are Met [Member]", "label": "Within 5 days after all conditions are met as stated in \u0093Schedule B - Statement of Work\u0094 [Member]" } } }, "localname": "WithinFiveDaysAfterallConditionsAreMetMember", "nsuri": "http://calethos.com/20221231", "presentation": [ "http://calethos.com/role/ScheduleOfPaymentsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r464", "r466", "r467" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r464", "r466", "r467" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r464", "r466", "r467" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r464", "r466", "r467" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/IntangibleAndOtherAssetsDetailsNarrative", "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative", "http://calethos.com/role/ScheduleOfImpairmentLossDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r472" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r464", "r466", "r467" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/IntangibleAndOtherAssetsDetailsNarrative", "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative", "http://calethos.com/role/ScheduleOfImpairmentLossDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://calethos.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ChiefFinancialOfficerMember": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "label": "Chief Financial Officer [Member]" } } }, "localname": "ChiefFinancialOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r244", "r245", "r246", "r247", "r308", "r401", "r424", "r434", "r435", "r449", "r450", "r452", "r501", "r544", "r545", "r546", "r547", "r548", "r549" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/EquityDetailsNarrative", "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails", "http://calethos.com/role/ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesDetails", "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r244", "r245", "r246", "r247", "r308", "r401", "r424", "r434", "r435", "r449", "r450", "r452", "r501", "r544", "r545", "r546", "r547", "r548", "r549" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/EquityDetailsNarrative", "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails", "http://calethos.com/role/ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r244", "r245", "r246", "r247", "r306", "r308", "r337", "r338", "r339", "r400", "r401", "r424", "r434", "r435", "r449", "r450", "r452", "r493", "r501", "r545", "r546", "r547", "r548", "r549" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/EquityDetailsNarrative", "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails", "http://calethos.com/role/ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesDetails", "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r244", "r245", "r246", "r247", "r306", "r308", "r337", "r338", "r339", "r400", "r401", "r424", "r434", "r435", "r449", "r450", "r452", "r493", "r501", "r545", "r546", "r547", "r548", "r549" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/EquityDetailsNarrative", "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails", "http://calethos.com/role/ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesDetails", "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r489", "r540" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative", "http://calethos.com/role/NotesPayableDetailsNarrative", "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative", "http://calethos.com/role/NotesPayableDetailsNarrative", "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://calethos.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expenses", "totalLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheets", "http://calethos.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/AccountsPayableAndAccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r10", "r451" ], "calculation": { "http://calethos.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionExpense": { "auth_ref": [ "r443", "r494" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.", "label": "Accretion of compensation cost for restricted stock awards" } } }, "localname": "AccretionExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://calethos.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r22", "r23", "r24", "r157", "r420", "r429", "r430" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r21", "r24", "r109", "r390", "r425", "r426", "r476", "r477", "r478", "r484", "r485", "r486" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r5", "r451" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r342", "r343", "r344", "r484", "r485", "r486", "r535" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).", "label": "Stock issued for accrued compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income (loss) to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r341" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Restricted stock grant compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfRestrictedStockGrantCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r29", "r38", "r117", "r279" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of convertible promissory note discounts" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r279", "r388", "r447", "r448", "r480" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Total potential future shares", "verboseLabel": "Dilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EarningsLossPerShareDetailsNarrative", "http://calethos.com/role/ScheduleOfIncomeAndLossPerShareAnti-dilutiveDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EarningsLossPerShareDetailsNarrative", "http://calethos.com/role/ScheduleOfIncomeAndLossPerShareAnti-dilutiveDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EarningsLossPerShareDetailsNarrative", "http://calethos.com/role/ScheduleOfIncomeAndLossPerShareAnti-dilutiveDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EarningsLossPerShareDetailsNarrative", "http://calethos.com/role/ScheduleOfIncomeAndLossPerShareAnti-dilutiveDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land held.", "label": "Area of Land" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative", "http://calethos.com/role/IntangibleAndOtherAssetsDetailsNarrative", "http://calethos.com/role/ScheduleOfPaymentsDetails", "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r38", "r64" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Impairment loss", "verboseLabel": "Impairment" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows", "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r124", "r136", "r153", "r177", "r223", "r226", "r230", "r236", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r369", "r371", "r379", "r451", "r499", "r500", "r542" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets [Default Label]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r149", "r158", "r177", "r236", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r369", "r371", "r379", "r451", "r499", "r500", "r542" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r312", "r313", "r314", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r336", "r337", "r338", "r339", "r340" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfCompanyRestrictedStockAwardsDetails", "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionPreacquisitionContingencyAmountOfSettlement": { "auth_ref": [ "r105", "r492" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount paid or received to resolve the preacquisition contingency.", "label": "Gross settlement amount" } } }, "localname": "BusinessAcquisitionPreacquisitionContingencyAmountOfSettlement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Incorporation of Korean entity" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r40", "r151", "r437" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r34", "r40", "r46" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, End of Period", "periodStartLabel": "Cash, Beginning of Period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r34", "r115" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in Cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash, FDIC Insured Amount" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r154", "r155", "r156", "r177", "r196", "r201", "r205", "r207", "r214", "r215", "r236", "r248", "r250", "r251", "r252", "r255", "r256", "r286", "r287", "r290", "r294", "r301", "r379", "r436", "r473", "r481", "r487" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheets", "http://calethos.com/role/BalanceSheetsParenthetical", "http://calethos.com/role/EquityDetailsNarrative", "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Issuance of warrant price per share", "verboseLabel": "Class of warrant exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Issuance of warrants to purchase of common stock", "verboseLabel": "Number of securities called by warrants or rights" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r18", "r129", "r140" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (Note 7)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r65", "r242", "r243", "r431", "r498" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r69", "r433" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r484", "r485", "r535" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EarningsLossPerShareDetailsNarrative", "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheetsParenthetical", "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized", "verboseLabel": "Common stock shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheetsParenthetical", "http://calethos.com/role/EquityDetailsNarrative", "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r4", "r78" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r4", "r451" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, par value $0.001, 100,000,000 shares authorized; 24,495,621 and 25,995,621 shares issued and outstanding" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r106", "r112", "r161", "r163", "r168", "r417", "r421" ], "calculation": { "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r108", "r439" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r43", "r44", "r45" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of shares" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r2", "r126", "r137" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Convertible promissory notes, net" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r0" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Convertible promissory notes" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfAccruedInterestDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.", "label": "SCHEDULE OF CONVERTIBLE PROMISSORY NOTES" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleNotesPayableCurrent": { "auth_ref": [ "r14" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible Notes Payable, Current", "periodEndLabel": "Net carrying amount" } } }, "localname": "ConvertibleNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r0", "r125", "r134", "r143" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/ScheduleOfConvertiblePromissoryNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r43", "r45" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Amount", "totalLabel": "Total" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r43", "r45" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Potential future shares" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r43", "r45" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Principal", "verboseLabel": "Conversion of debt" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative", "http://calethos.com/role/ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r73", "r175", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r273", "r280", "r281", "r283" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "CONVERTIBLE PROMISSORY NOTES" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r0", "r1", "r2", "r125", "r126", "r134", "r180", "r257", "r258", "r259", "r260", "r261", "r263", "r269", "r270", "r271", "r272", "r274", "r275", "r276", "r277", "r278", "r279", "r389", "r444", "r445", "r446", "r447", "r448", "r482" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/NotesPayableDetailsNarrative", "http://calethos.com/role/ScheduleOfConvertiblePromissoryNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": { "auth_ref": [ "r84" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.", "label": "Debt Instrument, Convertible, Beneficial Conversion Feature" } } }, "localname": "DebtInstrumentConvertibleBeneficialConversionFeature", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r72", "r259" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Conversion price per share", "terseLabel": "Debt Instrument, Convertible, Conversion Price", "verboseLabel": "Debt instruments, conversion price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/EquityDetailsNarrative", "http://calethos.com/role/ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentDecreaseForgiveness": { "auth_ref": [ "r482" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.", "label": "Debt instrument decrease forgiveness" } } }, "localname": "DebtInstrumentDecreaseForgiveness", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r118", "r119", "r257", "r389", "r445", "r446" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt instrument, face amount", "periodEndLabel": "Balance, end of year", "periodStartLabel": "Balance, beginning of year" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/NotesPayableDetailsNarrative", "http://calethos.com/role/ScheduleOfConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r16", "r118", "r284", "r389" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.", "label": "Increase in interest rate" } } }, "localname": "DebtInstrumentInterestRateIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r16", "r258" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt instrument, interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r159", "r444", "r537" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt instrument, maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r17", "r180", "r257", "r258", "r259", "r260", "r261", "r263", "r269", "r270", "r271", "r272", "r274", "r275", "r276", "r277", "r278", "r279", "r389", "r444", "r445", "r446", "r447", "r448", "r482" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/NotesPayableDetailsNarrative", "http://calethos.com/role/ScheduleOfConvertiblePromissoryNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r17", "r132" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt instrument, periodic payment" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r17", "r79", "r82", "r83", "r84", "r117", "r118", "r119", "r133", "r180", "r257", "r258", "r259", "r260", "r261", "r263", "r269", "r270", "r271", "r272", "r274", "r275", "r276", "r277", "r278", "r279", "r282", "r389", "r444", "r445", "r446", "r447", "r448", "r482" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r117", "r119", "r502" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Original issue discount", "periodEndLabel": "Balance, end of year", "periodStartLabel": "Balance, beginning of year" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/ScheduleOfConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtPolicyTextBlock": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.", "label": "Debt Discounts" } } }, "localname": "DebtPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault": { "auth_ref": [ "r47", "r71" ], "lang": { "en-us": { "role": { "documentation": "Discussion of the facts and amounts pertaining to each failure to comply with an affirmative or negative covenant of a long-term debt instrument, including violating payment terms or an inability to meet certain minimum financial requirements or achieve or maintain certain financial ratios. The discussion would generally be expected to also include whether or not the failure can and will be overcome and a description of the terms of any waivers, including the amount of the waiver and the period of time covered by the waiver, and if reclassification of long-term debt to current has been made in the current balance sheet.", "label": "Events of default description" } } }, "localname": "DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent": { "auth_ref": [ "r14" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).", "label": "Deferred compensation" } } }, "localname": "DeferredCompensationShareBasedArrangementsLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfCompanyRestrictedStockAwardsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://calethos.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Intangible assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r530" ], "calculation": { "http://calethos.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Deferred tax assets, net of valuation allowance" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r530" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred tax assets net" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/DeferredTaxAssetsAndIncomeTaxProvisionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r103", "r531" ], "calculation": { "http://calethos.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Expected income tax benefit from NOL carry-forwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": { "auth_ref": [ "r103", "r531" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.", "label": "Net operating loss deferred tax" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/DeferredTaxAssetsAndIncomeTaxProvisionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r103", "r531" ], "calculation": { "http://calethos.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Interest expense limitations" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r103", "r531" ], "calculation": { "http://calethos.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "verboseLabel": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses": { "auth_ref": [ "r103", "r531" ], "calculation": { "http://calethos.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated impairment losses.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses", "verboseLabel": "Impairment loss" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r354" ], "calculation": { "http://calethos.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Less valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeVariableInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable interest rate in effect as of the balance sheet date related to the interest rate derivative.", "label": "Secured overnight financing, variable interest rate" } } }, "localname": "DerivativeVariableInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r169", "r186", "r187", "r188", "r189", "r190", "r194", "r196", "r205", "r206", "r207", "r211", "r375", "r376", "r418", "r422", "r440" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net income (loss) per share, basic", "verboseLabel": "Basic EPS" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r169", "r186", "r187", "r188", "r189", "r190", "r196", "r205", "r206", "r207", "r211", "r375", "r376", "r418", "r422", "r440" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net income (loss) per share, diluted", "verboseLabel": "Diluted EPS" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r50", "r51" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r208", "r209", "r210", "r212" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "EARNINGS (LOSS) PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EarningsLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r539" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfReconciliationOfIncomeTaxDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r178", "r350", "r363" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Federal statutory income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfReconciliationOfIncomeTaxDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r529", "r532" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Change in valuation allowance on net operating loss carry-forwards" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfReconciliationOfIncomeTaxDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "auth_ref": [], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for employee benefit and equity-based compensation.", "label": "Fair value of equity-based compensation" } } }, "localname": "EmployeeBenefitsAndShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r78", "r147", "r165", "r166", "r167", "r181", "r182", "r183", "r185", "r191", "r193", "r213", "r237", "r303", "r342", "r343", "r344", "r359", "r360", "r374", "r380", "r381", "r382", "r383", "r384", "r385", "r390", "r425", "r426", "r427" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EscrowDeposit": { "auth_ref": [ "r128", "r432" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.", "label": "Escrow Deposit" } } }, "localname": "EscrowDeposit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r38", "r74" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair value of warrants" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "SCHEDULE OF FAIR VALUE OF WARRANTS" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r238", "r239", "r240", "r241", "r403", "r404" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/IntangibleAndOtherAssetsDetailsNarrative", "http://calethos.com/role/ScheduleOfImpairmentLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/IntangibleAndOtherAssetsDetailsNarrative", "http://calethos.com/role/ScheduleOfImpairmentLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r58", "r59" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/IntangibleAndOtherAssetsDetailsNarrative", "http://calethos.com/role/ScheduleOfImpairmentLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r60", "r403" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "verboseLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfImpairmentLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Translation" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r27" ], "calculation": { "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "INTANGIBLE AND OTHER ASSETS" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/IntangibleAndOtherAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r38", "r61" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "verboseLabel": "Impairment loss" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/IntangibleAndOtherAssetsDetailsNarrative", "http://calethos.com/role/ScheduleOfImpairmentLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r25", "r122", "r130", "r142", "r223", "r225", "r229", "r231", "r419", "r441" ], "calculation": { "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r178", "r351", "r352", "r357", "r361", "r364", "r366", "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "DEFERRED TAX ASSETS AND INCOME TAX PROVISION" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/DeferredTaxAssetsAndIncomeTaxProvision" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r179", "r192", "r193", "r222", "r349", "r362", "r365", "r423" ], "calculation": { "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r164", "r347", "r348", "r352", "r353", "r356", "r358" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r42" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r37" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r37" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "auth_ref": [ "r197", "r198", "r199", "r207" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.", "label": "Warrants" } } }, "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "auth_ref": [ "r202", "r203", "r207" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.", "label": "Convertible notes" } } }, "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r197", "r198", "r200", "r207", "r311" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Restricted stock awards" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Foreign exchange loss" } } }, "localname": "IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfImpairmentLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndDebtExpense": { "auth_ref": [ "r116" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity.", "label": "Interest" } } }, "localname": "InterestAndDebtExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfPotentialFutureSharesIssuanceOfConversionNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r29", "r277", "r285", "r447", "r448" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest expense, debt", "verboseLabel": "Interest Expense, Debt" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r171", "r173", "r174" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://calethos.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued interest", "verboseLabel": "Balance, end of the year" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/NotesPayableDetailsNarrative", "http://calethos.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails", "http://calethos.com/role/ScheduleOfAccruedInterestDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r9", "r127", "r139", "r451", "r483", "r490", "r538" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and stockholders\u2019 deficit" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r15", "r150", "r177", "r236", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r370", "r371", "r372", "r379", "r451", "r499", "r542", "r543" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r495", "r496", "r497" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Damages value" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDomicileOfLitigation": { "auth_ref": [ "r66", "r67", "r68" ], "lang": { "en-us": { "role": { "documentation": "Identifies the domicile or jurisdiction of the court of law, arbitration or mediation proceeding.", "label": "Litigation description" } } }, "localname": "LossContingencyDomicileOfLitigation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Measurement Input, Share Price [Member]" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r172" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash (Used in) Provided by Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows From Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r172" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net Cash Used in Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows From Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r34", "r36", "r39" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash Used in Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows From Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r26", "r39", "r131", "r141", "r148", "r160", "r162", "r167", "r177", "r184", "r186", "r187", "r188", "r189", "r192", "r193", "r204", "r223", "r225", "r229", "r231", "r236", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r376", "r379", "r441", "r499" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net income (Loss)", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative", "http://calethos.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://calethos.com/role/StatementsOfCashFlows", "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit", "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-cash investing and financing activities" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r28" ], "calculation": { "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expenses" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expenses)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r2", "r126", "r137" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes payable", "periodEndLabel": "Balance, end of the year", "periodStartLabel": "Balance, beginning of the year", "verboseLabel": "Promissory note" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheets", "http://calethos.com/role/ScheduleOfNotesPayableDetails", "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r13" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes Payable, Current", "verboseLabel": "Notes payable" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfAccruedInterestDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating (income) expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r223", "r225", "r229", "r231", "r441" ], "calculation": { "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r48", "r49", "r55", "r113" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "ORGANIZATION AND ACCOUNTING POLICIES" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r123", "r135", "r152" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r20" ], "calculation": { "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Change in foreign currency translation", "verboseLabel": "Foreign currency translation income" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit", "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNonoperatingIncome": { "auth_ref": [ "r170" ], "calculation": { "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income related to nonoperating activities, classified as other.", "label": "Interest income" } } }, "localname": "OtherNonoperatingIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForRent": { "auth_ref": [ "r35" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments to lessor's for use of assets under operating leases.", "label": "Payments for rent" } } }, "localname": "PaymentsForRent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherProductiveAssets": { "auth_ref": [ "r30" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.", "label": "Payments to Acquire Other Productive Assets", "negatedLabel": "Other assets" } } }, "localname": "PaymentsToAcquireOtherProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfRestrictedStockGrantCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfRestrictedStockGrantCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r3", "r286" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheetsParenthetical", "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheetsParenthetical", "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r3", "r286" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r3", "r451" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, value" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r475" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid and other current expenses" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r438", "r442", "r491" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r32" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from the issuance of convertible promissory notes", "verboseLabel": "Proceed from convertible debt" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r31" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "verboseLabel": "Issuance of common stock purchase price payable" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative", "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r32" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from the issuance of notes payable" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r32" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from related party" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r31", "r100" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from the exercise of options", "verboseLabel": "Proceeds from stock options exercised" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative", "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r144", "r145" ], "calculation": { "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r307", "r393", "r394" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r121", "r393" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Due to related parties" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r146", "r393", "r394", "r541" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/IntangibleAndOtherAssetsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r146" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/IntangibleAndOtherAssetsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r307", "r393", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r541" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r391", "r392", "r394", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r33" ], "calculation": { "http://calethos.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedLabel": "Repayments of notes payable", "negatedTerseLabel": "Payments" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfNotesPayableDetails", "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r33" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Payment to related party" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/IntangibleAndOtherAssetsDetailsNarrative", "http://calethos.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfCompanyRestrictedStockAwardsDetails", "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r6", "r85", "r138", "r428", "r430", "r451" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheets", "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r147", "r181", "r182", "r183", "r185", "r191", "r193", "r237", "r342", "r343", "r344", "r359", "r360", "r374", "r425", "r427" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r220", "r221", "r224", "r227", "r228", "r232", "r233", "r234", "r304", "r305", "r402" ], "calculation": { "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalariesAndWages": { "auth_ref": [ "r479" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold" } } }, "localname": "SalariesAndWages", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockDescriptionOfTransaction": { "auth_ref": [ "r107", "r110", "r111" ], "lang": { "en-us": { "role": { "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.", "label": "Sale of Stock, Description of Transaction" } } }, "localname": "SaleOfStockDescriptionOfTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of stock shares price per share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/AccountsPayableAndAccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "SCHEDULE OF ACCRUED INTEREST" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/AccountsPayableAndAccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EarningsLossPerShareDetailsNarrative", "http://calethos.com/role/ScheduleOfIncomeAndLossPerShareAnti-dilutiveDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "SCHEDULE OF INCOME AND LOSS PER SHARE ANTI-DILUTIVE" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "SCHEDULE OF NOTES PAYABLE" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/DeferredTaxAssetsAndIncomeTaxProvisionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EarningsLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "SCHEDULE OF RECONCILIATION OF INCOME TAX" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/DeferredTaxAssetsAndIncomeTaxProvisionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r58", "r59", "r403" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/IntangibleAndOtherAssetsDetailsNarrative", "http://calethos.com/role/ScheduleOfImpairmentLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of impaired intangible assets excluding goodwill. This may include a description of the facts and circumstances leading to the recording of impairment charges of intangible assets in the period, the amount of the impairment charges, the methods of determining fair value of the associated assets, the caption in the income statement in which the impairment losses are aggregated, and the segment in which the impaired intangible assets are reported.", "label": "SCHEDULE OF IMPAIRMENT LOSS" } } }, "localname": "ScheduleOfImpairedIntangibleAssetsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/IntangibleAndOtherAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r120", "r121" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r309", "r310", "r312", "r313", "r314", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r336", "r337", "r338", "r339", "r340" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfCompanyRestrictedStockAwardsDetails", "http://calethos.com/role/ScheduleOfRestrictedStockGrantCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "SCHEDULE OF COMPANY RESTRICTED STOCK AWARDS" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r89", "r95", "r97" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "SCHEDULE OF STOCK OPTION ACTIVITIES" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/NotesPayableDetailsNarrative", "http://calethos.com/role/ScheduleOfConvertiblePromissoryNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r75", "r76", "r77", "r79", "r80", "r81", "r82", "r83", "r84", "r85", "r154", "r155", "r156", "r214", "r286", "r287", "r288", "r290", "r294", "r299", "r301", "r449", "r473", "r481" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r86", "r88" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "SCHEDULE OF WARRANTS ACTIVITY" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.", "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]" } } }, "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r37" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Compensation expenses" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Cancellation of restricted stock awards" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r324", "r325" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Shares, balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfCompanyRestrictedStockAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": { "auth_ref": [ "r338" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.", "label": "Dividend payments" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Date of issuance volatility percentage", "verboseLabel": "Fair value assumptions, expected volatility rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Fair value of common stock risk free interest rate", "verboseLabel": "Risk Free Interest Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfCompanyRestrictedStockAwardsDetails", "http://calethos.com/role/ScheduleOfRestrictedStockGrantCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Number of warrants issued, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.", "label": "Number of warrants issued, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Number of warrants issued, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r90", "r91" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Number of warrants issued, Outstanding, Ending of period", "periodStartLabel": "Number of warrants issued, Outstanding, Beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "negatedLabel": "Number of Stock Option Shares, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Number of Stock Option Shares, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Number of Stock Option Shares, Granted", "verboseLabel": "Option to purchase shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative", "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r99" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Aggregate Intrinsic Value, Beginning Balance", "periodStartLabel": "Aggregate Intrinsic Value, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r316", "r317" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Number of Stock Option Shares, Outstanding, Beginning Balance", "periodStartLabel": "Number of Number of Stock Option Shares, Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r316", "r317" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Outstanding, Beginning", "periodStartLabel": "Weighted Average Exercise Price, Outstanding, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r312", "r313", "r314", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r336", "r337", "r338", "r339", "r340" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfCompanyRestrictedStockAwardsDetails", "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Weighted Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Weighted Average Exercise Price, Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Weighted Average Exercise Price, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche One [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche Three [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheThreeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche Two [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r315", "r334", "r335", "r336", "r337", "r340", "r345", "r346" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/EquityDetailsNarrative", "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails", "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Fair value of common stock estimated life", "verboseLabel": "Expected Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r99" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "periodEndLabel": "Aggregate Intrinsic Value, Vested and Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r331" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-based compensation arrangement by share-based payment award, options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Option to purchase shares vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Fair value of options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "verboseLabel": "Shares issued, price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative", "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/NotesPayableDetailsNarrative", "http://calethos.com/role/ScheduleOfConvertiblePromissoryNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r154", "r155", "r156", "r177", "r196", "r201", "r205", "r207", "r214", "r215", "r236", "r248", "r250", "r251", "r252", "r255", "r256", "r286", "r287", "r290", "r294", "r301", "r379", "r436", "r473", "r481", "r487" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheets", "http://calethos.com/role/BalanceSheetsParenthetical", "http://calethos.com/role/EquityDetailsNarrative", "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r19", "r78", "r147", "r165", "r166", "r167", "r181", "r182", "r183", "r185", "r191", "r193", "r213", "r237", "r303", "r342", "r343", "r344", "r359", "r360", "r374", "r380", "r381", "r382", "r383", "r384", "r385", "r390", "r425", "r426", "r427" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheets", "http://calethos.com/role/BalanceSheetsParenthetical", "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative", "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r181", "r182", "r183", "r213", "r402" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheets", "http://calethos.com/role/BalanceSheetsParenthetical", "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative", "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r43", "r44", "r45" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Common stock issued from forgiven debt" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r3", "r4", "r78", "r85" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Issuance of common stock, shares", "negatedLabel": "Stocks returned, shares", "terseLabel": "Stock issued during period, shares, new issues", "verboseLabel": "Stock issued during period shares new issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative", "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative", "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit", "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Stocks issued for debt forgiveness, shares" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r78", "r85" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Restricted common stock awards issued for compensation, shares" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r3", "r4", "r78", "r85" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Restricted common stock shares granted" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r3", "r4", "r78", "r85" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Stock-based compensation, shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares (or other type of equity) forfeited during the period.", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited", "negatedLabel": "Forfeiture of stock-based compensation, shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r3", "r4", "r78", "r85", "r321" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock issued on exercise of options, shares", "negatedLabel": "Number of Stock Option Shares, Exercised", "verboseLabel": "Number of share options exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative", "http://calethos.com/role/ScheduleOfStockOptionActivitiesDetails", "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock options issued for services", "verboseLabel": "Stock Issued During Period, Value, Issued for Services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative", "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r3", "r4", "r78", "r85" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stocks returned", "terseLabel": "Stock Issued During Period, Value, New Issues", "verboseLabel": "Issuance of common stock, value" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesDetailsNarrative", "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit", "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock issued for debt forgiveness" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r3", "r4", "r78", "r85" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Restricted common stock awards issued for compensation" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r78", "r85" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r3", "r4", "r85", "r96" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited": { "auth_ref": [ "r98" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-Based Payment Arrangement, Forfeited", "negatedLabel": "Forfeiture of stock-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationForfeited", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r19", "r78", "r85" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock issued on exercise of options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionPlanExpense": { "auth_ref": [ "r38" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for option under share-based payment arrangement.", "label": "Option expense" } } }, "localname": "StockOptionPlanExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r4", "r7", "r8", "r56", "r451", "r483", "r490", "r538" ], "calculation": { "http://calethos.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheets", "http://calethos.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 deficit" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r87", "r176", "r287", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r300", "r303", "r373" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r386", "r398" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r386", "r398" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r386", "r398" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r386", "r398" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r397", "r399" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative", "http://calethos.com/role/IntangibleAndOtherAssetsDetailsNarrative", "http://calethos.com/role/ScheduleOfPaymentsDetails", "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r52", "r53", "r54", "r216", "r217", "r218", "r219" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/OrganizationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r355" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/DeferredTaxAssetsAndIncomeTaxProvisionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValueAddedTaxReceivableCurrent": { "auth_ref": [ "r474" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Value added tax" } } }, "localname": "ValueAddedTaxReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/IntangibleAndOtherAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ConvertiblePromissoryNotesDetailsNarrative", "http://calethos.com/role/EarningsLossPerShareDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Dividend yield" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and rights outstanding, term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfFairValueOfWarrantsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Dilutive potential common shares" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "verboseLabel": "Effect of dilutive instruments" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r195", "r207" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted average common shares outstanding \u2013 diluted", "verboseLabel": "Denominator for diluted EPS" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r194", "r207" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average common shares outstanding \u2013 basic", "verboseLabel": "Denominator - for basic EPS" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://calethos.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Denominator" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://calethos.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1828-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2029-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(d)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r453": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r454": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r455": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r456": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r457": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r458": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r459": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r461": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r462": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r463": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r464": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r465": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r466": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r467": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r468": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r469": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r471": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r472": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r48": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r49": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org/topic&trid=2122394", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 2.A.6)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105049-122735", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r498": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org/topic&trid=2144416", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "c(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 70 0001493152-23-012482-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-012482-xbrl.zip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ɑ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�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